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ABSTRACT 
 
Cryptosporidium is an apicomplexan parasite causing diarrhoeal illness. Two 
species C. parvum and C. hominis are of public health relevance. C. parvum and 
C. hominis genome sequences showed only 3-5% sequence divergence. 
Putatively species-specific genes were identified in silico. The specificity of these 
genes was tested experimentally by PCR in a collection of Cryptosporidium 
clinical isolates and reference strains. 90% of the genes tested were common to 
both species. PCR product sequence analysis detected 78 SNPs, 78.3% (61) of 
which were species-specific. 64.2% of the SNPs were synonymous. The 
sequences of these novel genetic loci allowed the construction of a robust and 
novel multi-locus analysis, which clearly discriminated with high bootstrap values 
Cryptosporidium species and subtypes. Evidence was found of one C. parvum 
(Cops-1) and one C. hominis (Chos-1) specific gene. The potential of Cops-1 as 
species determinant and virulence factor was considered. Cops-1 is positioned 
telomerically and annotated as encoding a 50 kDa protein which is secreted, 
serine rich and containing internal repeats. The predicted protein has interesting 
features (signal peptide, transmembrane domain and myristoylation motif), 
which are highly suggestive of a potential role in virulence and host-parasite 
interaction. Subsequent analysis showed that Cops-1 has a truncated ortholog in 
C. hominis. The N terminus is conserved, suggesting that the characteristic 
features are likely to be maintained, if the ortholog is expressed. Interestingly, 
sera from C. parvum-infected patients recognized a 50 kDa protein in C. parvum 
but not C. hominis antigen preparations, consistent with the protein being 
antigenic for patients. An anti-Cops-1 monoclonal antibody stained C. parvum 
oocyst contents and sporozoite surface consistent with a role in host-cell 
interaction. This is the first report of a C. parvum specific protein and has 
important implications for diagnosis and typing of this neglected pathogen.  
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1.1 Historical background 
 
Cryptosporidium is thought to have been first described by Clarke in 1895 as 
“swarm spores lying upon the gastric epithelium of mice” (Clarke, 1895). In 
retrospect, these small organisms were probably the motile merozoites of 
Cryptosporidium muris, the validated species named and described in 1907 by 
the American parasitologist Tyzzer (1907) from the gastric epithelium of 
laboratory mice (Mus musculus). These small coccidian organisms were placed in 
a new genus Cryptosporidium meaning hidden sporocysts because unlike the 
previously known coccidia, the oocyst of this parasite did not have sporocysts 
surrounding the sporozoites (Current and Garcia, 1991). In 1910, Tyzzer 
described in detail the various life cycle stages of C. muris (Tyzzer, 1910) and in 
1912, he described a smaller size protozoan parasite than C. muris, from the 
intestine of mice (Tyzzer, 1912). Based on morphology, life cycle and 
experimental infection, he proposed a new Cryptosporidium species: C. parvum. 
In addition, Tyzzer also reported the first description of Cryptosporidium in birds 
(Tyzzer, 1929). He considered it as C. parvum; however, this was not confirmed.  
 
Following Tyzzer reports of C. muris and C. parvum (Tyzzer 1907, 1919, 1912), 
several studies relying primarily on oocyst’s structural features resulted in the 
naming of an additional 19 Cryptosporidium species, most of which are not 
considered valid now (Current and Garcia, 1991). Slavin reported 
Cryptosporidium from turkeys (Meleagridis gallopavo) and called the species 
C. meleagridis (Slavin, 1955). This study, in which Slavin describes severe 
diarrhoea and mortality of the infected birds, is the first to demonstrate the 
pathogenicity of Cryptosporidium species. Other Cryptosporidium species include 
C. wrairi, described from the small intestine of guinea pigs (Cavia porcellus) 
(Vetterling et al., 1971), C. felis isolated from the domestic cat (Felis catus) (Iseki, 
1979), C. serpentis from snakes (Elaphe guttata) (Levine, 1980, Brownstein et al., 
1977) and C. baileyi discovered in the small and large intestine, the sinuses, 
trachea and conjunctiva of chicken (Gallus gallus) (Current et al., 1986).  
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Recently described Cryptosporidium species include C. saurophilum isolated from 
lizards (Eumeces schneideri) (Koudela and Modry, 1998), C. galli described from 
chicken (Gallus gallus) (Pavlasek, 1999), C. andersoni isolated from cattle (Bos 
taurus) (Lindsay et al., 2000), C. canis described from domestic dogs (Canis 
familiaris) (Fayer et al., 2001) and C. molnari from sea bream (Sparus aurata) 
(Alvarez-Pellitero and Sitjà-Bobadilla, 2002). In 2002, Morgan-Ryan and 
colleagues (2002) proposed to rename C. parvum human genotype (genotype 1 
or genotype H) and create a new Cryptosporidium species C. hominis based on 
biological and molecular data. New Cryptosporidium species have been described 
including C. suis isolated from domestic pig (Sus scrofa) (Ryan et al., 2004), 
C. scophthalmi found in turbot (Scophthalmus maximus) (Alvarez-Pellitero et al., 
2004), C. bovis described in domestic cattle (Bos taurus) (Fayer et al., 2005), 
C. fayeri isolated from Kangaroo (Macropus rufus) (Ryan et al., 2008), C. ryanae 
found in cattle (Bos taurus) (Fayer et al., 2008), C. macropodum described in 
kangaroos (Macropus giganteus) (Power and Ryan, 2008) and C. xiaoi isolated 
from sheep (Ovis aries) (Fayer and Santín, 2009). These species are currently 
considered valid by Xiao and Fayer (2008) as summarized in Table 1.1. 
 
Until 1970, Cryptosporidium species were not considered economically or 
medically important, but the veterinary importance of Cryptosporidium was 
highlighted by the association of C. parvum with bovine diarrhoea (Panciera et 
al., 1971). Since then, several sporadic cases and outbreak reports were 
published and C. parvum is now regarded as an important cause of neonatal 
diarrhoea in calves and lambs associated with economic loses (O'Handley and 
Olson, 2006, De Graaf et al., 1999, Current and Garcia, 1991, Moore and Zeman, 
1991, Holland, 1990, Tzipori et al., 1980, Meuten et al., 1974). Another species, 
C. baileyi, is now recognized as an important cause of respiratory disease in 
poultry (O'Donoghue, 1995, Goodwin, 1989, Current and Snyder, 1988, Blagburn 
et al., 1987).  
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Species Original description Type host 
Cryptosporidium andersoni* Lindsay et al. (2000) Bos taurus (domestic cattle) 
Cryptosporidium baileyi Current et al. (1986) Gallus gallus (chicken) 
Cryptosporidium bovis Fayer et al. (2005) Bos taurus (domestic cattle) 
Cryptosporidium canis* Fayer et al. (2001) Canis familiaris (domestic dog) 
Cryptosporidium fayeri Ryan et al. (2008) Macropus rufus (red kangaroo) 
Cryptosporidium felis* Iseki (1979) Felis catus (domestic cat) 
Cryptosporidium galli Pavlasek (1999) Gallus gallus (chicken) 
Cryptosporidium hominis* Morgan-Ryan et al. (2002) Homo sapiens (human) 
Cryptosporidium macropodum Power and Ryan (2008) Macropus giganteus (grey kangaroo) 
Cryptosporidium meleagridis* Slavin (1955) Meleagris gallopavo (turkey) 
Sparus aurata (gilthead sea bream) Cryptosporidium molnari Alvarez-Pellitero and Sitja-
Bobadilla (2002) Dicentrarchus labrax (European seabass) 
Cryptosporidium muris* Tyzzer (1910) Mus musculus (house mouse) 
Cryptosporidium parvum* Tyzzer (1912) Mus musculus (house mouse) 
Cryptosporidium scophthalmi Alvarez-Pellitero et al. (2004) Scophthalmi maximus (turbot) 
Elaphe guttata (corn snake) 
Elaphe subocularis (rat snake) 
Cryptosporidium serpentis Levine (1980)  
Brownstein et al., (1977) 
Sanzinia madagascarensus (Madagascar boa) 
Cryptosporidium suis* Ryan et al. (2004) Sus scrofa (domestic pig) 
Cryptosporidium varanii Pavlasek et al. (1995) Varanus prasinus (Emerald monitor) 
Cryptosporidium wrairi Vetterling et al. (1971) Cavia porcellus (guinea pig) 
 
 
Table 1.1: Valid Cryptosporidium species, their original host and details of the 
original report (Reproduced from Xiao and Fayer (2008), with modification). (*) 
species found to infect humans. 
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The first cases of human cryptosporidiosis were reported in 1976 and associated 
with severe watery diarrhoea (Meisel et al., 1976, Nime et al., 1976). The public 
health significance of cryptosporidiosis became apparent when Cryptosporidium 
was recognized as a common cause of acute diarrhoea in immunocompetent 
individuals (Jokipii et al., 1983, Current et al., 1983, Tzipori et al., 1983) and when 
chronic infections were associated with several mortalities in patients infected 
with human immunodeficiency virus (HIV) who had developed acquired 
immunodeficiency syndrome (AIDS) (O'Donoghue, 1995, Crawford and Vermund, 
1988, Fayer and Ungar., 1986, Soave et al., 1984, Current et al., 1983, Ma and 
Soave, 1983, Forgacs et al.,1983). 
 
The first report of a waterborne cryptosporidiosis outbreak was by D’Antonio 
and colleagues (1985). Since then, Cryptosporidium has been associated with 
several waterborne outbreaks. The importance of Cryptosporidium as a water 
borne pathogen was highlighted by the massive outbreak in Milwaukee 
(Wisconsin, USA) in 1993 affecting 403,000 persons (Mac Kenzie et al., 1994). 
However, this estimate was disputed as retrospective community-based studies 
of diarrhoeal disease were shown to overestimate the incidence of illness 
(Hunter and Syed, 2001). The estimated cost of the Milwaukee outbreak was 
over 90 million US dollars (Corso et al., 2003). Karanis and colleagues reviewed 
over 150 waterborne Cryptosporidium outbreaks worldwide (Karanis et al., 
2007), demonstrating the high prevalence and the widespread distribution of 
Cryptosporidium. The investigation of these outbreaks allowed an improved 
understanding of the epidemiology of Cryptosporidium, particularly identification 
of risk factors and transmission routes and provided better insight into the public 
health impact of waterborne cryptosporidiosis. 
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1.2 Taxonomy 
 
When Tyzzer first identified C. muris he was uncertain of its systematic position, 
“its possession of an organ of attachment and of iodophilic granules, it resembles 
the gregarines”, but “in its morphology, in the lack of motion in the adult, and in 
sexual dimorphism it resembles the coccidia” (Tyzzer, 1907). However, when he 
further characterized the parasite and officially proposed the new genus and 
species Cryptosporidium muris, it was placed in the class Sporozoa, subclass 
Telosporidia, order Coccidiomorpha, suborder Coccidia and within the family 
Eimeridae (Tyzzer, 1910). No flagella were demonstrated with the microgametes 
of C. muris but all the other requirements of the family were met, especially after 
the definition of the group had been modified to include extracellular Coccidia 
(Robinson, 2005, Tyzzer, 1910). Despite this classification, Tyzzer stated once 
more “it would appear that the mode of life of this species is essentially that of a 
gregarine as it undergoes the greater part of its development either attached to 
the surface of the epithelium or free in the lumen of the gastric glands” (Tyzzer, 
1910). 
 
The classification of Cryptosporidium has changed since then, the most current 
classification published by the Society of Protozoologists, is by Lee and 
colleagues (2000 a) (see Robinson, 2005): 
 
Phylum Apicomplexa Levine, 1970 
Class Conoidasida Levine, 1988 
Subclass Coccidiasina Leuckart, 1879 
Order Eucoccidiorida Leger and Duboscq, 1910 
Suborder Eimeriorina Leger, 1911 
Family Cryptosporidiidae Leger, 1911 
Genus Cryptosporidium Tyzzer, 1907 
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This classification was based on the following biological characteristics of each 
group (Current and Garcia, 1991):  
 
 Apicomplexa: Invasive forms have apical complex with polar rings, 
rhoptries, micronemes, conoid and sub-pellicular microtubules. 
 Sporozoasida: locomotion of invasive forms by body flexion gliding or 
undulation. 
 Coccidiasina: life cycle with merogony, gametogony and sporogony. 
 Eucoccidiorida: merogony present, found in vertebrate hosts. 
 Eimeriorina: male and female gametes develop independently. 
 Cryptosporidiidae: homoxenous (one host life cycle), with developmental 
stages just under the membrane of the host cell. Oocysts without 
sporocysts and with four sporozoites. Microgametes with flagella. 
 
However, the taxonomy of Cryptosporidium remains controversial until today, 
particularly the classification within the subclass Coccidiasina. Carreno and 
colleagues (1999) showed, based on SSU rRNA gene sequences, that 
Cryptosporidium species (C. baileyi, C. parvum, C. wrairi, C. serpentis, C. muris) 
form a monophyletic clade that is a sister group to the gregarines, parasites of 
invertebrates, belonging to the subclass Gregarinasina. This gregarine-
Cryptosporidium clade was separated from the coccidia clade including 
Sarcocystis, Toxoplasma and Eimeria and supported by 95% bootstrap value. 
Other studies provided further support to the hypothesis that Cryptosporidium 
lineage is separate from Coccidia and is an early emerging lineage among the 
Apicomplexa (Kuo et al., 2008, Leander et al. 2003, Zhu et al. 2000 a, Morrison 
and Ellis, 1997, Barta et al., 1991). 
 
These phylogenetic data were supported by biological evidence. In fact, despite 
C. parvum being a typical Coccidium in its morphology (apical complex, dense 
bodies, micronemes, rhoptries) and lifestyle, there are some fundamental 
differences between this parasitic protist and the eucoccidia (Zhu et al., 2000 a). 
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These include: (i) the extracytoplasmic but intracellular location of C. parvum in a 
parasitophorous vacuole just beneath the enterocyte apical membrane; (ii) the 
presence of an acristate, ribosome-studded mitochondrion posterior to the 
nucleus (Riordan et al., 1999); (iii) plant-like polyamine biosynthesis by 
decarboxylation of arginine rather than ornithine (Keithly et al., 1997); (iv) the 
apparent lack of a plastid or plastid genome (Zhu et al., 2000 b); (v) insensitivity 
to most anticoccidial drugs (Coombs, 1999, Woods et al., 1996) and (vi) 
sporulation of oocysts within the intestine resulting in enterocyte reinvasion and 
prolonged life-threatening infection in immunocompromised patients. On the 
other hand, Cryptosporidium has common biological features with the gregarines 
including a monoxenous life cycle, oocysts with four sporozoites, a usual location 
in the host gastrointestinal tract and extracellular gamonts or trophozoites (Barta 
and Thompson, 2006). The last characteristic was established recently, when 
Hijjawi and colleagues (2002) described for the first time developmental stages 
in the life cycle of C. andersoni and C. parvum (extracellular trophozoites/gamont 
stages), which have similar characteristics to the gregarines. These results have 
subsequently been reproduced and validated in cell culture (Rosales et al., 2005). 
The similarity to the gregarines was further supported by the cross reactivity of 
an anti-Cryptosporidium monoclonal antibody with the sporocysts of the 
gregarine Monocystis species (Bull et al., 1998).  Barta and Thompson (2006) 
compiled molecular and biological evidence for distancing Cryptosporidium 
species from the Coccidia conceptually, biologically and taxonomically.  
 
The taxonomy at the species level of Cryptosporidium has also changed over 
time. Since the first description by Tyzzer of C. muris and C. parvum, 
Cryptosporidium was commonly confused with members of the coccidian genus 
Sarcocystis as they have similar morphological characteristics (thin walled 
oocysts that rupture releasing free sporocysts, each containing four sporozoites) 
(Xiao et al., 2004). This ambiguity was resolved when the criterion of possession 
of unique attachment organelle was used as the key feature to define the family 
“Cryptosporidiidae” and the genus “Cryptosporidium”(Xiao et al., 2004). After 
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the recognition of clear differences between Cryptosporidium and Sarcocystis, 
the erroneous concept of strict host specificity was applied to Cryptosporidium 
spp., which led to the description of several new species. Subsequently, cross-
transmission studies showed that Cryptosporidium isolates from different 
animals can be transmitted from one host species to another and several of the 
proposed new species were synonymised (Xiao et al., 2004). One disadvantage of 
adopting this methodology was the widespread use of the name C. parvum for 
Cryptosporidium parasites from all kinds of mammals including humans. More 
recently, the development of molecular characterization tools helped to clarify 
Cryptosporidium taxonomy and validate the existence of multiple species (Xiao et 
al., 2004). These molecular data, supported by multiple parameters including 
morphology, developmental biology, host specificity and histopathology allowed 
the definition of new species (Morgan-Ryan et al., 2002, Alvarez-Pellitero and 
Sitja-Bobadilla, 2002, Fayer et al., 2001, Lindsay et al., 2000). In fact, the 
suggested criteria for naming of a new Cryptosporidium species are i) 
morphometric measurement of the oocysts, ii) genetic analysis of common loci, 
iii) demonstration of natural and/or experimental host specificity and iv) 
compliance with the rules of the International Commission of the Zoological 
nomenclature (ICZN) (valid taxonomic description and name-bearing type 
established from syntypes (two or more specimens) (Xiao et al., 2004, Egyed et 
al., 2003). The establishment of these tailored species definition criteria for 
Cryptosporidium is important because of the difficulty in fulfilling the classical 
definition of species as groups of interbreeding natural populations 
reproductively isolated from other groups (Mayr, 1942). The evaluation of the 
interbreeding potential is tricky because it is difficult to conduct genetic crossing 
studies in Cryptosporidium, although few studies showed the occurrence of 
intraspecies sexual recombination (Feng et al., 2002, Mallon et al., 2003 b). In 
addition, Cryptosporidium has a large bias toward a clonal population structure, 
as mating normally occurs between siblings (high numbers of genetically similar 
parasites in localized areas) (Awad-El-Kariem, 1999, Gibbons et al., 1998, 
Sulaiman et al., 2001). 
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Xiao and colleagues (2004) reviewed the taxonomy of Cryptosporidium and 
concluded that only 13 Cryptosporidium species are valid and associated with a 
particular host range. These include C. andersoni (cattle), C. baileyi (chicken and 
some other birds), C. canis (dogs), C. felis (cats), C. galli (birds), C. hominis 
(humans), C. meleagridis (birds and humans), C. molnari (fish), C. muris (rodents 
and some other mammals), C. parvum (ruminants and humans), C. wrairi (guinea 
pigs), C. saurophilum (lizards and snakes) and C. serpentis (snakes and lizards). 
Since then, Xiao and Fayer (2008) updated the valid number of species to 18 to 
take into consideration the newly validated and newly discovered 
Cryptosporidium species as shown in Table 1.1.  In addition, the authors 
described 40 Cryptosporidium genotypes, which are genetically distinct 
populations for which there is insufficient biological information to assign to 
species status. The genotypes are usually named after the host they were 
isolated from (such as rabbit genotype, cervine genotype, goose genotype, skunk 
genotype, deer genotype). However, this practice is confusing as the genotype 
may not exclusively infect that animal or even that the named species is the 
major host (Robinson, 2005). As biological and molecular data increase, many of 
these genotypes are expected to be named as valid species. This was the case of 
C. parvum genotype 1 now known as C. hominis, dog genotype called C. canis 
and pig genotype 1 considered C. suis (Morgan-Ryan et al., 2002, Fayer et al., 
2001, Ryan et al., 2004).  
 
1.3 Life cycle 
 
The Cryptosporidium life cycle can be divided into six major developmental 
stages (Current and Garcia, 1991): excystation (the release of infective 
sporozoites), merogony (the asexual multiplication within host cells), 
gametogony (the formation of micro- and macro-gametes), fertilization (the 
union of micro- and macro-gametes), oocyst wall formation (to produce the 
environmentally resistant stage responsible for the transmission of the infection 
from one host to another) and sporogony (the formation of infective 
sporozoites). 
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Cryptosporidium species have a monoxenous life cycle completed within the 
gastrointestinal tract of a single host. During the whole cycle, the different forms 
are confined to the apical surfaces of the intestine epithelial cells (enterocytes). 
The infective forms attach to the apical surfaces by a poorly understood process 
and become internalized within an intracellular but extracytoplasmic 
compartment separated from the cytoplasm by an electron dense layer that 
appears to be predominantly of host origin (Barta and Thompson, 2006). The 
parasite is located within a parasitophorous vacuole, where it is protected from 
the hostile gut environment and is supplied with energy and nutrients by the 
host cell through a feeder organelle, which is unique among apicomplexan 
parasites (Tzipori and Ward 2002). 
 
The life cycle begins with the ingestion of the sporulated oocysts by the 
susceptible host; the oocysts undergo excystation and release four infective 
sporozoites (Figure 1.1). The excystation of the oocysts has been reported to be 
triggered upon ingestion by various factors including reducing conditions, carbon 
dioxide, temperature, pancreatic enzymes and bile salts (O'Donoghue, 1995, 
Robertson et al., 1993, Sundermann et al., 1987, Reduker and Speer, 1985, Fayer 
and Leek, 1984). The excystation allows the emergence of the four infectious 
sporozoites through a suture in the oocyst wall (Reduker et al., 1985). The 
released sporozoites glide over the intestinal cell releasing material from the 
apical complex (Okhuysen and Chappell, 2002). Gliding motility allows the zoites 
to migrate across the surface of host cells and to actively invade them (Wetzel et 
al., 2005). This form of motility is conserved among different apicomplexan 
parasites. C. parvum sporozoites undergo circular and helical gliding movements, 
which are actin-myosin-tubulin dependent mechanisms (Wetzel et al., 2005, 
Chen et al., 2004). During gliding motility, sporozoites deposit trails of proteins, 
which are involved in attachment and invasion of host cells (Wanyiri and Ward, 
2006). 
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Figure 1.1: Schematic representation of Cryptosporidium life cycle stages.  
(a) The oocyst excysts in the lumen of the intestine, releasing the infective sporozoites. (b) The 
sporozoite attaches to the surface of the enterocyte. (c) The sporozoite penetrates into host cells 
and develops into trophozoites within a parasitophorous vacuole. (d) and (e) The trophozoites 
undergo merogony to form merozoites. (f) After being released from type I meront, the invasive 
merozoites enter adjacent host cells to form additional type I meronts (recycling of type I 
meronts) or to form type II meronts. (g) and (h) Type II meronts enter host cells to form the 
sexual stages microgamonts and macrogamonts. (i) The zygote, product of fertilization of the 
macrogamont by the microgametes (released from microgamont). (j) The majority (80%) of the 
zygotes develop into environmentally resistant, thick-walled oocysts. (k) The thick walled oocysts 
undergo sporogony to form sporulated oocysts containing four sporozoites, which will be 
released in the faeces and allow transmission of the infection. (l) A smaller proportion (20%) of 
the zygotes have a unit membrane surrounding the four sporozoites, these are the thin-walled 
oocysts, which are the auto-infective forms that can maintain the parasites in the host without 
repeated exposure. 
(Reproduced from Current and Garcia, 1991 with modifications) 
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In addition, Cryptosporidium sporozoites possess an apical complex composed of 
micronemes, a single rhoptry and dense granules (Tetley et al., 1998). These 
secretory organelles are also present in closely related parasites such as 
Toxoplasma, Plasmodium and Eimeria and are involved in host-cell attachment 
and invasion (Boulter-Bitzer et al., 2007, Okhuysen and Chappell, 2002). The 
pellicle mediates movement and attachment to the host cell membrane via 
molecules exposed on the surface that drive movement of the zoite, while the 
rhoptries and micronemes enable the zoite to adhere to and invade the cell, 
inducing the cell membrane to enclose the parasite in the parasitophorous 
vacuole (Boulter-Bitzer et al., 2007, Bonnin et al., 1993, Petersen et al., 1992b, 
Tomley and Soldati, 2001). 
 
Each sporozoite develops into a spherical trophozoite, which undergoes 
merogony and forms a type I meront containing eight merozoites (O'Donoghue, 
1995). These merozoites are released and attach again to the surface of an 
epithelial cell where they undergo merogony once more and either form a 
further type I meront or a type II meront (Figure 1.1). A type II meront contains 
four merozoites. These merozoites, when released, attach again to the 
epithelium but instead of developing into further meronts, they initiate 
gametogony (Robinson, 2005). Individual merozoites produce either 
microgamonts or macrogamonts (Smith and Rose, 1998, Göbel and Brändler, 
1982). Each microgamont undertakes nuclear division and differentiates to form 
up to 16 microgametes, which when released from the parasitophorous vacuole, 
locate and fertilise a unicellular macrogametocyte that has developed from a 
macrogamont (Figure 1.1). The product of fertilization, the zygote, undergoes 
two asexual cycles of sporogony to produce an oocyst with either a thick wall or 
a thin wall, containing four sporozoites (Current and Reese, 1986).  
 
The thick-walled oocysts are released into the lumen of the intestine and 
excreted from the host in the faeces and are immediately infective allowing the 
spread of the infection to other susceptible hosts (Smith and Rose, 1998). In 
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addition, unlike other coccidian parasites, Cryptosporidium is able to autoinfect 
the same host. The auto-infection occurs through the thin-walled oocysts, which 
excyst once separated from the epithelium and the cycle starts again (Siński and 
Behnke, 2004, Current and Reese, 1986). The autoinfection and the recycling of 
type I meronts provide an explanation for the persistent chronic infection and 
the low infective dose (DuPont et al., 1995, Okhuysen et al., 1999, Jokipii and 
Jokipii, 1986).  
 
1.4 Cryptosporidium culture 
 
Attempts to culture Cryptosporidium in vitro have not been particularly 
successful, often resulting in an incomplete cycle or only short term maintenance 
of the infection. However, there have been reports of successful in vitro culture 
of Cryptosporidium. Gut and colleagues (1991) reported the culture of C. parvum 
and the observation of the different life stages (trophozoites, meronts, 
microgametocytes, and macrogametocytes) in Madin-Darby canine kidney 
(MDCK) cells. C. parvum culture was also successful using RL95-2 (human 
endometrial carcinoma) cell line (Rasmussen et al., 1993), HCT-8 (human 
ileocecal colorectal adenocarcinoma) cells (Upton et al., 1995, Meloni and 
Thompson, 1996), BFTE (bovine fallopian tube epithelial) cells (Yang et al., 1996), 
Caco-2 (human colorectal adenocarcinoma) cell line (Arrowood et al., 1994), 
HT29.74 (human enterocyte) cell line (Elliot et al., 1997) and BS-C-1 (African 
green monkey kidney) cell line (Deng and Cliver, 1998). The cell lines used to 
culture Cryptosporidium were reviewed by Carey and colleagues (2004). Upton 
and colleagues (1994) compared the efficiency of 11 cell lines to culture 
Cryptosporidium and showed that HCT-8 supported a high number of parasite 
developmental stages. This cell line was considered an accurate alternative to 
animal infectivity models (Rochelle et al., 2002). Furthermore, the use of surface-
sterilized oocysts (by pre-treatment with sodium hypochlorite) seems to improve 
the efficiency of cell monolayers infection (Upton et al., 2004 b). Hijjawi and 
colleagues (2001) reported for the first time the long-term maintenance of the 
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life cycle stages of C. hominis and C. parvum in HCT-8 cell line. In addition, 
C. andersoni was also successfully cultured in HCT-8 cells (Hijjawi et al., 2002).  
 
Later, Hijjawi and colleagues (2004) reported the continuous development of 
C. parvum in cell-free medium through all life cycle stages. These results suggest 
that Cryptosporidium may not be an obligate intracellular parasite as previously 
stated. The implication of these findings are that the greatly reduced biochemical 
repertoire retained by Cryptosporidium species after the loss of both a functional 
mitochondrion and an apicoplast only requires a nutrient-rich environment to 
salvage its metabolic needs (Hijjawi et al., 2004). However, attempts to 
reproduce cell-free culture of Cryptosporidium were unsuccessful (Girouard et 
al., 2006, Karanis et al., 2008, Petry et al., 2009). In addition, Woods and Upton 
(2007) reported that the developmental stages described by Hijjawi and 
colleagues (2004) correspond to budding yeasts, host cells and fungal conidia. 
Therefore, the ability of Cryptosporidium to develop extracellularly is still 
controversial (Xiao and Fayer, 2008). Since then, the same group showed that 
the extracellular developmental stages are indeed specific of Cryptosporidium 
using antibody staining (anti-sporozoite and anti-oocyst wall antibodies) and a 
Cryptosporidium specific rRNA oligonucleotide probe for fluorescent in-situ 
hybridization (FISH) in combination with non-specific dyes (Boxell et al., 2008). 
Hijjawi (2010) reviewed the factors that can influence the success of 
Cryptosporidium cell-free culture (excystation, pre-treatment of oocysts, physical 
and chemical conditions, host cell type and maturity and culture media 
supplementation and formulation) and proposed improved methods for 
visualizing life cycle stages in cell-free culture. 
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1.5 Epidemiology 
 
Cryptosporidiosis is a common cause of gastroenteritis worldwide. In England 
and Wales, an average of 4,500 laboratory identified cases is reported each year 
(1998-2008) according to the Health Protection Agency (HPA) (www.hpa.org.uk). 
The two Cryptosporidium species of public health importance are C. hominis and 
C. parvum. C. hominis is generally restricted to human infections and C. parvum 
is zoonotic and mostly associated with human and ruminant infections 
(Roberston and Gjerde, 2007). A long-term survey at the national level 
conducted by Chalmers and colleagues (2009 c) showed that the majority of 
human infective Cryptosporidium species were either C. parvum or C. hominis. 
Cryptosporidium is recognized mainly as a waterborne parasite, Karanis and 
colleagues (2007) reviewed over 150 worldwide waterborne outbreaks.  
 
The epidemiology of Cryptosporidium has mainly been investigated at the genus 
level (Robertson et al., 2002, Roy et al., 2004, Horman et al., 2004, Becher et al., 
2004, Wallis et al., 1996, Okafor et al., 1996, Nimri and Batchoun, 1994) and no 
attempt was made to distinguish between Cryptosporidium species or genotypes 
in case control studies until Hunter and colleagues (2004 b) showed different risk 
factors for C. hominis and C. parvum. Subsequently, several epidemiological 
investigations with speciation (Blanco et al., 2009, Mueller-Doblies et al., 2008, 
Leoni et al., 2006) and even subtyping (Brook et al., 2009, Xiao et al., 2009, 
Geurden et al., 2009, Zintl et al., 2009, Chalmers et al., 2008, Hunter et al., 2007) 
have been reported. Identification of isolates at the species level has improved 
our understanding of the epidemiology and risk factors associated with these 
two Cryptosporidium species and has been valuable in outbreak investigations 
(Chalmers, 2008 b). In recent years, the epidemiology of Cryptosporidium has 
been extensively reviewed (Xiao, 2010, Yoder and Beach, 2010, Xiao and Fayer, 
2008, Tzipori and Widmer, 2008, Xiao and Feng, 2008, Hunter and Thompson, 
2005, Caccio, 2005, Ramirez et al., 2004, Hunter and Nichols, 2002, Fayer et al., 
2000, Meinhardt et al., 1996). 
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1.5.1 Geographical and seasonal distribution 
 
Epidemiologic surveys indicate that human Cryptosporidium infection is 
distributed worldwide in urban and rural populations (Meinhardt et al., 1996). 
Geographic differences exist in the disease burdens attributable to C. hominis 
and C. parvum. C. hominis has been shown to be more prevalent in North and 
South America, Australia and Africa suggesting that the transmission cycle of the 
anthroponotic parasite is of greatest importance in these regions (Kosek et al., 
2001). However, C. parvum is the predominant species in UK, Northern Ireland, 
France, Switzerland, Portugal, Slovenia, Czech Republic and New Zealand (Xiao 
and Feng, 2008, Boulter-Bitzer et al., 2007, Ong et al., 1999).  
 
Seasonal differences in the distribution of C. parvum and C. hominis have also 
been reported. In the UK and New Zealand, the spring increase in the reported 
cryptosporidiosis cases is mostly due to C. parvum whereas the autumn increase 
is largely due to C. hominis (Leoni et al., 2006, Learmonth et al., 2004, Hunter et 
al., 2004 b, McLauchlin et al., 2000). This suggests that seasonal differences 
between the specific transmission routes might exist: it was speculated that the 
increase in C. parvum in the spring was due to lambing, calving and farm runoff 
from spring rains and the autumn C. hominis peak was likely the result of 
increased recreational water activities and international travel during late 
summer and early autumn (Xiao and Feng, 2008, Goh et al., 2004, Hunter et al., 
2004 b).  
 
1.5.2 Transmission 
 
Several direct and indirect transmission routes of Cryptosporidium have been 
identified. Direct transmission occurs by the faecal-oral route through infected 
subjects, this includes animal to animal, animal to human (zoonotic) and human 
to human (anthroponotic) transmission (Xiao and Feng, 2008, Hunter and 
Thompson, 2005, Casemore et al., 1985). Human to human contamination is 
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well-described, particularly in secondary cases, in outbreak settings (Glaberman 
et al., 2002) and in day care centres and hospitals (Guerrant, 1997). The 
epidemiological evidence for zoonotic transmission of cryptosporidiosis is from 
studies associating cattle with outbreaks in veterinary students and animal 
researchers, who had contacts with infected young calves and in children visiting 
farms (Xiao and Feng, 2008, Kiang et al., 2006, Smith et al., 2004, Preiser et al., 
2003). Indirect transmission involves contact with Cryptosporidium faecally 
contaminated material, including water, food, clothes and footwear. Indirect 
transmission also occurs through environmental contamination, usually involving 
the release of untreated sewage by accident or as overflow following heavy rain 
events (Jiang et al., 2005, Xiao et al., 2000, Hayes et al., 1989). Another mode of 
transmission via inhalation of oocysts was reported in immunocompromised 
patients and in children (Egger et al., 1990, Harari et al., 1986, Ma et al., 1984) 
and was supported by experimental intranasal infection of piglets (Tzipori and 
Ward, 2002). The symptoms associated with this route are respiratory 
(laryngotracheitis) and could be accompanied by mild diarrhoea. 
 
The oocyst is responsible for the dissemination of the infection. It is of small size 
(from 3.8 by 4.6 μm to 6.3 by 8.4 μm, depending on species) of spheroid or 
ellipsoid shape and is notoriously robust (Roberston and Gjerde 2007). Oocysts 
are excreted into the environment by the infected hosts and remain viable for a 
long time in moist and relatively cold environments (six months between 0 and 
20°C, three months at 25-30°C, two months at -5°C, one week at 35°C, 8h at         
-20°C, while freezing below -20°C causes immediate killing of oocysts (Fayer et 
al., 2000). Relatively little is presently known about the chemical composition of 
oocysts and how this composition is associated with survival ability (Millar et al., 
2002). The infective dose is low; Dupont et al. (1995) reported an ID50 of 132 
oocysts (C. parvum Iowa) in healthy volunteers. Another human volunteer study 
using three Cryptosporidium strains showed the ID50 is variable between strains 
and the reported ID50 values were 9, 87 and 1042 for TAMU, Iowa and UCP 
strains, respectively (Okhuysen et al., 1999).  
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Infected hosts act as reservoirs, allowing the perpetuation of the infection. 
Human and dairy effluents are probably the most important sources of 
environment and surface water contamination. The duration of oocyst shedding 
has been documented in humans and varies from 6.9 days to two months after 
the cessation of symptoms which normally last between 2-26 days in 
immunocompetent individuals (Jokipii and Jokipii, 1986). It is now recognised 
that the infectious dose as well as the duration and severity of illness are 
influenced by several factors including the species and strain of the parasite, as 
well as the age and immune status of the host (Robinson, 2005). 
 
Oocysts are incompletely retained by sand filtration and are highly resistant to 
conventional water disinfection used in the water industry (Fayer et al. 1998). In 
addition, it has been demonstrated that the oocysts maintain their infectivity for 
several months in both salt and fresh water. The vulnerability of the water supply 
to Cryptosporidium oocysts has heightened biodefense concerns (Striepen and 
Kissinger, 2004). Cryptosporidium is now considered one of the most ubiquitous 
and difficult to control agent of waterborne disease. Therefore, and due to the 
relative ease of intentional contamination of water supplies, Cryptosporidium has 
been listed as a Category B priority pathogen for Bioterrorism by                            
the Centre for Disease Control and Prevention (CDC) and                                                        
National Institutes of Health (NIH) in the United States 
(http://www.bt.cdc.gov/agent/agentlist.asp#categorybdiseases). 
 
Cryptosporidium has been incriminated in many waterborne outbreaks. Smith 
and Rose (1998) documented 19 outbreaks in UK and USA between 1984 and 
1996, affecting an estimated number of 427,100 individuals. Karanis and 
colleagues (2007) updated the number of waterborne cryptosporidiosis 
outbreaks and highlighted that Cryptosporidium is responsible for 50% of 
waterborne outbreaks associated with protozoan parasites. Cryptosporidium 
oocysts also survive for long periods on different foodstuffs. Several studies 
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(Smith et al., 2007, Millar et al., 2002) highlighted the importance of foodborne 
cryptosporidiosis and documented related outbreaks.  
 
1.5.3 Cryptosporidium risk factors 
 
As discussed above, most of the data on transmission pathways for 
Cryptosporidium come from reports of outbreaks, the majority of which are 
waterborne (Karanis et al., 2007). However, outbreaks represent only a small 
proportion of recorded cryptosporidiosis cases. The transmission routes for 
endemic diseases may or may not be the same as in outbreak settings. This has 
been evaluated in case control studies, the majority of which were reviewed by 
Yoder and Beach (2010) and Hunter and Thompson (2005). The key risk factors 
are ingestion of contaminated drinking or recreational water, contact with 
infected persons or animals, travel to disease endemic areas, contact with 
children < 6 years old (especially but not exclusively with diarrhoea) as shown in 
Table 1.2. These investigations also showed a consistent negative association 
with eating raw vegetables (Hunter et al., 2004, Roy et al., 2004, Robertson et al., 
2002). The authors suggested that repeated exposure to small numbers of 
Cryptosporidium oocysts on raw vegetables provide a protective immunity. This 
hypothesis was supported by a study by Frost and colleagues (2005), who 
reported that higher levels of anti-Cryptosporidium antibodies were associated 
with reduced reporting of diarrhoea in a subsequent diary-based study. The 
authors suggested that the lower levels of illness in people with increased 
antibodies may be due to enhanced immunity from repeated exposure to 
oocysts in drinking water.  
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Reference Location No. of 
cases 
No. of 
controls 
Significant  risk factors Odds ratios 
(95% CI) 
Robertson et al., 
2002 
Melbourne 201 795 Eating uncooked carrots 
Swimming in public pool 
Children<6 at home with diarrhoea 
Persons>5 at home with diarrhoea 
Animal contact in home 
Calf contact away from home 
Drink unboiled water from river, lake 
or dam 
0.6 (0.4–0.9) 
2.7 (1.9–3.8) 
7.4 (4.0–13.8) 
1.8 (1.1–2.9) 
0.6 (0.4–0.8) 
2.9 (1.5–5.7) 
1.5 (0.8–2.7) 
Robertson et al., 
2002 
Adelaide 134 536 Eating uncooked carrots 
Swimming in public pool 
Children<6 at home with diarrhoea 
Persons>5 at home with diarrhoea 
Animal contact in home 
Calf contact away from home 
Drink unboiled water from river, lake 
or dam 
0.6 (0.4–0.9) 
1.2 (0.8–1.9) 
8.6 (4.8–15.6) 
3.7 (2.2–6.2) 
0.6 (0.4–0.9) 
5.1 (1.5–17.3) 
3.1 (1.5–6.5) 
Roy et al., 2004 USA 282 490 Contact with persons (>2 to 11 yr 
old) with diarrhoea 
Contact with calves or cows 
International travel 
Freshwater swimming 
Eating raw vegetables 
Chronic medical condition 
3.0 (1.5–6.2) 
 
3.5 (1.8–6.8) 
7.7 (2.7–22.0) 
1.9 (1.0–3.5) 
0.5 (0.3–0.7) 
2.2 (1.2–4.0) 
Hunter et al., 2004 b Wales and 
England 
427 427 Travel outside of UK 
Case contact 
Touch cattle 
Toileting child<5 years 
No. of glasses unboiled water 
Eat ice cream 
Eat raw vegetables 
Eat tomatoes 
5.7 (2.9–11.2) 
4.6 (2.4–8.7) 
3.9 (1.4–10.0) 
1.9 (1.1–3.2) 
1.1 (1.0–1.3) 
0.5 (0.3–0.7) 
0.5 (0.3–0.8) 
0.6 (0.4–1.0) 
Goh et al., 2004 Cumbria, 
England 
152 466 Drinking cold unboiled tap water 
Visiting farms 
1.4 (1.14-1.71) 
2.02 (1.04-3.9) 
Pintar et al., 2009 Ontario, 
Canada 
36 803 Swimming in a lake or a river 
Drinking municipal water 
Having a family member with 
diarrhoeal illness  
2.9 (1.2-7.4) 
2.4 (1.04-5.7) 
2.9 (1.3-6.4) 
Valderrama et al., 
2009 
Colorado, 
USA 
47 92 Swallowing untreated water from 
lake, river or stream 
Exposure to recreational water 
Contact with child or diapers 
8.0 (1.3-48.1) 
 
4.6 (1.4-14.6) 
3.8 (1.5-9.6)  
 
Table 1.2: Cryptosporidium risk factors as determined by case control studies in 
developed nations reported since the early 1990s. Table compiled from data 
obtained from the following publications: Hunter and Thompson, 2005, Pintar et 
al., 2009, Valderrama et al., 2009, Goh et al., 2004. 
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In immunocompromised subjects, mainly those with HIV infection, several 
studies investigated the specific risk factors for this high risk group and found 
that drinking untreated tap water, exposure to pets and animals, unsafe 
homosexual activity and use of public toilets are associated with Cryptosporidium 
infection (Dwivedi et al., 2007, Colford et al., 2005, Hellard et al., 2003). 
 
As has already been discussed, C. hominis and C. parvum have different host 
range and transmission cycles, and so epidemiological studies that looked at risk 
factors for both species combined, would emphasise risk factors common to 
both species and downplay risk factors unique to one or the other species 
(Hunter and Thompson, 2005). Therefore, a case control study discriminating 
C. hominis from C. parvum was performed in immunocompetent subjects by 
Hunter and colleagues (2004 b) and allowed the identification of species-specific 
risk factors. The major risk factor for C. parvum was touching or handling farm 
animals, whilst for C. hominis the main risk factors were travel outside the UK 
and nappy changing. 
 
1.6 Clinical symptoms 
 
Cryptosporidium is recognized worldwide as a common cause of infectious 
gastroenteritis, which characteristically results in watery diarrhoea that may 
sometimes be profuse and prolonged (Meinhardt et al., 1996, Current and 
Garcia, 1991). Diarrhoea is generally the symptom leading to Cryptosporidium 
diagnosis. Other less common clinical features include abdominal pain, nausea, 
vomiting and mild fever. Occasionally, non-specific symptoms such as myalgia, 
weakness, malaise, headache and anorexia occur (Current and Garcia, 1991). The 
severity, persistence and ultimate outcome of the infection are typically 
dependent on a variety of parasite characteristics and host factors. Host factors 
include both the immune status and frequency of exposure of the infected 
individual, however, little is known regarding the pathogenic characteristics of 
the parasite (Meinhardt et al., 1996). The severity of a Cryptosporidium infection 
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can vary from asymptomatic shedding of the oocysts to a severe and                  
life-threatening disease. Immunocompetent individuals experience a short-term 
illness with complete spontaneous recovery. However, in immunocompromised 
patients, cryptosporidiosis symptoms are persistent and may become life-
threatening (Chen et al., 2002, O'Donoghue, 1995). Thus, only 1% of the 
immunocompetent patients require hospitalization, with very little risk of 
mortality. In immunocompromised patients, cryptosporidiosis is associated with 
a high rate of mortality (50%) (Junarek, 1995). In addition, Cryptosporidium 
infection causes atypical manifestations in immunocompromised patients, such 
as atypical gastrointestinal disease, biliary tract disease, respiratory tract disease 
and pancreatitis (Hunter and Nichols, 2002). Cryptosporidium species are 
significant sources of gastrointestinal infection particularly in developing nations, 
where cryptosporidiosis is common in children and it is frequently associated 
with persistent diarrhoea, malnutrition and stunted growth (Guerrant, 1997).  
  
C. hominis and C. parvum account for more than 90% of the human cases of 
cryptosporidiosis (Cacciò, 2005). A retrospective study conducted by Hunter and 
colleagues (2004) showed differences between infections caused by C. hominis 
and C. parvum in immunocompetent subjects. In fact, C. hominis infection was 
associated with non-intestinal sequelae (joint pain, eye pain, recurrent headache 
and fatigue), which were not reported in people infected with C. parvum. This 
aspect further highlights the usefulness of speciation in Cryptosporidium 
diagnosis. 
 
1.7 Treatment 
 
The major health problem associated with cryptosporidiosis, mainly in 
immunocompromised patients, has been the lack of effective cure. Despite many 
attempts to identify antigens that will stimulate a protective immune response, 
no immunotherapeutics or vaccines are presently approved for prevention or 
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treatment of cryptosporidiosis in animals or humans (Sunnotel et al., 2006, 
Fayer, 2004, Tzipori, 1998, Tzipori and Griffiths, 1998).  
 
Many compounds were screened for anti-cryptosporidial activity and the 
majority were ineffective. Among the most commonly used treatments against 
cryptosporidiosis are paramomycin, azithromycin and nitazoxanide (Gargala, 
2008). However, they have varying success, often with promising results in 
immunocompetent but poor efficacy in impaired immune system patients 
(Amadi et al., 2009, Amadi et al., 2002, Hewitt et al., 2000). Nitazoxanide 
significantly shortened the duration of diarrhoea and decreased mortality in 
adults and in malnourished children (Gargala, 2008, Cohen 2005). However, it is 
not effective without an appropriate immune response. Therefore, in AIDS 
patients, combination therapy restoring immunity along with antimicrobial 
treatment of Cryptosporidium infection is necessary to control the infection 
(Gargala, 2008, Smith and Corcoran, 2004). Since then, highly active 
antiretroviral therapy (HAART) has been used to successfully cure cryptosporidia 
and microsporidia in HIV patients (Miao et al., 2000). This success was related to 
increasing the patient’s immune system by suppressing the virus and boosting 
the levels of CD4 lymphocytes (Schmidt et al., 2001) and to the presence of 
protease inhibitors thought to have a direct effect on cryptosporidial infection 
(Mele et al., 2003). Therefore, HAART is currently used for therapeutic and 
prophylactic treatment of cryptosporidiosis in persons at risk, especially AIDS 
patients (Sunnotel et al., 2006, Willemot and Klein, 2004). However, treatment of 
underlying immunosuppression with antiretrovirals is not effective in 
immunocompromised patients without HIV (Abubakar et al., 2007). Therefore, 
discovering an effective treatment for cryptosporidiosis is still highly desirable. 
To promote the development of new therapeutic and prophylactic treatment, 
further research is required to understand parasite metabolism, the invasion 
process and host-parasite interactions (Smith et al. 2005). 
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1.8 Prevention and control 
 
Preventative measures are the most effective methods to control 
cryptosporidiosis in the absence of effective treatment. Measures such as limited 
human access to the countryside, containment of animals and restriction of 
livestock movement for trade or to pastures, which operated during the foot and 
mouth disease (FMD) epidemic in the UK in 2001, correlated with a marked 
decline (36.5%) in human cases of cryptosporidiosis caused by C. parvum 
(Smerdon et al., 2003, Hunter et al., 2003). 
 
Ramirez and colleagues (2004) suggested measures to decrease the spread of 
the oocysts in the environment and to prevent water supply contamination 
including good hygiene, good cattle husbandry, diagnosis of cryptosporidiosis in 
domestic animals and household decontamination. These measures are relevant 
to C. parvum infection. Awareness of specific risk factors and taking relevant 
actions such as hand washing after nappy changing should likewise reduce 
C. hominis infection (Hunter et al., 2004 b). For foodborne cryptosporidiosis, 
Millar and colleagues (2002) highlighted the importance of the ingestion of 
contaminated water and foodstuffs as a transmission route and issued 
recommendations to the food industry to reduce the likelihood of contamination 
in the human food chain. In addition, during the high prevalence season (as 
described in 15.3), water companies should reinforce the monitoring of water 
sources to ensure early detection of oocysts. In addition, a mobilization of 
medical staff and increased awareness of both medical staff and general public is 
likely to assist the prevention and control of cryptosporidiosis. 
 
1.9 Detection 
 
The detection of Cryptosporidium is important, not only for identifying the cause 
of disease but also in epidemiological surveys, disease surveillance and drinking 
water monitoring (Robinson, 2005). Several microscopic, molecular and 
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immunological methods have been developed to detect Cryptosporidium from 
different sources such as faeces, water, food and environmental samples. 
Cryptosporidium diagnosis is based upon oocysts visualization or detection of 
Cryptosporidium DNA or antigens.  
 
1.9.1 Conventional methods 
 
The conventional detection methods involve the microscopic identification of 
oocysts of 4-6 μm x 5-6 μm (Robinson, 2005, Fayer et al., 2000). This method is 
widely used due to its relatively low cost. Differential staining using the modified 
Ziehl-Neelsen acid fast technique (Chalmers et al., 2002, Nimri and Batchoun, 
1994, Garcia et al., 1983, Henriksen and Pohlenz, 1981) is the most commonly 
used technique to stain Cryptosporidium oocysts. In addition, other staining 
methods were also used such as Giemsa (Fischer, 1982), Auramine (Ratnam et 
al., 1985), Kinyoun (Ma and Soave, 1983) and safranin-methylene blue stain 
(Baxby et al., 1984). Staining techniques have poor specificity due to the 
presence of oocyst-like structures in faecal debris and because they stain other 
protozoan parasites such as Isospora and Cyclospora (Sunnotel et al., 2006). 
Thus, immunological and molecular techniques have replaced staining for 
diagnostic of cryptosporidiosis. 
 
1.9.2 Immunological techniques 
 
Immunological and molecular techniques usually require further purification of 
oocysts using density gradient (Clark, 1999), saturated-salt solution 
centrifugation (Elwin et al., 2001) or immunomagnetic separation (IMS) (Rochelle 
et al., 1999, Bukhari et al., 1998, Deng et al., 1997). 
 
The Immunofluorescence assay (IFA) is widely used for the detection of 
Cryptosporidium oocysts due to its high sensitivity and specificity (Deng and 
Cliver, 1998, Xiao et al., 1993, Rusnak et al., 1989, Garcia et al., 1987, Stibbs and 
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Ongerth, 1986). IFA is based on the microscopic screening after staining with 
monoclonal antibodies tagged with fluorescein isothiocyanate (FITC) and several 
commercial IFA kits for Cryptosporidium detection are available. 
Immunofluorescence stains are often used in combination with a DNA strain 
mainly 4’,6-diamidino-2- phenylindole (DAPI) to allow the identification of up to 
four sporozoites in the oocyst (Robinson, 2005). Internal structures can also be 
observed using differential interference contrast (DIC) microscopy. Several 
studies have compared staining protocols for the detection of Cryptosporidium 
oocysts (Quilez et al., 1996, Alles et al., 1995, MacPherson and McQueen, 1993, 
Mtambo et al., 1992, Garcia et al., 1992, Rusnak et al., 1989, Arrowood and 
Sterling, 1989, Garcia et al., 1987, Stibbs and Ongerth, 1986, Baxby et al., 1984, 
Garcia et al., 1983), the majority of which demonstrated that 
immunofluorescence staining techniques have not only superior sensitivity, 
especially when small number of oocysts were present in the samples, but also 
improved specificity due to the use of Cryptosporidium specific antibodies. 
 
In addition, Enzyme immunoassays (EIA) have been used to detect 
Cryptosporidium oocysts. The first EIA developed for the detection of 
Cryptosporidium in faecal smears were described in 1990 (Robert et al., 1990, 
Ungar, 1990, Anusz et al., 1990). The threshold of detection of these techniques 
was >10
6
 and 3x10
5
 oocysts per ml, so their sensitivity was much lower than IFA 
(10
3
 oocysts per ml) (Marks et al., 2004, Garcia and Shimizu, 1997). Since these 
first generation assays, several EIA kits were developed and are commercially 
available. Ignatius and colleagues (1997) compared three EIA kits and showed 
that they exhibit lower sensitivities than the routinely used microscopic 
methods.  
 
1.9.3 Molecular detection techniques 
 
Several molecular methods have been developed for the detection of 
Cryptosporidium. The majority of these methods involve the amplification of 
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Cryptosporidium nucleic acid, usually by polymerase chain reaction (PCR) (Bouzid 
et al., 2008). PCR-based methods can often detect much lower parasite numbers 
than other detection techniques. Single oocyst detection has been reported by 
several authors and for different PCR systems as reviewed by Wiedenmann and 
colleagues (1998). In addition to the high sensitivity, the use of genus or species-
specific primers has increased the assay specificity. Due to this high sensitivity 
and specificity, PCR has been extensively used for Cryptosporidium detection 
(Clark, 1999, Fischer et al., 1998, Fayer et al., 2000). Several genetic targets were 
used, the most popular targets include COWP (Cryptosporidium oocyst wall 
protein), HSP70 (Heat shock protein 70), SSU rRNA (Small subunit rRNA), ITS1-2 
(Internal spacer 1), 18S rRNA (18S ribosomal RNA), GP60 (Glycoprotein 60), 
Trap1 and 2 (Thrombospondin related adhesive protein of Cryptosporidium 1 and 
2) and DHFR (dihydrofolate reductase) genes. The different PCR protocols used 
have been widely reviewed (Sunnotel et al., 2006, Carey et al., 2004, Cacciò, 
2005, Chappell and Okhuysen, 2002, Morgan and Thompson, 1998, Quintero-
Betancourt  et al., 2002). One major limitation of PCR is its susceptibility to 
inhibition by a variety of substances, which can be present not only in stool 
samples but also in environmental materials and food (Wiedenmann et al., 
1998). These inhibitors can be removed using sucrose flotation, Percoll density 
gradient centrifugation, fluorescence activated cell sorting (FACS) and 
immunomagnetic separation (IMS) followed by DNA or RNA extraction methods 
(Wiedenmann et al., 1998). 
 
To increase the PCR specificity and sensitivity, several PCR variants have been 
developed such as nested PCR (Kostrzynska et al., 1999, Balatbat et al., 1996, Zhu 
et al., 1998, Sturbaum et al., 2001) and real-time PCR assays (Higgins et al., 2001, 
MacDonald et al., 2002, Limor et al., 2002, Fontaine and Guillot, 2002) for 
oocysts detection in water (including sewage) with a sensitivity as low as one 
oocyst (Guy et al., 2003).  
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1.9.4 Oocysts viability assessment 
 
For an improved assessment of the human risk related to acquiring 
cryptosporidiosis from detected oocysts, viability techniques have been 
developed aiming to differentiate between viable and non viable oocysts in 
various sample types (Sunnotel et al., 2006, Quintero-Betancourt et al., 2002, 
Robertson and Gjerde, 2007). These methods include the inclusion or exclusion 
of vital dyes by the oocysts, such as 4’-6-diamidino-2-phenylindole (DAPI) and 
propidium iodide (PI) (Schupp and Erlandsen, 1987). Sporozoite nuclei, which 
take up DAPI but fail to stain with PI, are viable, while nuclear material that 
stains with both fluorochromes is not viable. Other nucleic acid stains (SYTO-9, 
hexidium) were also used to access oocyst viability (Belosevic et al., 1997). 
Another method to assess oocyst viability is the in vitro excystation method 
(Campbell et al., 1992). Nucleic acid staining and in vitro excystation methods are 
used in many laboratories and have similar performances, but they tend to 
overestimate oocyst viability (Black et al., 1996). In addition, RT-PCR has been 
used to assess oocyst viability by reverse transcription of mRNA targeting several 
markers (heat shock protein, β-tubulin, amyloglucosidase) (Stinear et al., 1996, 
Widmer et al., 1999, Jenkins et al., 2000). Other methods allowing viability 
studies are cell culture (Slifko et al., 1997, Rochelle et al., 1997, Di Giovanni et al., 
1999), mouse infection (Korich et al., 1990) and fluorescent in situ hybridization 
(FISH) (Vesey et al., 1998). Among the methods described, animal infectivity and 
cell culture are the most reliable; animal infectivity being the gold-standard and 
cell culture frequently considered as providing equivalent results (Robertson and 
Gjerde, 2007).  
 
It is worth bearing in mind that the presence of oocysts in the water supply, 
whether alive or dead, still represents an undeniable risk of human infection to 
the recipient community. In addition, whenever Cryptosporidium oocysts are 
detected, an investigation of the source and means of water contamination 
should be carried out to prevent future contamination of the water supply.  
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1.10 Molecular characterization of Cryptosporidium species 
 
As discussed above, the detection of Cryptosporidium is important for diagnosis, 
epidemiological surveys, disease surveillance and drinking water monitoring. The 
identification of Cryptosporidium isolates at the species level enabled an 
improved understanding of the public health importance and revealed 
differences in the transmission and epidemiology of human infective 
Cryptosporidium species (Xiao and Ryan, 2004). In addition, the characterization 
of Cryptosporidium isolates to the subtype level is desirable as it provides 
information about the population structure and the pathogenicity of isolates and 
allows tracking of contamination sources during outbreaks (Chalmers et al., 
2008, Hunter et al., 2007).  
 
1.10.1 Genotyping 
 
The vast majority of the molecular methods currently used to differentiate 
between Cryptosporidium species and/or genotypes are based on PCR, followed 
by Restriction Fragment Length Polymorphism (RFLP) (Jiang and Xiao, 2003). 
PCR-RFLP of the COWP gene differentiates C. parvum, C hominis and C. wrairi 
(Spano et al., 1997), PCR-RFLP of DHFR gene distinguishes C. parvum and 
C. hominis (Gibbons et al., 1998) and PCR-RFLP of the SSU rRNA discriminates 
C. parvum, C. muris, and C. baileyi (Leng et al., 1996). PCR-RFLP is a popular 
genotyping technique due to the ease of use in modestly equipped laboratories. 
However, it can be difficult to interpret PCR-RFLP results when the isolate gives 
an unusual pattern. Sulaiman and colleagues (1999) reviewed the sensitivity and 
specificity of 11 PCR-RFLP techniques for Cryptosporidium genotyping. The 
genotyping techniques targeted SSU rRNA (Awad-El-Kariem et al., 1994, Leng et 
al., 1996, Xiao et al., 1999), ITS-1 (Carraway et al., 1996), COWP (Spano et al., 
1997), DHFR (Gibbons et al., 1998), Poly-T (Carraway et al., 1997), TRAP-C1 
(Spano et al., 1998), TRAP-C2 (Sulaiman et al., 1998) and two undefined genomic 
regions (Bonnin et al., 1996, Morgan et al., 1997). PCR-RFLP was used to test 
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DNA of C. parvum, C. hominis, C. muris, and C. serpentis. The authors reported 
that SSU rRNA and DHFR genes are the most accurate targets for 
Cryptosporidium genotyping (Sulaiman et al., 1999).  
 
Jiang and Xiao (2003) compared the performance of ten commonly used 
genotyping techniques for the detection and differentiation of seven human-
pathogenic Cryptosporidium spp. (C. hominis, C. parvum, C. meleagridis, C. felis, 
C. canis, C. muris and Cryptosporidium pig genotype I). The evaluated methods 
were based on the amplification and RFLP and/or sequencing of the following 
genes: COWP (Pedraza-Diaz et al., 2001, Homan et al., 1999), HSP70 (Gobet and 
Toze, 2001), TRAP-C1 (Spano et al., 1998), TRAP-C2 (Elwin et al., 2001), DHFR 
(Gibbons et al., 1998), SSU rRNA (Sturbaum et al.,2001, Ward et al., 2002, Xiao et 
al., 2001 b) and an undefined genomic region (Guyot et al., 2002). The authors 
found that all three SSU rRNA techniques amplified DNA from all 
Cryptosporidium species tested, but only two techniques (Xiao et al., 2001 b, 
Ward et al., 2000) allowed the discrimination of all species. The SSU rRNA gene is 
the only genetic locus so far characterized, which is able to detect and 
differentiate between all human pathogenic Cryptosporidium species. 
 
1.10.2 Subtyping  
 
Subtyping methods have been developed to examine the relationships between 
Cryptosporidium isolates. Several genetic loci were investigated: 
 
1.10.2.1 The GP60 locus 
 
The GP60 locus is currently the most commonly used genetic locus for 
Cryptosporidium subtyping (GP60, synonymous with gp15 or gp15/45/60) (Alves 
et al., 2003 a, Peng et al., 2003, Peng et al., 2003 b, Zhou et al., 2003, Wu et al., 
2003, Glaberman et al., 2002, Leav et al., 2002, Sulaiman et al., 2001, Peng et al., 
2001, Strong et al., 2000).  
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The GP60 locus encodes a 60 kDa surface-expressed glycoprotein. The 60 kDa 
precursor protein is cleaved into two subunits, gp15 and gp45 by a furin-like 
protease activity that is calcium-dependent (Wanyiri et al., 2007). Gp15 and gp45 
are localised in the apical region of sporozoites and merozoites and are present 
in the protein trails of gliding zoites, implying a functional role in parasite 
attachment, invasion and motility (Power et al., 2009, O’Connor et al., 2007, 
O’connor et al., 2007 b, Wanyiri and Ward, 2006, Alves et al., 2003 a, Sestak et 
al., 2002, Cevallos et al., 2000, Priest et al., 2000). A monoclonal antibody against 
gp15 neutralized infectivity in vitro and passively protected against the disease 
in vivo (Strong et al., 2000, Gut and Nelson, 1994). GP60 N and C terminal 
peptides include the hypothetical signal sequence and the GPI anchor 
attachment site are highly conserved among all Cryptosporidium isolates, 
suggesting that both features are important (Strong et a., 2000). The rest of the 
gene has a high degree of polymorphism, which is far greater than any other 
Cryptosporidium protein coding locus examined to date (Leav et al., 2002, 
Sulaiman et al., 2001, Strong et al., 2000). GP60 locus contains a homopolymer 
serine tract encoded by a trinucleotide repeat, which is often hypervariable and 
manifests numerous single-nucleotide and single-amino-acid polymorphisms 
(SNPs and SAAPs) (Strong et al., 2000). 
 
A sub-genotyping technique based on PCR and sequencing of GP60 was 
developed and used to examine population structure and transmission dynamics 
of C. parvum and C. hominis (Strong et al., 2000, Peng et al., 2001, Peng et al., 
2003, Alves et al., 2003 a, Alves et al., 2006, Xiao and Ryan, 2004, Sulaiman et al., 
2005, Mallon et al., 2003, Feltus et al., 2006, Trotz-Williams et al., 2006, 
Thompson et al., 2007). GP60 sequencing allowed the classification of isolates 
into subtype families defined by the number of trinucleotide repeats (TCA/TCG) 
coding for the amino acid serine according to the nomenclature described by 
Sulaiman and colleagues (2005). For example, in the allele family IIa, one subtype 
had 15 copies of the TCA repeat and 1 copy of the TCG repeat, whereas the other 
subtype had 15 copies of the TCA repeat and two copies of the TCG repeat. 
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Therefore, the two subtypes were designated IIaA15G1R1 and IIaA15G2R1, 
respectively. In the subtype name IIaA15G1R1, IIa indicates that the subtype 
belongs to allele family IIa, A15 indicates that the subtype has 15 copies of the 
TCA repeat, and G1 indicates that the subtype has one copy of the TCG repeat. 
Because some subtypes have one copy of the sequence ACATCA immediately 
after the trinucleotide repeats whereas others have two copies of the sequence, 
R1 and R2 are used to differentiate these two types (Sulaiman et al., 2005).  
 
GP60 sequencing allowed the identification of several subtype families and 
numerous subtypes within each family. C hominis subtype families were called Ia, 
Ib, Ic, Id, Ie, If and C. parvum families were called IIa, IIb, IIc, IId, IIe. The subtype 
IbA10G2 seems to be the most common C. hominis subtype in UK, US, Peru, 
Australia and South Africa, while IIaA15G2R1 is the predominant C. parvum 
subtype in Europe, US, Canada and Australia (O’Brien et al., 2007). Subtyping of 
C. parvum isolates showed that IIa and IId families were reported from humans 
and animals while IIb and IIc families were only found in humans (Alves et al., 
2006). Subtyping of a great number of isolates from different geographic 
locations never reported the presence of the IIc family in any animal species 
(Leav et al. 2002, Xiao and Ryan 2004, Xiao et al., 2004). Thus, the IIc subtype 
family is considered anthroponotic (Alves et al., 2006).  The case control study 
conducted by Hunter and colleagues (2007) confirmed these findings. 
Interestingly, some GP60 subtypes were associated with strain virulence. Cama 
and colleagues (2007) reported differences in clinical manifestations (association 
with diarrhoea and/or vomiting) among Cryptosporidium species and subtypes. 
In addition to GP60 sequencing, PCR-RFLP and PCR-RFLP-SSCP (Single Strand 
Conformation Polymorphism) of GP60 have also been used for Cryptosporidium 
subtyping (Wu et al., 2003).  
 
Despite the extensive use of the GP60 marker, subsequent studies showed that 
the level of discrimination is not in accordance with multi-locus subtyping and 
GP60 genotype by itself is difficult to reconcile with the concept of subtype 
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defined as a genetically distinct population within a species (Widmer, 2009). 
Thus, Widmer stated that GP60 may not a reliable marker of C. parvum and 
C. hominis population structure. In addition, Hunter and colleagues (2008) stated 
that it is still unclear if the identification of different subtypes in outbreak 
settings represented different lineages or evolution of strains during the 
outbreaks. The ambiguities surrounding GP60 subtyping need to be clarified in 
the near future for an improved understanding of the epidemiology and 
population structure of Cryptosporidium isolates. 
 
1.10.2.2 The rDNA Unit 
 
The rDNA unit has been used for Cryptosporidium subtyping. The rDNA unit 
consists of five sequential loci: 5’ small subunit rRNA (SSU rRNA, synonymous 
with 18S rRNA), internal transcribed spacer 1 (ITS1), 5.8S rRNA, internal 
transcribed spacer 2 (ITS2), and large subunit rRNA (LSU rRNA) 3’ (Robinson, 
2005). The rDNA unit in C. parvum has been described by Le Blancq and 
colleagues (1997). It has five copies per genome, shared over at least three 
chromosomes. The sequence analysis of the ITS1-5.8S rRNA-ITS2 region did not 
have sufficient discriminating power and only allowed genotyping of 
Cryptosporidium isolates (Morgan et al., 1999). Sequence analysis of the SSU 
showed higher level of sequence divergence, but the subtyping potential of this 
locus for epidemiological purposes is questionable due to the limited variation 
within C. hominis and C. parvum isolates and to the intra-isolate heterogeneity 
attributed to the multiple copy number of the gene (Carraway et al., 1994, 
Glaberman et al., 2001, Sulaiman et al., 2001, Gibbons-Matthews and Prescott, 
2003). 
 
1.10.2.3 Microsatellite and Minisatellite loci 
 
Mini and microsatellites have been extensively used for Cryptosporidium 
subtyping, with 22 microsatellites and three minisatellites (MS1, MS5, MS12) 
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targets being described (Robinson et al., 2005). ML1 was the most widely used 
microsatellite marker and allowed identification of two C. hominis alleles and five 
C. parvum alleles (Mallon et al., 2003 b, Enemark et al., 2002, Huetink et al., 
2001, Caccio et al., 2000). In addition, sequence and fragment size analysis of the 
ML2 microsatellite has also been described (Caccio et al., 2001, Alves et al., 2003 
b) and allowed identification of nine alleles (one C. hominis and eight C. parvum). 
ML2 seems to provide a higher level of discrimination than ML1 (Caccio et al., 
2001). Feng and colleagues (2000) described a method based on fragment size 
and sequence analysis of nine different microsatellite loci (4E12, Cp273, 12C07, 
2G04, 6B03, 5B12, 1G09, 1F07, 7E1C) and Widmer and colleagues (2000) used 14 
microsatellite loci for C. hominis and C. parvum subtyping and showed high level 
of discrimination. 
 
1.10.2.4 The HSP70, the β-tubulin, TRAP-C2 and Poly-T loci 
 
Several studies used the HSP70 locus for Cryptosporidium subtyping from clinical 
sources and environmental waters (LeChevalier et al., 2003, Sulaiman et al., 
2001, Di Giovanni et al., 1999, Peng et al., 2003 b). The HSP70 locus was found to 
have several nucleotide substitutions and allowed the identification of high 
number of subtypes from a relatively few isolates. 
 
Other genetic loci were also used for subtyping purposes, including β-tubulin, 
TRAP-C2 and Poly-T. However, they showed low levels of discrimination 
(Sulaiman et al., 2001, Widmer et al., 1998, Rochelle et al., 2000). 
 
1.10.2.5 Multi-locus subtyping 
 
In addition to using an individual locus for subtyping, a combination of several 
loci was used to provide greater discriminatory power. Several investigations 
used multi-locus subtyping and showed the importance of multi-locus 
fingerprinting (Mallon et al., 2003, Mallon et al., 2003 b, Feng et al., 2002, Caccio 
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et al., 2001, Widmer et al., 2000). Sulaiman and colleagues (2001) used sequence 
analysis of one microsatellite locus (MS1) and the TRAP-C2, Poly-T, SSU rRNA, 
HSP70 and GP60 genes to increase the discriminatory power when subtyping 62 
C. hominis isolates. Similarly, Glaberman and colleagues (2001) used DNA 
sequences of the SSU rRNA, GP60 and HSP70 loci on 11 C. meleagridis samples 
and showed higher discrimination using the multi-locus approach. Mallon and 
colleagues (2003, 2003 b) described a multi-locus approach using four 
microsatellite (TP14, MS9, ML1 and GP15) and three minisatellite (MS5, MS12 
and MS1) loci to subtype human and animal isolates of Cryptosporidium using 
sequence and fragment size analysis. A total of 58 multi-locus subtype 
fingerprints was identified, which included seven C. hominis subtypes, 48 
C. parvum subtypes, two C. parvum monkey genotype subtypes and one 
C. meleagridis subtype. The multi-locus approach has shown its usefulness in 
increasing the amount of information that can be obtained from each isolate and 
in turn has provided a higher level of discrimination between isolates.  
 
Mallon and colleagues (2003) reported that C. hominis isolates are primarily of 
closely related multi-locus genotypes, suggesting a clonal population, while, 
C. parvum has a panmictic population structure. Subsequently, Peng and 
colleagues (2003 b) reported that in C. hominis isolates from Malawi, linkage 
disequilibrium analysis of HSP70 and GP60 loci showed possible intraspecific 
recombination. This result suggests that C. hominis can also have a panmictic 
population structure. Hunter and colleagues (2007) used three microsatellite loci 
(ML1, ML2, and GP60) to subtype Cryptosporidium clinical isolates and showed 
good discriminatory power. In addition, the authors reported low diversity of 
C. hominis strains as previously reported (Mallon et al., 2003, 2003 b). This is 
supported by the theory of adaptive polymorphism, predicting that species 
occupying broad ecological niches are likely to be more diverse on the genotypic 
and phenotypic level when compared to species with a narrow host range 
(Hunter and Fraser, 1990). Several investigators currently acknowledge that the 
population structure of C. hominis and C. parvum is more complex than 
Chapter 1 
 
 
- 49 - 
previously suggested and that both clonal and panmictic population structure are 
possible, depending on the geographic distribution (Beck et al., 2009, Jex et al., 
2008, Morrison et al., 2008, Tanriverdi et al., 2008, Tait et al., 2004, Xiao and 
Ryan, 2004). 
 
The ideal number of genetic loci that enables optimal degree of discrimination 
between Cryptosporidium species and subtypes is still ambiguous. Similarly, the 
identification of genetic loci that would accurately represent Cryptosporidium 
species population structure is still needed. In the actual situation, the 
identification of novel genetic loci is desirable and should be facilitated by the 
vast amount of genetic data generated from genome projects. 
 
1.11 Virulence 
 
1.11.1 Virulence factors and virulence determinants 
 
Virulence is defined as the ability of a microorganism to cause disease (Alonso-
Monge et al., 2003, Poulin and Combes, 1999, Ebert and Herre, 1996, Garnick, 
1992, Bloch, 1950, Pike and Mackenzie, 1940, Mellon, 1926, Smiley and Pearse, 
1926). Virulence and pathogenicity are often used interchangeably, but virulence 
may also be used to indicate the degree of pathogenicity. Virulence is commonly 
used to define the likelihood of an infected person getting an illness and, if so, to 
express the severity of the symptoms. Therefore, virulence could be considered 
as an increased risk of infection and/or an increased severity of illness. 
Woolhouse and colleagues (2002) defined virulence as “the direct or indirect 
reduction in host fitness attributable to pathogen infection, often measured as 
pathogen induced host mortality”. Pathogen-centred views of virulence assert 
that pathogens are distinguished from non-pathogens by their expression of 
virulence factors. Although this concept appears to apply to some microbes that 
cause disease in normal hosts, it does not apply to most microbes that cause 
disease primarily in immunocompromised hosts (Casadevall and Pirofski, 2001). 
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The authors acknowledged that virulence, despite being a microbial 
characteristic, can only be expressed in a susceptible host and depends on the 
context and nature of host-microbe interaction. They therefore considered that 
virulence is directly linked to host damage (Casadevall and Pirofski, 2001). 
 
The view that virulence is a single characteristic is difficult to reconcile with the 
fact that host-pathogen interaction is continuous and subject to changes on the 
basis of host, microbial and exogenous factors (Casadevall and Pirofski, 2001). In 
fact, virulence is often multi-factorial, involving a complex interplay between the 
parasite and the host. Various host factors, including age, sex and the status of 
the immune system affect the outcome of the host-parasite interaction 
(Okhuysen and Chappell, 2002). In addition, the genotypic and phenotypic 
characteristics of the parasite define intrinsic diversity in isolate pathogenicity 
and virulence (Fayer et al., 2009). Therefore, an integrated view of microbial 
pathogenesis and virulence accounting for the contribution of both host and 
pathogen factors is considered more accurate (Woolhouse et al., 2002, 
Casadevall and Pirofski, 1999).  
 
Each of the microbiological attributes that contribute to virulence can in general 
be linked to specific structural elements or biochemical compounds within the 
organism, which are generally termed virulence factors. Although the terms 
“virulence determinants” and “virulence factors” are widely used to describe 
traits contributing to pathogenicity, a subtle distinction exists between the two 
terms. Virulence factors are microbial traits that promote host damage (Poulin 
and Combes, 1999) and more precisely, a virulence factor is a gene product 
necessary but not sufficient to cause disease. While, virulence determinants are 
the factors present in a microorganism that are responsible for the relative 
capacity of a parasite to cause damage in a host (Okhuysen and Chappell, 2002). 
A more precise definition of a virulence determinant could be a gene enabling an 
organism to colonize the host successfully and which may then result in host 
pathology. An operational definition of a virulence determinant has been 
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proposed as a gene belonging to a pathogen whose inactivation or deletion leads 
to a decrease in virulence of the pathogen and whose genetic reintroduction 
restores virulence (Alonso-Monge et al., 2003).  
 
On a practical note, Edberg (2009) stated “For a microbe to generate disease, a 
number of sequential virulence factors must be active. While clearly the genes 
that code for virulence must be present in the microbe, disease generation is a 
phenotypic phenomenon”. This clearly suggests that the presence of a virulence 
gene does not mean that it will be active and that the organism will be virulent. 
This further complicates the picture and should be taken into account when 
investigating the presence of virulence genes in different species and isolates. To 
support his theory, Edberg (2009) gives several examples, particularly, 
Cryptosporidium spp., for which several Nucleotide Excision Repair (NER) genes 
were described (Rochelle et al., 2004), however, these genes do not seem to be 
active as UV was shown to be a reliable disinfectant for Cryptosporidium causing 
irreversible DNA damage. 
 
When considering how each individual virulence factor contributes to an overall 
virulence phenotype, it is crucial to identify a measure of virulence (McClelland 
et al., 2006, Alonso-Monge et al., 2003, Poulin and Combes, 1999). The ability of 
a microbe to cause disease in an animal model, which is central to Koch’s 
postulate, has been the cornerstone of the measurement of virulence, but this 
relies on the availability of a susceptible experimental animal model (Casadevall 
and Pirofski, 2001). Some commonly used measures of virulence are mortality, 
microbial burden on tissue, lifetime reproductive success of infected hosts versus 
uninfected hosts (McClelland et al., 2006, Alonso-Monge et al., 2003, Poulin and 
Combes, 1999). Additional measurements of virulence could include different 
measures of the host damage and the immune response. 
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1.11.2 Cryptosporidium virulence factors 
 
Several studies have tried to determine the factors responsible for the initiation, 
establishment and perpetuation of Cryptosporidium infection. Cryptosporidium is 
a relatively non-invasive parasite that establishes itself in a membrane-bound 
compartment on the apical surface of the intestinal epithelium (Okhuysen and 
Chappell, 2002). Nevertheless, it causes significant abnormalities in the 
absorptive and secretory functions of the gut. This damage could be the result of 
direct injury to the host epithelial cell or indirectly through the effect of 
inflammatory cells and cytokines recruited to the site of infection (Okhuysen and 
Chappell, 2002). 
 
For Cryptosporidium, if virulence factors are considered to be the processes and 
substances by which the parasite initiates and maintains disease in the host, 
these factors can affect the host at any time during the life cycle from the time 
the parasite enters the body until it is killed or completes the cycle and leaves 
(Fayer et al., 2009). To date Cryptosporidium specific virulence factors have not 
been characterised to the point of unequivocally establishing their roles in 
causing damage or proving that deletions result in a decrease of virulence 
(Okhuysen and Chappell, 2002). This is mainly due to the fact that, unlike other 
apicomplexan parasites such as Toxoplasma and Plasmodium spp., no transient 
or stable transfection systems have been developed for Cryptosporidium. 
Therefore, genes cannot be knocked out or knocked down, thus making it 
impossible to conclusively demonstrate the function of the protein encoded by 
these genes (Wanyiri and Ward, 2006). 
 
Putative virulence factors for Cryptosporidium have been identified as genes 
involved in the initial interaction processes of Cryptosporidium oocysts and 
sporozoites with host epithelial cells including excystation, gliding motility, 
attachment, invasion, parasitophorous vacuole formation, intracellular 
maintenance and host cell damage (Fayer et al., 2009, Wanyiri and Ward, 2006): 
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1.11.2.1 Adherence factors 
 
A critical initial step in establishing infection is parasite attachment to host cells. 
Two classes of proteins namely mucin-like glycoproteins and thrombospondin-
related adhesive proteins have been characterized (Wanyiri and Ward, 2006) and 
showed to mediate adhesion as summarized in Table 1.3:  
 
 CSL (circumsporozoite-like glycoprotein) of ~ 1300 kDa was described by 
Riggs and colleagues (1997) and is associated with the apical complex of 
sporozoites and merozoites (Schaefer et al., 2000, Langer and Riggs, 
1999). CSL is released as a soluble glycoprotein and contains a ligand that 
binds specifically to a receptor on the surface of human and bovine 
intestinal epithelial cells (Langer and Riggs, 1999). The zoite ligand was 
shown to be involved in attachment and invasion (Langer et al., 2001). 
Monoclonal antibodies to CSL elicited changes in sporozoites and 
merozoites, similar to the malarial circumsporozoite precipitate (CSP) 
reaction and caused complete neutralization of sporozoite infectivity 
(Riggs et al., 1997). 
 
 Gp900 is a large glycoprotein identified by immunoprecipitation of 
sporozoite extracts with hyperimmune bovine colostrum (Petersen et al., 
1992 b). This large mucin-like glycoprotein is located in micronemes and 
at the surface of invasive merozoites and sporozoites. Gp900 is deposited 
in trails during gliding motility and is known to mediate invasion (Bonnin 
et al., 2001, Barnes et al., 1998). The deduced aminoacid sequence of 
Gp900 has a signal peptide and a transmembrane domain (Barnes et al., 
1998). Specific antibodies to gp900 can competitively inhibit infection in 
vitro (Barnes et al., 1998, Petersen et al., 1997). 
 
 Sporozoite and merozoite cell surface protein: gp15/40/60 complex 
(Cpgp40/15): Strong and colleagues (2000) reported that gp15/40/60 
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mRNA is translated into a ~ 60 kDa glycoprotein precursor during the 
intracellular stages of C. parvum life cycle. This precursor is proteolytically 
processed shortly after synthesis to generate 15 and 45 kDa 
glycoproteins. Independently, Cevallos and colleagues (2000) cloned and 
sequenced the same gene from C. parvum genomic DNA and called it 
Cpgp40/15. Gp40 is localized at the surface and apical region of the 
parasite and is shed from the surface, while gp15 is on the surface of 
sporozoites and is shed in trails during gliding movement (Boulter-Bitzer 
et al., 2007, Cevallos et al., 2000). In C. parvum, gp15 is attached to the 
membrane via a glycophosphatidylinositol (GPI) anchor (Priest et al., 
2001). Both gp40 and gp15 display O-linked-α-N-acetylgalactosamine (α-
GalNAc), which are thought to be involved in invasion and attachment 
since lectins that recognize these determinants block sporozoite 
attachment (Cevallos et al., 2000 b, Winter et al., 2000, Gut and Nelson, 
1994).  
 
 P23 is a 23 kDa sporozoite surface protein that is antigenically conserved 
across geographically diverse isolates (Perryman et al., 1996) and is 
deposited in trails during the initial stages of the infection (Arrowood et 
al., 1991). P23 elicits antibody response in animals and humans exposed 
to C. parvum (Reperant et al., 1994, Riggs et al., 1994, Tilley et al., 1993, 
Mead et al., 1988). P23 has neutralization-sensitive epitopes and 
monoclonal antibodies were found to significantly reduce infection in 
mice and protect calves against cryptosporidiosis (Boulter-Bitzer et al., 
2007). 
 
Cpgp40/15 and P23 were successfully expressed in the related 
apicomplexa Toxoplasma gondii as recombinant proteins with post-
translational modifications similar to those of the native protein, which 
would be impossible using bacterial expression systems (O’Connor et al., 
2003, Shirafuji et al., 2005). The recombinant proteins showed 
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appropriate localization and glycosylation. The expression of 
Cryptosporidium proteins in this heterologous expression system is a 
major advance and would assist an improved understanding of the 
functional role of several Cryptosporidium proteins. 
 
 TRAP-C1 (thrombospondin-related adhesive protein Cryptosporidium 1) is 
a 76 kDa protein localized on the apical pole of sporozoites (Spano et al., 
1998 b). It showed sequence and structural homology to members of the 
thrombospondin family adhesive proteins in other apicomplexan 
parasites (Plasmodium spp., Toxoplasma gondii, Eimeria tenella and 
Neospora spp. (Boulter-Bitzer et al., 2007). TRAP and structurally related 
proteins are involved in parasite gliding motility and cell penetration 
(Boulter-Bitzer et al., 2007). Putignani and colleagues (2008) 
characterized “CpTSP8”, one of the 12 C. parvum thrombospondin-
related proteins (CpTSP2- CpTSP12) family identified by bioinformatic 
tools. The authors showed that CpTSP8 is located at the apical complex of 
sporozoites and merozoites and is translocated onto the parasite surface, 
as it is typical of micronemal proteins (MICs). Therefore, CpTSP8 was 
renamed CpMIC1. MIC proteins have been shown to be essential in host-
cell attachment/invasion and gliding motility (Soldati et al., 2001).   
 
GP900, gp40, gp15, Cpa135, Cp2, P23 and TRAP-C1 (Table 1.3) have or are 
predicted to have mucin-type O –glycosylation, suggesting that this type of post-
translational modification is common in proteins involved in attachment and 
invasion (Wanyiri and Ward, 2006). 
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Table 1.3: Cryptosporidium putative virulence factors identified by immunological 
and molecular methods. Table compiled from data obtained from the following 
publications: Fayer et al, 2009, Wanyiri et al., 2009, O’Connor et al., 2009, 
Putignani et al., 2008, Boulter-Bitzer et al., 2007, Okhuysen and Chappell, 2002. 
 
 
Virulence factor 
gene/protein 
Putative function Reference 
Serine protease Excystation Forney et al., 1996a, 1996b 
Aminopeptidase Excystation Okhuysen et al., 1994 
Circumsporozoite like 
Glycoprotein (CSL) 
Adhesion  Riggs et al., 1997 
Glycoprotein 900 (gp900) Adhesion Petersen et al., 1992 b 
GP60/40/15 Adhesion Cevallos et al., 2000, 2000 b, 
Strong et al., 2000 
P23 Adhesion, locomotion Arrowood et al., 1991 
Perryman et al., 1996 
TRAP-C1 Adhesion, locomotion Spano et al., 1998 
Cp47 Adhesion Nesterenko et al., 1999 
CPS-500 Adhesion, locomotion Riggs et al., 1989 
Bjorneby et al., 1990 
Cp2 Invasion, membrane integrity O’Hara et al., 2004 
Cpa135 Invasion Tosini et al., 2004 
Secretory phospholipase Invasion, intracellular 
establishment  
Pollok et al., 2003 
Hemolysin H4 Membrane lysis Steele et al., 1995 
Cryptosporidium ATP binding 
cassette (CpABC) 
Transport, nutrient transport Perkins et al., 1999 
C. parvum ATPase2 
(CpATPase2) 
Biomembrane heavy metal 
transporter 
LaGier et al., 2001 
C. parvum ATPase3 
(CpATPase3) 
Biomembrane ion or    
phospholipid transporter 
LaGier et al., 2002 
HSP70 Stress protection Khramtsov et al., 1995 
HSP90 Stress protection Woods et al., 1999 
Type I polyketide synthase 
(CpPKS1) 
Unknown function  Zhu et al., 2002 
Cysteine protease Immune/cytokine modulation Nesterenko et al., 1995 
Acetyl co synthetase Fatty acid metabolism Camero et al., 2003 
C. parvum Subtiline like serine 
protease (CpSUB) 
Invasion Wanyiri et al., 2009 
C. parvum  micronemal 
protein (CpMIC1)  
Adhesion, locomotion Putignani et al., 2008 
C. parvum Mucin like (CpMuc) Invasion O’Connor et al., 2009 
Chapter 1 
 
 
- 57 - 
Because mucin-like proteins were shown to be important for Cryptosporidium 
host-parasite interactions, O’Connor and colleagues (2009) undertook data 
mining of the Cryptosporidium genome databases to identify other mucin-like 
genes. They discovered a single locus of seven small mucin sequences (CpMuc1-
7), which were expressed throughout the intracellular development stages. 
Specific antibodies inhibited infection in vitro, which is consistent with a role in 
host-cell invasion. 
 
Proteolytic processing of surface and apical complex proteins by parasite 
proteases has be shown to be required for invasion of host cells and for egress 
from them. Further effort was focused on identification of Cryptosporidium 
proteases. Wanyiri and colleagues (2009) characterized a C. parvum subtiline like 
serine protease (CpSUB) and showed that this protein is likely to be responsible 
for the processing of gp40/15 (Table 1.3). 
 
As detailed above, Cryptosporidium has several distinct molecules to mediate 
attachment to and invasion of the epithelial intestinal cells. These proteins have 
features in common with other apicomplexans proteins implicated in mediating 
host-cell interaction (Tzipori and Ward, 2002). In addition, proteins and 
glycoproteins expressed on the surface of the invasive C. parvum sporozoite and 
merozoite stages and shed in trails by gliding zoites are thought to play essential 
roles in parasite motility and in parasite attachment to and invasion of host 
epithelial cells (Strong et al., 2000). The relative contribution of each individual 
molecule remains to be determined. It is likely that by using a large number of 
seemingly redundant adhesive molecules, the parasite can maximize the 
opportunity for cell attachment across a broad range of potential hosts. It is also 
possible that quantitative or qualitative differences in these glycoproteins may 
confer selectivity for host attachment (Okhuysen and Chappell, 2002). 
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1.11.2.2 Cellular damage 
 
Cell damage in enterocyte monolayers has been documented through disruption 
of tight cell junctions, loss of barrier function, release of lactate dehydrogenase 
and increased cell death (Adams et al., 1994). The mechanisms causing cellular 
damage during Cryptosporidium infection remain unknown, however, several 
molecules can cause direct tissue damage such as phospholipases, proteases and 
haemolysins (Okhuysen and Chappell, 2002). 
 
Proteases have been described to have important functions in a parasite’s life 
cycle, such as mediating protein degradation, invasion of host tissues and 
evasion of host immunity (Shenai et al., 2000, Que and Reed, 2000, Shin et al., 
2001). Distinct types of protease activities have been identified in 
Cryptosporidium sporozoites such as aminopeptidase, cysteine protease and 
serine protease implicated in the excystation process (Forney et al., 1996 a, 
Okhuysen et al., 1996, Nesterenko et al., 1995). The identification of functional 
proteases in sporozoites during excystation and the prevention of infection in 
the presence of protease inhibitors suggest that proteases are important in the 
initial stages of Cryptosporidium infection (Okhuysen and Chappell, 2002).  
 
A haemolysin H4 has been identified by screening a C. parvum expression library 
on sheep blood agar (Steele et al., 1995). H4 has sequence similarity to the 
haemolysin of enterohemorrhagic E. coli 0157 H7. The function of H4 is unknown 
but its ability to disrupt cell membranes suggest a role in cellular invasion and/or 
the disruption of vacuolar membranes would allow merozoites to exit the 
parasitophorous vacuole and spread to adjacent cells (Okhuysen and Chappell, 
2002). Another Cryptosporidium protein of interest is an ABC transporter gene 
(CpABC) localized in the electron dense feeding organelle of the parasitophorous 
vacuole (Perkins et al., 1999). Interestingly, these genetic elements share 
structural similarities with bacterial genes, which are critical in producing 
secretory diarrhoea (Okhuysen and Chappell, 2002). 
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1.11.2.3 Heat shock proteins  
 
Heat shock proteins (HSPs) are a family of large conserved proteins. They are 
usually defined by their apparent molecular weight in sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), with HSP90, HSP70 and HSP65 
being common families (Miller et al., 2000). Synthesis of HSPs, especially HSP70, 
increases dramatically under stressful conditions (sudden shifts in temperature, 
decreased availability of nutrients, immune attack). HSPs function as intra-
cellular chaperones for other proteins, which play an important role in protein-
protein interactions and facilitate transport, folding, assembly, biosynthesis and 
secretion of newly formed proteins (Okhuysen and Chappell, 2002).  
 
In Cryptosporidium two HSPs (HSP70 and HSP90) have been described (Woods et 
al., 1999, Khramtsov et al., 1995). Considerable polymorphism in the HSP70 gene 
has been identified and was used for genotyping purposes (Morgan et al., 2000, 
Sulaiman et al., 2000). However, HSPs are under selective pressure and their high 
degree of polymorphism might not reflect the genetic relationships between 
isolates or subtypes. In the closely related apicomplexa T. gondii, it has been 
demonstrated that quantitative and qualitative differences in the HSP expression 
are directly related to parasite virulence (Miller et al., 2000, Lyons and Johnson, 
1998). In fact, high levels of expression of HSP70 were detected in virulent 
strains grown in mice, but only little expression of HSP70 was observed in 
avirulent strains (Lyons and Johnson, 1995). The relationship between the level 
of HSP expression and Cryptosporidium virulence warrants further investigation. 
 
1.11.3 Host factors and Cryptosporidium virulence 
 
Age is a major factor in the epidemiology of infection, with children being most 
at risk of cryptosporidiosis as shown by the cumulative data of cryptosporidiosis 
cases detected between 1989 and 2008 (Figure 1.2). The illness in children is not 
necessarily more or less severe than in older age groups and infection may even 
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be sub-clinical. Indeed asymptomatic carriage in children has been suggested as 
being an important reservoir for C. hominis infection (Hunter et al. 2004 b). As 
discussed above, the high incidence of cryptosporidiosis in children probably 
reflects lack of immunity due to few prior exposures (Yoder and Beach, 2010, 
Hunter and Thompson, 2005, Guerrant, 1997). 
 
Perhaps not surprising given that many of the earliest identified cases of human 
cryptosporidiosis were in immune suppressed individuals (Current and Garcia, 
1991), immune suppression is an important human specific risk factor for 
increased virulence. The severity of illness may be much greater in immune 
suppressed compared to immune compromised patients (Chalmers and Davis, 
2010, Hunter and Nichols, 2002, Chen et al., 2002, O'Donoghue, 1995, Guerrant, 
1997). In such subjects, cryptosporidiosis is no longer self limiting and can be life-
threatening (Chen et al., 2002, O'Donoghue, 1995, Junarek, 1995). However, not 
all forms of immune suppression lead to increased disease severity of 
cryptosporidiosis. The main risk seems to be immune suppressive disorders that 
impact on T cell function, the most obvious being HIV/AIDS (Hunter and Nichols, 
2002). In AIDS patients, the most severe disease occurs in people with a CD4 
count of less than 50. There is also evidence that patients with solid organ 
transplantation and with other malignancies may also be at increased risk, 
though the weight of evidence is less strong probably reflecting less common 
infections in these groups (Hunter and Nichols 2002).  
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Figure 1.2: Total number of cryptosporidiosis cases detected in England and 
Wales by age group between 1989 and 2008 as reported by the Health 
protection Agency (www.hpa.org.uk). 
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Of particular relevance in developing country settings is the issue of malnutrition 
in children. There is good evidence from animal studies that cryptosporidiosis 
exacerbates malnutrition and that cryptosporidiosis is more severe in 
malnourished mice (Coutinho et al., 2008). In human situations, the evidence 
also supports this synergistic relationship (Mor and Tzipori 2008, Hunter and 
Nichols 2002). However, the exact mechanisms behind the increased severity of 
illness in the malnourished child are not yet fully clear. One explanation is that in 
the malnourished child, the damage to the gut mucosa with a new 
Cryptosporidium infection would lead to further impaired nutrient absorption 
and stunting that would not be such an issue in the well nourished child (Mor 
and Tzipori 2008). 
 
1.11.4 Cryptosporidium species-specific virulence factors 
 
Cryptosporidium putative virulence factors detailed in 1.11.2, which mediate 
sporozoite attachment and invasion of the epithelial intestinal cells and which 
inactivation can prevent infection in vitro and in vivo, are common to all 
Cryptosporidium spp. These virulence factors were mostly identified in 
C. parvum. Among 13 valid Cryptosporidium species, only eight infect human 
(C. hominis, C. parvum, C. canis, C. felis, C. muris, C. andersoni and C. meleagridis) 
and among 40 Cryptosporidium genotypes, only two infect human: pig and 
cervine genotypes (Fayer et al., 2009). The virulence factors in other human 
infective Cryptosporidium species require investigation.  
 
In addition to inter-species differences in virulence, there were reports of intra-
species and inter-isolate virulence variability (Xiao et al., 2000, Okhuysen et al., 
1999, Widmer et al., 1998). The genetic determinants of virulence and host 
range for Cryptosporidium species and genotypes and the specific mechanisms 
that shape this biological diversity are not elucidated (Morgan et al., 1999, 
Sulaiman et al., 2000). The discovery of such factors is desirable as it would 
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advance our understanding of the pathogenesis, host tropism, evolution and 
epidemiology of Cryptosporidium species. 
 
1.11.5 Virulence factors and species determinants 
 
The consideration of genetic determinants of host tropism as virulence factors is 
legitimate as these genes would enable the parasite to adhere and invade 
epithelial cells from different host species. However, the relationships between 
the host range and the virulence of human infective Cryptosporidium species is 
not clear. The Red Queen hypothesis postulates that species continually evolve 
but do not become better adapted (Venditti et al., 2010, Van Valen, 1973), 
therefore the interactions between hosts and parasites lead to constant natural 
selection for adaptation and counter adaptation (Lively and Dybdahl, 2000). 
Antagonistic coevolution between hosts and parasites can involve rapid 
fluctuations of genotype frequencies and recombinations in the host, which may 
be advantageous and can quickly produce disproportionately fit offspring 
(Engelstädter and Bonhoeffer, 2009). In fact, successful parasite species should 
evolve to become less virulent overtime and therefore, only the maladapted 
novel parasites are harmful (Ebert, 1994). Considering the host range for 
C. hominis and C. parvum, the latter is thought to be more virulent allowing it to 
infect a wide range of species, while the former is expected to be less virulent as 
postulated by the theory of host-parasite co-evolution and virulence attenuation. 
However, Hunter and colleagues (2004) showed that C. hominis is more virulent. 
Based on similar observations, Woolhouse and colleagues (2002) stated that 
host-parasite co-evolution is in principal a powerful determinant of the biology 
and genetics of infection and disease, which has proven difficult to demonstrate 
rigorously in practice. A theory on the evolution of the virulence states that 
pathogenicity can be maintained when it is a direct or indirect consequence of 
the parasite’s exploitation of the host (Ebert, 1994). Therefore, the parasite is 
expected to balance parasite reproduction against host survival, such that 
parasite transmission is maximised (Ebert, 1994, Anderson and May, 1984).  
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The identification of genetic determinants of host tropism in human infective 
Cryptosporidium species would improve our understanding of evolution, 
virulence and epidemiology of Cryptosporidium species. In addition, these 
virulence factors could be used as potential drug target and vaccine candidate 
(Casadevall and Pirofski, 2001, Brubaker, 1985). 
 
1.12 Genomics of Cryptosporidium species 
 
1.12.1 Genome organisation 
 
Several studies tried to reveal the characteristics of Cryptosporidium genome 
prior the sequencing era. Karyotypic analyses suggested that Cryptosporidium 
contains eight chromosomes, ranging in size from 0.945 to 2.2 Mb, giving a total 
haploid genome size of approximately 10 Mb (Blunt et al., 1997, Hays et al., 
1995). In addition, C. parvum was shown to have two small extrachromosomal 
cytoplasmic virus-like double-stranded RNAs (of 1,786 and 1,374 nucleotides, 
respectively) (Khramtsov et al., 1997). The RNAs have a single open reading 
frame each, which encodes a putative RNA-dependent RNA polymerase and a 
protein with limited homology to mammalian protein kinases, respectively 
(Clark, 1999). Le Blancq and colleagues (1997) investigated C. parvum rRNA gene 
organization and reported that the small and large rRNA subunits are 1.7 and 3.6 
kb, respectively, plus a 151 bp putative 5.8S rRNA. It was also demonstrated that 
Cryptosporidium has mitochondrial biosynthesis genes (LaGier et al., 2003) and 
unlike other apicomplexan, it lacks an apicoplast (Zhu et al., 2000 a). 
 
1.12.2 Genome sequencing projects 
 
As a pathogen of public health relevance, Cryptosporidium was included in 
genome sequencing projects. Two reference strains served as genome 
representatives: C. parvum Iowa and C. hominis TU502. Genome sequences 
showed similar genome sizes of 9.11 and 9.16 Mb, respectively (Abrahamsen et 
al, 2004, Xu et al, 2004). Genome analysis revealed extremely streamlined 
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metabolic pathways and lack of many cellular structures and metabolic pathways 
found in other apicomplexans (Wanyiri and Ward, 2006). Energy metabolism is 
largely from glycolysis and both aerobic and anaerobic metabolisms are 
available, thus conferring environmental flexibility (Barta and Thompson, 2006). 
Limited biosynthetic capabilities and minimal metabolism were reported, 
suggesting a large dependence on nutrient acquisition from the host (Rider and 
Zhu, 2010). Cryptosporidium has genes associated with apical complex organelles 
despite the fact that they lack an apicoplast and possess a degenerate 
mitochondrion that has lost its genome (Abrahamsen et al, 2004, Xu et al, 2004).  
 
A comprehensive genome database, CryptoDB (www.CryptoDB.org), serves as a 
public interface to Cryptosporidium genome sequences (Puiu et al., 2004). This 
website offers access to sophisticated tools, which enable the identification of 
genes based on text, sequence similarity and motif queries (Striepen and 
Kissinger, 2004). Expressed sequence tag (EST) and genome sequence survey 
(GSS) DNA-sequencing projects are in progress, together with the genome 
sequencing of C. muris RN66 strain.  
 
Pain and colleagues (2005) summarized the similarities between C. hominis and 
C. parvum. Like C. parvum, C. hominis seems to lack an apicoplast and has an 
atypical mitochondrion with a minimal set of mitochondrial proteins. In addition, 
the two species have a reduced number of metabolic pathways. Energy 
metabolism is mainly from glycolysis and both aerobic and anaerobic metabolic 
pathways are available. Several biochemical pathways are absent from the 
C. hominis genome, including the tricarboxylic acid cycle, urea and nitrogen 
cycle, shikimate pathway, isoprenoid biosynthesis and the type-II fatty-acid 
biosynthesis pathway. Biosynthetic capabilities are also restricted, C. hominis 
cannot synthesize some simple sugars, amino acids and nucleotides, while starch 
and amylopectins can be generated from precursors by C. hominis enzymes. The 
apparent lack of biosynthetic capability of C. hominis is compensated for by the 
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presence of an extensive array of amino-acid and other transporters that enable 
import of essential nutrients from the host.  
 
1.12.3 Genomics and virulence factors 
 
Genome sequences revealed a vast amount of information, contributing to a 
better knowledge of the microbial biology, pathogenicity, evolution and 
virulence as described above. The quest for the molecular basis of virulence can 
exploit the genomic data to search for genes that may ultimately unravel the 
regulation of virulence at the genetic level (Casadevall and Pirofski, 2001). 
Particularly, post-genomic analysis is a potential tool to identify genes involved in 
host-parasite interaction and adaptation. These contingency genes as opposed to 
conserved housekeeping genes are expected to be highly variable (Moxon et al., 
1994). Barry and colleagues (2003) stated that genes responsible for the 
successful invasion of the host are subject to spontaneous recombination rates 
higher than the background rate that applies to the other genes in the genome. 
Contingency genes are common in pathogenic microbes including viral, bacterial, 
fungal and protozoan pathogens (Henderson et al., 1999, Deitsch et al., 1997). 
These genes enable, through mutational events, rapid switches in phenotype 
that are conductive to survival and proliferation in the host and are often 
associated with telomeres (Barry et al., 2003). Some examples of contingency 
genes include a variant surface protein (VSG) in Trypanosoma brucei, which 
undergoes antigenic variation to evade the host immune response and allow 
parasite survival (Yang et al., 2009, Barry et al., 2003) and var genes in 
Plasmodium falciparum coding for erythrocyte protein-1, which also undergo 
antigenic variation to evade the immune system (Kyes et al., 2001). Genetic 
determinants of host tropism are likely to be among these contingency genes 
and genomic data would assist in identifying them. 
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1.13 Aims and scope of the research in this thesis 
 
C. hominis and C. parvum are the Cryptosporidium species of public health 
relevance. Genomes representative of these two species have been sequenced 
and showed only 3-5% sequence divergence. No further investigation of this 
minimal diversity was performed. The aim of this thesis is to exploit the 
published genomic data to identify species-specific Cryptosporidium genes 
accountable for this sequence variability. This research objective is novel and 
might represent a unique opportunity to identify genetic determinants of host 
tropism and species-specific virulence factors.  
 
The investigation was based on the in silico identification of putatively species-
specific genes using bioinformatic tools. The predicted specificity was assessed 
experimentally by PCR in a collection of Cryptosporidium clinical isolates 
provided by the Cryptosporidium reference unit and commercially obtained 
reference strains. The putative specific genes were further characterized at the 
genomic and molecular level and a preliminary investigation of their role in the 
host-parasite interaction was undertaken. 
 
A detailed study plan: 
 
 Comparative genomics was performed using Reciprocal BLAST and used 
to assign a similarity score to every C. parvum and C. hominis gene  
 Initial selection for highly variable genes was undertaken by applying a 
threshold of 10% sequence identity 
 Selected genes were individually tested by BLAST and only genes with no 
known sequence similarity were retained. In addition, query of genomic 
databases was performed for ortholog identification. This additional 
screening allowed elimination of genes showing any sequence similarity 
to other Cryptosporidium species 
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 Experimental evaluation of the predicted specificity was undertaken by 
PCR in a collection of Cryptosporidium clinical isolates and reference 
strains 
 PCR product sequence analysis was performed to determine genetic 
polymorphism 
 Further investigation and characterization of species-specific genes was 
planned and involved 
 Sequence polymorphism in clinical isolates 
 Evaluation of the diagnostic applications for specific genes 
 Expression and characterization of the recombinant proteins 
encoded by the species-specific genes 
 Production of monoclonal antibodies  
 Protein localization studies by IFA 
 Evaluation of the role of specific proteins in host-parasite 
interaction in vitro using blocking assays in Caco2 cell monolayers 
 Assessment of the immunogenicity of the recombinant proteins 
by Western Blot screening of sera from infected patients  
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2.1 Identification of putative species-specific genes by comparative 
genomics 
 
2.1.1 Reciprocal BLAST 
 
The genome sequences of C. parvum and C. hominis have been sequenced as 
described previously (Abrahamsen et al, 2004, Xu et al, 2004) and are available 
online (http://CryptoDB.org). In order to investigate the sequence variability 
between the genome representatives of these 2 species, estimated to be 3-5%, 
Reciprocal BLAST was used. Reciprocal BLAST is a variant of BLAST (Basic local 
alignment search tool), originally described by Altschul and colleagues (1990). 
Reciprocal BLAST is a common computational tool for predicting putative 
orthologs (http://www.ncbi.nlm.nih.gov/blast/blast_overview.shtml). Orthologs 
are homologous sequences found in different species and derived from a 
common ancestor. Reciprocal BLAST is used to identify orthologous genes 
between 2 species as follows: Each gene of species 1 is Blasted to a database of 
gene sequences from the organism of interest (species 2). The highest scoring 
gene is taken and Blasted to a database of species 1 gene sequences. If the 
BLAST hit returns the gene originally used for reciprocal BLAST as the highest 
BLAST scorer, then the 2 genes are considered putative orthologs.  
 
For this study, Reciprocal BLAST was used to compare the genomes of C. parvum 
and C. hominis and identify orthologous genes. It conferred a similarity score to 
each of the ~ 3900 genes of C. parvum and C. hominis. Applying a threshold of 
10% identity allowed the identification of putative species-specific genes. In 
addition, within this selection, each gene was individually Blasted using Blastn 
algorithm (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to confirm specificity and 
reveal sequence similarity to genes from the other Cryptosporidium species. 
Furthermore, orthology queries were performed using the CryptoDB database. 
Whenever a gene showed sequence similarity, it was eliminated from the 
selection. 
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2.1.2 Gene selection 
 
Amongst the putative species-specific genes selected as described in 2.1.1, 13 
genes were chosen with preference to annotated genes The name and 
annotation of the selected genes are detailed in Table 2.1. 
 
2.2 Screening of putative species-specific genes by PCR 
 
2.2.1 Primer design 
 
For each gene, a pair of primers was designed using OligoPerfect™ Designer 
software (www.invitrogen.com). The primers were ordered from Operon/ 
Eurofins MWG (Cologne, Germany). Table 2.1 detailed the primers sequences 
and the PCR product sizes for each gene tested. In addition, reference primers 
Cry15 and Cry9 amplifying a 555 bp fragment of the COWP (Cryptosporidium 
oocyst wall protein) gene (Spano et al, 1997) were used as a positive control. 
 
2.2.2 PCR conditions 
 
PCR conditions were carried out as described previously (Bouzid et al., 2010). The 
PCR mix consisted of 1.5 mM MgCl2, 0.2 mM of each dNTP (Bioline, UK), 0.6 µM 
of Forward and reverse primers and 2.5 U of HotStarTaq ® DNA polymerase 
(Qiagen Ltd., Crawley, UK) in 50 μl reaction. The cycling conditions were as 
follows: an initial hot-start at 95
◦
C for 15 min, followed by 40 cycles of 94
◦
C for 
50s, 60 (or 57) 
◦
C for 30s and 72
◦
C for 50s, and a final extension at 72
◦
C for 10 
min. PCR reactions were performed using Techne TC-512 thermal cycler (SLS, 
Nottingham, UK). The PCR products were run on a 2% agarose gel and visualised 
under UV.  
 
  
 
 
Table 2.1: List of the genes selected for this study, the corresponding primer sequences and PCR product sizes. Primer name is the 
gene name followed by F or R (for forward and reverse, respectively). 
 
Primer name Gene function                          
(CryptoDB) 
Sequence Tm (
◦
C) Annealing 
temperature (
◦
C) 
Size of amplified 
fragment 
cgd2_80 F GGA TTG GGG GTG ATA TGT TG 68 
cgd2_80 R 
ABC transporter family protein 
ACC TCC AAG CTG TGT TCC AG 70 
60 266 bp 
cgd6_200 F CGT TCC AAC AAT GGT GTG TC 68 
cgd6_200 R 
Oocyst wall protein 8 
GCA GCT GGA GTG CAA TCA TA 68 
60 447 bp 
cgd8_2370 F CAG GAA TTG CTC ACG GAA AT 66 
cgd8_2370 R 
Adenosine kinase like ribokinase 
CCT TAA ATG CAT CCC CAC AG 68 
60 685 bp 
Chro.50317 F GAT TTT GAT GGA GGG TCT CG 68 
Chro.50317 R 
RNA polymerase A/beta'/A'' subunit 
CTG GCA GCT TCA ACA CCA TA 68 
60 752 bp 
Chro.30149 F GGG ATT AGA TGC AGG TGG TG 70 
Chro.30149 R 
Ubiquitin-protein ligase 1 
TGG ATG CTC CAG CAT TAC AT 66 
60 331 bp 
Chro.50457 F CCT TTG GAT TGT CCC GAA TA 66 
Chro.50457 R 
Erythrocyte membrane-associated 
antigen CAA TGC CAT ATG ATT TGA GAA AAA 65 
60 394 bp 
cgd6_5020 F AAC AGG AGC TGA CGA TTG CT 60.4 
cgd6_5020 R 
Protein with WD40 repeats 
ACA TTG TGC CAT TCC AAG GT 58.35 
57 271 bp 
cgd2_2430 F GTA ACG CAT GGC GAA CCT AT 60.4 
cgd2_2430 R 
Ximpact ortholog conserved protein 
seen in bacteria and eukaryotes AAG ATC AGC CTT GCA GCA TT 58.35 
57 389 bp 
cgd2_4380 F AAG GGG TGG ACC TAG ATG CT 62.45 
cgd2_4380 R 
signal peptide, repeats, gene 
anchored to telomere GAA GAG GTG GGC GTG ATC TA 62.45 
57 665 bp 
Chro.20156 F TTC GCT TGA AGC CGT AAA CT 58.35 
Chro.20156 R 
Hypothetical protein 
GGC ATT GAT ACC AGG CAA GT 60.4 
57 247 bp 
Chro.50330 F TCG GTA CAG CAT CAG GTT CA 60.4 
Chro.50330 R 
Leucyl tRNA synthetase 
GTT TTT GCT CCC CCA GTT TT 58.35 
57 368 bp 
Chro.00003 F ACC TGC TCT CCG TTG TCA AT 60.4 
Chro.00003 R 
Sensor histidine kinase 
ATG CGA ACC TCC TCA CTG TC 62.45 
57 610 bp 
Chro.50011 F AGG AAA CGT GGC ATT TTC TG 63.9 
Chro.5001 R 
Hypothetical protein 
TTG ACA GCA CTT CCT GAA CG 64.1 
57 287 bp 
Cry-15 GTA GAT AAT GGA AGA GAT TGT G 57.08 
Cry-9 
Oocyst wall protein gene 
(Spano et al., 1997) GGA CTG AAA TAC AGG CAT TAT CTT G 61.3 
60 555 bp 
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2.3 Cryptosporidium DNA 
 
During this study, a panel of clinical samples from the collection of the UK 
Cryptosporidium Reference Unit (CRU), Swansea was used for the screening of 
putative species-specific genes. These isolates originated from diarrhoea patients 
with confirmed cryptosporidiosis. DNA was isolated from semi-purified oocyst 
suspensions prepared from stool samples by saturated-salt solution 
centrifugation and extracted using QIAamp DNA mini kit spin columns (Qiagen 
Ltd, Crawley, UK) as previously described by Elwin and colleagues (2001). For 
each isolate, speciation was performed by PCR-RFLP of the Cryptosporidium 
oocyst wall protein (COWP) gene as previously described by Spano and 
colleagues (1997) and by real-time PCR using simplex Lib 13 primers for 
C. parvum and C. hominis as described by Tanriverdi and colleagues (2003). In 
addition, genotyping and subtyping of these isolates was performed by 
sequencing of the SSU rRNA and GP60, as previously described (Xiao et al., 2001 
and Mallon et al., 2003 b).  
 
DNA from three C. hominis isolates (Ch2, Ch3 and Ch4), 3 C. parvum isolates 
(Cp2, Cp3, and Cp4) and four C. parvum anthroponotic subtype isolates (W65, 
W66, W67 and W70) were tested. The anthroponotic C. parvum group was 
identified using Gp60 subtyping; IIc subtype was only reported to infect humans, 
which led to this sub-categorisation (Xiao and Fayer, 2008). Table 2.2 details the 
origin, epidemiological and genotyping data of the isolates tested. In addition, 
DNA of four rabbit genotype isolates, one isolate from the Northamptonshire 
outbreak (Chalmers et al., 2009) and three sporadic cases isolates, were also 
analysed. Furthermore, genomic DNA of three reference strains C. parvum Iowa 
(ATCC/ LGC Promochem, Teddington, UK), C. parvum Moredun (Moredun 
Research Institute, Midlothian, UK) and C. hominis TU502 (BEI Resources, 
Manassas, USA) were tested. 
.
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Table 2.2:  Details of the host, the geographical origin and the genotyping data of 
C. parvum and C. hominis isolates and reference strains, whose DNA was tested 
during this study. Numbers in bold are the Genbank accession number for 
sequences used to genotype and subtype these clinical isolates. 
 
Isolate Host Origin COWP- RFLP 18s sequencing 
(genotyping) 
Gp60 
sequencing 
(subtyping) 
C. parvum  Iowa Bovine  Iowa, USA C parvum   
C. hominis TU502 Human  Uganda C hominis   
C. parvum Moredun Cervine  Scotland C parvum   
Ch2 Human Yorkshire, England C hominis C. hominis 
GQ983348 
IbA10G2  
GQ983356 
Ch3 Human North  Wales C hominis C. hominis 
GQ983350 
IbA10G2 
GQ983358 
Ch4 Human Cumbria, England C hominis  C. hominis 
GQ983352 
IbA10G2  
GQ983360 
Cp2 Human Devon, England C parvum C parvum  
GQ983349 
IIaA18G3R1   
GQ983357 
Cp3 Human Cumbria, England C parvum C parvum  
GQ983351 
IIaA17G1R1   
GQ983359 
Cp4 Human Grampian,   
Scotland 
C parvum C. parvum 
GQ983353 
IIaA15G2R1    
GQ983361 
W65 Human Leicestershire, 
England 
C parvum C. parvum 
GU971620 
IIcA5G3 
GU971624 
W66 Human Leicestershire, 
England 
C parvum C. parvum 
GU971621 
IIcA5G3 
GU971625 
W67 Human Leicestershire, 
England 
C parvum C. parvum 
GU971622 
IIcA5G3 
GU971626 
W70 Human Leicestershire, 
England 
C parvum C. parvum 
GU971623 
IIcA5G3 
GU971627 
Rabbit 1                
(17330) 
Human Northampton-
shire, England 
C hominis Rabbit genotype  
FJ262726 
VaA18            
FJ262732 
Rabbit 2                 
(18455) 
Human Shropshire, England
 
C hominis Rabbit genotype 
GU971628 
VaA23  
GU971631 
Rabbit 3                   
(17525) 
Human Suffolk, England C hominis Rabbit genotype 
GU971629 
VaA32 
GU971632 
Rabbit 4                    
(17435) 
Human Essex, England C hominis Rabbit genotype 
GU971630 
VaA22  
GU971633 
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In addition, DNA from other Cryptosporidium species was also obtained from 
CRU and tested to further validate the predicted specificity of in silico identified 
genes. DNA from C. andersoni, C. felis, cervine genotype, C. meleagridis and 
C. baileyi was tested. Table 2.3 summarizes the epidemiological and genotyping 
data of these isolates. 
 
2.4 Sequence analysis of PCR products and data analysis 
 
Positive PCR products were purified using QIAquick® PCR purification Kit (Qiagen 
Ltd., Crawley, UK). Purified PCR products were sequenced in both directions 
using PCR primers in duplicate. In order to confirm sequences, two independent 
sequencing facilities were used: the genome lab, John Innes Centre 
(www.jicgenomelab.co.uk) and the sequencing service at the University of 
Dundee (www.dnaseq.co.uk), both using Dye-terminator chemistry technology 
and Applied Biosystems automated capillary DNA sequencer (3770 and 3730 
model, respectively). Sequences were assembled using CAP3 software 
(http://pbil.univ-lyon1.fr/cap3.php) (Huang and Madan, 1999) and aligned using 
AlignX
® 
application of Vector NTI Advance™ 10 software (www.Invitrogen.com). 
Phylogenetic analysis was performed using MEGA (Molecular Evolutionary 
Genetic Analysis) software (www.megasoftware.net) (Tamura et al., 2007).  
 
When required, the sequences were analyzed for the presence of         
endonuclease restriction sites using NEBcutter V2.0 online tool 
(http://tools.neb.com/NEBcutter2/) (Vincze et al., 2003). 
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Table 2.3: Details of the host, the geographical origin and the genotyping data of 
other Cryptosporidium species DNA used for this study. All species and genotypes 
were identified using 18S rRNA sequencing, except for C. andersoni, which was 
genotyped using HSP70 locus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Isolate Species  Host COWP- RFLP 18s sequencing Other loci  
W13086 C. andersoni Bovine Not detected  HSP70 100% 
C. andersoni 
W14508 C. felis Human Not detected 100% C. felis  
W15916 cervine genotype Human cervine genotype 100% cervine gt  
W10509 C. meleagridis Human C. meleagridis 100% C. meleagridis  
W14184 C. baileyi Chicken Not detected 100% C. baileyi  
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2.5 Whole Genome Amplification (WGA) 
 
2.5.1 WGA kits 
 
Three commercial WGA kits were tested during this study: illustra GenomiPhi V2 
DNA amplification Kit (GE healthcare, Buckinghamshire, UK), REPLI-g Ultra fast 
Mini Kit (Qiagen, Crawley, UK) and GenomePlex® Complete WGA Kit (Sigma, 
Dorset, UK). Illustra GenomiPhi and REPLI-g kits are MDA-based WGA, while the 
GenomePlex kit is based on the Omniplex technique. All 3 kits were used 
according to the manufacturer’s instructions.  
 
2.5.2 Cryptosporidium DNA 
 
 Ten clinical samples were selected from the collection of the CRU and used for 
the WGA kit trial. They originated from diarrhoea patients with confirmed 
cryptosporidiosis from different geographical locations in the UK (Table 2.4). DNA 
was isolated as described in 2.3. For each isolate, the speciation was performed 
by PCR-RFLP of the COWP gene and by real-time PCR using simplex Lib 13 as 
described in 2.3. In addition, DNA of the C. parvum Iowa reference strain 
(ATCC/LGC Promochem, Teddington, UK) was also tested. All DNA samples were 
quantified by spectrometry using Nanodrop ND-1000 (Thermo Fisher scientific, 
Leicestershire, UK).  
 
2.5.3 Quantification of genomic DNA after WGA 
 
After WGA, the amplified products were analyzed by agarose gel electrophoresis 
as a semi-quantitative approach to evaluate the level of amplification of the 
genomic DNA. The electrophoresis profiles were also used for densitometry-
based DNA quantification using GeneTools software (Syngene, Cambridge, UK).  
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Table 2.4: Details of the origin and epidemiological data of clinical isolates of 
C. hominis and C. parvum, whose DNA was used for WGA kits trial.  
 
 
 
 
 
 
 
 
Sample 
reference 
Age of 
case 
Gender of 
case 
Origin of case RFLP of the  COWP 
gene (speciation) 
W15504 43 F Scotland C hominis 
W15507 9 F Wales C hominis 
W15508 31 Not stated England C hominis 
W15519 68 F England C hominis 
W15521 14 F Scotland C hominis 
W15509 12 Not stated England C parvum 
W15511 19 F Scotland C parvum 
W15516 21 F England C parvum 
W15517 12 M England C parvum 
W15518 2 M England C parvum 
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In addition, 3 methods were used to quantify the amplified genomic DNA: 
Nanodrop, Hoechst and PicoGreen. Nanodrop is an absorbance-based method 
and was used to estimate the amount of DNA available in each sample before 
and after WGA. However, because this method is influenced by the presence of 
free nucleotides in the reaction mix, alternative quantitation methods were 
used.  
 
Hoechst 33258 dye was used for quantification of the amplified DNA. It exhibits 
enhanced fluorescence when bound to dsDNA under high ionic strength 
conditions (Goumenou and Machera, 2004). For standard curve purposes, serial 
dilutions of calf thymus DNA stock solution (1 mg/ ml) (Sigma, Dorset, UK) were 
performed, yielding concentrations ranging from 100 ng/ ml to 2500 ng/ ml. 
Then, 50 μl of each preparation was placed in duplicates for measurement. All 
DNA samples were diluted in TNE buffer (100 mM Tris, 1 M NaCl, 10 mM 
Na2EDTA, pH 7.5). For each DNA sample, an equal volume of 2x Hoechst Dye 
solution (200 ng/ ml) (Sigma, Dorset, UK) was added. Fluorescence was read 
using microplate reader FLUOstar, BMG Labtech (Aylesbury, UK) after 5 min 
incubation at room temperature. The blank solution was prepared by adding an 
equal volume of TNE buffer and 2x dye solution. The average value of the blank 
measurement was subtracted from the duplicate measurements made at each 
concentration and the results plotted. A linear regression was performed on the 
standard curve to allow the determination of the DNA concentrations of the 
samples tested.  
 
PicoGreen was also used as an ultrasensitive fluorescent nucleic acid stain for 
accurate quantitation of double stranded DNA (dsDNA). Quanti-iT
TM
 Picogreen® 
dsDNA kit (Molecular Probes, Invitrogen, Paisley, UK) was used according to the 
manufacturer’s instructions.  
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2.5.4 Integrity and fidelity of amplified genomic DNA 
   
The integrity of the amplified DNA after WGA was evaluated by PCR using Cry15/ 
Cry 9, Cgd6_5020 and Chro.20156 primers, amplifying 550 bp, 270 bp and 247 
bp, respectively. All DNA templates were diluted 1/25 after WGA. PCR conditions 
were identical for genomic DNA and for post-WGA subsequent amplifications 
and are as described in 2.2.2.  
 
The fidelity of the amplification was assessed by PCR product sequence analysis 
before and after WGA of two C. hominis samples (W15507, W15519), two 
C. parvum samples (W15511, W15516) and the reference strain C. parvum Iowa. 
PCR products were purified, sequenced and analyzed as described in 2.4.  
 
2.5.5 Comparative analysis of Cryptosporidium genomic DNA before and after 
WGA 
 
The comparative analysis of genomic Cryptosporidium DNA and paired WGA DNA 
was limited to the samples that were prepared using the most promising WGA 
method. After WGA, the amplified products were compared to the original 
genomic DNA using a species-specific, semi-quantitative real-time PCR assay. 
Briefly, real-time PCR using simplex Lib 13 primers (Tanriverdi et al., 2003) was 
used in triplicate to amplify 2 µl genomic DNA and 2 µl of its paired WGA DNA 
(both diluted 1 in 25 v/v). Melt curve analysis was performed to identify 
Cryptosporidium species and CT values were recorded to compare each paired 
sample, before and after WGA. This assay shows a demonstrable difference of 3 
CT units per 10-fold difference in DNA target copy number (CRU unpublished 
data). Since the WGA DNA originated from 1 µl of genomic DNA producing 10 µl 
of product (representing a 10-fold dilution in comparison with the genomic 
DNA), the final CT values for the WGA DNA were decreased by 3 CT units.  
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2.6 Cryptosporidium parvum specific gene (Cops-1): Cgd2_4380 
 
2.6.1 Primers used for Cops-1 amplification 
 
In addition to Cgd2_4380F and R primers described in 2.2.1, Cgd2_4380 FF and 
FR primers amplifying the full gene length (1434 bp) were designed. The primer 
sequences are detailed in Table 2.5. Several internal primers were also designed. 
These internal primers were used to test the presence of the gene in C. hominis 
and to retrieve the gene sequence in a primer walking approach. In addition, a 
primer amplifying the 3’ flanking region to Cgd2_4380 gene was also designed 
and tested. Primer sequences are detailed in Table 2.5. PCR was carried out as 
previously described in 2.2.2. The annealing temperature was 55
◦
C for all the 
primers but was lowered to 52
◦
C or 47
◦
C for some primer combinations to 
decrease the stringency and allow amplification.  
 
2.6.2 Cops-1 protein encoding gene 
 
The predicted Cops-1 encoded protein was analyzed using                                   
online software tools for protein analysis: Protein                                                
Calculator v3.3 (http://www.scripps.edu/~cdputnam/protcalc.html), InterProScan 
(http://www.ebi.ac.uk/Tools/InterProScan/), PSORT II (http://psort.ims.u-tokyo.ac.jp/) 
and SignalP3.0 (http://www.cbs.dtu.dk/services/SignalP/).  
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Table 2.5: Primers used to amplify Cops-1 gene in a primer walking approach. 
The primers sequence and Tm are detailed. In addition, the position on the Cops-
1 gene is detailed for each primer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Primer name Sequence  Gene position Tm (
◦
C) 
Cgd2_4380FF ATGGGTAATAGTTTAAATGTTTTT 1-24 52.61 
Cgd2_4380FR TTATTTTCGGCATAACGG 1417-1434 53.07 
Cgd2_4380_2F GGGGTGGACCTAGATGCTC 245-263 64.48 
Cgd2_4380_2R GAGGTGGGCGTGATCTAGTAAA 883-904 62.67 
Cgd2_4380_flanking_5’end AAAAGCGCAAGTAATCTGGA Upstream sequence 56.3 
Cgd2_4380_flanking_3R CCTAAACCTAACCCCCTAAACCT Downstream 
sequence 
62.77 
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2.6.3 Monoclonal peptide antibody to Cops-1 
 
In order to further characterize the Cops-1 protein, a monoclonal peptide 
antibody was produced by Cambridge Research Biochemicals 
(www.crbdiscovery.com). Predicted protein sequence as retrieved from 
CryptoDB database (477 aa), was submitted for peptide design. Two sequences 
were selected corresponding to high immunogenicity: antigen 1 (Tyle-1) 
CDHEGFKPPRRTTT-amide (position 404-417) and antigen 2 (Tyle-2) [C]-
RSRPPLPTRKPYSGS-amide (position 297-311). Briefly, 5 mg of each antigen was 
prepared at >95% purity (as determined by HPLC analysis), 3 mg were conjugated 
to keyhole limpet hemocyanin (KLH) carrier protein and used to immunize Balb/c 
female mice. Mice bleeds were tested by ELISA and the animal having the 
highest titre (for each antigen) was used for spleen extraction and fusion with 
mouse myeloma cells. The cells were cultured in selective medium. After 10 days 
incubation, hybridoma supernatants were tested for the presence of specific IgG 
anti-Tyle 1 and Tyle 2 antibodies by ELISA. Immunopositive hybridoma cultures 
were expanded to large scale culture to allow production of antibodies. 
 
2.7 Cloning and expression of Cops-1 recombinant protein 
 
2.7.1 Cloning of Cops-1 
 
Two approaches were used to clone the Cops-1 gene. Cloning was performed 
into pGEM®-T Easy Vector System (Promega, Southampton, UK) according to the 
manufacturer’s instructions. Briefly, Iowa strain DNA (supplied as previously 
described in 2.3) was amplified by PCR using the Expand High Fidelity PCR system 
(Roche, Hertfordshire, UK) to reduce PCR errors. The full length of the cgd2_4380 
gene was amplified using Cgd2_4380_FF and FR primers in a 50 μl reaction. The 
PCR product was visualized by agarose gel electrophoresis and then purified 
using the QIAquick® PCR purification Kit as described in 2.4. The DNA was 
quantified using Nanodrop ND-1000. 50 ng of pGEM®-T Easy Vector, 80 ng of PCR 
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product and 3U of T4 DNA ligase were incubated overnight at 4
◦
C as instructed 
by the manufacturer. The ligation mix was used to transform JM109 High 
efficiency competent cells (genotype: e14–(McrA–) recA1 endA1 gyrA96 thi-1 hsdR17 (rK– mK+) 
supE44 relA1 Δ(lac-proAB) [F´ traD36 proAB lacIqZΔM15]). The positive clones were identified 
through the blue/white selection on LB/Ampicillin/IPTG/X-Gal agar plates. At 
least 3 positive colonies were used to isolate the recombinant plasmid using a 
Qiagen plasmid purification Midi kit according to the manufacturer’s instructions 
(Qiagen, Ltd., Crawley, UK). Briefly, one colony was used to inoculate 5 ml of LB 
(Luria-Bertani) medium (1% bacto-tryptone, 0.5% yeast extract, 1% NaCl, pH 7.0) 
containing 50 μg/ ml Ampicillin. After 8h incubation at 37
◦
C, the culture was 
diluted 1/500 into 100 ml LB selective medium. After overnight incubation, the 
cells were harvested by centrifugation at 6000 x g for 15 min at 4°C. The pellet 
containing the plasmid was then purified using the spin columns provided. 
Alternatively, the PCR product was cloned using forward primer: 
Cgd2_4380FF_XhoI CTCGAGATGGGTAATAGTTTAAATGTTTTT (Tm= 60.53
◦
C) and a 
reverse primer: Cgd2_4380FR_BamHI GGATCCTTATTTTCGGCATAACGG (Tm= 
62.86
◦
C). The underlined sequences correspond to the restriction sites XhoI and 
BamHI, respectively. The PCR product was visualized by agarose gel 
electrophoresis before digestion using XhoI and BamHI enzymes to allow cloning 
into the expression vector.  
 
In addition, Champion™ pET100 Directional TOPO® Expression Kit (Invitrogen, 
Paisley, UK) was used according to the manufacturer’s instructions. Briefly, 
Cgd2_4380FF_TOPO primer (CACCATGGGTAATAGTTTAAATGTTTTT) was designed 
(Tm= 57.8
◦
C). The underlined sequence will allow directional cloning of the PCR 
product by the GTGG overhang in the cloning vector pET100/D-TOPO® and to the 
action of Topoisomerase I. Amplification of the full length of Cgd2_4380 gene 
from Iowa DNA was performed using Cgd2_4380FF_TOPO and Cgd2_4380FR 
primers. PCR conditions were as described above. The PCR product was 
integrated into the pET100/D-TOPO® vector by incubation for 30 min at room 
temperature and used to transform One shot® TOP10 competent cells 
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(genotype: endA1, recA1, gyrA96, thi, hsdR17 (rk
–
, mk
+
), relA1, supE44, Δ( lac-proAB), [F´ traD36, proAB, 
laqI
q
ZΔM15]). Positive transformants were identified by PCR using T7 and 
Cgd2_4380_FR primers. The recombinant plasmid was isolated as described 
above. 
 
The isolated recombinant plasmids from pGEM®-T Easy Vector and pET100/D-
TOPO® vector were sequenced in both directions to confirm gene sequence and 
orientation. 
 
2.7.2 Expression vectors 
 
Two cloning vectors were used as described in 2.7.1. For pGEM®-T Easy Vector 
containing the Cgd2_4380 gene, 1 μg of plasmid preparation was used for double 
digestion using BamHI and XhoI enzymes (10U each) in 1x SuRE/Cut Buffer B 
(Roche, Hertfordshire, UK) in a final volume of 20 μl. The Expression vector 
pTrcHisA (commonly used in our laboratory and originally from Invitrogen) was 
digested using the same restriction enzymes. The linearized pTrcHisA vector and 
the Cgd2_4380 gene (released from the pGEM®-T Easy Vector by digestion) were 
purified using QIAquick Gel Extraction Kit (Qiagen, Ltd., Crawley, UK) and 
quantified by Nanodrop ND-1000. The molar ratio insert to vector was 
determined according the following formula: 
  
 
 
 
 
 
Different molar ratios were tested to determine the optimal ligation conditions: 
1:1, 3:1 and 10:1 and ligation was performed overnight at 4
◦
C using T4 DNA 
ligase (Promega, Southampton, UK). The pET100/D-TOPO® vector is used as a 
cloning and expression vector, so no further subcloning was required.  
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2.7.3 Bacterial strains used for expression 
 
The recombinant pTrcHisA vector was used to transform DH5α competent cells 
(genotype: F– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1). 10 ng of vector was used to transform a 200 μl cell aliquot. Cells were 
then heat shocked at 42
◦
C for 45s and incubated in 400 μl SOC medium for 1h. 
100 μl of each transformation was then plated on selective LB plate containing 
50 μg/ ml Ampicillin.  
 
The pET100/D-TOPO® vector containing the insert was used to transform BL21 
Star™(DE3) competent cells (genotype: F– ompT hsdSB(rB–, mB–) gal dcm rne131 (DE3)) 
according to the manufacturer’s instructions. Briefly, 10 ng of plasmid DNA was 
used to transform 50 μl of BL21 Star™ (DE3) One Shot® cells, which were then 
heat shocked at 42
◦
C for 30s and incubated in 250 μl SOC medium for 1h. The 
entire transformation reaction was then added to 10 ml of LB containing 50 μg/ 
ml Ampicillin. 
 
2.7.4 Specialized bacterial expression strains  
 
In addition to standard bacterial expression strains (described in 2.7.3), 
specialized bacterial strains were used in order to optimize the expression of the 
recombinant protein. These strains were kindly donated by Dr Matt Hutchings 
(School of Biological Sciences, UEA). Two of these strains were engineered to 
contain extra copies of genes that encode rare tRNAs, which allows high-level 
expression: BL21-CodonPlus-RP (genotype: F– ompT hsdS(rB– mB–) dcm+ Tetr gal endA Hte 
[argU proL Camr]) and Rosetta™2(DE3) (genotype: F- ompT hsdSB(rB
-
 mB
-
) gal dcm (DE3) pRARE2 
(Cam
R
)). The former supplies tRNAs for seven rare codons (AUA, AGG, AGA, CUA, 
CCC, CGG, GGA) and the latter supplies tRNAs for three rare codons (AGA, AGG, 
CCC). In addition, two bacterial strains engineered to allow expression of 
membrane proteins (Wagner et al., 2008) were used: C41(DE3) (genotype: F – 
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ompT hsdSB (rB- mB-) gal dcm (DE3)) and C43 (DE3) (genotype: F – ompT hsdSB (rB- mB-) gal dcm 
(DE3)). 
 
These bacterial strains were made chemically competent following this protocol: 
100 μl of liquid culture were plated on LB-agar plate without antibody selection. 
After overnight culture at 37
◦
C, a single colony was used to inoculate 15 ml LB 
and incubated overnight. 500 μl of this culture was used to inoculate 100 ml LB 
and the bacterial growth was monitored by OD600. When the mid-log phase was 
reached (OD600 range 0.4-0.6), the cells were centrifuged (5000 xg for 5 min at 
4
◦
C). Bacterial pellet was re-suspended in 10 ml of 0.1M CaCl2 and incubated on 
ice for 20 min. Cells were then centrifuged as previously and the pellet was re-
suspended in 10 ml of 0.1M CaCl2 containing 10% glycerol. Cells were then 
aliquoted and frozen in a dry ice/ ethanol bath and stored at -80
◦
C. 
 
These specialized expression strains were transformed as described in 2.7.3. 
BL21-CodonPlus-RP and Rosetta™2(DE3) strains have pACYC and pRARE 
plasmids, respectively, conferring Chloramphenicol resistance, so 
Chloramphenicol (34 μg/ml) was added to the LB medium for host strain 
selection. 
 
2.7.5 Expression of Cops-1 recombinant protein 
 
The expression of the recombinant protein was induced at mid-log phase by 
addition of 1mM IPTG (isopropyl-beta-D-thiogalactopyranoside). A pilot 
expression was performed from 5 ml cultures and the expression was monitored 
every hour for a time course (1-6 hours). A non-induced culture served as a 
negative control. At each time point, 500 μl aliquot was removed and centrifuged 
at 6000 xg for 5 min and cell pellets were stored at -20
◦
C until use. Each pellet 
was then re-suspended in SDS-PAGE Sample buffer, boiled for 5 min and used for 
protein analysis by Coomasie staining and Western blot. 
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In addition, pET100/D/lacZ, a control expression vector provided with the 
Champion™ pET100 Directional TOPO® Expression Kit, was used. It encodes β-
galactosidase and the fusion protein has an expected size of 121 kDa. The control 
expression plasmid was used to transform BL21 Star™ (DE3) One Shot® cells as 
described previously. 
  
The pilot expression allowed the determination of the optimal expression 
conditions, which were adopted for the production of recombinant protein on a 
larger scale. Briefly, one positive colony was used to inoculate 5 ml of liquid LB 
media containing 50 μg/ ml Ampicillin and 34 μg/ml of Chloramphenicol (when 
appropriate). After overnight incubation, the whole culture was added to 100 ml 
liquid LB media containing the same antibiotics as detailed above. The bacterial 
growth was monitored by spectrophotometry until mid-log phase (OD600= 0.5). 
The culture was then split into 2 flasks of 50 ml each. 1 mM IPTG was added to 
one flask, while the other was kept as uninduced culture. Both flasks were 
cultured for 4 h at 37
◦
C. 
 
2.7.6 Preparation of cell lysate 
 
After expression, the cells (both induced and uninduced) were harvested by 
centrifugation at 6,000 x g for 15 min at 4
◦
C. The cell pellets were stored at -80
◦
C 
until use. Preparation of protein samples was carried out according to the 
Champion™ pET100 vector manual. Briefly, cell lysates were thawed on ice and 
then re-suspended in 500 μl of lysis buffer (400 mM NaCl, 100 mM KCl, 10% 
glycerol, 0.5% glycerol, 0.5% Triton X-100, 10 mM imidazole, 500 mM potassium 
phosphate, pH 7.8). The samples were subjected to 3 cycles of freeze/ thaw and 
then centrifuged at 15,000 rpm for 1 min. The supernatants were transferred to 
clean tubes. In order to prevent protein degradation, 20 μl of complete EDTA-
free protease inhibitor cocktail (Roche, Hertfordshire, UK) and 10 μl of 
phosphatase inhibitor cocktail set II (Calbiochem, Merck Chemicals Ltd., 
Nottingham, UK) were added. The protein samples were kept at -20
◦
C until use. 
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The pellet was re-suspended in lysis buffer and used for the detection of 
insoluble proteins. 
 
2.8 Western Blot 
 
2.8.1 Protein samples preparation 
 
For Western Blot analysis, recombinant proteins prepared as described in 2.7.6 
were used. Alternatively, native antigen preparations were prepared as follows: 
2x10
8
 oocysts were pelleted by centrifugation at 2500 rpm for 10 min at 4
◦
C. The 
pellet was washed in PBS and the suspension was centrifuged at 10000 rpm for 
10 min at 4
◦
C and this step was repeated 3 times. The pellet was then 
resuspended in PBS, then 5 μl of complete EDTA-free protease inhibitor cocktail 
and 5 μl of phosphatase inhibitor cocktail were added. The reaction was kept on 
ice and sonicated for 15 min. The parasite lysate was subjected to 3 cycles of 
freeze/ thaw and then centrifuged at 15000 rpm for 30 min at 4
◦
C. The 
supernatant was collected and aliquoted and the antigen preparations were kept 
-20
◦
C until use. 
 
2.8.2 Protein quantification 
 
Protein quantification was carried out using BCA™ protein assay kit (Pierce, 
Thermo Fisher Scientific, Leicestershire, UK) according to the manufacturer’s 
instructions. Briefly, a working reagent solution was prepared by mixing 50 parts 
of BCA Reagent A with 1 part of BCA Reagent B. 200 μl of the working solution 
was added to 25 μl of protein samples (tested in duplicates) in a microplate 
format. In addition, 25 μl of bovine serum albumin (BSA) Standards ranging from 
20–2000 μg/ml was used. The samples were incubated for 30 min at 37
◦
C and 
the absorbance was read using a DYNAtech MRX plate reader at 550 nm. A 
standard curve was prepared by plotting the blank-corrected absorbance for 
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each BSA standard versus its concentration and was used to determine the 
protein concentration of each protein sample. 
 
2.8.3 SDS-PAGE 
  
The protein preparations were analyzed by sodium dodecyl sulphate-
polyacrylamide gel (SDS-PAGE) electrophoresis (Laemmli et al., 1970). The 
separation and stacking gels had a concentration of 10% and 4%, respectively. 
Gels were made with 30% acrylamide/bis solution, 10% sodium dodecyl sulphate 
(SDS), 10% ammonium persulphate and TEMED (all the reagents are from 
BioRad, Hertfordshire, UK). Protein samples were mixed with SDS-PAGE sample 
buffer (0.25 M Tris-HCl pH 6.8, 8% SDS, 30% Glycerol, 0.02% Bromophenol Blue, 
10% β-mercaptoethanol) and heated at 100
◦
C for 5 min. The protein samples 
were loaded on the SDS-PAGE gel alongside Precision plus Protein standards dual 
colour marker (BioRad, Hertfordshire, UK). The gels were run at 100 V for 2h at 
room temperature in a 1x running buffer made from 10x stock (0.25 M tris,     
1.92 M Glycine, 10% SDS). The gels were then stained with Coomassie blue 
solution (0.2% Coomassie Blue, 7.5% Acetic Acid, 50% Ethanol) for one hour and 
then de-stained in the Coomassie destaining solution (20% methanol, 5% glacial 
acetic acid) for protein visualization.  
 
2.8.4 Protein transfer 
 
Proteins were transferred from the acrylamide gel to a Polyvinylidene Fluoride 
(PVDF) membrane (Thermo Fisher scientific, Leicestershire, UK) using a Trans-
Blot SD Semi-dry Transfer cell (Biorad, Hertfordshire, UK) at 25 V for 30 min. The 
gel and membrane were soaked in Transfer buffer (25 mM Tris pH8.5, 0.2 M 
Glycine, 20% Methanol) prior to transfer.  
2.8.5 Immunolabelling 
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After transfer, the membrane was blocked in 1x TBST (Tris-Buffered Saline 
Tween-20) (25 mM Tris, 150 mM NaCl, 0.05% Tween 20) containing 5% skimmed 
dried milk for 1 h. The membrane was then washed 3 times for 5 min with TBST 
and incubated with the primary antibody 9E1 (1/100 dilution) to label the 
membrane overnight at 4
◦
C. The membrane was then washed 4 times for 15 min 
with TBST to remove the excess of unbound antibody. The membrane was then 
incubated with the secondary antibody Goat anti-mouse conjugated to 
horseradish peroxidase (HRP) (Jackson Immuno Research, Stratech Scientific Ltd, 
Suffolk, UK) diluted 1:20,000 in TBST containing 5% skimmed dried milk for 1 
hour at room temperature. After incubation, the membrane was washed 4 times 
for 15 min in TBST and finally in PBS (phosphate buffered saline). Alternatively, 
for the detection of the recombinant protein, a monoclonal anti- polyhistidine 
peroxidase conjugate antibody (Sigma, Dorset, UK) was used. The membrane 
was incubated with the antibody diluted 1:10,000 in TBST containing 5% 
skimmed dried milk for 2 hours at room temperature and then washed 4 times 
for 15 min in TBST and rinsed in PBS. 
  
The detection of the HRP signal was performed by adding 1 ml per membrane of 
Supersignal
®
 West Pico Chemiluminescent Substrate (Pierce, Thermo Fisher 
Scientific, Leicestershire, UK) for 5 min. The reaction was revealed on an X-ray 
film developed using SRX-101A X-ray processor (Konica Minolta, Banbury, UK). 
 
2.8.6 Reprobing of the membrane 
 
When reprobing of the labelled membrane was desirable, the membrane was 
washed in TBST for 5 min and then in deionised water for 5 min before being 
incubated in a 0.2 M sodium hydroxide solution for 5 min. The membrane was 
then washed in deionised water for 5 min and blocked in TBST solution 
containing 5% skimmed dried milk. The immunolabelling was then performed as 
described in 2.8.5 using a different antibody. 
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2.9 Immunofluorescence assay (IFA) 
 
2.9.1 Oocysts suspensions 
 
Purified Cryptosporidium oocyst suspensions were used for IFA testing. 
C. parvum Moredun oocysts (Moredun Research Institute, Midlothian, UK) and 
C. parvum Iowa (Bunch Grass Farm, Deary, ID) were purchased at 1x10
9
 titre. In 
addition, purified clinical oocyst suspensions were provided by CRU and tested 
by IFA. They correspond to the clinical isolates, whose DNA was tested by PCR as 
described in 2.3. The parasite concentration in clinical samples was determined 
using an improved Neubauer hemacytometer counting chamber, with 10 μl of 
each diluted oocyst suspension being added to the chamber. For each of the four 
counting grids, the number of cells was counted and an average was calculated. 
The grid surface is 0.1 mm below the coverslip. The volume of each grid (of 1 
mm
2
 area) is therefore 0.1 cubic mm. The number of cells per cubic mm is the 
average calculated number multiplied by 10
4
. The calculated parasite titres for 
each suspension are summarized in table 2.6. 
 
2.9.2 Antibodies and labelling reagents 
 
Cryptosporidium oocyst suspensions, as detailed in 2.9.1, were stained using the 
monoclonal antibody (9E1) as primary antibody. Different secondary antibodies 
were used to detect the reaction. A Fluorescein (FITC)-conjugated Goat Anti-
Mouse IgG (Jackson ImmunoResearch, Stratech Scientific Ltd, Suffolk, UK) was 
used at 1:200 dilution. Alternatively, a Cy™5- conjugated Donkey Anti-Mouse IgG 
(Jackson ImmunoResearch, Stratech Scientific Ltd, Suffolk, UK) or Alexa 
Fluor®546 Goat Anti-Mouse IgG (Molecular Probes, Invitrogen, Paisley, UK) were 
used at 1:800 and 1:200 dilutions, respectively.  
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Table 2.6: Determination of the titre of clinical Cryptosporidium oocyst 
suspensions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cryptosporidium isolate Concentration (oocysts/ml) 
Ch2 22x10
5
 
Ch3 1x10
5
 
Ch4 43x10
5
 
Cp2 2x10
7
 
Cp3 1x10
7
 
Cp4 0.5x10
5
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In addition, a staining protocol with two antibodies was used for improved 
binding specificity. Biotinylated Rat Anti-Mouse IgG (1:1000) was used as a 
secondary antibody and was subsequently detected using streptavidin substrate 
conjugated to Alexa Fluor®568 (1:100) (both reagents were purchased from 
Invitrogen, Paisley, UK). Furthermore, the effect of a further blocking step using 
Streptavidin/Biotin Blocking kit (Vector laboratories, Peterborough, UK) was also 
assessed.  
 
A direct conjugation kit was utilized to prepare fluorescent conjugates of the 
monoclonal antibody in order to eliminate possible cross-reaction of conjugated 
secondary antibody with the sample.  The subtype of the monoclonal antibody 
(9E1) was determined using Iso-Gold™ Rapid Mouse-Monoclonal Isotyping Kit 
(Amsbio, AMS Biotechnology Ltd., Abingdon, UK) according to the 
manufacturer’s instructions. Protein quantitation of 9E1 was determined by 
absorbance at 280 nm using Nanodrop ND-1000. Zenon® Alexa Fluor®594 Mouse 
IgG1 Labelling kit (Molecular Probes, Invitrogen, Paisley, UK) was used according 
to the manufacturer’s instructions and the freshly labelled antibody was utilized 
in IFA. Alexa Fluor®594 Monoclonal Antibody Labelling kit (Molecular Probes, 
Invitrogen, Paisley, UK) was also used for long term stable labelling of the 
monoclonal antibody. 
 
A Fluorescein isothiocyanate (FITC)-labelled genus-specific anti-Cryptosporidium 
species monoclonal antibody: Crypto-cell (TCS BioSciences Ltd., Buckingham, UK) 
staining the oocyst wall of Cryptosporidium spp. was used as a counter-stain 
according to the manufacturer’s instructions.  
 
2.9.3 Immunolocalization of Cops-1 
 
Approximately 10
3
 oocysts were deposited on a single welled-microscope slide 
(Hendley-Essex, Essex, UK), which was cleaned with methanol-soaked tissue prior 
to use. The parasite suspension was allowed to air-dry at room temperature and 
fixed by applying 20 μl of methanol. Then, 25 μl of the monoclonal peptide 
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antibody (9E1) was used to stain the oocysts in a humidified staining chamber for 
1h at room temperature. The antibody excess was washed twice in PBS. The 
secondary antibody and/or the appropriate substrate was used at the 
recommended dilution as detailed in 2.9.2 and incubated for 30 min at room 
temperature in a humidified staining chamber. The secondary antibody was then 
washed twice in PBS. For directly conjugated 9E1 antibody, this step was 
omitted. Crypto-cell antibody (30 μl) was added to the slide (when applicable) 
and incubated at 37
◦
C for 15 min. The antibody was then carefully removed and 
the slide was stained using 50 μl of a 1:2000 solution of 4',6-diamidino-2-
phenylindole (DAPI) for 2 min. The slide was then washed in deionized water and 
allowed to air-dry. It was then mounted in Fluoromount-G™ (SouthernBiotech, 
Cambridge BioScience Ltd., Cambridge, UK) and the edges of the coverslip were 
sealed using clear nail polish. Zeiss AxioPlan 2 microscope (Zeiss, Hertfordshire, 
UK) was used for the microscopic observation of the stained slides. 
 
2.10 Gliding assay  
 
Approximately, 10
6
 oocysts were excysted in a solution of 0.8% sodium 
deoxycholate at 37
◦
C for 30 min. The mixture was then filter-sterilized (0.2 μm) 
to separate sporozoites from empty shells and unexcysted oocysts. 5 μl of 
purified sporozoite suspension was deposited on a SuperFrost microscope slide 
(VWR International Ltd., West Sussex, UK). Excysted sporozoites undertake 
gliding motility and sporozoite proteins involved in host cell attachment and 
invasion are shed in these trails. The proteins present in trails are able to adhere 
to the slide when left to dry at room temperature. The slides were then stained 
using 9E1 monoclonal antibody. As a positive control, slides were stained using 
4C1 monoclonal antibody, kindly provided by Dr. A. Sheoran (Tufts Cummings 
School of Veterinary Medicine, Massachusetts, USA), raised against a sporozoite 
protein deposited in trails (Feng et al., 2006). A FITC-conjugated Goat Anti-
Mouse IgG secondary antibody was used as described in 2.9.2. The slides were 
also stained with DAPI as detailed in 2.9.3. The formation of gliding trails was 
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revealed by microscopic observation of stained slides using Zeiss AxioPlan 2 
microscope and FITC, DAPI and DIC filters.  
 
2.11 Co-culture of Cryptosporidium and Caco-2 cells 
 
2.11.1 Parasite preparation 
 
Purified C. parvum oocysts of the Iowa isolate (10
9
) were purchased from Bunch 
Grass Farm (Idaho, USA) and stored in PBS pH 7.2 containing 1000 U Penicillin 
and 1000 µg Streptomycin at 4°C. A 10 ml aliquot of this suspension was 
subjected to surface sterilization by suspension in 10% (vol/vol) commercial 
bleach solution (sodium hypochlorite) in PBS as previously described (Choudhry 
et al., 2008). The parasites were washed three times in PBS and pelleted by 
centrifugation at 13000 rpm for 6 min before enumeration using an improved 
Neubauer hemacytometer counting chamber as described in 2.9.1 to evaluate 
the number of parasite in the purified suspension. The purified oocyst 
suspension was used for co-culture. 
 
2.11.2 Excystation of the oocysts 
 
The bile salt sodium deoxycholate (Sigma, Dorset, UK) was suspended in 0.1% 
wt/vol in DMEM (Dulbecco’s Modified Eagle Medium) and filter-sterilized. Then, 
250 μl of this solution was equilibrated to 37
◦
C for 10 min, 10
6
 oocysts were 
added and the suspension was incubated at 37
◦
C in an aerobic incubator as 
previously described (Choudhry et al., 2008). The excystation was monitored 
microscopically; when the majority of the oocysts (~ 80%) were excysted, the 
reaction was stopped by taking the reaction back to room temperature. 
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2.11.3 Cell culture 
 
The Caco-2 (Human colorectal adenocarcinoma) epithelial cell line was kindly 
donated by Dr. N. Belshaw (Institute of Food Research, Norwich). The cells were 
routinely grown in T-75 Tissue culture Nunclon™ coated flasks (Nunc, Thermo 
Fisher Scientific, Leicestershire, UK) and maintained in DMEM supplemented 
with 10% heat-inactivated foetal calf serum, 10 mM L-glutamine, 100 U of 
penicillin/ml and 100 µg of streptomycin/ml (all reagents are from Gibco, 
Invitrogen, Paisley, UK). Cells were grown in an incubator at 37°C with 5% CO2 
and 95% air until confluence. The culture medium was removed and the cells 
were washed twice in PBS. Adherent cells were detached by adding 1 ml trypsin 
(Sigma, Dorset, UK) and incubation for 5-7 min at 37°C (until all the cells were 
detached). The trypsin action was neutralized by adding 10 ml of DMEM. The 
cells were homogenised by pipetting up and down. Then, 5 ml of the cell 
suspension was used to seed a new culture flask containing 10 ml of culture 
media. When a cell count was required, it was performed as described in 2.9.1. 
All cell culture manipulations were carried out under sterile conditions in an 
advanced Bio safety class II cabinet (Microflow, BioQuell, Hampshire, UK).  
 
2.11.4 Cell monolayers growth 
 
2x10
5
 cells from the cell suspension as described in 2.11.3 were used to seed 
sterile 13 mm diameter coverslips placed in 24-well plastic tissue culture plates 
(Nunc, Thermo Fisher Scientific, Leicestershire, UK) in 1 ml of supplemented 
DMEM medium. The cells were grown to confluence over 3-5 days.  
 
2.11.5 Infection of cell monolayers 
 
When Caco-2 cell monolayers reached confluence, the culture medium was 
removed and the coverslips were washed twice with PBS before the addition of 
1x10
6
 oocysts in 500 µl of serum-free DMEM. As a control, coverslips were 
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incubated in medium without oocysts. In some experiments, the cell monolayers 
were infected with excysted oocysts as described in 2.11.2. For invasion assays, 
the oocysts were incubated with the cells for either 3 or 24 hours at 37°C to 
allow host-cell attachment and invasion. After incubation, the culture medium 
was removed and the cells were washed twice in PBS before adding 1 ml of 
supplemented DMEM as described in 2.11.3. The cell monolayers were then 
cultured for a further 24 hours at 37°C.  
 
2.11.6 Fixation and staining of cell monolayers 
 
The culture medium was removed from the infected cell monolayers and the 
wells were washed twice with PBS to remove any remaining traces of medium. 
Each coverslip was incubated with 100 µl of 1% paraformaldehyde at room 
temperature for 15 min and then washed three times with PBS to remove any 
traces of paraformaldehyde. After fixation, the cells were stained with Giemsa 
(Giemsa stock solution diluted in 0.1 M phosphate buffer pH 6.8) for 2h at room 
temperature. The slides were then washed and allowed to air-dry, before being 
mounted. The intracellular multiplication stages of the parasite were identified 
by microscopic observation. 
 
2.11.7 Inhibition of Cryptosporidium adhesion-invasion of the host cells in vitro 
 
The role of Cops-1 protein in host-cell attachment and invasion was evaluated in 
a blocking assay by pre-incubation of the parasite suspension with 9E1 before 
coculture in Caco-2 cell monolayers. The monoclonal antibody 9E1 was 
incubated with 1x10
6
 oocysts from a purified suspension as described in 2.11.1. 
The 9E1 antibody was used at two concentrations (1mg/ml and 0.1 mg/ml). As a 
negative control, a mouse IgG1 isotype (AbD Serotec, MorphoSys UK Ltd, Oxford, 
UK) was used at 0.1 mg/ml. As a positive control, 1x10
6
 oocysts were incubated 
in PBS (no blocking). Antibody and parasite suspensions were incubated at 37°C 
for 90 min as previously described (Nishikawa et al., 2000) and the mixture was 
used to infect confluent Caco-2 cell monolayers in duplicate as described in 
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2.11.5. After 3h incubation, parasite suspensions were removed and the 
monolayers were cultured for a further 24 h as described in 2.11.5. Coverslips 
were washed, fixed and stained as described in 2.11.6. The parasites infecting 
host cells were observed by bright field microscopy. The effect of the pre-
incubation with the antibody was assessed by parasite count for each condition 
from 20 randomly chosen fields. 
 
2.12 Screening of Cryptosporidium antigens by Western Blot using 
sera from cryptosporidiosis patients 
 
2.12.1 Cryptosporidium antigens 
 
The recombinant Cops-1 protein produced as detailed in 2.7.5 and 2.7.6 was 
screened by Western Blot using patient’s sera. In addition, native antigen 
preparations from C. hominis and C. parvum oocysts were also screened. 
C. hominis oocysts were kindly donated by Prof. G. Widmer (Tufts Cummings 
School of Veterinary Medicine, Massachusetts, USA) and C. parvum Iowa oocysts 
were purchased as detailed in 2.9.1. Approximately, 2x10
6
 oocysts were 
concentrated by centrifugation 13000 rpm for 10 min at 4°C. The pelleted 
parasites were re-suspended in a small volume of PBS. The oocysts were frozen 
in a dry ice/ ethanol bath and immediately thawed in a water bath at 42°C. This 
cycle was repeated 4 times to ensure the breakage of the oocyst wall. Then, 2 μl 
of protease inhibitors and 2 μl of phosphatase inhibitors were added as 
previously described in 2.7.6 and Western Blot analysis was performed as 
described in 2.8. 
 
2.12.2 Cryptosporidiosis patient sera 
 
Native or recombinant antigen preparation proteins were tested by immunoblot 
using sera from Cryptosporidium-infected patients to check the immunogenicity 
of Cops-1 protein. The sera are from laboratory-confirmed cryptosporidiosis 
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cases kindly donated by Dr. K. Elwin (Cryptosporidium Reference Unit, Singleton 
Hospital, Swansea, UK). Cryptosporidium isolates were genotyped, so, it was 
possible to differentiate between C. parvum and C. hominis serological 
responses. Initially, one C. hominis serum and one C. parvum serum were tested 
at 1:50 dilution. These sera were previously tested at CRU and showed high level 
of expression of the 15/17 and 27KDa Cryptosporidium immunodominant 
proteins. In addition, a negative serum (no detected cryptosporidiosis) was 
tested as a negative control. The reaction was detected using a Goat Anti-Human 
IgG HRP-conjugated secondary antibody (Abcam, Cambridge, UK) diluted 
1:20,000. 
  
- 101 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: 
Identification of species-specific markers 
of anthroponotic Cryptosporidium species 
using comparative genomics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3 
- 102 - 
3.1 Introduction 
 
At least seven Cryptosporidium species infect humans (Xiao and Fayer, 2008); 
however, only two species are of most significance for public health causing the 
majority of human cases both as sporadic and outbreak related cases: C. hominis and 
C. parvum (Cacciò and Pozio, 2006, Cacciò, 2005, Xiao and Ryan, 2004, Morgan et al., 
1999). C. parvum is zoonotic and mostly associated with human and ruminant 
infections, while C. hominis is generally restricted to humans (Robertson and Gjerde, 
2007). These two Cryptosporidium species differ mainly in host range, but differences 
in geographical and temporal distribution, pathogenicity and risk factors have also 
been identified (Cacciò, 2005, Hunter and Thompson, 2005). Formerly, these species 
were considered one single species, with the anthroponotic subtype called C. parvum 
genotype 1 and the zoonotic subtype called C. parvum genotype 2. Subsequently, 
based on molecular and phylogenetic analysis, in combination with biological 
differences, Morgan-Ryan and colleagues (2002) suggested the creation of new 
species: C. hominis for C. parvum genotype 1. In addition, some Cryptosporidium 
species and genotypes, initially not associated with human infection, were shown to 
cause cryptosporidiosis outbreaks. These species and genotypes are therefore 
considered emergent. This is for example the case of the rabbit genotype, identified 
as the aetiological agent in a medium-sized outbreak of waterborne human 
cryptosporidiosis in the Northamptonshire area (Robinson and Chalmers, 2009, 
Chalmers et al., 2009).  
 
The public health relevance of C. parvum and C. hominis has driven a bias in 
Cryptosporidium research towards these two human infective species. In fact, 
genomes representatives of C. parvum and C. hominis species have been sequenced 
(Abrahamsen et al., 2004, Xu et al., 2004). In addition, the genome sequencing of 
C. muris, a less relevant Cryptosporidium species from a public health perspective, is 
underway (Widmer et al., 2007). The genomic data for all three genome 
representatives are available online (http://CryptoDB.org).  
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The genome sizes for C. parvum and C. hominis are 9.11 and 9.16 Mb, respectively 
(Table 3.1). The GC content is ~ 30% and the coding region is ~ 6 Mb (Xu et al., 2004). 
The number of published genes is slightly higher in C. hominis than in C. parvum: 
3,994 genes versus 3,952 genes. The average gene length is comparable between the 
two species: 1.57 kb and 1.72 kb, for C. hominis and C. parvum, respectively (Table 
3.1).  
 
The genome analysis of C. hominis and C. parvum showed extremely streamlined 
metabolic pathways and a reliance on the host for nutrients (Abrahamsen et al., 
2004). Biosynthesis capabilities are limited, explaining an extensive array of 
transporters that enable import of essential nutrients from the host (Pain et al., 
2005, Xu et al., 2004). Genome sequences showed that Cryptosporidium species have 
genes associated with apical complex organelles despite the fact that they lack an 
apicoplast and possess a degenerate mitochondrion that has lost its genome 
(Abrahamsen et al, 2004, Xu et al, 2004). The existence of a relict mitochondrion was 
later confirmed by ultrastructural studies (Keithly et al., 2005). 
 
About 60% of Cryptosporidium genes exhibit similarity to known genes. The 
annotations for Cryptosporidium, Plasmodium and Saccharomyces are remarkably 
similar, suggesting that their phenotypic differences are a reflection of non-
conserved or previously unreported gene families of unknown function rather than 
to the functional specialization of conserved gene families (Xu et al., 2004).  
 
 
 
 
 
 
 
 
Chapter 3 
- 104 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1: Genomic and proteomic characteristics of C. hominis TU502 and C. parvum 
Iowa strains based on full genome sequences (reproduced from Xu et al., 2004) 
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Several comparative genomics studies were performed after the completion of 
genome sequences of apicomplexan parasites of medical and veterinary importance. 
Templeton and colleagues (2004) showed that Cryptosporidium spp and Plasmodium 
spp. share over 150 ancestral “apicomplexan” proteins, mainly involved in 
interactions with eukaryotic host cells and the biogenesis of the apical complex. 
Gordon and Sibley (2005) used genome sequences of Toxoplasma gondii, 
Plasmodium spp., Cryptosporidium spp. and Theileria spp. to show the conservation 
of actin-like proteins among these parasites relying on actin-based motility for cell 
invasion. In addition, comparative genomics of Plasmodium spp., Cryptosporidium 
spp. and Toxoplasma gondii revealed that calcium-regulated proteins (plant-like 
pathways for calcium release channels and calcium-dependent kinases) were also 
conserved (Nagamune and Sibley, 2006).  
 
Genome comparison of C. hominis and C. parvum showed a high level of similarity, 
which limited the ability of comparative genomics to improve annotation, identify 
conserved non-coding elements and study gene and protein evolution (Widmer et 
al., 2007). More importantly, this high sequence similarity hindered better 
understanding of host specificity and virulence mechanisms of these Cryptosporidium 
species, as was initially anticipated from the genome projects (Widmer et al., 2002). 
In fact, C. hominis and C. parvum genomes exhibit only 3–5% sequence divergence, 
with no large insertions, deletions or rearrangements (Xu et al., 2004). The authors 
stated that the gene complements of the two species are essentially identical 
because the few C. parvum genes not found in C. hominis are proximal to known 
sequence gaps (there are 246 gaps in the C. hominis genome sequence). However, 
the total number of genes was similar: 3,994 and 3,952 for C. hominis and C. parvum, 
respectively (as shown in Table 3.1). The significance of the 42 missing genes is not 
clear. In fact, uncertainty about the amount of sequence variation between C. 
parvum and C. hominis persists due to the incomplete status of the C. hominis 
genome. It has been concluded, however, that the phenotypic differences between 
C. hominis and C. parvum are caused by polymorphisms in coding regions and 
differences in gene regulation (Pain et al., 2005, Xu et al., 2004). Nevertheless, the 
role of what genetic variability is present in the phenotypic differences between C. 
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hominis and C. parvum is now much more accessible for investigation. In fact, this 
subset of genes displaying the most variation may include hitherto unnoticed genetic 
determinants of host specificity and virulence. 
 
3.2 Aims 
 
The aim of this study is to identify potential genetic determinants of host tropism for 
C. parvum and C. hominis species. This was undertaken using a comparative genomic 
approach, aiming to investigate the reported 3-5% sequence divergence between the 
two species. These areas of high sequence variation in the coding regions are 
putatively species-specific genes. These genes could be responsible for the 
phenotypic and pathogenic differences between these two important human 
infective Cryptosporidium species.  
 
3.3 Results 
 
3.3.1 Reciprocal BLAST  
 
Based on the published genome sequences for C. parvum and C. hominis available on 
CryptoDB database, the Reciprocal BLAST tool was used to identify putative species-
specific genes as described in 2.1.1. This comparative genomic tool was used to 
assign a similarity score to every C. hominis gene when tested by BLAST against the 
genomic database of C. parvum. Similarly, each coding sequence from C. parvum was 
tested by BLAST against C. hominis genomic sequences and a similarity score was 
assigned. Putatively species-specific genes correspond to regions of high sequence 
variation; therefore, a threshold of 10% sequence identity was adopted. Only genes 
showing a level of identity below 10% were considered. This initial screening allowed 
the identification of 117 and 272 putative species-specific genes for C. hominis and 
C. parvum, respectively (Appendix II). The majority of C. parvum putative specific 
genes were annotated, while C. hominis selection corresponded mainly to 
hypothetical proteins. All the putative species-specific genes were individually tested 
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using Blastn algorithm as described in 2.1.1. In addition, the genomic database 
CryptoDB was used to identify orthologs in other Cryptosporidium species. This 
secondary screening was undertaken to increase the prediction stringency. The 
number of the predicted putative species-specific genes was 93 and 211 genes for 
C. hominis and C. parvum, respectively (Appendix III). 
 
3.3.2 PCR testing of putative species-specific genes in C. hominis and C. parvum 
strains 
 
The specificity of a subset of putative species-specific genes identified in silico was 
assessed experimentally by PCR in a collection of C. hominis and C. parvum clinical 
isolates obtained from the Cryptosporidium reference Unit as described in 2.3. In 
addition, DNA of three reference strains was also tested: C. hominis TU502, 
C. parvum Iowa and C. parvum Moredun. For each gene, primers were designed and 
PCR was carried out as described in 2.2. PCR products were purified and sequenced 
in both directions and sequence analysis was performed as described in 2.4.  
 
Initially, ten putative species-specific genes were tested by PCR. Surprisingly, 90% 
(9/10) of the genes tested were common to C. hominis and C. parvum. Figure 3.1 
shows the PCR results for the amplification of cgd2_80 and chro.50330 genes. There 
was no discernable difference between PCR results of clinical isolates and reference 
strains by agarose gel electrophoresis. All isolates DNA was amplified by PCR, except 
for one isolate (Cp4), which did not amplify using Chro.30149 primers.  
 
Further testing of additional predicted species-specific genes confirmed the general 
trend, therefore, the majority of the genes identified in silico seems to be common to 
both Cryptosporidium species. 
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Figure 3.1: Amplification of Cryptosporidium DNA from clinical isolates and reference 
strains. A: amplification of 266 bp of Cgd2_80 gene, B: amplification of 368 bp of 
Chro.50330 gene. Both Cryptosporidium species and all isolates were PCR positive. 
MW: molecular weight, 1: Cp2, 2: Cp3, 3: Cp4, 4: Ch2, 5:Ch3, 6: Ch4, 7: Iowa, 8: Moredun, 9: TU502, 
NTC: non template control. 
 
 
 
 
 
MW    1   2   3   4    5   6   7    8   9   NTC 
500 bp 
200 bp 
A 
     MW   1   2   3    4    5    6   7   8   9  NTC 
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B 
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3.3.3 PCR testing of putative species-specific genes in other Cryptosporidium 
species 
 
Whether the observed ubiquity of the predicted specific genes represented the 
closeness between C. hominis and C. parvum or whether these genes are orthologous 
in other Cryptosporidium species was assessed by experimentally testing DNA from 
other Cryptosporidium species and genotypes. C. andersoni, C. felis, cervine 
genotype, C. meleagridis and C. baileyi DNAs were kindly donated by CRU and used 
for PCR screening as described in 2.3 using primers designed to amplify the ten novel 
genetic loci. 
 
C. meleagridis DNA was amplified by PCR for 8/10 genes (80%). Only, Cgd2_2430 and 
Chro.20156 PCR reactions were negative (Table 3.2). Interestingly, for Cgd2_2430 
gene, only C. andersoni DNA was amplified by PCR. For Cgd6_5020, only C. felis DNA 
was PCR positive and for Chro.30149 primers, cervine genotype DNA was amplified. 
C. andersoni, cervine genotype and C. felis DNA was amplified by 10% (1/10) of 
primers tested. C. baileyi DNA was not amplified by any of the primers tested. 
 
3.3.4 Sequence analysis of PCR products 
 
All positive PCR products were purified and sequenced using forward and reverse 
primers in two independent sequencing facilities as described in 2.4. The alignments 
of PCR product sequences for each gene are shown in Appendix IV. PCR product 
sequences were submitted to GenBank and are available online (GU904212- 
GU904405). One PCR product of C. meleagridis DNA using Chro.50330 primers did 
not give good sequence and was therefore excluded from the analysis. PCR products 
for C. andersoni, C. felis and cervine genotype, as mentioned in 3.3.3, did not yield 
good quality sequences and they were not included in the analysis. 
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 C. andersoni C. felis Cervine genotype C. meleagridis C. baileyi 
Cgd2_80 - - - + - 
Cgd2_2430 + - - - - 
Cgd6_200 - - - + - 
Cgd6_5020 - + - + - 
Cgd8_2370 - - - + - 
Chro.20156 - - - - - 
Chro.50317 - - - + - 
Chro.50330 - - - + - 
Chro.30149 - - + + - 
Chro.50457 - - - + - 
 
 
Table 3.2: PCR results from other Cryptosporidium species using newly designed 
primers amplifying fragments from the ten novel genetic loci. PCR product sizes are 
shown in table 2.1. 
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The majority of the genes tested were common to both Cryptosporidium species. Not 
surprisingly, the sequences in the different strains were highly conserved, but some 
polymorphism was seen mainly as Single nucleotide polymorphisms (SNP)s. A total of 
78 SNPs were detected from 4150 nucleotides, this corresponds to an average of 1 
SNP every 53 bp. The details of the position and type of SNPs for each gene are 
shown in Appendix V. The SNP result is summarized in Table 3.3. The number of SNPs 
was variable for each gene, ranging from 1 SNP every 30 bp for Cgd2_2430 to less 
than one SNP per 330 bp for Chro.30149 (Table 3.3).  
 
Interestingly, 78.3% (61/78) of the SNPs were species-specific, thus defining an 
interesting feature of this subset of genes identified by comparative genomics. The 
proportion of species-specific SNPs ranged from 66.7% for Cgd8_2370 and 
Chro.50317 genes to 100% for Chro.50330 and Chro.50457. The majority of the SNPs 
detected (64.2%) were synonymous, thus maintaining the protein sequence. The non 
synonymous SNPs were not evenly distributed between the loci. In general, the 
proportion of the non synonymous SNPs was low for the majority of the genes 
ranging from 0% to 25% for Chro.50330 and Cgd6_200, respectively (Table 3.3). On 
the contrary, for Chro.50317 and Chro.20156 genes, 66.7% and 83.4% of the SNPs 
were non synonymous. In addition to 61 species-specific SNPs allowing discrimination 
between C. hominis and C. parvum, the sequence analysis revealed five SNPs specific 
for rabbit genotype isolates and three SNPs specific for anthroponotic C. parvum 
subtype (Appendix V). 
 
Some of the newly identified species specific SNPs were predicted to form restriction 
sites, which was confirmed experimentally by PCR-RFLP. The sequences alignments 
were used to identify differential restriction sites between the main species tested. 
For example, the sequence alignment of Cgd6_200 PCR products showed a SNP at 
position 202 (C T) in C. hominis isolates, which creates a ClaI restriction site 
(ATCGAT). C. hominis and C. parvum PCR products were digested with ClaI and the 
digestion profile is presented in Figure 3.2. For C. hominis, the 447 bp PCR product 
was digested into two fragments of 210 bp and 240 bp, as predicted, while C. parvum 
PCR product lacks the restriction site and remained undigested.  
  
 
 
 
 
 
Table 3.3: Summary of genetic polymorphism detected by PCR product sequence analysis of 10 genetic loci from C. parvum and 
C. hominis isolates. 78 SNPs were detected, 78.3% of which were species specific. For each gene, the number and proportion of 
species-specific SNPs were provided. The effect of the genetic polymorphism on amino acid composition was also indicated. 
 
 
 
 
 
 
 
Gene name Gene 
annotation 
PCR 
product 
size 
Number of 
SNPs 
detected 
Average 
number of 
nucleotides  
per SNP 
Number of 
Species specific 
SNPs (%) 
Number of non 
synonymous 
SNPs (%) 
Cgd2_80 ABC transporter family protein 266 bp 7 38 6 (85.5%) 1 (14.3%) 
Cgd2_2430 Ximpact ortholog conserved protein seen in bacteria and eukaryotes 389 bp 13 30 9 (69.3%) 3 (23.1%) 
Cgd6_200 Oocyst wall protein 8 447 bp 8 56 6 (75%) 2 (25%) 
Cgd6_5020 Protein with WD40 repeats 271 bp 2 136 2 (100%) 1 (50%) 
Cgd8_2370 Adenosine kinase like ribokinase 685 bp 12 58 8 (66.7%) 1 (8.4%) 
Chro.20156 Hypothetical protein 247 bp 6 42 5 (83.4%) 5 (83.4%) 
Chro.50317 RNA polymerase A/beta'/A'' subunit 752 bp 15 51 10 (66.7%) 10 (66.7%) 
Chro.50330 Leucyl tRNA synthetase 368 bp 3 123 3 (100%) 0 (0%) 
Chro.30149 Ubiquitin-protein ligase 1 331 bp 0 331   
Chro.50457 Erythrocyte membrane-associated antigen 394 bp 12 33 12 (100%) 5 (41.7%) 
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Figure 3.2: PCR-RFLP using ClaI restriction enzyme of Cgd6_200 gene PCR 
products. The C. hominis PCR product is digested into 2 fragments of 210 bp and 
240 bp; however, C. parvum PCR product is not digested. MW: molecular weight, 1: 
Cp2, 2: Ch2, 3: Cp3, 4: Ch3,  
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3.3.5 Multi-locus analysis (MLA) 
 
For MLA analysis, 11 gene sequences were included. Ten genes were derived as 
in 3.3.3, in addition to sequences of the COWP gene. The retrieved sequences 
allowed comparison of a total of 4469 bp. A Neighbor-Joining Tree was 
generated using MEGA software. The tree showed clear discrimination between 
C. parvum and C. hominis isolates (Figure 3.3 (A)). Within each group, there were 
two clusters corresponding to isolate subtypes. C. parvum anthroponotic subtype 
isolates (W65, W66, W67, W70) were separated from the other C. parvum 
isolates and the rabbit genotype isolates were segregated from the C. hominis 
isolates. All groups and clusters were supported by high bootstrap values. 
Unweighted Pair Group Method with Arithmetic Mean (UPGMA) phylogenetic 
method was also tested to construct a phylogenetic tree, which gave identical 
topology with similar bootstrap values. 
 
Within each main group, there was no discrimination between the different 
isolates, despite distinct GP60 subtypes. However, TU502 strain showed some 
sequence divergence and was grouped separately within the C. hominis cluster. 
This is due to the presence of a unique SNP at position 132 on Cgd8_2370 gene 
(Appendix V). This SNP was confirmed by three independent rounds of 
sequencing reactions.  
 
C. meleagridis DNA did amplify for 8/10 loci tested as detailed in 3.3.3. 
C. meleagridis sequences were included in MLA and used as an out group for the 
construction of a Neighbor-Joining phylogenetic tree as described above. 
Sequences from Cgd8_2370 and Chro.50330 genes did not generate high quality 
sequences. Therefore, the differences between this strain and the other isolates 
were based only on 2853 bp comparisons for seven genetic loci. The 
phylogenetic tree having C. meleagridis as an out group showed an identical 
clustering of the isolates tested with similar bootstrap values (Figure 3.3 (B)). 
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Figure 3.3: Phylogenetic Tree based on the gene sequences of 10 new loci and 
the COWP gene sequence. The trees were constructed using Neighbor- Joining 
algorithm of MEGA software. A: Phylogenetic tree constructed with 
C. meleagridis sequences. B: Phylogenetic tree with C. meleagridis as an out-
group. Cryptosporidium species and subtypes for each cluster are shown in red. 
 
A 
B C. parvum 
Anthroponotic 
C. parvum 
C. hominis 
Rabbit         
genotype 
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3.3.6 SNP analysis 
 
The SNP analysis was performed using the logical function “IF” of the Microsoft 
Excel software to discriminate between variables. Isolate groups and subtypes 
were compared in a pair-wise manner. When the SNPs are identical between the 
two groups, the value “0” is attributed, while if the two SNPs are different, the 
value “1” is assigned. Then, the values are summed for each group to represent 
the genetic variability between the main isolate groups. The calculated values 
are presented in Table 3.4. The newly identified SNPs showed a clear genetic 
difference pattern between species and subtypes of Cryptosporidium and the 
number of base pair differences between the groups is shown in Table 3.4.  
 
It is noticeable that the genetic differences of C. hominis and C. parvum to 
C. meleagridis were comparable (5.50 and 5.05%, respectively). This is supported 
by minimal genetic variability between C. hominis and C. parvum (1.72%). 
Interestingly, the genetic difference between C. parvum and C. parvum 
anthroponotic subtype was 0.13%, while a slightly higher genetic difference was 
observed between C. hominis and rabbit genotype isolates (0.27%).   
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4: Genetic differences (number and percentage of base pair polymorphisms) between the main groups and subtypes of 
Cryptosporidium tested. 
 
 
 
 
 
 C. hominis C. parvum Anthroponotic 
C. parvum 
Rabbit 
genotype 
C. meleagridis 
C. hominis 0     
C. parvum 77 (1.72%) 0    
Anthroponotic C. parvum 78 (1.75%) 5 (0.12%) 0   
Rabbit genotype 12 (0.27%) 75 (1.68%) 76 (1.70%) 0  
C. meleagridis 157 (5.50%) 144 (5.05%) 144 (5.05%) 155 (5.50%) 0 
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3.3.7 C. parvum specific gene (Cops-1) 
 
Among the subset of genes tested for specificity by PCR, only one gene was 
C. parvum specific as predicted by comparative genomics. This gene Cgd2_4380, 
gave a correct size PCR product (665 bp) from C. parvum DNA but not from 
C. hominis DNA (Figure 3.4). Different PCR conditions were tried (different primer 
concentration and lower annealing temperature) to allow amplification of C. hominis 
DNA with no success. The PCR product was negative from rabbit genotype DNA. 
However, when other Cryptosporidium spp. DNA was tested, only, C. meleagridis 
gave amplification. 
 
 
 
 
 
 
 
 
 
Figure 3.4: Amplification of 665 bp of Cgd2_4380 gene from C. parvum isolates and 
reference strains DNA. C. hominis DNA did not amplify. MW: molecular weight, 1: Cp2, 2: 
Cp3, 3: Cp4, 4: Ch2, 5: Ch3, 6: Ch4, 7: Iowa, 8: Moredun, 9: TU502, NTC: non template control. 
 
 
 
 
MW      1   2    3   4    5   6    7    8   9   NTC 
500 bp 
  1500 bp 
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3.3.8 C. hominis specific gene (Chos-1) 
 
Among the initial genes tested by PCR, none was C. hominis specific. Subsequent 
testing of additional putatively specific C. hominis genes allowed the identification of 
one C. hominis specific gene: Chro.50011. The primers enabled amplification of the 
right product size (287 bp) from C. hominis isolates but not from C. parvum DNA 
(Figure 3.5). Different conditions were tried to optimize the amplification of 
C. parvum DNA (as described in 3.7.4), but were unsuccessful. The rabbit genotype 
DNA gave the same profile as C. hominis DNA (not shown). Testing of other 
Cryptosporidium spp. DNA (C. andersoni, C. felis, cervine genotype, C. meleagridis 
and C. bailey) did not allow amplification even from C. meleagridis DNA. 
 
 
 
 
 
 
 
 
 
Figure 3.5: Amplification of 287 bp of Chro.50011 gene from C. hominis clinical 
isolates and reference strains DNA. No amplification of C. parvum DNA was possible. 
MW: molecular weight, 1: Ch2, 2: Ch3, 3: Ch4, 4: Cp2, 5: Cp3, 6: Cp4, 7: Iowa, 8: Moredun, 9: TU502, 
NTC: non template control. 
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3.4 Discussion 
 
In this study, comparative genomic tools were used to identify putative species-
specific genes for C. hominis and C. parvum. The bioinformatic primary and 
secondary screening allowed the identification of 93 and 211 genes for C. hominis 
and C. parvum, respectively. Initially, ten of these genes were tested by PCR in a 
collection of Cryptosporidium clinical isolates and reference strains. The PCR 
screening of the putative species-specific genes showed that the majority of the 
genes were not as predicted. In fact, 90% of the genes tested were common to 
C. hominis and C. parvum isolates and some were present in C. meleagridis. This 
result reflects the quality and the status of the published genome sequences. 
C. hominis TU502 genome is neither completed nor fully assembled, which clearly 
hindered the accuracy of the comparative genomic analysis performed. The majority 
of the predicted genes are not specific and may correspond to sequence gaps 
reported (Xu et al., 2004). 
 
Further testing of an additional ten genes confirmed the general trend of orthology. 
An improved comparative genomic analysis has been made possible by the fast 
progress made towards the completion of C. muris genome. In fact, 8.9 Mb from the 
C. muris genome has recently been made available for download from CryptoDB 
database, of which 7.2 Mb corresponds to coding sequences. Based on these newly 
added genomic sequences, 58.4% of the selected putative species-specific genes 
appear to have orthologs in C. muris. This information, if known previously, would 
have decreased dramatically the number of putative species-specific genes 
predicted by comparative genomics, which would assist the successful discovery of 
genetic determinants of host tropism. 
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In order to verify whether these common genes reflected the closeness between 
C. hominis and C. parvum or whether they are orthologous genes common to other 
Cryptosporidium species. C. andersoni, C. felis, cervine genotype, C. meleagridis and 
C. baileyi DNA were also tested. C. meleagridis DNA amplified using 80% of the 
primers tested, C. andersoni, cervine genotype and C. felis DNA amplified with only 
10% of primers. This result is in accordance with the taxonomy and evolution of 
Cryptosporidium species (Xiao et al., 2004). In fact, C. meleagridis is the closest 
species to the cluster formed by C. hominis, C. parvum and rabbit genotype based on 
partial SSU rRNA gene (Xiao et al., 2004). C. meleagridis DNA did not amplify using 
primers for Cgd2_2430 and Chro.20156 genes. The lack of amplification could be 
explained by either nucleotide mismatch in the primer region or the absence of 
these genes. 
 
PCR product sequence analysis of these novel genetic markers showed interesting 
genetic variation as Single Nucleotide Polymorphisms (SNPs). 78 SNPs were 
detected, 78.3% (61) of which were species-specific. The presence of species-specific 
SNPs was reported previously for several genetic markers and was exploited for 
Cryptosporidium genotyping and subtyping (Sulaiman et al., 1999). PCR-RFLP of the 
18S rRNA (Xiao et al., 1999), the COWP gene (Spano et al., 1997), the DHFR gene 
(Gibbons et al., 1998), TRAP-C1 (Spano et al., 1998) and TRAP-C2 gene (Sulaiman et 
el., 1998), Polythreonine (Poly-T) repeats (Carraway et al., 1997) and HSP70 (Gobet 
and Toze, 2001) allowed discrimination between Cryptosporidium species from 
various sources.  
 
The majority of the SNPs detected (64.2%) were synonymous. It has long been 
assumed that synonymous SNPs are inconsequential as the primary sequence of the 
protein is preserved. However, it has been demonstrated that synonymous 
mutations can alter the structure, function and expression level of the protein by 
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affecting messenger RNA splicing, stability, protein folding and structure (Hunt et al., 
2009). 
 
C. meleagridis PCR product sequence analysis allowed data enrichment. In fact, 
C. meleagridis species have 108 additional SNPs, 20 of which are in the Chro.30149 
gene (Appendix V). For this gene, C. meleagridis has in average 1 SNP every 15 
nucleotides. Interestingly, no SNPs were detected in this gene from C. hominis and 
C. parvum comparison. Chro.30149 has a predicted function as Ubiquitin ligase. 
Surprisingly, all the detected SNPs are synonymous. This gene, being a housekeeping 
gene, shows a low level of sequence divergence between species and isolates when 
compared to contingency genes consistently under environmental pressure and 
characterized by high spontaneous recombination rates (Barry et al., 2003), such as 
the hypervariable GP60 locus used for Cryptosporidium typing (Widmer, 2009). 
 
The new SNPs uncovered at ten loci allowed the construction of a robust and novel 
multi-locus analysis (MLA). The Neighbor-Joining phylogenetic tree constructed 
clearly grouped and discriminated with high bootstrap values the previously 
described lineage of anthroponotic C. parvum from C. parvum and C. hominis from 
the rabbit genotype. These novel genetic loci can potentially be used for genotyping 
purposes and to expand the genetic markers already used for epidemiological 
analysis.  
 
In addition, the newly identified SNPs were used to determine genetic differences 
between the main Cryptosporidium species and subtypes tested. This analysis 
showed that the genetic difference between C. hominis and C. parvum was only 
1.72%. When compared to C. meleagridis, the genetic differences were estimated to 
be 5% for C. hominis and C. parvum. Within the C. parvum group, the anthroponotic 
subtype isolates showed only a 0.12% difference from the main zoonotic C. parvum 
isolates. Similarly, rabbit genotype isolates exhibited only 0.27% genetic differences 
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to C. hominis isolates. This closeness between C. hominis and rabbit genotype was 
also observed in the commonly used genotyping loci (SSU rRNA, 70 kDa HSP, Actin 
and COWP), which showed an extremely low sequence variability (> 0.51%).  
 
In this study, ten novel genetic markers were studied for the first time. PCR 
screening and sequencing of genes experimentally found to be common to both 
species provided de novo sequence information at incomplete regions of the 
Cryptosporidium genome projects and was used to examine polymorphism in these 
regions. The sequence analysis revealed several interesting species-specific SNPs 
that can be exploited for genotyping and subtyping purposes. In addition, these 
results gave insights about the variability and the population structure of the human 
infective Cryptosporidium species circulating in the UK. 
 
It is anticipated that more genomic data from a multitude of Cryptosporidium 
isolates from different species and genotypes will be available shortly. This is 
feasible due to the major biotechnological advances, mainly next generation 
sequencing. This technology would enable extensive comparative genome sequence 
surveys, which in conjunction with in vitro and in vivo studies, would improve the 
understanding of this important protozoan parasite and would assist in the search 
for novel intervention strategies against human cryptosporidiosis (Jex and Gasser, 
2010, Striepen and Kissinger, 2004). 
 
The aim of this chapter was to identify putative species-specific genes for C. hominis 
and C. parvum. However, the majority of the predicted species-specific genes were 
found to be common to C. parvum and C. hominis. Despite this limitation, Evidence 
was found that one C. parvum gene (Cops-1) and one C. hominis gene (Chos-1) 
generated the appropriate PCR product from only one species. This result suggests 
that within the predicted genes, a small proportion may be species specific. No PCR 
amplification was possible from the other species even after relaxing PCR 
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conditions. A second pair of primers targeting a different region within the coding 
sequence for each gene was designed and tested and the PCR results were 
comparable between the two set of primers.  
 
Cops-1 and Chos-1 are the only genes confirmed experimentally to be species-
specific and were identified after testing 6/211 (2.85%) of the predicted C. parvum 
specific genes and 16/93 (17.2%) of the putatively C. hominis specific genes. This 
result questions the accuracy of the in silico prediction, which is likely attributable to 
incomplete status of the C. hominis genome. As discussed above, comparative 
genomic analysis with the three Cryptosporidium species: C. hominis, C. parvum and 
C. muris would improve future analysis and offer realistic chances for in silico 
identification of genetic determinant of host tropism. 
 
The putative species-specific genes identified in this study could be exploited for 
diagnosis purposes to discriminate between C. hominis and C. parvum in a duplex 
PCR assay. This technique could discriminate between these two relevant 
Cryptosporidium species in a single reaction. However, this technique would need to 
be tested for sensitivity and specificity before realistically considering its potential as 
a diagnostic tool. In addition, the sequence of these species-specific loci should be 
determined in several clinical and environmental isolates to evaluate the genetic 
polymorphism.  
 
If these putative species-specific genes were proven to be determinants of host 
tropism, they are likely to be contingency genes under selection pressure reflecting 
the characteristics of host-parasite interaction in the preferred niche. 
Characterization of the newly discovered species-specific genes warrants further 
investigation and would reveal the relevance of these findings. Additionally, the 
determination of the biological role of the encoded proteins, focussing on the 
involvement in host-parasite interaction should be assessed. Finally, screening of all 
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predicted species-specific genes may uncover additional undiscovered genetic 
determinants potentially involved in host tropism and virulence.  
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3.5 Summary 
 
In this study, comparative genomic tools were used to identify putatively species-
specific genes for human infective Cryptosporidium species. A subset of these genes 
identified in silico was tested experimentally by PCR using a collection of clinical 
isolates and reference strains. The majority of these genes were common to both 
species. This was attributable to the incomplete and partially assembled state of 
C. hominis genome, which had impaired the accuracy of the in silico prediction. The 
fast progress towards the finishing of the gastric C. muris genome would allow 
better comparative genomics and would offer insights about the evolution, host 
tropism and pathogenicity of Cryptosporidium species.  
 
PCR product sequences revealed interesting SNPs, the majority of which were 
species specific. Sequence analysis of these novel genetic loci allowed the 
construction of a robust and novel multi-locus analysis (MLA). The Neighbor-Joining 
phylogenetic tree clearly grouped and discriminated with high bootstrap values the 
Cryptosporidium species and subtypes tested. 
 
Despite this limitation, evidence was found for one C. parvum (Cops-1) and one 
C. hominis (Chos-1) putative species-specific gene. These genes could be used as 
diagnostic targets. The evaluation of the potential of these genes as species 
determinant and virulence factors should be carried out to validate the relevance of 
these findings. 
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4.1 Introduction 
 
The availability of adequate amounts of high quality genomic DNA is essential for 
several molecular diagnostic techniques and typing methods, particularly PCR. 
Genotyping and subtyping of clinical and environmental isolates is desirable as it 
allows source tracking and improved understanding of molecular epidemiology and 
population structure (Smith et al., 2007, Burgos et al., 2004, Mallon et al., 2003, 
Anderson et al., 2000, Han et al., 2000). Unfortunately, such isolates are often 
unculturable, yielding a very limited amount of DNA for study. This is the case of 
Cryptosporidium, which is particularly difficult to propagate. Although 
Cryptosporidium oocysts are excreted in high numbers in the faeces during acute 
clinical episodes (Goodgame et al., 1993), the purification methods used to obtain 
clean DNA, suitable for downstream molecular methods, usually result in losses. 
Thus, Cryptosporidium DNA, especially from sub-clinical infections and 
environmental samples is considered a precious resource. These issues have limited 
biological studies to C. parvum calf-propagated strains, particularly Iowa reference 
strain (Cama et al. 2006). 
 
Several subtyping techniques have been applied to Cryptosporidium species using 
different markers: glycoprotein GP60 (Strong et al., 2000, Leav et al., 2002), double 
stranded RNA element (Leoni et al., 2003) and mini and microsatellite repeats 
(Cacciò et al., 2000, Mallon et al., 2003). Ideally, each new isolate should be tested 
using a panel of markers. However, this is usually limited by the amount of DNA 
available. Whole genome amplification (WGA) can be used to increase the amount 
of nucleic acid available from clinical and environmental samples of waterborne 
pathogens (reviewed in Bouzid et al., 2008) and application of this technique to 
Cryptosporidium isolates should address the perceived need for multi-locus typing 
(Smith et al., 2006).  
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The first described WGA methods were degenerate oligonucleotide primed PCR 
(DOP-PCR) (Telenius et al., 1992, Cheung and Nelson, 1996) and primer extension 
preamplification (PEP) (Zhang et al., 1992). However, these PCR-based techniques 
produced short products (< 3 kb) and were limited by substantial amplification bias 
and incomplete coverage of genetic markers (Park et al., 2005, Dean et al., 2002, 
Hawkins et al., 2002, Paunio et al., 1996).  
 
New strategies for WGA have been developed including multiple displacement 
amplification (MDA) and OmniPlex WGA (Park et al., 2005). MDA is an isothermal 
amplification using degenerate hexamers and the bacteriophage phi-29 DNA 
polymerase, which possesses high processivity, strand-displacement abilities and a 
proofreading activity resulting in error rates 100 times lower than the Taq 
polymerase (Dean et al, 2002, Nelson et al., 2002, Hawkins et al., 2002, Eckert and 
Kunkel, 1991, Esteban et al., 1993). MDA was firstly described by Blanco et al. (1989) 
and then used for WGA of different targets such as lymphoma and leukemia clinical 
specimens (Luthra and Medeiros, 2004), complex mixtures of DNA (Shoaib et al., 
2008), whole blood and tissue culture cells (Dean et al., 2002), human blastomeres 
(Snabes et al. 1994), plasmid constructs and whole bacterial genomes (Detter et al., 
2002). The OmniPlex WGA technique uses libraries of 200–2,000 bp fragments 
created by random chemical cleavage of genomic DNA, followed by ligation of 
adaptor sequences to both ends and PCR amplification. (Bergen et al., 2005, Barker 
et al., 2004). This fragmentation/ligation/PCR-based method amplifies the entire 
genome several thousand-fold, and could be even re-amplified to achieve a final 
amplification of over million-fold without introducing inaccuracies (Langmore, 
2002). Currently, several commercial kits for MDA and Omniplex based WGA are 
available and have been tested for several microorganisms. No trial of WGA kits for 
the amplification of Cryptosporidium DNA has been published to date.  
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In this study, a short supply of Cryptosporidium DNA and a reliance on CRU 
resources were the main limitations faced when testing numerous genetic loci 
(Chapter 3) and a solution was sought in WGA. 
 
4.2 Aims 
 
The aim of this study is to evaluate the suitability of WGA commercial kits for the 
accurate expansion of genomic DNA from Cryptosporidium clinical isolates DNA. This 
includes the ability to amplify the genomic DNA (success rate). In addition, the 
integrity and fidelity of the amplification is also assessed. The assessment of the 
WGA kits performance would determine the usefulness of the amplified DNA for 
downstream genotyping and subtyping applications. 
 
4.3 Results 
 
4.3.1 WGA kits and DNA templates concentration  
 
Three WGA commercial kits were trialled during this study: illustra GenomiPhi V2 
DNA amplification Kit, REPLI-g Ultra fast Mini Kit and GenomePlex® Complete WGA 
Kit as described in 2.5.1.  
 
The performance of WGA kits was tested by evaluation of the amplification of 
Cryptosporidium genomic DNA from clinical isolates and reference strains as 
described in 2.5.2. Prior to WGA, each DNA sample was quantified by 
spectrophotometry as described in 2.7.1. DNA concentrations are shown in Table 
4.1. They ranged from 3.5 to 13.2 ng/ μl (with a mean of 7.7 ng/ μl). One μl of each 
sample was used for WGA. The manufacturer’s recommended starting genomic DNA 
concentration was 1 ng for the illustra kit and 10 ng for both REPLI-g and 
GenomePlex kits. WGA techniques are well established in the literature to give 
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amplification levels from 10-fold less than the lowest template concentration (0.3 
ng) to 20-fold higher than the highest concentration (300 ng) (Dean et al., 2002), 
which raises the prospect for them to be used widely for clinical samples. Thus, in 
this study all of the samples lie well within the range that would expect to give good 
amplification by the kits under test and the range recommended by the 
manufacturers. 
 
4.3.2 Success rate of WGA kits 
  
The ability of WGA kits to amplify genomic DNA from Cryptosporidium clinical 
samples was assessed by agarose gel electrophoresis, which also served as a semi-
quantitative approach to assess the level of amplification. A successful amplification 
was considered when genomic DNA was visible on the gel. One sample (W15508) 
did not amplify with any of the three kits tested.  
 
Illustra GenomiPhi and REPLI-g kits genomic amplified DNA was of high molecular 
weight (~10 kb) for all the tested samples. The success rate was estimated by 
agarose gel electrophoresis, when the genomic DNA was visible, the WGA 
amplification was considered successful. The success rate was 90.9% (10/11 
samples) for illustra GenomiPhi kit and 45.4% (5/11) for REPLI-g kit (Figure 4.1). For 
the GenomePlex amplified samples, the generated DNA had a smeary aspect and 
was of smaller size ranging between 200 and 1,000 bp (mean size ~ 400 bp) (Figure 
4.1). The success rate of the GenomePlex kit was 72.7 % (8/11 samples). For illustra 
GenomiPhi and REPLI-g kits, samples W15521, W15516 and Iowa showed the 
strongest bands, suggesting better amplification. However, when the GenomePlex 
kit was used, W15504, W15521, W15516 and W15517 showed a high level of 
amplification, but, surprisingly, commercially obtained Iowa DNA did not. 
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Figure 4.1: Agarose gel electrophoresis of amplified genomic DNA. MW: molecular 
weight marker, 1: W15504, 2: W15507, 3: W15508, 4: W15519, 5: W15521 (1-5: C. hominis samples), 
6: W15509, 7: W15511, 8: W15516, 9: W15517, 10: W15518 (6-10: C. parvum), 11: C. parvum Iowa.  
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4.3.3 Yield of WGA kits  
 
DNA quantification after WGA was initially assessed by four methods: nanodrop 
spectrophotometry, Hoechst and PicoGreen fluorimetry and agarose gel-based 
ethidium bromide fluorescence densitometry as described in 2.5.3. For the first two 
methods, the calculated DNA concentrations were similar in all the samples (Table 
4.1) and not in accordance with the electrophoresis patterns. This is presumably due 
to the presence of residual random hexamers in the reaction mix. Thus, these 
methods may require additional purification before DNA quantification. PicoGreen 
quantification was more accurate as previously reported (Singer et al., 1997, Ahn et 
al., 1996), because it is not affected by the residual hexamers. This technique gave 
good quantitative data for two of the three kits tested (illustra GenomiPhi and 
GenomePlex kits). PicoGreen quantification was in accordance with the 
electrophoresis pattern, for example W15521 and W15516 had the highest 
concentration, while W15508 has a concentration of 2.5 ng/ μl (corresponding to 
the detection threshold of the technique). For REPLI-g amplified samples, only gel-
based densitometry was able to provide DNA concentrations without an additional 
purification step.  
 
For each kit, yield was determined by calculating the amount of DNA in the final 
reaction volume (10 µl for illustra GenomiPhi kit, 20 µl for REPLI-g kit and 75 µl for 
GenomePlex kit). Yield range was calculated based on the highest and lowest sample 
concentrations. The level of amplification was determined as a ratio of concentrations 
between template and WGA DNA for each sample. The typical yield of illustra 
GenomiPhi kit was in the 0.7-7 µg range, corresponding to 6-60 fold-amplification 
(Table 4.2). The highest yield was 10 µg achieved from Iowa DNA, giving over 180 
fold-amplification. The typical yield of GenomePlex kit was 4.5- 46 µg range and the 
level of amplification was in the 10-70-fold. For the REPLI-g kit, the yield was in the 
0.6-2 µg range, corresponding to 50-160 fold amplification.  
  
 
 
 
 
 
Table 4.1: Quantification of Cryptosporidium DNA before and after WGA using the 3 trialled kits by densitometry, 
Nanodrop, Hoechst and PicoGreen methods. Nanodrop was used to determine the DNA concentration in clinical samples 
prior to WGA (2
nd
 column). After WGA, the DNA concentration was determined using Nanodrop and Hoechst, but the 
concentrations were similar for all the samples. Therefore, PicoGreen was used to determine the DNA concentration 
post-WGA. Picogreen DNA quantification was more accurate and in accordance with the electrophoresis patterns.   
 
Post-WGA DNA quantification 
Nanodrop (ng/μl) Hoechst 33258  (ng/μl) PicoGreen  (ng/μl) 
 
Sample 
reference 
 
Nanodrop 
concentration  
(ng/μl) illustra 
Genomi 
Phi 
REPLI-g Genome 
Plex 
illustra 
Genomi 
Phi 
REPLI-g Genome 
Plex 
illustra 
Genomi 
Phi 
REPLI-g Genome 
Plex 
W15504 12 891.5 1120.9 1072.6 588.9 751.9 740.9 77.3 2.5 302.5 
W15507 4.3 887.4 1221.5 999.2 594.4 876.8 672.9 2.5 2.5 178.9 
W15508 3.5 967.2 1144.5 917.2 573.6 657.8 646.7 2.5 2.5 2.5 
W15519 5.5 890.7 1233.3 968.3 613.6 764.9 995.3 2.5 2.5 118.9 
W15521 11.5 805.2 1053.7 889.9 580.5 619.4 822.6 704.1 2.5 369.9 
W15509 6.7 865.6 1152.7 912.9 574.2 606.1 570.6 78.5 2.5 7.5 
W15511 6.2 819.9 1150.3 941.7 578.7 592.8 596.9 197.2 2.5 60.1 
W15516 8.9 815.3 1105.8 938.1 699.6 568.7 766 604.9 2.5 609.8 
W15517 6.4 875.8 1109.5 979.3 598.4 573.8 726.8 2.5 2.5 410.3 
W15518 13.2 890.0 1179.7 947.0 585.3 663.6 692.6 68.7 2.5 2.5 
Iowa 5.8 791.0 1221.7 903.3 631.1 586.4 649 1086.1 2.5 2.5 
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4.3.4 Integrity of the amplified DNA 
 
The integrity of the amplified genomic DNA was assessed by comparing PCR results 
using three primer sets before and after WGA as described in 2.5.4. For Cry 15/9 
primers, amplifying 550 bp fragment of the COWP gene, all 11 samples were positive 
before WGA. After WGA, 10/11 illustra GenomiPhi amplified samples (91%), 6/11 
REPLI-g amplified samples (54.6%) and 9/11 GenomePlex amplified samples (81.9%) 
were PCR positive (Figure 4.2). For Cgd6_5020 primers, amplifying 270 bp, all 11 
samples were also positive before WGA. After WGA, 10/11 illustra GenomiPhi 
amplified samples (91%), 8/11 REPLI-g amplified samples (72.8%) and 11/11 
GenomePlex amplified samples (100%) were PCR positive (Figure 4.3). For 
Chro.20156 primers, amplifying 247 bp, 10/11 samples were positive before WGA, 
with only the W15519 sample negative. After WGA, 9/11 illustra GenomiPhi 
amplified samples (81.9%), 7/11 REPLI-g amplified samples (63.7%) and 11/11 
GenomePlex amplified samples (100%) were PCR positive (Figure 4.4).  
 
The overall post-WGA PCR success rates from the three kits were 87.8%, 63.6% and 
93.9% for illustra GenomiPhi, REPLI-g and GenomePlex kits, respectively (Table 4.2). 
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Figure 4.2: PCR products of WGA-amplified Cryptosporidium DNA isolates using 
Cry15/9 primers. MW: molecular weight marker, 1: W15504, 2: W15507, 3: W15508, 4: W15519, 
5: W15521, 6: W15509, 7: W15511, 8: W15516, 9: W15517, 10: W15518, 11: C. parvum Iowa, NTC: 
non template control. 
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Figure 4.3: PCR products of WGA-amplified Cryptosporidium DNA isolates using 
cgd6_5020 primers. MW: molecular weight marker, 1: W15504, 2: W15507, 3: W15508, 4: 
W15519, 5: W15521, 6: W15509, 7: W15511, 8: W15516, 9: W15517, 10: W15518, 11: C. parvum 
Iowa, NTC: non template control. 
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Figure 4.4: PCR products of WGA-amplified Cryptosporidium DNA isolates using 
chro.20156 primers. MW: molecular weight marker, 1: W15504, 2: W15507, 3: W15508, 4: 
W15519, 5: W15521, 6: W15509, 7: W15511, 8: W15516, 9: W15517, 10: W15518, 11: C. parvum 
Iowa, NTC: non template control. 
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Table 4.2: Comparison of the performances of the 3 trialled WGA commercial kits. The performance was evaluated by 
comparing the success rate, the size of the amplified genomic DNA and the yield for each kit. In addition, the integrity, 
fidelity and the specific amplification of Cryptosporidium DNA were evaluated. 
Success rate was the number of samples with positive amplification as determined by agarose gel electrophoresis. The 
size of amplified product was determined by comparison to a molecular weight marker. Picogreen quantification column 
showed the successful quantification without prior sample purification. Yield and level of amplification were determined 
based on PicoGreen results for illustra GenomiPhi and GenomePlex kits. * for REPLI-g kit, densitometry was used to 
determine the yield and the level of amplification. Secondary amplification was the success rate of post-WGA PCR 
reactions. Fidelity was determined by the number of identical nucleotides before and after WGA. 
 
 Success 
rate 
(electro-
phoresis) 
Size of 
amplified 
product 
PicoGreen 
quantification 
Yield Level of 
amplification 
Secondary 
amplification 
(post WGA PCR) 
Fidelity 
(nucleotide 
sequence 
match) 
Specific amplification of 
Cryptosporidium DNA 
(Real-Time PCR) 
Illustra 
GenomiPhi 
90.9% > 10 kb Yes 0.7-10 μg 6-180 fold 87.8% 100% Yes  (11/11 samples) 
REPLI-g 45.4% > 10 kb No * 0.6-2  μg   * 50-160 fold 63.6% 99.62% Not tested 
GenomePlex 72.7% < 1 kb Yes 4.5-46 μg 10-70 fold 93.9% 99.87% Not tested 
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4.3.5 Fidelity of WGA kits 
 
The fidelity of amplification was assessed by comparing PCR product sequences, 
generated with and without a WGA intermediate step. For Cry 15/9 primers, PCR 
product sequences were identical using all three kits for the W15507, W15511 and 
Iowa isolates (Appendix VI). For the W15516 isolate, WGA using REPLI-g kit 
produced three nucleotide errors and the use of GenomePlex kit produced one 
error, corresponding to 99.34% and 99.78% sequence concordance, respectively. For 
Cgd6_5020 and Chro.20156 primers, PCR product sequences were identical before 
and after WGA for all the samples. The overall fidelity of the three kits was 100%, 
99.62% and 99.87% for illustra GenomiPhi, REPLI-g and GenomePlex kits, 
respectively (Table 4.2).  
 
Interestingly, one of the samples tested (W15519) failed to amplify using 
Chro.20156 primers without WGA or after WGA using illustra GenomiPhi and REPLI-
g kits, but did amplify when GenomePlex amplified DNA was used. The identity of 
the PCR product was confirmed by sequencing.  
 
4.3.6 Comparative analysis of Cryptosporidium genomic DNA before and after 
WGA 
 
The evaluation of the specific amplification of Cryptosporidium DNA after WGA was 
performed by comparing the amplified products and the original genomic DNA using 
a species-specific, semi quantitative Real-time PCR assay as described in 2.5.5. Melt 
curve analysis of genomic DNA and WGA DNA amplified using the Illustra GenomiPhi 
kit confirmed the specific amplification of Cryptosporidium DNA after WGA in each 
of the samples tested. The unadjusted CT values showed that 8/11 of the samples 
had a lower CT after WGA than before, indicating that in these samples the WGA did 
amplify Cryptosporidium DNA. After adjustment to allow for the 10-fold dilution 
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applied through the WGA process, all of the samples had a lower CT value after 
WGA, confirming that Cryptosporidium DNA was present in higher copy numbers in 
the samples post WGA than before (Table 4.3).  
 
The highest difference of CT before and after WGA was 10.13 for sample W15516, 
which corresponds to over 30-fold increase in DNA target copy number. This is in 
accordance with the electrophoresis result. For the other samples, the difference in 
CT values before and after WGA ranged between 2.63 (for sample W15504) and 8.11 
(for sample W15511), corresponding to an 8 to 27 fold increase in copy number. For 
sample W15508, the difference in CT value was 0.73 supporting a poor amplification. 
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Table 4.3: Real-time PCR analysis of Cryptosporidium DNA before and after WGA and 
estimation of the increase in copy numbers after WGA using illustra GenomiPhi kit. 
 
 
 
 
 
 
 
 
Sample Genomic DNA / 
WGA DNA 
Mean CT 
(adjusted) 
CT value 
difference 
Fold increase in 
copy numbers 
W15504 Genomic DNA 31.63 ±0.14 2.63 ±0.45  8.8 ±0.45 
 WGA DNA 29.00 ±0.43   
W15507 Genomic DNA 22.62 ±0.19 4.53 ±0.21 15 ±0.21 
 WGA DNA 18.09 ±0.11   
W15508 Genomic DNA 29.06 ±0.16 0.73 ±0.80 2.5 ±0.80  
 WGA DNA 28.33 ±0.79   
W15519 Genomic DNA 32.56 ±0.71 2.54 8.5 
 WGA DNA 30.02   
W15521 Genomic DNA 23.72 ±0.11 4.41 ±0.82 14.8 ±0.82 
 WGA DNA 19.31 ±0.82   
W15509 Genomic DNA 28.82 ±0.25 4.09 ±0.41 13.7 ±0.41 
 WGA DNA 24.73 ±0.33   
W15511 Genomic DNA 23.57 ±0.22 8.11 ±0.22 27 ±0.22 
 WGA DNA 15.46  ±0.06   
W15516 Genomic DNA 29.57 ±0.41 10.13 33.8 
 WGA DNA 19.44    
W15517 Genomic DNA 28.87 ±0.04 4.08 ±0.54 13.6 ±0.54 
 WGA DNA 24.79 ±0.53   
W15518 Genomic DNA 25.99 ±1.11 7.81 ±1.13 26 ±1.13 
 WGA DNA 18.18 ±0.25   
Iowa Genomic DNA 19.15 ±0.03 7.96 ±0.06 26.6 ±0.06 
 WGA DNA 11.46 ±0.61   
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4.4 Discussion 
 
WGA commercial kits were successfully used for the amplification of 
Cryptosporidium genomic DNA from clinical isolates. Illustra GenomiPhi and 
GenomePlex kits successfully amplified the majority of the tested isolates (90.9% 
and 72.7%, respectively). The REPLI-g Kit, however, amplified less than half of the 
samples. One sample, W15508, did not amplify with any of the three kits tested. 
While the template concentration was well within the recommended range for the 
kits under test, it did correlate with the sample having the lowest concentration of 
template DNA tested and thus may reflect some degree of degradation of the DNA 
in that sample or relative enrichment of inhibitors carried through the DNA 
purification process. 
 
For MDA-based kits (illustra GenomiPhi and REPLI-g), it was noticeable that most of 
the DNA remains in the well when run out on an agarose gel, this is due to the 
formation of very high molecular weight DNA, independent of the genome size, as 
previously reported by Detter et al. (2002). OmniPlex-amplified DNA was of smaller 
size, because this method is based on fragmentation of the genomic DNA followed 
by linker ligation to enable amplification (Thorstenson et al. 1998; Fiegler et al. 
2007). 
 
PicoGreen DNA quantification of the amplified DNA proved effective for Illustra 
GenomiPhi and GenomePlex kits. The yield range was 0.7-10 μg and 4.5-46 μg, 
respectively, which is in accordance with the manufacturer’s claims. The apparent 
higher yield of GenomePlex kit is due to a higher reaction volume (10 μl versus 75 
μl). The PicoGreen quantification of REPLI-g kit amplified samples was not effective 
without prior purification of the amplified DNA. This could be in part explained by 
the fact that high proportion of the amplified DNA may be present as single-
stranded product rather than dsDNA. 
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The integrity of the amplified DNA was assessed by the ability to generate PCR 
products for three genes. The overall post-WGA PCR success rate was 87.8%, 63.6% 
and 93.9%, for illustra GenomiPhi, REPLI-g and GenomePlex kits, respectively. For 
one sample, the W15519 isolate, no PCR amplification using Chro.20156 primers 
was observed before WGA or after WGA using illustra GenomiPhi and REPLI-g kits. 
However, GenomePlex amplified DNA of the same sample was PCR positive and the 
identity of the PCR product was confirmed by sequencing. These results suggest that 
the use of WGA amplified DNA as PCR template could increase PCR sensitivity from 
clinical samples. Similar findings were reported for the detection of Trypanosoma 
species from blood samples (Pinchbeck et al., 2008). Further work to more 
thoroughly test the integrity of the amplified DNA and assessing amplification biases 
should focus on amplification of longer sequences and broader genomic coverage 
utilizing sequences from each of the eight nuclear chromosomes, from the 
telomeres, centromeres, ribosomal DNA, mitochondrial DNA, and repetitive regions. 
 
The fidelity of the amplification was assessed by sequence analysis of the PCR 
products, before and after WGA. For this sample set, the overall error rate observed 
was 0% for illustra GenomiPhi kit, 0.38% for REPLI-g kit and 0.13% for GenomePlex 
kit. Interestingly, all the errors arose from the same clinical sample using the same 
set of primers. This could be explained by a variety of factors, such as the presence 
of impurities affecting the enzyme proofreading activity, the secondary structure of 
the DNA, or by a low concentration of the starting material, which can decrease the 
amplification fidelity as previously reported (Bergen et al., 2005). 
 
Sequence analysis of WGA amplified PCR products using Cry 15/9 primers showed 
the preservation of six species-specific Single Nucleotide Polymorphisms (SNP)s, one 
of which at position 66 is of particular interest as it corresponds to an RsaI 
restriction site used for Cryptosporidium genotyping as previously described (Spano 
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et al., 1997). In addition, sequence analysis showed the preservation of one species-
specific SNP for Cgd6_5020 gene and five species-specific SNPs for Chro.20156. 
 
Comparative analysis of Cryptosporidium genomic DNA and paired WGA DNA using a 
real-time PCR assay confirmed that Cryptosporidium DNA was specifically amplified 
using illustra GenomiPhi kit, resulting in higher copy numbers post WGA than before 
for all the samples tested. 
 
For this collection of Cryptosporidium clinical isolates, the illustra GenomiPhi WGA 
kit had the best performance, with 90.9% success rate, generating high 
concentration of high molecular weight DNA with 100% fidelity. The additional cost 
of WGA is not prohibitive for clinical usage when added to the PCR cost for routine 
detection of Cryptosporidium DNA. These are preliminary results, highlighting the 
usefulness of MDA based WGA for the accurate amplification of Cryptosporidium 
genomic DNA for the purposes of creating a bank of clinical isolates, thus enabling 
extensive genetic testing. 
 
These results were obtained from semi-purified oocyst suspensions, themselves 
requiring reasonable numbers of oocysts in the original sample. They carry 
significant contamination of bacterial and fungal DNA, which can also be amplified 
by the WGA process. Real-time PCR for faecal marker DNAs such as genes from 
Bacteroides, Clostridium and E. coli might be useful to determine whether there is 
any predisposition to amplifying contaminating DNAs rather than the 
Cryptosporidium DNA in the samples. Additional investigation of the effect of other 
oocyst purification methods (immunomagnetic separation) on the performance of 
WGA should be carried out. Importantly, since many investigators use DNA 
extracted from raw stool without prior oocyst purification, independent validation 
of the suitability of this material for WGA and downstream analysis should also be 
undertaken. 
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This study investigated the suitability of Cryptosporidium DNA after WGA for 
genotyping purposes. The COWP marker was tested as it is routinely used for 
Cryptosporidium speciation by RFLP, together with 2 novel markers. These results 
showed efficient and specific amplification of Cryptosporidium DNA. Further 
validation of these WGA techniques for the preservation of routine subtyping 
targets of Cryptosporidium (GP60 and mini and micro-satellite repeats) would be 
necessary and desirable before adopting WGA for routine characterization of clinical 
and environmental isolates of Cryptosporidium species. 
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4.5 Summary 
 
During this study, three WGA commercial kits were trialled to evaluate their 
efficiency to resolve the issue of the limited DNA amounts available from clinical 
samples especially with the perceived need for extensive genetic testing. This is 
particularly relevant in the case of fastidious in culture pathogens like 
Cryptosporidium. The performance of these kits was assessed on the base of the 
success rate, the coverage and the fidelity of amplification of genomic DNA from five 
C. hominis and five C. parvum clinical isolates and C. parvum Iowa reference strain.  
 
The higher success rates were obtained using Illustra GenomiPhi and GenomePlex 
kits: 90.9% and 72.7%, respectively, REPLI-g Kit, however, amplified less than half of 
the samples. The yield was comparable between the three kits and in accordance 
with the manufacturer’s claims. Using these DNA samples, REPLI-g Kit had the 
lowest performance with a low success rate, poor coverage, reduced fidelity and 
inadequacy for direct PicoGreen DNA quantification. The main limitation of the 
GenomePlex kit was the production of small-sized DNA due to the fragmentation 
and linker ligation steps required for Omniplex based technique for WGA, which 
might limit downstream applications. 
 
One kit, Illustra GenomiPhi, amplified the majority of Cryptosporidium samples tested 
generating high amounts of genomic DNA with high fidelity. These results highlight the 
usefulness of MDA based WGA for the accurate amplification of Cryptosporidium 
genomic DNA and for the creation of genomic banks of clinical isolates, which would 
enable extensive genetic testing. 
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5.1 Introduction 
 
During the genomic era, advances in sequencing technologies have generated 
ever larger and more complex genomic data sets that have poured into public 
databases (Collins et al., 2003), which have started to improve the understanding 
of the biology of health and disease at an unprecedented level of molecular 
detail. Thus, genomics has come to be considered a central and cohesive 
discipline in biomedical research (Guttmacher et al., 2003, Collins et al., 2003). 
The first completed bacterial genome project was Haemophilus influenzae 
(Fleischmann et al., 1995); subsequently several genome sequencing projects 
were conducted including many important human pathogens. Initially, the 
simplest known free-living model organisms Escherichia coli and Bacillus subtilis 
and the first eukaryote Saccharomyces cerevisiae were sequenced as reviewed 
by Fraser and colleagues (2000). Since then, the genomes of many more 
microbes, mammals, vertebrates have been published and culminating in 
publication of the human genome project as reviewed by Collins and colleagues 
(2003). 
 
In the post-genomic era, great progress in sequencing technologies and 
platforms has been achieved and the amount of novel microbial genomic 
information being generated is so vast that only a multidisciplinary approach 
integrating bioinformatics, statistics and mathematics is able to assess it 
effectively (Medini et al., 2008). Apicomplexan parasites are a successful group 
of eukaryotic parasites. The diseases they cause in humans and animals pose 
major threats to world health and global economy (Tomley, 2009). Protozoan 
parasites have not been left behind in the rush to genomics and proteomics 
(Wastling et al., 2009). Genomes of 32 apicomplexans are now finished and are 
deposited in comprehensive and publicly accessible genomics and proteomics 
databases (Zarlenga and Gasbarre, 2009). These databases give investigators the 
ability to analyze biodiversity, evolution and population genetics, functional 
genomics, host-parasite relationships and epigenetics, transmission dynamics, 
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pathogenicity determinants, metabolic pathways, gene expression and could 
drive the discovery of novel diagnostic, drug and vaccine targets (Rider and Zhu, 
2010, Zarlenga and Gasbarre, 2009, Tomley, 2009, Medini et al., 2008). While the 
biology of each parasite differs, all the apicomplexan parasites share many 
functions and pathways related to their intracellular niche (Tomley, 2009). 
Approximately, 150 ancestral apical complex apicomplexan proteins are 
conserved between Cryptosporidium spp and Plasmodium spp (Templeton et al., 
2004). In particular, actin-like proteins implicated in cell invasion are 
characteristically conserved among Toxoplasma gondii, Plasmodium spp., 
Cryptosporidium spp. and Theileria spp (Gordon and Sibley, 2005).  
 
Genome sequences of C. parvum and C. hominis were published in the same year 
(Abrahamsen et al., 2004, Xu et al., 2004). Genome sizes were comparable and 
quite small compared to P. falciparum and T. gondii genomes. The reduced size is 
partly due to a lack of genes for plastid maintenance (apicoplast) and variant 
surface antigen gene families, the reduced number of introns and smaller 
intergenic regions (Rider and Zhu, 2010, Xu et al., 2004). The complete genome 
sequences of these two Cryptosporidium species has stimulated recent progress 
in identifying conserved vital Cryptosporidium molecules through genome 
comparisons and data mining, including DNA replication machinery, DNA repair, 
transcription factors, gene silencing and regulation, histone modification and 
methylation as reviewed by Rider and Zhu (2010). Tomley (2009) stated that the 
priority for apicomplexan research in the post-genomic era should be the 
functional characterization of unique parasite molecules, which have no 
counterparts in other organisms and which are implicated in parasite-specific 
metabolic pathways or host-parasite interactions at the molecular and structural 
levels.  
 
C. hominis and C. parvum comparative genomics showed that the two genome 
sequences are very similar and exhibit only 3–5% sequence divergence, with no 
large insertions, deletions or rearrangements (Xu et al., 2004). The authors 
concluded that the phenotypic differences between C. hominis and C. parvum 
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are caused by polymorphisms in coding regions and differences in gene 
regulation (Pain et al., 2005, Xu et al., 2004). The role of what genetic variability 
is present in the phenotypic differences between C. hominis and C. parvum is 
now much more accessible for investigation. In fact, the subset of genes 
displaying the most variation may include valuable epidemiological markers and 
unnoticed genetic determinants of host specificity and virulence. This hypothesis 
was investigated in Chapter 3 and although the majority of the predicted genes 
were common to C. parvum and C. hominis and some to C. meleagridis, evidence 
was found of one C. parvum putative specific gene (Cops-1) and one C. hominis 
putative specific gene (Chos-1). 
 
5.2 Aims 
 
The aim of this chapter is to characterize Cops-1 gene and its gene products. The 
investigation includes determination of the full length gene sequence to assess 
genetic polymorphism in C. parvum isolates, characterization of the protein using 
a monoclonal peptide antibody and evaluation of the antigenicity of Cops-1 
protein by screening of patient sera using the recombinant protein. Finally, in 
vitro assessment of the role of Cops-1 protein in host-cell attachment and 
invasion using a blocking assay with the monoclonal antibody in coculture with 
Caco-2 cell line. 
 
5.3 Results 
 
5.3.1 Cops-1 predicted features 
 
The initial annotation of the Cops-1 gene provided by the C. parvum genome 
project shows no apparent orthologs in other genomes, including C. hominis. The 
limited annotation provided describes a serine-rich protein containing repeated 
motifs, with an N-terminal secretory peptide, situated proximal to the telomeric 
repeats of chromosome 2 (1.08Mb). The Cops-1 genomic position as retrieved 
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from CryptoDB is 983,586- 985,019. The telomeric location might have hindered 
the detection of Cops-1 in other Cryptosporidium species. In fact, the telomeric 
regions are highly repetitive and renowned to be tricky to assemble, especially in 
genome sequencing projects. In C. hominis, there is no contig covering the Cops-
1 genomic region. Similarly, Cops-1 was not detected in the ongoing genome 
sequencing of C. muris so far. Based on C. parvum genome sequence, Cops-1 is 
1434 bp, the encoded protein is predicted to be 50.164 kDa with an isoelectric 
point of 11.  
 
Using InterPro software, Cops-1 protein is predicted to have a signal peptide 
(position 1-24) and a transmembrane domain (position 5-27). SignalP 3.0 
software predicts that Cops-1 is likely to be a secreted protein and predicts that 
the protein would be cleaved between position 24 and 25 due to the recognition 
of the motif “LQT-FF”, generating a mature polypeptide of 47.477 kDa. In 
addition, PSORT software analysis showed that the protein has an N-
myristoylation motif “MGNSLNV” and is more likely to have nuclear location. 
However, this motif would be cleaved off in the mature protein. The gene has 
putative N-glycosylated site and multiple potential sites for phosphorylation, 
suggesting that under appropriate conditions, Cops-1 protein can be heavily 
phosphorylated. In fact, the protein sequence shows 47 potential serine 
phosphorylation sites, 18 threonine sites and 5 tyrosine phosphorylation sites. 
The Cops-1 protein is predicted to have a hydrophobic N terminus, but one 
which would be cleaved off in the mature protein.  
 
Using BLAST, it was noted that from positions 74 to 264 in the Cops-1 of 
C. parvum, there was low level similarity (32% identity over 477 amino acids) to a 
region of the product of the Drosophila melanogaster gene “shot” (short stop), 
which is a calcium-binding protein involved in cross-linking microtubules to 
microfilaments. This fly protein is very large (5155 amino acids) and no other part 
of the Short polypeptide has detectable similarity to Cops-1, so the biological 
significance of this homology is questionable. 
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5.3.2 Cops-1 as diagnostic target 
 
The Cops-1 gene was the only putative C. parvum specific gene confirmed 
experimentally, amplifying 665 bp from C. parvum but not C. hominis isolates as 
shown in Chapter 3. The full length Cops-1 gene was amplified from C. parvum 
DNA only (Figure 5.1). Agarose gel electrophoresis of PCR products using 
Cgd2_4380 F and R primers showed that, at increased UV exposure, these 
primers amplified three bands from C. parvum Iowa DNA of 655, 450 bp and 200 
bp (Figure 5.1). The 200 bp band was also present in PCR products from 
C. hominis. This band could serve as a useful internal control for the presence of 
human infective Cryptosporidium. When DNA from other Cryptosporidium 
species was tested, only C. meleagridis was PCR positive, generating a 665 bp 
product, no 200 bp band was visible. This assay as it stands confirms and 
discriminates C. hominis from C. parvum. 
 
5.3.3 Cops-1 has an ortholog in C. hominis 
 
The identity of the 200 bp band amplified from C. hominis DNA was confirmed by 
sequencing, since its intensity was strong enough to allow purification and 
sequencing as described in 2.4. Interestingly, the retrieved sequence showed 
99% sequence identity to Cgd2_4380 (Figure 5.2). The 200 bp is a fraction of the 
650 bp. Therefore, Cops-1 seems to have an ortholog in C. hominis. CpCops-1 and 
ChCops-1 are used to name the gene in C. parvum and C. hominis, respectively.  
 
5.3.4 Cops-1 PCR products sequence analysis 
 
Cops-1 PCR products were used for sequence analysis. Sequences from Cp2, Cp3, 
Cp4 and Moredun isolates were identical to the published Cgd2_4380 gene 
sequence. The anthroponotic subgroup isolates showed four SNPs specific to this 
subgroup. The alignment of Cops-1 PCR product sequences are shown in 
Appendix VII. C. hominis PCR products, despite being shorter, showed high 
sequence similarity to PCR products from C. parvum isolates. 
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Figure 5.1: Amplification of full and partial Cops-1 from C. parvum and C. hominis 
isolates. A: amplification of the full gene length using Cgd2_4380 FF and FR 
primers. PCR was positive from C. parvum DNA only. B: Amplification of a 
fragment of Cops-1 using Cgd2_4380 F and R primers. From C. parvum DNA, the 
primers amplified 3 bands of 650 bp, 450 bp and 200 bp. The 200 bp band was 
also visible in C. hominis PCR products (arrow). MW: molecular weight, 1: Ch2, 2: Ch3, 3: 
Ch4, 4: Iowa, 5: Moredun, 6: TU502, NTC: non template control. 
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Figure 5.2: BLAST result of the PCR product using Cgd2_4380 F and R primers 
amplifying 655 bp from C. parvum Iowa DNA (A) and 200 bp from C. hominis 
TU502 DNA (B). A: The sequence and location of C. parvum PCR product was as 
expected (662 bp) corresponding to hybridization sites for the Forward primer 
(243-262) and Reverse primer (888-907) and showed 100% sequence identity to 
the published Cgd2_4380 gene sequence. B: The 200 bp fragment amplified from 
C. hominis DNA showed 99% sequence identity to Cgd2_4380 gene and 
corresponded to a fragment of the C. parvum PCR product. 
A 
B 
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Nevertheless, the alignment revealed four C. hominis-specific SNPs. Rabbit 
genotype PCR products were faint and did not generate good quality sequences 
and therefore were excluded from the analysis. Each of the anthroponotic 
C. parvum SNPs were non-synonymous, resulting in a change of the protein 
sequence. Of the C. hominis SNPs, two were synonymous and two non-
synonymous. Overall, 6/8 (75%) of the SNPs detected were non synonymous. 
Sequence analysis of C. meleagridis PCR product showed only one SNP difference 
between this fragment and the C. parvum (non-anthroponotic) sequences and 
that this change was non-synonymous. 
 
The 650 bp PCR product sequences from C. parvum were used to build a 
Neighbor-Joining Tree (NJ), which showed a good discrimination of C. parvum 
and C. parvum anthroponotic subtype (Figure 5.3 A). The sequences of the 200 
bp PCR product, detected in all isolates except rabbit genotype, were also used 
to construct a NJ Tree (Figure 5.3 B). This tree showed that the variability 
associated with this short fragment has a good discriminatory power and allowed 
discrimination of Cryptosporidium genotypes and subtypes, which was consistent 
with the polymorphism seen in the other genetic loci used for MLA as shown in 
Chapter 3. 
 
5.3.5 Determination of the full gene length of ChCops-1  
 
These initial findings suggested that Cops-1 gene, first thought to be C. parvum 
specific, has an ortholog in C. hominis. The primers (Cgd2_4380 FF and FR) that 
had initially been used to amplify the full gene length in C. parvum did not 
generate PCR product from C. hominis DNA. In addition, a set of primers 
targeting the 5’ upstream region and 3’ downstream region 
(Cgd2_4380_flanking_5’end and Cgd2_4380_flanking_3R) were also tested on 
C. hominis genomic DNA. However, these, too, did not generate any PCR 
product. Therefore, a primer walking approach was used in an attempt to 
determine the full sequence of the ChCops-1 gene. Several primers were 
designed as shown in Figure 5.4 and tested. 
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Figure 5.3: Neighbour-joining trees of Cops-1 sequences from C. hominis, 
C. parvum and C. meleagridis, based on: A: sequences of 650 bp PCR product 
retrieved from C. parvum and C. meleagridis. B: sequences of 200 bp PCR 
product retrieved from C. parvum, C. meleagridis and C. hominis. 
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Figure 5.4: Details of the different primers used for primer walking approach 
aiming to uncover the full gene sequence of ChCops-1. A: primer sequences and 
position on the Cops-1 gene, B: schematic representation of the primer locations, 
C: PCR product results from C. parvum and C. hominis DNA. 
 
  
 
 
 PCR products 
Primer combination C. parvum C. hominis 
Cgd2_4380 F/R 650 bp 
450 bp 
200 bp 
200 bp 
Cgd2_4380 FF/FR 1434 bp No 
Cgd2_4380 2F/2R 650 bp 
450 bp 
200 bp 
450 bp 
200 bp 
Cgd2_4380 FF/2R 900 bp 
650 bp 
450 bp 
650 bp 
450 bp 
 
Cgd2_4380 FF/flanking_3R 1500 bp 1300 bp 
Cgd2_4380_flanking_3R 
100 bp  
Cops-1 gene 
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Cgd2_4380_2F and 2R were designed based on the 200 bp band sequences (as 
described in 5.3.3). They overlap with Cgd2_4380 F and R primers and they 
target the repeat region. PCR products using Cgd2_4380_2F and 2R primers 
amplified three bands (650, 450, 200 bp) from C. parvum Iowa and only two 
bands 450, 200 bp) from C. hominis DNA (Figure 5.5). No PCR product was 
amplified from TU502 DNA. Since repeats are prone to duplication and loss, the 
difference observed in Figure 5.5 could be the result of a reduced repeat 
number. Each of the three bands amplified from C. parvum DNA represents a 
repeat, while C. hominis PCR profile suggests that Cops-1 could be truncated at 
the C terminus in part from loss of a repeat. 
 
In order to evaluate the magnitude of truncation of ChCops-1, several primer 
combinations were tested. The following primer combinations allowed 
amplification of C. parvum DNA only: Cgd2_4380 F/FR, Cgd2_4380_2F/FR and 
Cgd2_4380 FF/R, therefore, did not assist in uncovering the ChCops-1 sequence. 
Cgd2_4380 FF and 2R primers generated three bands of 900, 650 and 450 bp 
from C. parvum DNA and two bands of 650 and 450 bp from C. hominis DNA, 
thus enabling the retrieval of extra length of ChCops-1. Interestingly, no 
amplification was achieved from the TU502 isolate. The use of Cgd2_4380 FF and 
Cgd2_4380_flanking_3R primers allowed amplification of a faint band > 1500 bp 
from Ch3 (not shown). PCR products from Ch2, Ch4 and TU502 were negative. 
 
All the positive PCR products were sequenced and assembled to retrieve ChCops-
1 gene sequence. The 5’ end was conserved between ChCops-1 and CpCops-1. 
PCR products from C. hominis clinical isolates (Ch2, Ch3 and Ch4) were identical. 
Sequencing of Ch3 PCR product (using Cgd2_4380 FF and 
Cgd2_4380_flanking_3R primers) enabled to retrieve the 3’ end of ChCops-1 
gene and the sequences were validated at two independent sequencing facilities 
as described in 2.4. The sequencing allowed the retrieval of 1737 bp from 
C. parvum Iowa and 1559 bp from C. hominis Ch3 isolate (Appendix VIII).  
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Figure 5.5: PCR results of Cgd2_4380_2F and 2R primers using C. parvum and 
C. hominis DNA. From C. hominis DNA, 2 bands of 450 and 200 bp were 
amplified. With C. parvum DNA, an additional band of 650 bp was also visible. No 
amplification using these primers was observed from TU502 DNA. MW: molecular 
weight, 1: Ch3, 2: Ch4, 3: TU502, 4: Iowa, NTC: non template control. 
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Using these primers (Cgd2_4380 FF and Cgd2_4380_flanking_3R), the PCR 
product also included the downstream flanking region, therefore, the 3’end of 
the ChCops-1 gene was determined by the presence of a stop codon TGA at 
position 1263. Therefore, ChCops-1 seems to be truncated to 1263 bp, while 
CpCops-1 is 1434 bp (Appendix VIII). Based on the ChCops-1 sequence, a reverse 
primer (Cops-1_C. hominis_R) targeting the 3’ end of the gene was designed, 
however, PCR product using Cgd2_4380_FF and Cops-1_C. hominis_R primers 
failed to amplify DNA from either C. hominis or C. parvum isolates.  
 
5.3.6 Comparison of CpCops-1 and ChCops-1 
 
Cops-1 gene was first thought to be C. parvum specific. Subsequent analyses 
showed that the gene is also present in C. meleagridis. In addition, a truncated 
ortholog was detected in C. hominis, which was determined using a primer 
walking approach to be 1263 bp. Therefore, Cops-1 is considered an orthologous 
gene and CpCops-1 and ChCops-1 were used to name the gene in C. parvum and 
C. hominis, respectively. The CpCops-1 sequence in C. parvum clinical isolates is 
identical to the published Cops-1 gene sequence (Cgd2_4380). ChCops-1 has 
eluded C. hominis genome project. In C. hominis clinical isolates (ch2, ch3, ch4) 
ChCops-1 sequence was identical on only a portion of the gene (650 bp). The full 
gene length was amplified and sequenced from only Ch3 isolate. The full length 
CpCops-1 and ChCops-1 are 1434 and 1263 bp, respectively. The two sequences 
exhibit 78.8% sequence identity when tested by GENESTREAM software (Pearson 
et al., 1997). The Alignment of CpCops-1 and ChCops-1 is shown in Appendix VIII. 
The difference in size between CpCops-1 and ChCops-1 corresponds to a 
truncation of ~ 170 bp in C. hominis. Alignment of CpCops-1 and ChCops-1 
revealed 101 SNPs. This corresponds to an average of one SNP every 13 
nucleotides for C. hominis and one SNP every 15 nucleotides for C. parvum.  
 
CpCops-1 and ChCops-1 encoded proteins are predicted to be 477 aa and 420 aa, 
respectively. The protein sequences are 70% identical. The protein sequence 
alignment are shown in Figure 5.6. The N terminus of the CpCops-1 and ChCops-1 
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encoded protein is conserved, thus maintaining the gene’s features (signal 
peptide, transmembrane domain and myristoylation motif). In addition, ChCops-
1 has also a cleavage site between position 24 and 25 “FQT-FF”. The biological 
significance of these findings needs to be assessed, especially that the predicted 
features, at the N terminus, support a role of cops-1 in host adaptation and 
virulence. Based on the protein sequences alignment, 79 aminoacid substitutions 
were detected, therefore 78.3% of the SNPs are non synonymous. 
 
5.3.7 Cloning of CpCops-1 
 
CpCops-1 gene was cloned in order to characterize the encoded protein. The full 
length gene was amplified from Iowa DNA. Two approaches were used to clone 
the Cops-1 gene. Cloning was performed into pGEM®-T Easy cloning vector and 
pTrcHisA expression vector. Alternatively, the full gene length was cloned using 
Champion™ pET100 Directional TOPO® Expression Kit. The construct orientation 
and sequence was checked by PCR using Cgd2_4380_FF and T7 terminator 
primers. Colonies which had the correct insert were used for expression of the 
recombinant protein. A map of the recombinant pET100/D-TOPO® vector is 
shown in Appendix IX. 
 
5.3.8 Expression of Cops-1 recombinant protein 
 
Both the recombinant pTrcHisA vector and pET100/D-TOPO® vector were trialled 
for the expression of the recombinant Cops-1 protein as described in 2.7.5. A 
pilot expression study was performed to determine the optimal expression time.  
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Figure 5.6: Protein sequence and characteristics of CpCops-1 and ChCops-1. The 
two proteins are 70% identical. The N terminus is conserved between C. hominis 
and C. parvum, thus maintaining the gene predicted features: signal peptide, 
transmembrane domain and myristoylation motif. 
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For DH5α transformed using the pTrcHisA recombinant vector, both supernatant 
and pellet samples failed to demonstrate detectable expression of the 
recombinant protein (~ 50 kDa) after Coomasie staining.  Because DH5α is not an 
expression bacterial strain, the recombinant pTrcHisA vector was transformed 
into BL21 bacterial strain adapted for expression of recombinant proteins and 
the level of expression was compared between the two strains after 4h induction 
(Figure 5.7). No detectable expression of the recombinant protein was achieved 
by BL21 either.  
 
In addition, the expression of the recombinant His-tagged proteins was tested by 
Western Blot revealed with anti-His peroxidase conjugated secondary antibody. 
Western Blot analysis supported SDS-PAGE results as no His-tagged proteins 
were detected at different time points and with the two bacterial strains. 
Similarly, the use of the high efficiency quick cloning and expression kit 
Champion™ pET100 Directional TOPO® allowed successful cloning of the 
Cgd2_4380 gene but no expression of the recombinant protein was detected, 
even though high levels of His-tagged recombinant β-galactosidase, used as a 
control, was detected. 
 
The absence of expression of the recombinant protein despite the stability of the 
construct in the bacterial host suggests some limitation in protein translation. A 
Cops-1 protein sequence analysis, performed using ProtParam software 
(http://www.expasy.ch/tools/protparam.html), showed that the following 
aminoacids are abundant in the Cops-1 gene sequence: Serine: 17.4%, Glycine: 
14.7%, Arginine: 9.4%). Therefore, a likely explanation for the lack of expression 
of the recombinant protein might be linked to differences in codon usage 
between the eukaryotic machinery of Cryptosporidium and the prokaryotic 
system of E. coli, especially for these predominant codons.  
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Figure 5.7: Comparison of the level of protein expression of two bacterial strains 
DH5α and BL21 Star™ (DE3) after 4h induction. There is no over-expression of a 
50 kDa recombinant protein. MW: molecular weight marker, N: not induced, 1 and 2: 
recombinant DH5α clones harbouring the recombinant pTrcHisA vector, 3 and 4: recombinant 
BL21 Star™ (DE3) clones harbouring the recombinant pTrcHisA vector. 
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To confirm this hypothesis, the codon frequency of the Cops-1 gene was 
calculated using the codon usage bioinformatics software 
(www.ebioinfogen.com/biotools/codon-usage.htm). The codon frequency 
analysis showed that 17 codons occur at a frequency ≥ 2% (Table 5.1).  
 
The average usage for each coding trinucleotide by C. parvum and E. coli was 
published by Fayer (1997). The predominant codons in the Cops-1 gene were 
assessed for efficient translation by the E. coli machinery. 11/17 (64.7%) codons 
had at least 20% difference in the average codon usage between C. parvum and 
E. coli (Table 5.1). For example, the codons GGA, TTA, AAT, CCA, CAA and AGA 
are extensively used by Cryptosporidium in comparison to E. coli. These results 
could explain the inability of E. coli bacterial strains to efficiently express the 
recombinant Cops-1 protein. 
 
5.3.9 Use of specialized bacterial strains for the expression of recombinant 
protein 
 
In order to resolve the codon bias observed, specialized bacterial strains were 
assessed for the expression of Cops-1 recombinant protein. This includes strains 
engineered for the expression of membrane proteins (C41 and C43) and strains 
having tRNAs for rare codons (Rosetta™2 and BL21-CodonPlus-RP) as detailed in 
2.7.4. The recombinant pET100/D-TOPO
®
 vector was used to transform these 
bacterial strains. Although several C41 colonies were Ampicillin resistant, 
screening for Cops-1 by PCR was negative. However, C43, Rosetta™2 and BL21-
CodonPlus-RP strains successfully maintained the recombinant plasmid. After 
induction, the bacterial lysates were used to visualize protein expression. SDS-
PAGE stained with Coomasie blue did not show clear expression of the 
recombinant protein at 50 kDa. However, immunoblot showed distinctive 
expression of the recombinant protein from 1h post-induction (Figure 5.8). The 
recombinant His-tagged protein has an approximate size of 53 kDa to account for 
the N terminal tag. No his-tagged protein was observed in the non-induced 
lysate. 
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Calculated codon frequency                              
(codon usage bio tool) 
Percent codon used by     
(Fayer, 1997) 
Amino acid Codon Number (%) within 
Cgd2_4380 gene sequence 
C. parvum    
codon usage 
E. coli           
codon usage 
Phe TTT 25 (5.3%) 63 50 
Gly GGA 29 (6%) 37 9 
Gly GGT 30 (6.3%) 50 37 
Leu TTG 11 (2.3%) 23 12 
Leu TTA 16 (3.4%) 35 10 
Asn AAT 16 (3.4%) 68 40 
Pro CCA 33 (7%) 62 19 
Gln  CAA 13 (2.8%) 80 30 
Arg AGA 22 (4.7%) 70 4 
Arg CGT 13 (2.8%) 17 43 
Ser AGT 19 (4%) 17 13 
Ser TCA 30 (6.3%) 33 11 
Ser TCT 21 (4.4%) 34 18 
Thr ACA 18 (3.8%) 42 12 
Thr ACT 19 (4%) 47 19 
Val GTT 10 (2%) 54 28 
Tyr TAT 12 (2.6%) 73 53 
 
 
 
Table 5.1: Codons present at a frequency ≥ 2% in the Cgd2_4380 gene as 
determined by the codon usage software. The percentage was calculated based 
on the total number of 478 trinucleotides (including stop codon). The average of 
codon usage in percentage was adopted from Fayer (1997). The highlighted 
codons showed over 20% difference between C. parvum and E. coli codon usage. 
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Figure 5.8: Immunoblot using anti-polyhistidine secondary antibody from BL21-
CodonPlus-RP lysates after IPTG induction. The bacterial lysates showed an 
expression of the His-tagged recombinant protein of ~ 50 kDa from 1h up to 6h 
after induction. N: not induced, 1-6: cell lysate were taken at one hour interval after IPTG 
induction. 
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The level of expression of the recombinant protein from the different bacterial 
strains was assessed 5h post induction. Immunoblot showed similar levels of 
expression of the recombinant protein between Rosetta™2 and BL21-CodonPlus-
RP strains (Figure 5.9). No expression of the His-tagged protein was visible before 
induction. C43 strain, however, did not allow expression of the full length 
recombinant protein although some short fragments were detected (Figure 5.9). 
 
Both immunoblots (time course expression and comparison of expression levels 
between bacterial strains) showed that there is either degradation of the newly 
produced recombinant protein as early as 1h post induction or production of 
truncated product. The same profile occurred also after increasing the amount of 
protease and phosphatase inhibitors and adopting more stringent handling 
procedures.  
 
5.3.10 Monoclonal peptide antibody anti-Cops-1  
 
In order to investigate the biological function of Cops-1 encoded protein, a 
monoclonal peptide antibody was produced as described in 2.6.3. Initially, two 
peptide regions were chosen due to high immunogenicity and are shown in 
Figure 5.10. The peptide sequences were synthesized and used to immunize 
mice. Mice bleeds were screened by ELISA and the spleens of the two highly 
reactive mice were used for cell fusion. For Tyle-1, screening of fusion cells 
showed only weak and unstable IgG production. In addition, no specific IgG or 
IgM secretion was detected after ten days culture. Therefore, no anti-Tyle-1 
antibody was produced. For Tyle-2 peptide, 13/900 clones were ELISA positive 
(OD450> 0.5). All 13 clones were expanded to assay viability, growth and stability 
and tested by specific anti-Tyle-2 IgG ELISA to check for stable IgG production. 
Only four hybridoma cultures expressed high specific antibody in their 
supernatant. All supernatants were further screened by IFA using purified 
Moredun oocyst suspension as described in 2.9. There was good concordance 
between ELISA and IFA results. The 9E1 hybridoma supernatant was found to 
have the strongest reactivity and was used for further IFA staining. 
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Figure 5.9: Comparison of the level of expression of the His-tagged recombinant 
Cops-1 protein among the three specialized strains (BL21-CodonPlus-RP, 
Rosetta™2 and C43 strains) 5h post induction. BL21-CodonPlus-RP and 
Rosetta™2 strains exhibited the same level of expression, while C43 strains failed 
to express the recombinant protein. 
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Figure 5.10: Location and sequence of the two peptides Tyle-1 and Tyle-2 
assayed for the production of peptide antibody at CRB. The peptide sequences 
were synthesized at high purity and used for mice immunization.  
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5.3.11 Immunolocalization of Cops-1 
 
The 9E1 monoclonal antibody was used to stain fixed parasites as described in 
2.9 to identify the location of Cops-1 protein. In addition, a FITC-conjugated 
antibody that stains the oocyst cell wall of Cryptosporidium species and DAPI 
staining of the sporozoites nuclei were used as counter stains. For C. parvum 
oocysts (Iowa and Moredun), the 9E1 monoclonal antibody clearly recognized 
the oocyst content (Figure 5.11) and the stain partially colocalized with DAPI 
staining of sporozoites, 9E1 stained intact oocysts, broken oocysts still preserving 
their sporozoites and free sporozoites (Figure 5.12). No 9E1 staining of empty 
oocysts was observed. 9E1 antibody enabled staining of intact oocyst contents 
when permeabilized. For impermeabilized oocysts (Paraformaldehyde fixation), 
oocyst content was stained only when the oocyst wall was broken. This staining 
pattern strongly implies that cops-1 is a surface sporozoite protein, which is not 
inconsistent with the protein being secreted.  
 
9E1 monoclonal antibody was also used to stain C. hominis purified oocyst 
suspensions from clinical sources (Ch3, Ch4) as described in 2.9.1. C. hominis 
oocysts showed weak staining of the oocyst content in comparison with the level 
of staining of C. parvum oocysts, which can be difficult to observe (Figure 5.13). 
Several secondary antibodies (FITC Goat Anti-Mouse IgG, Cy™5- conjugated 
Donkey Anti-Mouse IgG, Alexa Fluor®546 Goat Anti-Mouse IgG) were tried as 
described in 2.9.1. The level of staining of C. hominis oocysts was similar for all 
these secondary antibodies. Subsequently, a two-step staining method using 
Biotinylated Rat Anti-Mouse IgG revealed with streptavidin substrate conjugated 
to Alexa Fluor®568 was used to improve the binding specificity. Even with the 
use of these reagents, residual staining of C. hominis oocysts was still observed 
and persisted even after adding a blocking step using a Streptavidin/Biotin 
Blocking kit.  
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Figure 5.11: Staining of purified C. parvum oocysts to identify the location of 
Cops-1 protein. A: DIC (Differential Interference Contrast) microscopy showed 
both empty (white arrowhead) and intact (black arrowhead) oocysts. B: FITC 
oocyst wall staining using Crypto-cell commercial antibody. C: DAPI staining of 
sporozoite nuclei. D: 9E1 staining of oocyst content revealed with Cy™5- 
conjugated Donkey Anti-Mouse IgG. Scale bar= 10 μm. 
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Figure 5.12: Microscopic observation of stained C. parvum oocysts and 
sporozoites using DIC, FITC, DAPI and Alexa Fluor®546 filters. The bottom picture 
is a merge of the 4 fields. 9E1 staining colocalized with DAPI staining of 
sporozoites in intact and ruptured oocysts and in free sporozoites. Scale bar= 10 
μm (unless stated otherwise). 
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Figure 5.13: Comparison of the level of staining of 9E1 antibody of C. hominis and 
C. parvum purified oocysts. Microscopic observation of stained oocysts using DIC, 
FITC, DAPI and Alexa Fluor®546 filters. 9E1 antibody stained oocyst content, 
while C. hominis staining was very faint.  
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The alternative of using a directly conjugated antibody offers the advantage of 
eliminating possible cross reaction of conjugated secondary antibody with the 
sample. Directly conjugated 9E1 antibody was tested to improve staining of 
C. hominis oocysts. Direct conjugation of 9E1 was performed using commercial 
direct conjugation kits. These kits are subtype specific, therefore, the class and 
subclass of 9E1 antibody was determined using Iso-Gold™ Rapid Mouse-
Monoclonal Isotyping Kit as described in 2.9.2. The 9E1 monoclonal antibody is 
IgG1 as shown on Figure 5.14. Subsequently, Zenon® Alexa Fluor®594 Mouse 
IgG1 Labelling kit was used to produce directly conjugated 9E1 antibody. 
However, the staining profile using this antibody was similar to those obtained 
with secondary antibodies previously used. Alternatively, Alexa Fluor®594 
Monoclonal Antibody Labelling kit was also used for direct conjugation of 9E1. 
The direct conjugated antibody also showed residual staining of C. hominis 
oocysts. The weak and diffuse staining of C. hominis oocysts has been consistent 
using different secondary antibodies and two direct conjugation kits.  
 
5.3.12 Gliding Assay  
 
It has been demonstrated that some antibodies raised against sporozoites 
surface proteins were able to stain gliding trails formed by sporozoites after 
excystation when they are left to glide against glass or plastic surfaces. In order 
to assess if Cops-1 is likely to be a sporozoite surface protein shed in trail, a 
gliding assay was performed as described in 2.10 and the slides stained with 9E1. 
In addition, a monoclonal antibody 4C1 was used as a positive control. 4C1 is an 
anti-C. parvum monoclonal antibody raised against sporozoite proteins shed 
during gliding motility of Cryptosporidium sporozoites (Feng et al., 2006). This 
4C1 antibody stained trails left by Cryptosporidium sporozoites when gliding on 
the slide as shown in Figure 5.15. However, no FITC staining of gliding trails was 
visible after staining with 9E1 antibody (not shown). 
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Figure 5.14: Typing of 9E1 monoclonal antibody using the Iso-Gold™ Rapid 
Mouse-Monoclonal Isotyping Kit, showing that 9E1 subclass is IgG1. C is a control 
band for each cassette. 
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Figure 5.15: Gliding trails of Cryptosporidium revealed using 4C1 monoclonal 
antibody. Scale bar= 10 μm. 
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5.3.13 Coculture of Cryptosporidium oocysts with Caco-2 cell monolayers 
  
Cryptosporidium oocysts and sporozoites were used to infect Caco-2 cell 
monolayers as described in 2.11. The excysted oocysts were added to the cells, 
after incubation, the non-adherent parasites were washed in PBS and 
supplemented DMEM medium was added to the cells. The cultures were 
subcultured for further 24h. Cryptosporidium intracellular life stages were visible 
in cell monolayers after Giemsa staining (Figure 5.16).  
 
5.3.14 Effect of 9E1 on Cryptosporidium invasion of Caco-2 cells in vitro 
  
The investigation of a potential role of Cops-1 protein in Cryptosporidium 
attachment and invasion of host cells was undertaken using an in vitro blocking 
assay as described in 2.11.7. Pre-incubation of the parasite with a neutralising 
blocking antibody was shown to inhibit host cell invasion by Neospora caninum 
(Nishikawa et al., 2000). A similar blocking assay was developed for 
Cryptosporidium. Briefly, Cryptosporidium oocysts were pre-incubated with 9E1 
monoclonal antibody at 1mg/ml and 0.1 mg/ml. In addition, a mouse IgG1 
antibody (0.1 mg/ml) was used as a negative control. As a positive control, 
oocysts were incubated in PBS. For each condition, the mixture was used to 
infect Caco-2 cell monolayers as described previously. After 24h subculturing, the 
numbers of parasites was counted in 20 random fields as shown in Table 5.2. The 
mean number of parasites per field was then determined as shown in Figure 5.17 
to allow comparison between the different conditions. Pre-incubation of 
Cryptosporidium oocysts with 9E1 did not influence Caco-2 cells invasion. The 
number of parasites detected in cell monolayers was comparable when the 
parasites were incubated with PBS or with 0.1 or 1 mg/ml 9E1: 113 versus 122 
and 117, respectively (Figure 5.17).  
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Figure 5.16: Intracellular life stages of Cryptosporidium visualized after Giemsa 
staining of infected Caco-2 cell monolayers.  
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Table 5.2: Number of parasites detected for each randomly selected field for 
each of the different conditions tested. Parasites were pre-incubated with 9E1 
antibody at 2 different concentrations, with PBS as a positive control and a 
mouse IgG antibody as a negative control before infection of Caco-2 cell 
monolayers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
No antibody Mouse IgG (0.1mg/ml) 9E1 (0.1 mg/ml) 9E1 (1 mg/ml) 
101 36 145 153 
83 58 60 178 
127 77 69 119 
78 77 104 116 
144 75 100 53 
89 111 114 108 
187 101 152 67 
95 67 196 79 
86 93 101 101 
91 43 110 139 
63 159 135 95 
58 85 76 45 
131 103 59 137 
102 100 125 153 
85 102 125 153 
90 88 121 83 
135 140 215 64 
148 66 136 149 
211 73 114 155 
161 124 184 197 
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Figure 5.17: Mean number of parasites per field for the different coculture 
conditions. Using 2 different concentration of 9E1 monoclonal antibody did not 
influence the level of invasion of Caco-2 cells by Cryptosporidium oocysts.   
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5.3.15 Screening of recombinant and native antigen preparations using sera 
from natural Cryptosporidium infection and 9E1 monoclonal antibody 
 
Recombinant protein preparations from BL21-CodonPlus-RP and Rosetta™2 
strains and native antigen preparations from C. parvum and C. hominis oocysts 
prepared as described in 2.12.1 were tested by Western Blot revealed using sera 
from patients infected with C. parvum and C. hominis. These sera originated from 
cryptosporidiosis cases, previously genotyped at CRU. In addition, a negative 
human serum for Cryptosporidium infection was tested as negative control.  
 
For the recombinant protein preparations, several bands were revealed with the 
polyclonal goat anti-human IgG secondary antibody. Both induced and non-
induced bacterial lysates were tested to confirm the detection of recombinant 
Cops-1 protein. There were no distinct profiles between the non-induced and the 
induced protein preparations for the two strains (Figure 5.18). A strong band of 
50 kDa was visible for Rosetta™2 protein preparation, but it was also present in 
the non-induced bacterial lysate. This protein was absent from the induced 
lysate when the blot was treated with the negative serum. A 70 kDa protein was 
also detected with C. parvum infection serum from induced and non-induced 
protein preparations but was also visible with the negative serum. C. hominis 
serum did not reveal any band. The native antigen preparations were also tested 
using patient’s sera. C. parvum serum detected a 75 kDa band from C. parvum 
and C. hominis antigen preparations; however, this band was also detected with 
the negative serum (Figure 5.18). This was also the case for a 20 kDa protein 
detected from C. hominis proteins.  
 
Interestingly, a protein of 50 kDa was detected from C. parvum native antigen 
preparation but not from C. hominis when the blot was treated with C. parvum 
infection serum. This protein was not detected with the negative serum. It is 
possible that the 50 kDa protein detected from C. parvum native antigen 
preparations with a C. parvum infected patient is Cops-1. 
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Figure 5.18: Immunoblot results of recombinant protein preparations from 
RosettaTM2 and BL21-CodonPlus-RP strains and native antigen preparations from 
C. hominis and C. parvum oocysts revealed with 9E1 monoclonal antibody, 
natural C. parvum infection serum and a negative serum.  
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The 9E1 antibody did not detect a 50 kDa protein from induced bacterial lysates 
and native antigen preparations. Only a band of 30 kDa from induced Rosetta
 
™2 
bacterial preparation was detected, which is likely to be a product of degradation 
of the full length recombinant Cops-1 protein. No such band was detected from 
BL21-CodonPlus_RP induced lysate, despite a 30 kDa band being detected using 
the anti-His tagged antibody. 
 
5.4 Discussion  
 
The characterization of the Cops-1 gene on the genetic and molecular level was 
undertaken to achieve an improved understanding of the protein characteristics 
and function. Cops-1 was first thought to be C. parvum specific, as the right size 
PCR product was generated only from C. parvum DNA, which has lead to its re-
labelling as Cryptosporidium parvum specific gene (Cops-1). Subsequently, 
sequencing of a smaller band of 200 bp generated using Cgd2_4380 F and R 
primers from both C. parvum and C. hominis showed high sequence similarity to 
Cgd2_4380 gene. This result suggested that Cops-1 has an ortholog in C. hominis. 
The two genes were named CpCops-1 and ChCops-1, for C. parvum and 
C. hominis, respectively.  
 
In order to follow up this discovery, a new pair of primers (based on the 
retrieved gene sequence) was designed and tested. These primers 
(Cgd2_4380_2F and 2R) allowed amplification of two bands from C. hominis and 
three bands from C. parvum, thus increasing the amount of known sequence for 
ChCops-1. These results were supported by BLAST analysis showing three 
potential primer binding sites for Cgd2_4380_2R primer. The last binding site 
(generating the highest molecular weight band) seemed to be absent in 
C. hominis, thus supporting the hypothesis of partial gene truncation in 
C. hominis. The recurrent primer binding sites were due to the presence of 
repeats in the Cgd2_4380 as was suggested by the gene annotation. 
Interestingly, PCR products using Cgd2_4380_2F and 2R primers were obtained 
only from clinical isolates of C. hominis but not from the reference strain TU502. 
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This might be explained by high sequence variability between the clinical isolates 
and reference strain of C. hominis and could justify the absence of the 
Cgd2_4380 gene from the C. hominis genome sequence.  
 
Sequence analysis of Cgd2_4380 F and R primers PCR products showed that 
clinical isolates of C. parvum had an identical sequence to the published gene 
sequence. The anthroponotic group had four specific SNPs. C. meleagridis DNA 
gave the correct size PCR product (655 bp) using Cgd2_4380 F and R primers, 
suggesting that Cops-1 is not exclusively a C. parvum gene. This result supports 
the phylogenetic relatedness of C. meleagridis to C. parvum as discussed in 
Chapter 3. The C. meleagridis PCR product had only one SNP. C. hominis PCR 
products, despite being shorter, showed some level of sequence variability as 
four species-specific SNPs were detected from the 200 bp product. 75% of the 
SNPs detected were non synonymous. This proportion of non synonymous SNPs 
per gene is within the range (0%-83.4%) detected in the other genetic loci as 
shown in Chapter 3. 
 
The identification of the full ChCops-1 gene sequence was undertaken using a 
primer walking approach. Not all primer combinations allowed DNA amplification 
from C. hominis isolates. This is probably due to targeting conserved versus 
deleted regions of the gene. Surprisingly, some primer combinations worked 
with the Ch3 isolate only. Thus, the determination of the full gene sequence was 
possible only from Ch3. ChCops-1 seems to be truncated to 1263 bp in this 
isolate. The sequence showed 78.8% sequence identity to the published 
Cgd2_4380 gene. Alignment of CpCops-1 and ChCops-1 sequences showed high 
sequence variability, 101 SNPs were detected in addition to few nucleotide 
insertions and deletions. On average this corresponds to 1 SNP for every 13 
nucleotides for C. hominis and 1 SNP for every 15 nucleotides for C. parvum. This 
is much higher than the most variable gene detected during this study 
Cgd2_2430 gene, for which an average of 1 SNP per 30 nucleotides was detected 
(Chapter 3). Despite this high sequence variability, the proportion of non-
Chapter 5 
- 187 - 
synonymous SNPs for the whole gene sequence was 78.3% which is within the 
range detected in the other genetic loci tested.  
 
Based on the ChCops-1 sequence, showing a conserved 5’ end, a reverse primer 
targeting the 3’ of the gene (Cops-1_C. hominis_R) was designed. PCR using 
Cgd2_4380 FF and Cops-1_C. hominis_R primers did not allow amplification from 
Ch3 or any other C. hominis isolates. At this stage, a technical limitation was 
encountered, testing a newly extracted Ch3 isolate DNA (from the same oocyst 
suspension stored at CRU) did not allow the previous results to be reproduced. 
This new sample differed in DNA quantity and quality, which may have 
influenced the PCR results. In addition, degradation of oocyst suspensions is 
likely after long term conservation at 4°C, but PCR reactions using other targets 
was positive. A new pair of primers aiming to amplify the full ChCops did not 
allow DNA amplification from Ch3 or any other C. hominis isolate. This suggests 
that the ChCops-1 may not be conserved amongst C. hominis clinical and 
reference strains. This is supported by the high level of sequence variability that 
was detected. However, it is clear that the internal part of the Cgd2_4380 gene is 
conserved among C. hominis clinical isolates since internal primers showed 
consistent amplification of DNA from C. hominis. The 5’ end of the gene seems 
also to be conserved in C. hominis isolates as confirmed by sequencing. The 
determination of the ChCops-1 3’ end, however, proved more challenging. 
Because of these limitations, the full length ChCops-1 sequence requires further 
validation and it is still unclear if Cops-1 is functional in C. hominis species.   
 
The potential of Cops-1 gene to be a species determinant was considered largely 
on account of the initial PCR results. In addition, the predicted protein features 
are highly suggestive of a role in host-parasite interaction. Particularly, the 
telomeric location indicates that the gene is prone to higher recombination rates 
and it is likely to be a contingency gene. Such genes were shown to be involved 
in host pathogen interaction and parasite survival in the host, such as VSG gene 
of T. brucei, which undergoes antigenic variation to evade the host immune 
responses and allow parasite survival (Yang et al., 2009, Barry et al., 2003). The 
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predicted protein has at its N terminus a signal peptide, a transmembrane 
domain and a myristoylation motif implying that Cops-1 encodes a secreted 
protein likely to be involved in host-pathogen interaction. Myristoylation of 
protein is a translational event catalyzed by the enzyme N-myristoyl transferase 
(NMT), which attaches myristic acid to the N-terminal glycine residues of 
eukaryotic and viral proteins (Farazi et al., 2001, Poli et al., 1991, Towler et al. 
1988). Myristoylated proteins aid subcellular targeting, protein-protein 
interaction and are involved in signal transduction cascades. NMTs have been 
characterized in several protozoan parasites. In Leishmania major and 
Trypanosoma brucei, NMT is a 48.5 kDa protein that localizes to both membrane 
and cytoplasmic fractions, is expressed in all life stages and was shown to be 
essential for viability (Price et al., 2003). NMT genes were detected in C. parvum, 
C. hominis and C. muris genome sequences. 
 
Cops-1 Protein BLAST showed low sequence identity to the Drosophila 
melanogaster gene “shot” (short stop). The shot gene encodes actin-binding 
proteins and is predicted to contain, at the N terminus, an actin-binding domain 
and at the C terminus two EF-hand calcium-binding motifs (Lee et al., 2000 b). 
Shot has been shown to coordinate actin and microtubule dynamics, which is 
important for cellular motility and morphogenesis (Lee and Kolodziej, 2002). 
Strangely, no EF hand or actin binding domain were detected by the analyse 
software. This suggests that Cops-1 protein may not share functional features 
with shot. 
 
In order to characterize the Cops-1 encoded protein, cloning of the full gene 
length from C. parvum Iowa DNA and expression of the recombinant protein in 
bacterial strains was performed. Cloning of the Cops-1 gene into various cloning 
and expression vectors was successful; however, the expression of the 
recombinant protein was less straightforward. Despite the stability of the 
recombinant plasmid in the bacterial strain, no expression of the recombinant 
protein was initially observed on SDS-PAGE or by Western Blot. This observation 
was suggestive of a translation malfunction, restraining the expression of the 
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recombinant protein. This could be driven by the differences in codon usage 
between the eukaryotic machinery of Cryptosporidium and the prokaryotic 
system of E. coli, which is particularly relevant for predominant codons in gene 
sequence. The codon composition for Cgd2_4380 gene was calculated and 
showed that 17 codons occurred at a frequency greater than 2%. Of the 17, 11 
(64.7%) had at least 20% difference in the average codon usage between 
C. parvum and E. coli. A biased codon usage in Cryptosporidium genes has been 
reported and was mainly attributed to the A+T rich genome (Grocock and Sharp, 
2001, Char et al., 1996). The codon bias has been anticipated by Fayer (1997) to 
limit the performance of E. coli recombinant expression libraries, as many 
Cryptosporidium DNA sequences may not be translated at detectable levels 
because the tRNAs necessary for efficient expression are present at too low 
concentration. Therefore, strains having tRNAs for rare codons (Rosetta™2 and 
BL21-CodonPlus-RP) were used and enabled expression of a 50 kDa recombinant 
protein. Despite this successful outcome, the expression of the recombinant 
Cops-1 protein remained at low level and limited stability. The recombinant His-
tagged protein seems to be either degraded as soon as expressed or partially 
produced. The degradation persisted after increasing the amount of protease 
inhibitors and adopting more stringent handling procedures, suggesting that the 
degradation process is more likely to be intrinsic to the bacterial strain. 
Alternative expression systems such as yeast, insect or mammalian cells could be 
used for expression of a stable recombinant Cops-1 protein. Such systems are 
very useful for expression of eukaryotic proteins because they perform many 
posttranslational modifications such as translocation and glycosylation necessary 
for production of active proteins (Weidner et al., 2010, Rothblatt and Meyer, 
1986).  
 
In order to investigate the biological function of Cops-1 protein, a monoclonal 
peptide antibody was produced. The highly reactive 9E1 hybridoma supernatant 
was used for immunolocalization studies. On purified C. parvum oocysts and 
sporozoites, the monoclonal antibody clearly recognized the contents of the 
oocyst when permeabilized and was able to stain free sporozoites, implying that 
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the protein is either a surface or secreted sporozoite protein. These 
characteristics are, along with the telomeric location, consistent with a role for 
Cgd2_4380 in host adaptation and virulence. On C. hominis oocysts and 
sporozoites, 9E1 showed a weaker internal staining of the oocysts. This level of 
staining persisted with several secondary antibody and also directly conjugated 
antibodies, suggesting that the staining is likely to be specific. This result is 
surprising because the Tyle-2 peptide (used to immunize mice) seems to be 
absent from the ChCops-1 sequence retrieved by sequencing. This could be 
explained by cross reactivity of the antibody with either a homologous region of 
the C. hominis ortholog or another C. hominis antigen. In addition, C. hominis 
oocyst suspensions were from clinical sources and showed high background 
staining by immunofluorescence which could partially explain the cross reactivity 
observed. Future studies would benefit from a polyclonal antibody directed 
against the whole recombinant protein for an improved determination of the 
localization of the Cops-1 protein and to confirm whether the gene is expressed 
in C. hominis. 
 
The assessment of the role of Cops-1 protein in host-cell infection was 
undertaken in vitro using a blocking assay in coculture of Cryptosporidium 
oocysts and Caco-2 cells. The pre-incubation of the parasite suspension with 9E1 
antibody did not influence the infectivity of Cryptosporidium when compared to 
controls as evidenced by comparable parasite counts. Although this result may 
suggest that Cops-1 protein does not have a role in host-parasite interaction, it 
could be that Tyle-2 epitope does not correspond to the region interacting with 
the intestinal cell receptors. The validation of this hypothesis would require the 
use of a polyclonal antibody targeting the whole recombinant Cgd2_4380 
protein. 
 
The immunogenicity of the Cops-1 protein was tested by Western Blot, treated 
with sera from C. parvum and C. hominis natural human infection. In 
recombinant preparations, Western Blot analysis with C. parvum serum showed 
a band of 50 kDa from Rosetta™2 lysates and to a lesser extent from BL21-
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CodonPlus_RP lysates. This protein, however, was visible in both induced and 
non-induced lysate. Interestingly, when native C. parvum and C. hominis antigen 
preparations were tested by Western Blot using the same serum, a 50 kDa band 
was detected from C. parvum but not C. hominis. This result was obtained using a 
single C. parvum infected patient serum; testing of other C. parvum sera or 
serum pools would be valuable to confirm this observation. Nevertheless, this is 
a first report of a C. parvum-specific immunodominant protein. This protein 
could be Cops-1, but this could not be confirmed because of the poor reactivity 
of the 9E1 antibody in immunoblotting. A possible explanation for this poor 
reactivity could be the alteration or degradation of the linear epitope when 
tested by Western Blot. The likelihood of this 50 kDa C. parvum protein being 
Cops-1 are mainly based on size. There was only one report of a protein of 
similar size Cp47 (47 kDa) by Nesterenko and colleagues (1999). Cp47 is 
membrane-associated protein, which possesses significant binding affinity for 
the surface of both human and animal intestinal cells. The gene encoding Cp47 
protein has not been discovered yet. Cp47 was identified by Western Blot using 
anti-C. parvum sporozoite membrane associated protein and is implicated in 
host-cell attachment (Nesterenko et al., 1999). An anti-Cp47 antibody or a 
polyclonal anti-Cops-1 recombinant protein is required to determine the identity 
of the 50 kDa protein. 
 
These preliminary data suggest that a C. parvum specific immunodominant 
protein of ~ 50 kDa is differentially expressed between C. parvum and C. hominis 
and could be the Cops-1 protein. This result, if confirmed, is the first evidence 
that Cops-1 is C. parvum-specific protein and would have several applications as 
diagnostic marker, species determinant and vaccine candidate. 
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5.5 Summary 
 
One gene, Cops-1, emerged from PCR based screening as putatively specific for 
C. parvum. This gene was positioned telomerically and its product is annotated 
as secreted, serine rich, containing internal repeats and bioinformatic analysis 
suggests that the protein may be myristoylated at the N terminus, which itself is 
hydrophobic and capable of membrane insertion. The predicted protein may be 
N-glycosylated and under appropriate conditions could be phosphorylated 
heavily. In addition, it shows moderate sequence identity to cytoskeletal 
interacting proteins such as shot gene of Drosophila melanogaster. 
 
The initial studies identified an orthologous gene in C. hominis (ChCops-1), but 
one which is considerably different in sequence and which is foreshortened 
lacking a repeat. This is suggestive of rapid evolution, therefore Cops-1 is a 
possible virulence factor candidate.  
 
Cops-1 PCR product sequence analysis showed that the variability associated 
with this short fragment has a good discriminatory power and allowed clustering 
of Cryptosporidium genotypes and subtypes, which was consistent with the 
polymorphism seen in the other genetic loci tested by MLA. This result suggests 
that Cops-1 is also a good marker for taxonomic analysis. 
 
A monoclonal peptide antibody 9E1 directed against a C. parvum-specific epitope 
clearly recognized the contents of the oocyst and stained free sporozoites, 
implying that the protein could be a surface or secreted sporozoite protein. 
These characteristics are, along with the telomeric location, consistent with a 
role for Cops-1 in host adaptation and virulence.  
 
The protein encoded by CpCops-1 was expressed as a recombinant protein in 
E. coli strains having tRNAs for rare codons because of the codon bias of 
Cryptosporidium and a particular Cops-1 gene composition. The recombinant 
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protein was expressed at low levels and had limited stability. Optimization of the 
expression of the recombinant protein in other expression systems is required 
for the production of a full length stable recombinant protein, which will be 
useful for further characterization studies. 
 
Native antigen preparations, from C. parvum and C. hominis oocysts, tested by 
immunoblot with C. parvum infected patient serum showed that a 50 kDa band 
was present in C. parvum but not C. hominis preparations. This is the first report 
of species-specific immunodominant protein for Cryptosporidium, which may be 
Cops-1 and would have several applications as diagnostic target, species 
determinant and vaccine candidate.  
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6.1 General discussion 
 
This thesis has exploited genomic data from the relatively recent sequencing of 
C. parvum and C. hominis genomes in order to identify species-specific 
Cryptosporidium genes. The data presented demonstrating that the minimal 
genetic variability existing between C. parvum and C. hominis (<5%) is likely to 
include interesting genetic determinants with predicted features suggesting a 
role in host-pathogen interactions. Hitherto, no similar analyses mining genetic 
variation between novel gene sequences for these two Cryptosporidium species 
has been undertaken. This lack of interest in species-specific genes reflects the 
focus of Cryptosporidium researchers on further characterization of established 
genes of interest and genetic loci commonly used for Cryptosporidium typing. 
However, recognition of the potential of proteins, with no known homology to 
polypeptides with known function, in mediating host-parasite interactions and 
parasite-specific metabolic pathways has been recently acknowledged (Tomley, 
2009). 
 
6.1.1 Identification of species-specific genes by comparative genomics 
 
Genome sequences of C. parvum and C. hominis were published in the same year 
(Abrahamsen et al., 2004, Xu et al., 2004). Genome sizes were comparable and 
only 3–5% sequence divergence was observed between the two species. The 
authors concluded that the phenotypic differences between C. hominis and 
C. parvum are caused by polymorphisms in coding regions and differences in 
gene regulation (Pain et al., 2005, Xu et al., 2004). In this study, attempts to 
identify genetic determinants that account for this minimal genetic variability 
were undertaken. Using Reciprocal BLAST, each gene was given a similarity score. 
Genes with <10% sequence identity were considered putatively species-specific. 
The highly variable genes were estimated at 93 for C. hominis and 211 genes for 
C. parvum. A subset of these genes was tested by PCR in a collection of 
Cryptosporidium clinical isolates and reference strains. Approximately 90% of the 
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genes tested were present in both C. hominis and C. parvum, indicating that the 
vast majority of the predicted genes seem to be common to both species. These 
results question either the accuracy of the in silico prediction or the quality of 
the published genome sequences. The latter explanation is most likely due to the 
incomplete status of the published C. hominis genome. Xu and colleagues (2004) 
reported over 240 gaps and no further progress of the genome sequence has 
been published to date. This partial completion impaired the accuracy of 
prediction of putative species-specific genes; especially for genes corresponding 
to sequence gaps. Therefore, the majority of the genes identified during this 
study (and shown in Appendix II) are not likely to be specific but are homologous 
genes that eluded the genome sequence due to incomplete coverage. An 
improved comparative genomic analysis is likely to be possible with fast progress 
being made towards the completion of the C. muris genome. The genomic 
sequences are being made accessible online prior to publication (Widmer et al., 
2007). At the time of writing this chapter, 8.9 Mb from the C. muris genome are 
available for download from CryptoDB, of which 7.2 Mb correspond to coding 
sequences. 58.4% of the subset of genes tested by PCR appear to have orthologs 
in C. muris. This result further supports that the majority of the genes tested are 
common to Cryptosporidium species more generally. Comparative genomics of 
C. parvum, C. hominis and C. muris genomes is expected to improve the 
understanding of Cryptosporidium species evolution and host adaptation 
(Widmer et al., 2007). A similar reciprocal BLAST analysis, performed when the 
data are complete, will add considerable power to the analysis, enabling further 
refining of the process of discovery for genetic determinants of Cryptosporidium 
host tropism. 
 
6.1.2 Sequence analysis of novel genetic loci and phylogenetic applications 
 
The ten genetic loci identified as described above were common to both 
Cryptosporidium species. Nevertheless, they are novel genetic determinants 
never before investigated. Sequence analysis of these genes revealed interesting 
genetic polymorphism: 78 SNPs were detected, 78.3% (61) of which were 
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species-specific. The presence of species-specific SNPs was reported previously 
for several genetic markers and have been exploited for Cryptosporidium 
genotyping and subtyping (Sulaiman et al., 1999). Several of the newly identified 
SNPs were confirmed by PCR-RFLP and showed a similar discriminatory power to 
the extensively used markers. Interestingly, this level of SNP frequency per gene 
is higher than in the routinely used Cryptosporidium loci. The majority (64.2%) of 
the SNPs were synonymous, suggesting a minimal effect on the protein function. 
However, it has been documented that synonymous mutations can also alter the 
structure, function and expression level of the protein by affecting messenger 
RNA splicing, stability, protein folding and structure (Hunt et al., 2009). Thus the 
actual effect of these SNPs on gene function can only be assessed 
experimentally. 
 
Sequence analysis of these novel genetic loci allowed the construction of a 
robust and novel MLA. The Neighbor-Joining phylogenetic tree constructed 
clearly grouped and discriminated with high bootstrap values the previously 
described lineage of anthroponotic C. parvum from C. parvum isolates and the 
rabbit genotype from C. hominis which has been recently proposed as a new 
C. hominis subspecies on the basis of this and other data (Chalmers et al., 2009 
b). The discriminatory power of these loci is powerful because not only does it 
allow discrimination of Cryptosporidium species/genotypes but also subtypes. 
This level of discrimination (for anthroponotic C. parvum and rabbit genotype) 
was only previously achieved using GP60 subtyping.  
 
There is a debate in the literature about the advantages and limitations of GP60 
subtyping of Cryptosporidium isolates. GP60 is undeniably the most commonly 
used population marker for Cryptosporidium spp (Jex and Gasser, 2010). This 
locus is hypervariable and isolates are classified in subtypes according to the 
number of repeats in a nomenclature proposed by Sulaiman and colleagues 
(2005). Subsequent studies showed that the level of discrimination is not in 
accordance with multi-locus subtyping and GP60 genotype by itself is difficult to 
reconcile with the concept of a subtype defined as a genetically distinct 
Chapter 6 
 
- 198 - 
population within a species (Widmer, 2009). Thus, Widmer has stated that GP60 
may not be a reliable marker of C. parvum and C. hominis population structure 
(Widmer, 2009). In addition, Hunter and colleagues (2008) pointed out that it is 
still unclear if the identification of different subtypes in outbreak settings 
represented different lineages or evolution of strains during the outbreaks. 
Another limitation of GP60 is that the high level of variability is under selective 
pressure as this locus was shown to be involved in sporozoite adhesion to host 
cells (Okhuysen and Chappell, 2002). In addition, Jex and Gasser (2010) reported 
that the genetic richness of Cryptosporidium isolates was associated with a 
surprisingly low diversity. In fact, despite the report of high number of subtypes 
(richness), the relative prevalence of each distinct type (diversity) was low. The 
authors reported that human cryptosporidiosis is mainly associated with six 
dominant GP60 subtypes.  
 
In this study, comparative genomics were used to identify novel genetic loci. 
These loci were common to C. hominis and C. parvum and some were also 
present in C. meleagridis. Sequence analysis showed interesting genetic 
polymorphism and excellent phylogenetic potential. One limitation of this 
approach is the high number of loci used to achieve high discriminatory power, 
which would limit its use for routine subtyping. However, a reduction of the 
number of loci while keeping the discriminatory power can be achieved by 
selecting a subset of highly variable genes, in which polymorphisms reflect the 
ecological adaptation of divergent subpopulations. The usefulness of these novel 
genetic loci for phylogenetic analysis needs to be validated by testing higher 
numbers of subtypes and isolates from different geographical locations. 
Moreover, further PCR testing of the remaining loci identified by comparative 
genomics will likely yield additional genes encoding proteins with roles in host-
parasite interaction in general and host range determinants and virulence factors 
in particular. 
 
In the current situation, typing of Cryptosporidium isolates is highly desirable 
because it provides insights about population structure and virulence of 
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particular subtypes and it allows source tracking for epidemiological 
investigation of outbreaks (Chalmers et al., 2008, Hunter et al., 2007). However, 
the identification of an adequate locus (or loci in the case of multi-locus typing) is 
dependent on the satisfaction of several evaluation criteria that still have to be 
delineated in the case of Cryptosporidium. To address the issues of 
Cryptosporidium typing, Medini and colleagues (2008) suggested that new typing 
systems need to incorporate whole genome sequences. In addition, Jex and 
Gasser (2010) recommended that future studies should use next generation 
sequencing to conduct comparative genome sequence surveys to test the 
validity of current genetic classifications based on gp60 data, which would 
overcome the limitations of classification based solely on the analysis of a small 
number of genetic loci.  
 
A less ambitious but probably more realistic approach is the hypothesis that the 
identification of new genetic markers can be drawn, using comparative genomic 
techniques, from the vast amount of genetic data generated by the three 
Cryptosporidium genome projects. Data presented in this thesis (Chapter 3) 
clearly showed the feasibility of this approach; in fact, this is the first report of 
genetic loci identified using a comparative genomics approach, which possess 
genotyping and subtyping discriminatory power.  
 
6.1.3 Whole genome amplification for generating practically unlimited 
quantities of isolate specific DNA 
 
A major barrier to the extensive testing of Cryptosporidium isolate DNA by typing 
and sequence analysis is the limited amount of material available (Smith et al., 
2006). This is particularly relevant for unculturable or fastidious microorganisms 
such as Cryptosporidium. Whole genome amplification (WGA) can be used to 
increase the amount of nucleic acid materials of waterborne pathogens isolated 
from clinical and environmental samples as reviewed by Bouzid and colleagues 
(2008). The study described in this thesis (Chapter 4) trialling three commercial 
WGA kits, showed that one MDA based kit: illustra GenomiPhi WGA kit had the 
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best performance amplifying Cryptosporidium DNA with 90.9% success rate, 
generating high concentration of high molecular weight DNA with 100% fidelity. 
Real-time PCR result showed over 30-fold increase specifically of 
Cryptosporidium DNA. The amplified DNA was also shown to be suitable for 
downstream genotyping and subtyping applications. However, a validation of the 
integrity and fidelity of amplification of highly polymorphic genetic loci (such as 
GP60) should be carried out to fully validate the usefulness of the amplified DNA 
for downstream applications. In addition, use of WGA amplified DNA as PCR 
template could increase PCR sensitivity from clinical samples. Similar findings 
were reported for the detection of Trypanosoma species from blood samples 
(Pinchbeck et al., 2008). Despite these advantages, the use of WGA is still limited 
in diagnosis and research laboratories and the WGA related publication is 
scattered. Several investigators agree about the usefulness of the technique but 
implementing it for routine and extensive use may require further 
demonstration of its utility. 
 
6.1.4 Cryptosporidium species-specific genes 
 
Although the genomes of C. hominis and C. parvum are 97% identical, their host 
range is strikingly different. C. parvum is the zoonotic species, while C. hominis 
normally only infects humans. The accepted consensus is that the two genomes 
are homologous and have essentially the same gene content (Xu et al., 2004, 
Abrahamsen et al., 2004). It has been postulated that the variable regions 
correspond primarily to the presence of micro or minisatellites (Tanriverdi and 
Widmer, 2006) and that the phenotypic differences between C. hominis and 
C. parvum are caused by polymorphisms in coding regions and differences in 
gene regulation (Pain et al., 2005, Xu et al., 2004). However, this minimal genetic 
divergence may include hitherto undetected genetic determinants of host 
specificity and virulence. Data presented in this thesis (Chapter 3) showed that 
despite the majority of the predicted specific genes being common to both 
Cryptosporidium species, evidence was found that one C. parvum gene (Cops-1) 
and one C. hominis gene (Chos-1) generated appropriate PCR product from only 
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one species. This result suggests that within the predicted genes, a small 
proportion may be species-specific. Those initial results suggest that these two 
loci could be used for diagnosis purposes to discriminate between C. hominis and 
C. parvum in a robust duplex PCR assay which reflects actual gene repertoire and 
is not simply dependent on maintenance of few single nucleotide 
polymorphisms. Sensitivity and specificity assays should be undertaken to 
validate the diagnostic potential of this test.  
 
6.1.5 C. parvum specific gene (Cops-1)  
 
The potential of Cops-1 as a species determinant and a virulence factor was 
reinforced by the predicted features of the gene and its encoded protein. Cops-1 
is positioned telomerically and annotated as a secreted, serine rich protein, 
containing internal repeats. The predicted protein may be N-glycosylated and 
under appropriate conditions could be phosphorylated heavily. It shows 
moderate sequence identity to cytoskeletal interacting proteins such as shot 
gene of Drosophila melanogaster. The telomeric location of the gene indicates 
that the gene is prone to higher recombination rates and it is likely to be a 
contingency gene. Such genes were shown to be involved in host-pathogen 
interaction and parasite survival in the host, in T. brucei it includes the genes of 
the subtelomerically positioned expression site (ESAGS) and notably the VSG 
gene, which undergoes antigenic variation to evade the host immune responses 
and allow parasite survival (Yang et al., 2009, Barry et al., 2003) and similarly, the 
var genes of Plasmodium falciparum coding for erythrocyte protein-1, which 
likewise are the subjects of antigenic variation (Kyes et al., 2001). Genetic 
determinants of host tropism are also likely to be among these contingency 
genes and such a role has been proposed for both the transferrin receptor 
encoded as a heterodimer by ESAG6 and ESAG7 and the serum resistance 
antigen (SRA) which confers resistance to human sera for T. brucei rhodesiense.  
 
The predicted Cops-1 protein has at its N terminus a signal peptide, a 
transmembrane domain and a myristoylation motif implying that Cops-1 encodes 
Chapter 6 
 
- 202 - 
a secreted protein involved in host pathogen interaction. Several 
Cryptosporidium surface and apical complex proteins are predicted to have a 
signal peptide (Gp900, gp40, Cpa135, Cp2, TRAP-C1) (Wanyiri and Ward, 2006). 
These proteins are potential virulence factors and have been shown to mediate 
host-cell attachment and invasion. One of these proteins, gp900 has a signal 
peptide and a transmembrane domain and was shown to mediate invasion of 
host cells (Barnes et al., 1998). The myristoylation motif mediates the covalent 
attachment of myristic acid to the N terminal glycine of eukaryotic and viral 
proteins and this process is catalyzed by an enzyme N-myristoyl transferase 
(NMT) (Farazi et al., 2001, Poli et al., 1991, Towler et al. 1988). Myristoylated 
proteins aid subcellular targeting, protein-protein interaction and are involved in 
signal transduction cascades. NMTs were characterized in several protozoan 
parasites. In Leishmania major and Trypanosoma brucei, NMT is a 48.5 kDa 
protein that localizes to both membrane and cytoplasmic fractions and is 
expressed in all life stages and was shown to be essential for viability (Price et al., 
2003).  
 
Cops-1 has a potential as a diagnostic target amplifying a 655 bp band from 
C. parvum isolates. In addition, a 200 bp band was present in PCR products from 
C. hominis and C. parvum DNA. This band could serve as a useful internal control 
for the presence of human infective Cryptosporidium. This assay as it stands 
types to the species level. Sequencing of the 200 bp band showed that Cops-1 
seems to have an ortholog in C. hominis. PCR product sequences were used to 
build a Neighbor-Joining Tree, which showed good discrimination of C. parvum, 
C. parvum anthroponotic subtype, C. hominis and the rabbit genotype. The 
phylogenetic tree showed that the variability associated with this short fragment 
has a good discriminatory power and allowed for subtyping of Cryptosporidium 
isolates  in a manner consistent with the multi-locus analysis from Chapter 3. 
 
The identification of the full ChCops-1 gene sequence was undertaken using a 
primer walking approach. Not all primer combinations allowed DNA amplification 
from C. hominis isolates. Surprisingly, some primer combinations worked with 
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Ch3 isolate only. Thus, the determination of the full gene sequence was possible 
only from Ch3. ChCops-1 seems to be truncated to 1263 bp in this isolate. The 
retrieved sequence showed 78.8% sequence identity to the published 
Cgd2_4380 gene. Interestingly, TU502 DNA did not generate PCR products using 
the majority of the primers tested. This result could possibly explain why Cops-1 
gene had eluded the genome sequence. A set of primers based on the predicted 
ChCops-1 gene sequence failed to generate DNA amplification from any isolate. 
Therefore, full length ChCops-1 sequence requires further investigation and 
validation. However, the 5’ end of the gene is conserved as shown by several 
primer combinations. Therefore, CpCops-1 and ChCops-1 have a conserved N 
terminus, suggesting that some of the Cops-1 characteristic features are likely 
maintained. These initial studies have identified an orthologous gene in 
C. hominis (ChCops-1), but one which is considerably different in sequence and 
which is foreshortened lacking a repeat. These findings support the rapid 
evolution of this gene and the candidature for the protein encoded by 
Cgd2_4380 as a virulence factor or host determinant.  
 
6.1.6 Cloning and expression of CpCops-1 protein  
 
The full length CpCops-1 gene from C. parvum Iowa DNA was successfully cloned 
into cloning and expression vectors. Despite maintenance of the plasmids in the 
bacterial hosts, no expression of the recombinant protein was detected by SDS-
PAGE or Western Blot. This might be due to differences in codon usage between 
the eukaryotic machinery of Cryptosporidium and the prokaryotic system of 
E. coli. Codon bias has been reported by Fayer (1997) to potentially limit the 
performance of E. coli as Cryptosporidium DNA sequences may not be translated 
at detectable levels because the tRNAs necessary for efficient expression are 
present at too low concentration. As a consequence of the codon bias, a solution 
was sought in using bacterial strains having tRNAs for rare codons: Rosetta™2 
and BL21-CodonPlus-RP. The full-length recombinant His-tagged protein was 
expressed, but only at low levels and this has hindered further purification and 
characterization of the recombinant protein. Alternative expression systems such 
Chapter 6 
 
- 204 - 
as yeast, insect or mammalian cells should be assessed for the expression of 
stable recombinant protein, especially because they allow posttranslational 
modifications (Weidner et al., 2010, Rothblatt and Meyer, 1986). In addition, 
gene synthesis using commercially available services (such as Genscript) claiming 
to produce high amounts of purified recombinant protein are also an option and 
could be investigated in the future.  
 
6.1.7 9E1 a monoclonal peptide antibody anti-CpCops-1  
 
A monoclonal peptide antibody directed against Cops-1 protein was produced 
and used to determine the localization of the protein on Cryptosporidium oocysts 
and sporozoites. The monoclonal antibody clearly recognized the contents of 
C. parvum oocysts and was able to stain free sporozoites, implying that the 
protein is either a surface or secreted sporozoite protein. On C. hominis oocysts 
and sporozoites, 9E1 showed a much weaker internal staining of the oocysts. The 
cross reactivity of the monoclonal antibody is surprising because the Tyle-2 
peptide (used to immunize mice) seems to be absent from C. hominis Cops-1 
sequence retrieved by sequencing. This could be explained by cross reactivity of 
the antibody with either a homologous region of the C. hominis ortholog or 
another C. hominis antigen entirely. In addition, C. hominis oocyst suspensions 
were from clinical sources and not purified, they showed high background 
staining by immunofluorescence which could partially explain the cross reactivity 
observed. Future studies would benefit from a polyclonal antibody directed 
against the whole recombinant protein for an improved determination of the 
localization of the Cops-1 protein and to confirm whether the gene is expressed 
in C. hominis. 
 
Cops-1 predicted characteristics, its telomeric location and the sporozoite 
staining pattern are all consistent with a role of the protein in host-parasite 
interaction. Several other sporozoite proteins involved in host-cell attachment 
and invasion have been shown to be deposited in trails during gliding motility 
(Wanyiri and Ward, 2006). 9E1 staining of glass slides, on which Cryptosporidium 
Chapter 6 
 
- 205 - 
sporozoites were left to glide after excystation, did not show staining of the 
trails, unlike the slides stained with 4C1 control antibody clearly showing 
fluorescent stain of the gliding trails as previously reported (Feng et al., 2006). 
This preliminary result suggests that Cops-1 protein is unlikely to be shed in 
trails. However, future confirmation would rely on colocalization studies of 4C1 
with 9E1 and additional Cops-1 specific antibody. 
 
An attempt to investigate the potential role of Cops-1 protein in host-cell 
attachment and invasion was undertaken in vitro using a blocking assay with the 
9E1 monoclonal antibody in coculture with Caco-2 cell monolayers. The pre-
incubation of the parasite suspension with 9E1 antibody did not influence the 
infectivity of Cryptosporidium when compared to controls as evidenced by 
comparable parasite counts. Although this result may suggest that Cgd2_4380 
protein does not have a role in host-parasite interaction, it could be that Tyle-2 
epitope does not correspond to the region interacting with the intestinal cell 
receptors. 9E1 seems to be a non blocking and non neutralizing antibody. 
Cryptosporidium antibodies against putative virulence factors described in the 
literature which showed blocking of infection in vitro and in vivo were directed 
against whole recombinant proteins (Boulter-Bitzer et al., 2007). The production 
of a polyclonal antibody raised to the whole recombinant Cops-1 protein may 
better demonstrate if Cops-1 protein is involved in Cryptosporidium pathogenesis 
and host-cell interaction.  
 
6.1.8 Immunogenicity of Cops-1 protein 
 
Immunogenicity of Cops-1 protein was investigated using both native and 
recombinant antigen preparations revealed by 9E1 and Cryptosporidium natural 
infection sera. Interestingly, sera from C. parvum infected patients recognized a 
50 kDa protein from native C. parvum antigen preparations but not C. hominis. 
This is the first report of a C. parvum specific immunodominant protein. This 
protein may be Cops-1, however, this could not be confirmed because of the 
poor reactivity of 9E1 monoclonal antibody in immunoblotting. A likely 
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explanation for this poor reactivity is the alteration or degradation of the linear 
epitope tested by Western Blot, especially given that 9E1 was reactive and 
stained oocyst content by IFA.  
 
6.2 Summary and Future work 
 
Despite recent advances in genomics, proteomics, biology and pathogenesis of 
Cryptosporidium, important questions remain unresolved. These include 
methods to discriminate rapidly, reliably and inexpensively between 
morphologically undistinguishable human infective and non infective oocysts, 
especially those found during filtration of drinking water supplies. Similarly, the 
search for loci with the ability to adequately type and subtype isolates in order to 
inform risk assessment is far from over. Finally, our understanding of host range 
and virulence of Cryptosporidium species is still in its infancy for this under 
researched but important pathogen.  
 
This thesis has exploited genomic data from C. parvum and C. hominis genome 
sequences to identify genetic determinants associated with host tropism. The 
majority of the loci identified by in silico screen were shown experimentally to be 
common to both species. This illustrates the pitfalls of some forms of 
comparative analyses in “finished” eukaryotic genomes, which are not actually 
fully completed and assembled. Unfortunately, when looking for contingency 
genes, repetitive regions such as the telomeres are often amongst the most 
difficult regions of the genome for complete assembly and it is likely that 
important pathogenicity factors may continue to lurk undiscovered in such areas. 
Nevertheless, sequence analysis of the genes highlighted by in silico screening 
showed interesting genetic polymorphism and excellent phylogenetic potential.  
 
In these studies, a C. parvum gene, Cops-1, was identified in silico and confirmed 
experimentally to be species-specific. A fragment from the 5’ end of the gene, 
which appears to be more conserved, amplified from all C. hominis isolates and a 
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truncated ortholog was identified in at least one isolate of C. hominis. 
Phylogenetic analysis of sequence from the fragments generated permitted 
subtyping of both C. hominis and C. parvum with a high degree of confidence in a 
manner consistent with multi-locus and microsatellite analyses and in a way that 
the hypervariable GP60 was not able to do. A direct comparison of divergence in 
Cops-1 sequence between the GP60 subtypes is a priority in the evaluation of 
Cops-1 as a candidate marker for subtyping. It is worth considering that single 
locus typing can bias results in organisms like Cryptosporidium, where sexual 
exchange occurs and this may limit the use of Cops-1 as a single marker for 
typing. In the future, whole genome sequencing from key subtypes will better 
define the genetic diversity of Cryptosporidium and enable better evaluation of 
the efficacy of Cops-1 as a subtyping marker.  
 
Cops-1 PCR based assay can be used for Cryptosporidium genotyping with no 
requirement for subsequent RFLP as with the routinely used targets. Subtyping is 
also possible by RFLP, sequencing and real-time PCR analysis to exploit the SNPs 
described. In addition, Cops-1 could be used as a target for loop-mediated 
isothermal amplification procedure (LAMP) of particular use for field studies and 
in modestly equipped laboratories.  
 
Cops-1 protein predicted features are highly suggestive of a potential role in 
virulence and host-parasite interaction. Unfortunately, the preliminary 
characterization studies faced several limitations. First, the full gene length was 
determined in only one C. hominis clinical isolate and was not subsequently 
amplifiable by PCR from this or other C. hominis isolates. Second, the expression 
of the recombinant protein was of low level and limited stability and finally, no 
evidence of Cops-1 being deposited in trails or mediating host-cell invasion were 
established. Nevertheless, an immunodominant 50 kDa protein was detected 
from C. parvum native antigen preparations and not C. hominis consistent with 
the idea that Cops-1, differentially expressed in C. parvum and C. hominis, may 
be discriminated serologically, if this is indeed the case. The recombinant Cops-1 
protein has the potential for use in serodiagnostic assays and to form the basis of 
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seroepidemiological studies based on comparison between groups with previous 
exposure to C. parvum compared with C. hominis as determined by ELISA and 
Western Blot. 
 
The first monoclonal antibody raised to a linear epitope of Cops-1 interacted well 
with the peptide to which it was raised and gave good immunofluorescence from 
purified C. parvum parasites. Unfortunately the antibody performed poorly on 
immunoblot against recombinant protein and appeared to give high background 
fluorescence from components of faecal samples suggesting that although it may 
be able to discriminate species in a single oocyst, it may not be an ideal 
diagnostic tool in its own right. Production of better antibody with higher 
specificity perhaps raised to whole recombinant proteins or other epitopes raises 
the prospect of a reagent which can be used to directly discriminate species in 
clinical and environmental isolates.  
 
The data presented in this thesis has laid foundation for future work, which 
includes applied and basic scientific research. Comparative genomics have been 
shown to be effective in discovering genetic determinants involved in virulence 
and host pathogen interaction. Genome comparison of C. parvum, C. hominis 
and C. muris is likely to improve the understanding of the biology, pathogenesis 
and evolution of Cryptosporidium species and is likely to shed light on the 
processes that had mediated host tropism and niche adaptation. Extension of 
comparative genomics approaches can also be usefully utilized to identify 
orthologous genes known to have roles in host pathogen interactions and which 
could be conserved functionally amongst apicomplexan parasites or orthologous 
genes in closely related species with highly divergent domains, which may be 
interesting biologically and useful for subtyping. 
 
Data presented in this thesis showed evidence of one C. hominis specific gene 
(Chos-1). Both Cops-1 and Chos-1 are predicted to have a signal peptide, thus 
they are likely to be secreted and might be involved in host-parasite interactions. 
Chos-1 characterization should be undertaken in the future both on the genetic 
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and molecular level. Interestingly, neither the Cops-1 nor Chos-1 gene has 
appeared in the published secretome of C. parvum although there is evidence for 
the transcription of these genes in the form of ESTs. In the future, platform 
technologies such as proteomics and transcriptomics may give additional insight 
into the likely function and partner proteins of these molecules. 
 
For Cops-1 though, ensuring full characterization is dependent on relating DNA 
sequence to structure and ultimately to function. Functional biology assays in 
vitro and in vivo should be performed to confirm the importance of this 
interesting protein in Cryptosporidium biology and pathogenesis. In addition, 
experimental evaluation of Cops-1 predicted features should be carried out. 
Myristoylation assays can be undertaken using radio-labelled myristic acid in 
vitro and in vivo. Glycosylated proteins can be purified using a pull down assay 
and the effect of deglycosylation (glycosidase) or glycosylation inhibitors can be 
assessed by western blot and in vitro. Trans-expression of GFP into 
Cryptosporidium was reported using a unique viral transfection system and could 
be used for trans-expression of tagged full length Cops-1. Perhaps more 
straightforwardly, the protein could be trans-expressed in Toxoplasma gondii to 
consider its trafficking pathway and further functional assays of host-parasite 
interaction. With the recombinant Cops-1 protein, it would be possible to 
evaluate its role in host-cell attachment, eliciting host-cell signalling and invasion 
by evaluation of coated bead attachment and uptake in vitro. Currently, genetic 
manipulations mainly “knock out” or “knock down” are not feasible in 
Cryptosporidium, but these trans-expression and coated bead systems would 
enable evaluation of the effect of targeted mutations on the protein function, 
once these assays are established. Such mutation could primarily target the 
predicted features, for instance myristoylation and glycosylation sites. 
Identification of proteins interacting with Cops-1 is likely to assist uncovering its 
function and could be investigated using yeast two-hybrid assay or co-
precipitation. Finally, the evaluation of the protective potential of Cops-1 can be 
assessed in vivo by immunization of mice using the recombinant protein and 
comparing the severity of symptoms and oocyst shedding after Cryptosporidium 
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infection to a non immunized control group. Furthermore, the immune response 
could be targeted by oral dose with viral or bacterial carriers to elicit a mucosal 
immune response in the gut. A protective vaccine against C. parvum is highly 
desirable for livestock. The evaluation of Cops-1 as a vaccine candidate using this 
approach would likely be C. parvum specific and may or may not be effective in 
humans. Nevertheless, animal vaccines are commercially viable and could 
dramatically reduce the number of human outbreaks derived from zoonotic 
transmission. 
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Appendix II
  
Appendix II: Results of the reciprocal BLAST applying a 10% sequence identity threshold. All coding sequences from C. parvum were blasted 
against C. hominis genomic data. For each gene, the best target in C. hominis was indicated. The number of identical nucleotides and the 
percentage of sequence coverage were presented. Similarly, every coding sequence of C. hominis was blasted to the genomic sequences of 
C. parvum. 272 and 117 putative species-specific genes were identified for C. parvum and C. hominis, respectively. 
 
Accession  
Number 
 
C. parvum 
gene name 
 
Gene annotation 
 
 
Best               
C. hominis 
target 
% identity 
 
Query 
length (bp) 
 
Number of 
identical 
nucleotides 
Sequence 
coverage 
(%) 
AAEE01000002 cgd6_5320 hypothetical protein with similarity to many plasmodium proteins Chro.60073 0 2811 19 0 
AAEE01000013 cgd2_80 ABC transporter family protein, 2x AAA domain Chro.80487 0 4431 35 1 
AAEE01000007 cgd5_330 hypothetical protein Chro.70096 0 3504 23 0 
AAEE01000007 cgd5_1000 hypothetical protein Chro.60190 0 2112 20 0 
AAEE01000010 cgd5_4500 possible vacuolar protein sorting associated protein (VPS) Chro.10424 1 1200 19 1 
AAEE01000002 cgd6_660 secreted pepsinogen like aspartyl protease having a signal peptide Chro.60138 1 1902 34 1 
AAEE01000008 cgd4_1740 possible HSMGG motif (esterase?) Chro.80330 1 3078 51 3 
AAEE01000009 cgd4_1330 NADPH-dependent FMN FAD containing oxidoreductase , transcripts identified by EST Chro.60070 1 2460 39 2 
AAEE01000009 cgd4_290 
putative protein phosphatase 2A regulatory B subunit, highly conserved but no plasmodium 
hits Chro.80116 1 2076 33 2 
AAEE01000004 cgd3_500 
putative fucose translocator with 8 transmembrane domains, within locus of 3 paralogous 
genes Chro.40126 1 1185 17 1 
AAEE01000004 cgd3_2870 
similarity of possible bacterial origin within discrete region similar to long-chain fatty acid acyl-
CoA synthetases Chro.00004 1 2334 37 2 
AAEE01000002 cgd6_440 PP2Cc like protein phosphatase Chro.80459 1 1602 22 1 
AAEE01000011 cgd8_680 large low complexity protein with repeats Chro.30010 1 3441 68 4 
AAEE01000006 cgd1_110 predicted secreted protein, signal peptide, paralogs Chro.10158 1 1221 20 1 
AAEE01000002 cgd6_540 Ser/Thr protein kinase Chro.10402 1 2841 54 3 
AAEE01000008 cgd4_1570 hypothetical protein, possible conserved Chro.50401 1 1224 21 1 
AAEE01000004 cgd3_4240 insulinase like peptidase Chro.50235 1 3342 63 4 
AAEE01000004 cgd3_2640 hypothetical protein with conserved domain Chro.40078 1 1311 19 1 
AAEE01000010 cgd5_4190 hypothetical protein Chro.20329 1 2247 38 1 
AAEE01000009 cgd4_1130 PhnP like hydrolase of the metallobetalactamase fold Chro.10012 1 1065 19 1 
AAEE01000005 cgd2_4380 signal peptide, repeats, gene anchored to telomere Chro.10099 1 1434 19 1 
  
AAEE01000010 cgd5_4000 hypothetical protein Chro.40042 1 2034 40 2 
AAEE01000004 cgd3_510 
putative fucose translocatorw ith 8 transmembrane domains, within locus of 3 paralogous 
genes Chro.30381 1 1170 17 1 
AAEE01000014 cgd6_320 
hypothetical protein with signal peptide and 8 transmembrane domains, amino terminl region 
conserved in plasmodium, transcripts identified by EST Chro.80433 1 2427 38 2 
AAEE01000013 cgd2_10 hypothetical protein Chro.50504 1 1338 20 1 
AAEE01000003 cgd8_2370 adenosine kinase like ribokinase Chro.40163 1 1188 21 1 
AAEE01000002 cgd6_670 
extacellular protein with a signal peptide, clostripain like caspase/hemoglobinase domain, 
notch domain and 2 EGF domains Chro.70432 1 4824 54 2 
AAEE01000006 cgd1_360 similar to Noc2p N-terminus Chro.60406 1 2511 28 1 
AAEE01000008 cgd4_1780 ring domain protein Chro.50317 1 1434 21 1 
AAEE01000007 cgd5_540 hypothetical protein Chro.50091 1 1524 24 1 
AAEE01000002 cgd6_720 unknown protein Chro.50392 1 3267 51 3 
AAEE01000012 cgd4_4100 hypothetical protein Chro.60053 1 939 18 1 
AAEE01000007 cgd5_2970 hypothetical protein Chro.20342 1 1869 37 3 
AAEE01000004 cgd3_3670 putative protein kinase CK2 regulatory subunit CK2B1 Chro.70481 2 759 19 2 
AAEE01000002 cgd6_5120 protein with two PHD Zn fingers that is probably involved in chromatin function Chro.40494 2 687 20 2 
AAEE01000012 cgd4_3990 hypothetical protein with possible transmembrane domain near N-terminus Chro.70342 2 1743 42 3 
AAEE01000002 cgd6_1130 hypothetical protein with signal peptide Chro.40330 2 1827 38 3 
AAEE01000016 cgd6_5510 telomeric insulinase-like protease with signal peptide Chro.40328 2 1473 33 3 
AAEE01000005 cgd2_3800 hypothetical protein Chro.60478 2 1110 33 4 
AAEE01000004 cgd3_630 hypothetical protein with signal peptide Chro.80019 2 948 24 2 
AAEE01000010 cgd5_3770 putative arginine N-methyltransferase Chro.80547 2 1998 40 2 
AAEE01000018 cgd5_4510 hypothetical protein Chro.40216 2 789 20 2 
AAEE01000007 cgd5_320 carboxylesterase , lysophospholipase, signal peptide Chro.10070 2 1422 33 3 
AAEE01000005 cgd2_2430 ximpact ortholog conserved protein seen in bacteria and eukaryotes Chro.10042 2 873 21 2 
AAEE01000012 cgd4_4090 putative Sec14d Chro.50438 2 3192 74 2 
AAEE01000013 cgd2_100 hypothetical protein Chro.30403 2 723 18 2 
AAEE01000004 cgd3_1090 Rrp9p/U3-55K-family snoRNP-associated protein with several WD40 repeats Chro.50400 2 1374 30 2 
AAEE01000003 cgd8_3150 hypothetical conserved protein, transcripts identified by EST Chro.30367 2 582 17 2 
AAEE01000009 cgd4_1510 similar to undecaprenyl pyrophosphate synthetase Chro.80332 2 759 21 2 
AAEE01000010 cgd5_4490 hypothetical protein, low complexity, limited similarity to gi Chro.60107 2 8076 213 12 
  
AAEE01000012 cgd4_4160 possible carboxypeptidase Chro.20426 2 1371 39 2 
AAEE01000006 cgd1_960 RING finger containing protein Chro.20379 2 1458 31 2 
AAEE01000007 cgd5_3290 transcription elongation factor TFIIS Chro.60122 2 702 19 2 
AAEE01000005 cgd2_3970 RRM domain containing protein Chro.40100 2 597 17 2 
AAEE01000011 cgd8_620 hypothetical protein Chro.20223 2 783 19 2 
AAEE01000002 cgd6_2530 hypothetical protein Chro.70569 2 858 24 2 
AAEE01000002 cgd6_1810 hypothetical protein Chro.10285 2 675 18 2 
AAEE01000004 cgd3_680 cathepsin like thiol protease possibly membrane associated, putative Chro.70394 2 897 20 2 
AAEE01000004 cgd3_2720 putative topoisomerase VIA Chro.20351 2 708 18 2 
AAEE01000001 cgd7_4890 hypothetical protein Chro.30428 2 1200 25 2 
AAEE01000003 cgd8_2990 hypothetical protein Chro.50389 2 543 16 2 
AAEE01000005 cgd2_1820 hypothetical protein Chro.10109 2 603 17 2 
AAEE01000003 cgd8_4700 hypothetical protein Chro.60225 2 654 17 2 
AAEE01000016 cgd6_5520 peptidase'insulinase like peptidase' Chro.40162 2 1713 48 4 
AAEE01000009 cgd4_100 hypothetical protein Chro.50507 2 681 18 2 
AAEE01000002 cgd6_5020 protein with WD40 repeats Chro.50196 3 651 20 3 
AAEE01000007 cgd5_3250 secreted lipopolysaccharide sugar transferase like family 8 glycosyltransferase Chro.10377 3 477 18 3 
AAEE01000007 cgd5_190 plasmodium conserved protein Chro.20379 3 1041 37 5 
AAEE01000012 cgd4_3920 DinB/family X-type DNA polymerase Chro.30486 3 1077 37 5 
AAEE01000009 cgd4_90 hypothetical protein, similarity to Rrp7p Chro.70603 3 531 18 3 
AAEE01000006 cgd1_3280 hypothetical protein Chro.40376 3 939 36 6 
AAEE01000007 cgd5_2260 Low complexity hypothetical protein Chro.60427 3 924 34 5 
AAEE01000014 cgd6_220 hypothetical protein, possible G-patch domain Chro.30092 3 534 21 3 
AAEE01000001 cgd7_730 hypothetical protein Chro.40021 3 441 17 3 
AAEE01000002 cgd6_3440 hypothetical protein Chro.30421 3 570 18 3 
AAEE01000010 cgd5_4460 hypothetical protein Chro.20065 3 1023 36 3 
AAEE01000004 cgd3_990 CG6144-like AlkB Chro.30338 3 543 17 3 
AAEE01000011 cgd8_210 transcription factor TFIID, TBP Chro.60267 3 588 21 3 
AAEE01000009 cgd4_20 hypothetical protein having a signal peptide, telomeric gene Chro.30460 3 1008 32 5 
AAEE01000007 cgd5_210 hypothetical protein Chro.50157 3 3258 105 5 
AAEE01000007 cgd5_2840 hypothetical protein with 4 transmembrane domains near carboxy terminus Chro.50091 3 7938 266 6 
  
AAEE01000012 cgd4_4000 possible ribosomal-protein-alanine acetyltransferase Chro.30486 3 459 18 3 
AAEE01000007 cgd5_3420 
cryptosporidium TRAP-C2 extracellular protein with the following domain organization: signal 
peptide-Tox1-notch-TSP(13)-Tox1-notch-Tox1-notch-Tox1- notch-Tox1-Tox1-notch-Tox1(4)-
sushi(4) Chro.50029 3 11610 359 3 
AAEE01000007 cgd5_290 hypothetical protein, 6 transmembrane domains Chro.10356 3 762 25 3 
AAEE01000003 cgd8_3690 mitosis protein DIM1 Chro.70416 3 429 17 3 
AAEE01000004 cgd3_2660 hypothetical protein Chro.30288 3 612 19 3 
AAEE01000005 cgd2_2250 putative integral membrane protein Chro.10095 3 495 18 3 
AAEE01000007 cgd5_140 ARF GTPase activating protein, putative Chro.10023 3 579 18 3 
AAEE01000002 cgd6_1650 conserved hypothetical protein Chro.30100 3 576 21 3 
AAEE01000003 cgd8_5070 hypothetical protein Chro.10357 3 429 17 3 
AAEE01000002 cgd6_2020 BT1 family protein Chro.80548 3 432 17 3 
AAEE01000005 cgd2_2970 DNA-directed RNA polymerase II, putative Chro.70455 3 537 17 3 
AAEE01000002 cgd6_3000 ferredoxin-like protein Fd1, putative Chro.30168 3 504 16 3 
AAEE01000006 cgd1_440 hypothetical protein Chro.80486 3 438 17 3 
AAEE01000001 cgd7_2500 Skp1 family protein, putative Chro.80163 3 489 19 3 
AAEE01000001 cgd7_2840 ubiquitin conjugating enzyme, putative Chro.70611 3 480 17 3 
AAEE01000003 cgd8_1040 hypothetical protein Chro.60374 3 651 26 3 
AAEE01000006 cgd1_2310 unnamed protein product Chro.20466 3 468 18 3 
AAEE01000003 cgd8_3630 Similar to CGI-126 protein, putative Chro.80363 3 468 16 3 
AAEE01000002 cgd6_970 hypothetical protein Chro.40119 3 525 18 3 
AAEE01000003 cgd8_4250 hypothetical protein Chro.40348 3 723 23 3 
AAEE01000006 cgd1_3470 fork head domain protein, putative Chro.20302 3 525 18 3 
AAEE01000002 cgd6_1390 ribosomal protein S23 Chro.60392 3 486 16 3 
AAEE01000003 cgd8_4900 clathrin assembly protein, putative Chro.60195 3 477 19 3 
AAEE01000004 cgd3_4320 possible similarity to RNA polymerase Rpb4 Chro.50268 4 375 17 4 
AAEE01000004 cgd3_1410 small hypothetical protein with transcripts identified by EST Chro.60411 4 333 16 4 
AAEE01000005 cgd2_4000 hypothetical protein Chro.40338 4 405 17 4 
AAEE01000014 cgd6_200 cryptosporidium oocyst wall protein 8, CpCOWP8, signal peptide Chro.60138 4 1374 65 12 
AAEE01000002 cgd6_4980 hypothetical protein Chro.80548 4 384 17 4 
AAEE01000004 cgd3_3760 small protein with possible EF hand domains, calmodulin like Chro.60242 4 432 18 4 
  
AAEE01000009 cgd4_1010 hypothetical protein Chro.40121 4 5589 239 8 
AAEE01000003 cgd8_5100 hypothetical protein Chro.30413 4 525 21 4 
AAEE01000002 cgd6_380 
hypothetical protein with signal peptide and 4 transmembrane domains, possible 
apicomplexan conserved Chro.10229 4 444 20 4 
AAEE01000008 cgd4_2400 60S ribosomal protein L31, transcript identified by EST Chro.50110 4 348 16 4 
AAEE01000002 cgd6_930 Dim1p-like ERMB/KSGA methylase Chro.70119 4 1158 47 8 
AAEE01000007 cgd5_2430 similar to prefoldin Chro.50088 4 492 20 4 
AAEE01000018 cgd5_4530 hypothetical protein with signal peptide and 2 cryptosporidium-specific paralogs Chro.20423 4 819 36 6 
AAEE01000008 cgd4_2290 hypothetical protein Chro.70304 4 417 18 4 
AAEE01000007 cgd5_260 hypothetical protein Chro.60196 4 2478 117 18 
AAEE01000014 cgd6_330 hypothetical protein Chro.40297 4 525 23 4 
AAEE01000006 cgd1_3770 hypothetical protein Chro.10098 4 303 15 4 
AAEE01000001 cgd7_2120 hypothetical protein Chro.70293 4 411 20 4 
AAEE01000007 cgd5_2650 hypothetical protein Chro.50182 4 423 18 4 
AAEE01000002 cgd6_1240 hypothetical protein Chro.50381 4 468 19 4 
AAEE01000006 cgd1_1050 
hypothetical protein with predicted 3x transmembrane domains, similarity to KOG1726 
(HVA22/DP1 gene product) Chro.50331 4 438 20 4 
AAEE01000001 cgd7_5070 small conserved protein Chro.70226 4 387 18 4 
AAEE01000002 cgd6_910 
protein with possible 2 transmembrane domains, possible ER retention signal, similar to 
Sec20 is a membrane glycoprotein associated with secretory pathway Chro.30424 4 405 19 4 
AAEE01000004 cgd3_2290 possible domain AAA, ATpase family Chro.20457 4 393 18 4 
AAEE01000006 cgd1_430 possible emp24/gp25L/p24 family protein, transmembrane domain, trancript detected by EST Chro.70470 4 393 18 4 
AAEE01000018 cgd5_4550 hypothetical protein Chro.80514 4 426 18 4 
AAEE01000007 cgd5_570 hypothetical protein, 5 transmembrane domains near N-terminus Chro.80285 4 408 18 4 
AAEE01000003 cgd8_4590 hypothetical protein Chro.10011 4 675 33 7 
AAEE01000006 cgd1_2270 40S ribosomal protein S26 Chro.10099 4 324 15 4 
AAEE01000009 cgd4_770 Low complexity protein with large Glu repeat Chro.50438 4 4320 203 33 
AAEE01000002 cgd6_1850 anaphase promoting complex subunit 10, putative Chro.70143 4 399 17 4 
AAEE01000005 cgd2_2440 hypothetical protein Chro.10417 4 366 18 4 
AAEE01000005 cgd2_2740 hypothetical protein Chro.80387 4 363 17 4 
AAEE01000005 cgd2_2820 transcription factor, putative Chro.70453 4 375 17 4 
AAEE01000002 cgd6_2400 hypothetical protein Chro.30048 4 303 15 4 
  
AAEE01000004 cgd3_2430 hypothetical protein Chro.20064 4 390 18 4 
AAEE01000005 cgd2_4330 hypothetical protein Chro.60160 4 411 17 4 
AAEE01000001 cgd7_2800 ubiquitin-conjugating enzyme E2, putative Chro.20030 4 414 18 4 
AAEE01000001 cgd7_4370 RNA polymerase II, putative Chro.20066 4 348 17 4 
AAEE01000001 cgd7_4870 hypothetical protein Chro.50468 4 414 17 4 
AAEE01000006 cgd1_3270 hypothetical protein Chro.40076 4 1815 87 11 
AAEE01000011 cgd8_580 ubiquitin-conjugating enzyme E2, putative Chro.80357 4 423 18 4 
AAEE01000007 cgd5_2160 hypothetical protein Chro.50015 4 414 17 4 
AAEE01000003 cgd8_2140 hypothetical protein Chro.60133 5 312 17 5 
AAEE01000006 cgd1_900 hypothetical protein Chro.50153 5 318 16 5 
AAEE01000007 cgd5_3440 hypothetical protein Chro.10387 5 312 18 5 
AAEE01000002 cgd6_4100 hypothetical protein Chro.80087 5 306 17 5 
AAEE01000010 cgd5_4200 transcription initiation factor IIA Chro.80451 5 336 20 5 
AAEE01000001 cgd7_1880 60S ribosomal protein L44 Chro.10216 5 315 17 5 
AAEE01000003 cgd8_1130 hypothetical protein Chro.80542 5 384 23 5 
AAEE01000002 cgd6_5220 cysteine-rich protein with zinc finger Chro.30098 5 1929 111 15 
AAEE01000004 cgd3_3400 
similar to hypothetical protein, domain with limited similarity to a domain RPA14, replication 
protein A (RPA), subunit RPA14 Chro.60246 5 333 19 5 
AAEE01000004 cgd3_1080 hypothetical protein Chro.10084 5 345 20 5 
AAEE01000004 cgd3_1040 hypothetical protein Chro.70399 5 345 18 5 
AAEE01000005 cgd2_3560 hypothetical protein with 8 transmembrane domains Chro.30110 5 1356 76 16 
AAEE01000006 cgd1_3140 P-loop nucleotide (UMP) kinase Chro.80460 5 618 35 9 
AAEE01000006 cgd1_3560 hypothetical protein Chro.80398 5 381 21 5 
AAEE01000009 cgd4_1260 possible tRNA-INTRON ENDONUCLEASE Chro.40032 5 477 25 5 
AAEE01000004 cgd3_2550 
hypothetical protein with carboxy terminus motif shared with DNA-directed RNA polymerase 
subunit and TFIIS Chro.80053 5 612 31 8 
AAEE01000004 cgd3_3890 60S ribosomal protein L30, pelota RNA binding domain containing protein Chro.40217 5 336 18 5 
AAEE01000001 cgd7_1070 snRNP core protein homolog Sm-X5.  SM domain containing protein. Chro.70451 5 324 19 5 
AAEE01000003 cgd8_1710 hypothetical protein Chro.70483 5 375 21 5 
AAEE01000001 cgd7_1870 hypothetical protein Chro.70265 5 312 18 5 
AAEE01000001 cgd7_690 small nuclear ribonucleoprotein Chro.30192 5 288 16 5 
AAEE01000009 cgd4_1250 hypothetical protein Chro.80610 5 306 18 5 
  
AAEE01000009 cgd4_1500 hypothetical protein Chro.10355 5 378 22 5 
AAEE01000007 cgd5_3390 very large hypothetical protein Chro.50033 5 11130 585 5 
AAEE01000003 cgd8_1930 large protein with a GCN1 domain Chro.80225 5 10188 581 5 
AAEE01000008 cgd4_2030 centromeric histone h3-like protein, cse4 like Chro.80310 5 297 15 5 
AAEE01000004 cgd3_2380 hypothetical protein Chro.30018 5 366 19 5 
AAEE01000006 cgd1_1190 hypothetical protein Chro.70205 5 324 17 5 
AAEE01000008 cgd4_2830 Mra1/NEP1 like protein, involved in pre-rRNA processing, adjacent genes putative paralogs Chro.80070 5 651 35 8 
AAEE01000005 cgd2_3910 hypothetical protein Chro.20131 5 321 17 5 
AAEE01000002 cgd6_4900 acylphosphatase, putative Chro.20235 5 369 21 5 
AAEE01000003 cgd8_3410 hypothetical protein Chro.70268 5 309 17 5 
AAEE01000008 cgd4_3760 hypothetical protein Chro.50015 5 336 17 5 
AAEE01000009 cgd4_1050 hypothetical protein Chro.60222 5 420 23 5 
AAEE01000007 cgd5_200 hypothetical protein Chro.60165 6 342 21 6 
AAEE01000004 cgd3_2340 hypothetical protein Chro.50232 6 309 21 6 
AAEE01000013 cgd2_70 
ABC transporter, with 12 x transmembrane domains and 2x AAA domains, transcripts 
identified by EST Chro.20017 6 4764 333 38 
AAEE01000006 cgd1_300 40S ribosomal protein S21 Chro.80601 6 243 17 6 
AAEE01000006 cgd1_2880 
13 kda membrane protein subunit [cryptosporidium parvum, sporozoites, peptide, 119 aa], 
transcript identified by EST Chro.40430 6 234 16 6 
AAEE01000014 cgd6_340 hypothetical protein Chro.50342 6 333 22 6 
AAEE01000004 cgd3_2360 putative nucleoporin, FG-rich motifs within N-terminal region Chro.30276 6 5418 364 13 
AAEE01000010 cgd5_3670 hypothetical protein Chro.50486 6 1215 80 6 
AAEE01000004 cgd3_1070 synaptobrevin like SNARE Chro.70137 6 312 20 6 
AAEE01000006 cgd1_720 apicomplexan-conserved protein Chro.80467 6 636 44 14 
AAEE01000003 cgd8_4560 hypothetical protein Chro.70144 6 486 30 9 
AAEE01000004 cgd3_1420 conserved small protein, transcript identified by EST Chro.80150 6 231 16 6 
AAEE01000001 cgd7_170 hypothetical protein Chro.20017 6 285 18 6 
AAEE01000007 cgd5_470 hypothetical protein, transcripts identified by EST Chro.30098 6 534 33 6 
AAEE01000004 cgd3_2250 60S ribosomal protein L37A, transcripts identified by EST Chro.80242 6 264 17 6 
AAEE01000007 cgd5_430 70 kDa peptidylprolyl isomerase, putative Chro.10018 6 237 16 6 
AAEE01000004 cgd3_2310 hypothetical protein Chro.80319 6 258 16 6 
AAEE01000001 cgd7_1520 peptidylprolyl isomerase, putative Chro.40479 6 252 17 6 
  
AAEE01000001 cgd7_4210 Sec61-gamma subunit of protein translocation complex, putative Chro.80306 6 264 17 6 
AAEE01000007 cgd5_3000 hypothetical protein Chro.10328 6 285 18 6 
AAEE01000008 cgd4_1660 small nuclear ribonucleoprotein, putative Chro.10062 6 264 17 6 
AAEE01000009 cgd4_890 hypothetical protein Chro.70285 6 258 17 6 
AAEE01000008 cgd4_3840 Ank, ankyrin repeats containing protein with 9 transmembrane domains at C-terminus Chro.40438 7 6564 492 7 
AAEE01000001 cgd7_3520 hypothetical protein Chro.80114 7 222 16 7 
AAEE01000003 cgd8_3550 hypothetical protein Chro.40249 7 309 22 7 
AAEE01000002 cgd6_1790 hypothetical protein Chro.60216 7 2880 202 7 
AAEE01000003 cgd8_4050 ribosomal protein S29 Chro.40360 7 195 15 7 
AAEE01000006 cgd1_3410 
possible domain similar to DUF392, domain of unknown function (DUF392), probable DNA 
replication complex GINS protein PSF2 Chro.30126 7 273 21 7 
AAEE01000004 cgd3_2770 hypothetical protein Chro.30315 7 2931 209 7 
AAEE01000005 cgd2_620 similar to protein translocation complex beta; protein transport protein SEC61 beta subunit Chro.50406 7 201 16 7 
AAEE01000002 cgd6_5110 large hypothetical protein with possible signal peptide Chro.60590 7 8136 630 7 
AAEE01000009 cgd4_1290 small hypothetical protein, possible conserved Chro.70065 7 240 17 7 
AAEE01000001 cgd7_4990 ubiquitin ligase with a HECT domain at the C-terminus Chro.70558 7 20043 1524 22 
AAEE01000007 cgd5_1430 hypothetical protein Chro.60269 7 387 30 12 
AAEE01000006 cgd1_3430 hypothetical protein Chro.70011 7 312 22 7 
AAEE01000006 cgd1_3370 similarity to domain KOG2265, KIAA1068 protein and nuclear distribution protein NUDC Chro.20426 7 636 45 7 
AAEE01000004 cgd3_2670 protein with UBC domain, ubiquitin conjugating enzyme E2 Chro.60479 7 453 36 7 
AAEE01000005 cgd2_2150 hypothetical protein Chro.10022 7 408 30 11 
AAEE01000010 cgd5_3810 hypothetical protein with a signal peptide Chro.50472 7 1044 78 7 
AAEE01000003 cgd8_1010 hypothetical protein Chro.80553 7 453 35 12 
AAEE01000013 cgd2_320 similar to uncharacterized expressed protein Chro.80073 7 405 30 11 
AAEE01000004 cgd3_1950 BIS(5'-nucleosyl)-tetraphosphatase (diadenosine tetraphosphatase), putative Chro.20448 7 288 22 7 
AAEE01000001 cgd7_700 N-acetylglucosaminyl-phosphatidylinositolde-N-acetylase Chro.30199 7 528 39 12 
AAEE01000008 cgd4_3260 putative DNA-directed RNA polymerases I, II, and III 8.3 kda polypeptide Chro.30046 7 219 16 7 
AAEE01000007 cgd5_280 signal peptide containing protein with 6 transmembrane domains Chro.50351 8 963 80 18 
AAEE01000008 cgd4_1810 hypothetical protein Chro.40032 8 354 29 12 
AAEE01000002 cgd6_3490 RNA-binding protein, putative Chro.10322 8 462 39 14 
AAEE01000001 cgd7_510 RNA polymerase III subunit C11 Chro.50080 8 189 17 8 
  
AAEE01000004 cgd3_370 hypothetical protein Chro.40348 8 315 27 8 
AAEE01000002 cgd6_3710 40S ribosomal protein S30, transcripts identified be EST Chro.40296 8 180 16 8 
AAEE01000003 cgd8_5360 
hypothetical protein with signal peptide, within telomeric locus of cryptosporidium-specific 
predicted secreted proteins Chro.50317 8 786 70 23 
AAEE01000009 cgd4_190 large low complexity protein Chro.40033 8 6300 542 8 
AAEE01000010 cgd5_4060 protein with N-terminal region ZnF U1 domain, similar to U1 snRNP-specific protein Chro.80265 8 597 50 18 
AAEE01000013 cgd2_140 similar to IMP4 family, transcript identified by EST Chro.60522 8 198 16 8 
AAEE01000006 cgd1_840 similar to GAJ protein Chro.80146 8 201 17 8 
AAEE01000004 cgd3_710 large  hypothetical protein with signal peptide Chro.30095 8 3963 350 8 
AAEE01000004 cgd3_3730 hypothetical protein Chro.30098 8 369 32 14 
AAEE01000002 cgd6_500 
membrane associated HD superfamily cyclic nucleotide phosphodiesterase domain 
containing protein Chro.60068 8 5904 476 15 
AAEE01000008 cgd4_2210 N-terminal region similar to putative epsilon-adaptin, probable adaptin Chro.40252 8 2733 238 8 
AAEE01000001 cgd7_4550 ubiquitin-like protein nedd8 homologue, putative Chro.30042 8 237 19 8 
AAEE01000003 cgd8_2360 hypothetical protein Chro.30090 8 192 16 8 
AAEE01000003 cgd8_2510 Cyclin dependent kinase regulatory subunit, putative Chro.40307 8 258 21 8 
AAEE01000013 cgd2_120 ribosomal protein L29 Chro.20151 8 207 17 8 
AAEE01000012 cgd4_4070 hypothetical protein Chro.20236 9 315 30 15 
AAEE01000005 cgd2_3690 WD repeat protein Chro.20394 9 11847 1093 9 
AAEE01000012 cgd4_4170 hypothetical protein Chro.40476 9 462 45 16 
AAEE01000003 cgd8_2730 
multidomain chromatinic protein with the following architecture: 3x PHD-bromo-3xPHD-SET 
domain and associated cysteine cluster at the C-terminus Chro.80318 9 6735 617 9 
AAEE01000005 cgd2_3280 hypothetical protein Chro.40348 9 375 36 9 
AAEE01000006 cgd1_1920 large protein with a SPRY domain and HECT domain Chro.10218 9 13839 1378 9 
AAEE01000008 cgd4_1750 hypothetical protein Chro.70464 9 333 30 14 
AAEE01000005 cgd2_2870 similar to 40S ribosomal protein S28, no good start Met Chro.10245 9 207 19 9 
AAEE01000001 cgd7_2440 giant membrane protein with homologs only in plasmodium Chro.70280 9 5370 526 9 
AAEE01000002 cgd6_3320 ypothetical protein Chro.10343 9 321 29 14 
AAEE01000006 cgd1_860 ubiquitin-like protein, putative Chro.70152 9 219 20 9 
AAEE01000004 cgd3_3550 hypothetical protein with signal peptide Chro.30400 10 3348 339 10 
AAEE01000013 cgd2_350 60S ribosomal protein L39, transcripts identified be EST Chro.80185 10 168 17 10 
AAEE01000001 cgd7_2770 uncharacterized low complexity protein Chro.70314 10 4554 498 10 
  
AAEE01000002 cgd6_1940 hypothetical protein Chro.60229 10 2838 301 10 
AAEE01000005 cgd2_3870 putative ABC transporter with 2x AAA and 11+ transmembrane domains Chro.20413 10 5787 612 20 
AAEE01000003 cgd8_1510 large protein with possibly 18 transmembrane domains Chro.80178 10 4815 521 10 
AAEE01000004 cgd3_3810 similar to clathrin adaptor complex, small subunit Chro.40020 10 420 45 22 
AAEE01000006 cgd1_1400 hypothetical protein Chro.10162 10 2889 294 10 
AAEE01000001 cgd7_2530 
large membrane protein with signal peptide and transmembrane domain near carboxy 
terminus Chro.70289 10 7164 737 10 
AAEE01000002 cgd6_2630 hypothetical protein Chro.60304 10 4830 486 10 
AAEE01000002 cgd6_4310 hypothetical low complexity Chro.60493 10 5796 594 10 
AAEE01000003 cgd8_4420 WD40 repeat and RING finger domain-containing protein Chro.80507 10 3129 332 10 
AAEE01000006 cgd1_1770 domain similar to KOG3415, putative Rab5-interacting protein Chro.70125 10 288 30 15 
AAEE01000008 cgd4_2050 hypothetical protein Chro.20017 10 402 42 22 
AAEE01000003 cgd8_1610 sacsin like HSP90 chaperone domain, likely plant origin Chro.80189 11 6363 729 11 
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AAEL01000003 Chro.70187 hypothetical protein cgd1_1330 0 3096 23 0 
AAEL01000717 Chro.00003 sensor histidine kinase cgd8_3370 0 1647 16 0 
AAEL01000018 Chro.40268 hypothetical protein cgd5_3560 0 2721 19 0 
AAEL01000017 Chro.70405 hypothetical protein cgd7_5010 1 1242 18 1 
AAEL01000004 Chro.70479 hypothetical protein cgd4_2720 1 1029 18 1 
AAEL01000170 Chro.80591 hypothetical protein cgd5_3850 1 1992 24 1 
AAEL01000059 Chro.80288 hypothetical protein cgd1_1390 1 1785 19 1 
AAEL01000028 Chro.70434 hypothetical protein cgd6_3390 1 1374 19 1 
AAEL01000267 Chro.50010 hypothetical protein cgd2_690 1 2082 38 2 
AAEL01000452 Chro.50317 RNA polymerase A/beta'/A'' subunit cgd8_4860 1 1419 25 1 
AAEL01000256 Chro.30271 hypothetical protein cgd6_3330 2 675 19 2 
AAEL01000369 Chro.50330 leucyl tRNA synthetase (134.5 kD) (lrs-1) cgd6_3190 2 681 18 2 
AAEL01000428 Chro.50457 erythrocyte membrane-associated antigen cgd8_4810 2 1080 22 2 
AAEL01000251 Chro.60010 hypothetical protein cgd4_1590 2 969 27 2 
AAEL01000267 Chro.00007 hypothetical protein cgd6_4830 2 942 21 2 
AAEL01000065 Chro.20156 hypothetical protein cgd8_2790 2 795 22 2 
AAEL01000301 Chro.50310 hypothetical protein cgd8_5420 2 828 20 2 
AAEL01000444 Chro.60598 hypothetical protein cgd2_3870 2 1755 37 3 
AAEL01000368 Chro.40321 hypothetical protein cgd8_2550 2 732 21 2 
AAEL01000117 Chro.70274 hypothetical protein cgd6_2540 2 621 18 2 
AAEL01000413 Chro.50011 hypothetical protein cgd8_20 3 1470 45 3 
AAEL01000001 Chro.30236 hypothetical protein cgd5_2230 3 543 17 3 
AAEL01000232 Chro.30149 ubiquitin-protein ligase 1 cgd8_1200 3 1500 57 8 
AAEL01000330 Chro.80592 hypothetical protein cgd6_4070 3 624 19 3 
AAEL01000045 Chro.20364 hypothetical protein cgd5_2840 3 447 17 3 
AAEL01000410 Chro.70032 hypothetical protein cgd6_3460 3 558 19 3 
AAEL01000081 Chro.30091 hypothetical protein cgd5_40 3 2991 114 11 
AAEL01000063 Chro.30044 hypothetical protein cgd2_3440 4 720 33 7 
  
AAEL01000687 Chro.60599 hypothetical protein cgd4_380 4 573 23 4 
AAEL01000458 Chro.50090 hypothetical protein cgd2_2600 4 459 19 4 
AAEL01000031 Chro.70013 hypothetical protein cgd7_90 4 714 32 7 
AAEL01000068 Chro.30290 hypothetical protein cgd3_4140 4 423 19 4 
AAEL01000813 Chro.10385 hypothetical protein cgd7_4990 4 429 21 4 
AAEL01000668 Chro.30347 hypothetical protein cgd3_3070 4 1470 64 4 
AAEL01000519 Chro.30030 hypothetical protein cgd2_1920 4 410 19 4 
AAEL01000057 Chro.60252 transmembrane protein cgd6_3860 4 789 32 6 
AAEL01000023 Chro.60543 hypothetical protein cgd8_1150 5 336 17 5 
AAEL01000657 Chro.00006 senescence-associated protein cgd4_3820 5 321 19 5 
AAEL01000239 Chro.20422 hypothetical protein cgd8_2800 5 276 16 5 
AAEL01000412 Chro.60093 hypothetical protein cgd1_3360 5 558 31 8 
AAEL01000256 Chro.30272 hypothetical protein cgd4_3560 5 297 17 5 
AAEL01000010 Chro.10301 hypothetical protein cgd6_270 5 288 17 5 
AAEL01000538 Chro.50065 hypothetical protein cgd2_3510 6 258 17 6 
AAEL01000090 Chro.40235 hypothetical protein cgd2_3510 6 264 17 6 
AAEL01000036 Chro.80427 hypothetical protein cgd8_2490 6 276 18 6 
AAEL01000103 Chro.80041 hypothetical protein cgd1_2670 6 279 17 6 
AAEL01001081 Chro.60044 hypothetical protein cgd5_3460 6 252 17 6 
AAEL01000180 Chro.80545 hypothetical protein cgd1_3250 6 288 20 6 
AAEL01000474 Chro.80550 hypothetical protein cgd2_3580 6 267 18 6 
AAEL01000005 Chro.80379 hypothetical protein cgd4_1340 6 243 17 6 
AAEL01000812 Chro.40398 hypothetical protein cgd8_2630 6 246 16 6 
AAEL01000119 Chro.80356 hypothetical protein cgd3_3230 6 252 17 6 
AAEL01000007 Chro.50283 hypothetical protein cgd5_1030 6 243 17 6 
AAEL01000015 Chro.80606 hypothetical protein cgd5_2790 6 237 16 6 
AAEL01000090 Chro.40237 hypothetical protein cgd5_4000 6 282 18 6 
AAEL01000139 Chro.80064 hypothetical protein cgd6_4460 6 246 16 6 
AAEL01000332 Chro.50315 hypothetical protein cgd8_1610 6 273 18 6 
AAEL01000440 Chro.10077 hypothetical protein cgd5_540 6 252 17 6 
AAEL01000124 Chro.60431 hypothetical protein cgd5_4000 6 237 16 6 
  
AAEL01000122 Chro.80417 hypothetical protein cgd7_3670 6 270 17 6 
AAEL01001123 Chro.70543 hypothetical protein cgd8_490 6 249 17 6 
AAEL01000117 Chro.70268 hypothetical protein cgd8_3470 6 300 18 6 
AAEL01000142 Chro.70073 hypothetical protein cgd2_2400 6 246 17 6 
AAEL01000153 Chro.80322 hypothetical protein cgd1_2740 6 246 17 6 
AAEL01000382 Chro.80170 hypothetical protein cgd4_580 7 267 21 7 
AAEL01000238 Chro.60358 hypothetical protein cgd2_1160 7 237 18 7 
AAEL01000429 Chro.60361 hypothetical protein cgd7_2260 7 246 18 7 
AAEL01000025 Chro.60126 cAMP-dependent protein kinase cgd3_1340 7 255 18 7 
AAEL01000114 Chro.30365 hypothetical protein cgd6_1940 7 213 17 7 
AAEL01000003 Chro.70195 hypothetical protein cgd8_3700 7 273 20 7 
AAEL01000060 Chro.60547 hypothetical protein cgd4_3520 7 237 17 7 
AAEL01000013 Chro.50199 hypothetical protein cgd8_3260 7 297 21 7 
AAEL01000039 Chro.40229 hypothetical protein cgd2_1440 7 237 17 7 
AAEL01000499 Chro.10090 hypothetical protein cgd1_3220 7 234 18 7 
AAEL01000039 Chro.40228 hypothetical protein cgd2_1430 7 282 22 7 
AAEL01000362 Chro.30104 hypothetical protein cgd8_4030 7 291 21 7 
AAEL01000017 Chro.70398 hypothetical protein cgd5_2440 7 228 16 7 
AAEL01000261 Chro.40211 hypothetical protein cgd6_610 7 207 16 7 
AAEL01000353 Chro.50226 hypothetical protein cgd1_1690 7 225 16 7 
AAEL01000003 Chro.70179 hypothetical protein cgd8_550 7 234 17 7 
AAEL01000347 Chro.10127 hypothetical protein cgd4_1390 7 270 21 7 
AAEL01000114 Chro.30364 hypothetical protein cgd3_50 7 240 18 7 
AAEL01000382 Chro.80169 hypothetical protein cgd4_650 8 204 18 8 
AAEL01000009 Chro.20113 hypothetical protein cgd5_210 8 207 18 8 
AAEL01000066 Chro.80037 hypothetical protein cgd5_3420 8 222 18 8 
AAEL01000137 Chro.60099 hypothetical protein cgd8_3030 8 216 19 8 
AAEL01000058 Chro.40286 hypothetical protein cgd7_5480 8 222 18 8 
AAEL01000127 Chro.40012 hypothetical protein cgd2_1380 8 225 20 8 
AAEL01000233 Chro.80531 hypothetical protein cgd3_400 8 231 19 8 
AAEL01000536 Chro.40447 hypothetical protein cgd5_500 8 213 18 8 
  
 
 
 
 
 
 
 
 
AAEL01000050 Chro.60575 hypothetical protein cgd4_1330 8 213 19 8 
AAEL01001242 Chro.70522 hypothetical protein cgd2_470 8 225 19 8 
AAEL01000003 Chro.70158 hypothetical protein cgd4_770 8 378 32 13 
AAEL01000620 Chro.10340 hypothetical protein cgd4_1360 8 222 19 8 
AAEL01000116 Chro.80349 hypothetical protein cgd8_4410 8 210 17 8 
AAEL01000179 Chro.50216 hypothetical protein cgd8_3220 8 273 22 8 
AAEL01000021 Chro.60179 hypothetical protein cgd3_4180 8 216 18 8 
AAEL01000679 Chro.40091 hypothetical protein cgd6_2260 8 183 16 8 
AAEL01000181 Chro.10351 hypothetical protein cgd5_4130 8 207 17 8 
AAEL01000291 Chro.30130 hypothetical protein cgd3_260 8 228 20 8 
AAEL01000611 Chro.80489 hypothetical protein cgd2_1980 8 240 21 8 
AAEL01000079 Chro.80248 hypothetical protein cgd8_2060 8 222 18 8 
AAEL01000506 Chro.30028 hypothetical protein cgd6_3160 8 207 18 8 
AAEL01000337 Chro.40251 hypothetical protein cgd6_5110 8 318 28 8 
AAEL01000127 Chro.40016 hypothetical protein cgd6_1920 8 243 20 8 
AAEL01000004 Chro.70478 hypothetical protein cgd8_620 8 213 18 8 
AAEL01000192 Chro.70515 hypothetical protein cgd3_600 9 222 20 9 
AAEL01000082 Chro.60476 hypothetical protein cgd4_3930 9 222 22 9 
AAEL01000237 Chro.60454 hypothetical protein cgd6_3690 9 234 23 9 
AAEL01000031 Chro.70026 hypothetical protein cgd4_820 9 216 21 9 
AAEL01000031 Chro.70011 hypothetical protein cgd1_3430 9 243 22 9 
AAEL01000101 Chro.20319 hypothetical protein cgd7_3810 9 207 19 9 
AAEL01000434 Chro.50247 hypothetical protein cgd5_4190 10 312 34 17 
AAEL01000234 Chro.80118 hypothetical protein cgd2_1590 10 228 24 10 
AAEL01000298 Chro.10105 hypothetical protein cgd8_1060 10 297 30 16 
AAEL01000453 Chro.80410 hypothetical protein cgd1_2850 10 300 30 16 
AAEL01000091 Chro.10038 hypothetical protein cgd8_1510 11 243 29 18 
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Appendix III: Identification of putative species-specific genes for C. parvum and C. hominis based on Reciprocal BLAST, individual BLAST and ortholog 
identification on CryptoDB database. 93 and 211genes are putatively specific for C. hominis and C. parvum, respectively. The selected genes show 
low level of sequence identity (<10%) to genes from the other species. 
A: C. hominis specific genes 
Reciprocal  BLAST 
 Data from CryptoDB and NCBI  BLAST 
 BLAST  
C. hominis 
gene 
Function 
 
C. parvum 
target 
% 
identity Sequence length C hominis C parvum 
% 
identity Probability Homologous gene(s) 
Chro.00003 sensor histidine kinase cgd8_3370 0 1647 bp / 548 AAs yes no 0%    
Chro.40268 hypothetical protein cgd5_3560 0 2721 bp / 906 AAs yes no 0%    
Chro.70405 hypothetical protein cgd7_5010 1 1242 bp / 413 AAs yes no 0%    
Chro.70479 hypothetical protein cgd4_2720 1 1029 bp / 342 AAs yes no 0%    
Chro.80591 hypothetical protein cgd5_3850 1 1992 bp / 663 AAs yes no 0%    
Chro.80288 hypothetical protein cgd1_1390 1 1785 bp / 594 AAs yes no 0%    
Chro.70434 hypothetical protein cgd6_3390 1 1374 bp / 457 AAs yes no 0%    
Chro.50010 hypothetical protein cgd2_690 1 2082 bp / 693 AAs yes no 8% 9e-09 C hominis Chro.50011 
Chro.50317 RNA polymerase A/beta'/A'' subunit cgd8_4860 1 1419 bp / 472 AAs yes no 0%    
Chro.30271 hypothetical protein cgd6_3330 2 675 bp / 224 AAs yes no 0%    
Chro.50330 leucyl tRNA synthetase (134.5 kD) (lrs-1) cgd6_3190 2 681 bp / 226 AAs yes no 0%    
Chro.50457 erythrocyte membrane-associated antigen cgd8_4810 2 1080 bp / 359 AAs yes no 0%    
Chro.60010 hypothetical protein cgd4_1590 2 969 bp / 322 AAs yes no 0%  C hominis Chro.00007 
Chro.00007 hypothetical protein cgd6_4830 2 942 bp / 313 AAs yes no 0%  C hominis Chro.60010 
Chro.20156 hypothetical protein cgd8_2790 2 795 bp / 264 AAs yes no 0%    
Chro.40321 hypothetical protein cgd8_2550 2 732 bp / 243 AAs yes no 0%    
Chro.70274 hypothetical protein cgd6_2540 2 621 bp / 206 AAs yes no 0%    
Chro.50011 hypothetical protein cgd8_20 3 1470 bp / 489 AAs yes no 9% 7e-09 C hominis Chro.50010  
Chro.30236 hypothetical protein cgd5_2230 3 543 bp / 180 AAs yes no 0%    
Chro.30149 ubiquitin-protein ligase 1 cgd8_1200 3 1500 bp / 499 AAs yes no 0%    
Chro.80592 hypothetical protein cgd6_4070 3 624 bp / 207 AAs yes no 0%    
Chro.20364 hypothetical protein cgd5_2840 3 447 bp / 148 AAs yes no 0%    
Chro.70032 hypothetical protein cgd6_3460 3 558 bp / 185 AAs yes no 0%    
  
 
Chro.30091 hypothetical protein cgd5_40 3 2991 bp / 996 AAs yes no 0%    
Chro.30044 hypothetical protein cgd2_3440 4 720 bp / 239 AAs yes no 0%    
Chro.50090 hypothetical protein cgd2_2600 4 459 bp / 152 AAs yes no 0%    
Chro.70013 hypothetical protein cgd7_90 4 714 bp / 237 AAs yes no 0%    
Chro.30290 hypothetical protein cgd3_4140 4 423 bp / 140 AAs yes no 0%    
Chro.10385 hypothetical protein cgd7_4990 4 429 bp / 142 AAs yes no 0%    
Chro.30030 hypothetical protein cgd2_1920 4 410 bp / 407/3 AAs yes no 0%    
Chro.20422 hypothetical protein cgd8_2800 5 276 bp / 91 AAs yes no 0%    
Chro.60093 hypothetical protein cgd1_3360 5 558 bp / 185 AAs yes no 0%    
Chro.30272 hypothetical protein cgd4_3560 5 297 bp / 98 AAs yes no 0%    
Chro.10301 hypothetical protein cgd6_270 5 288 bp / 95 AAs yes no 0%    
Chro.50065 hypothetical protein cgd2_3510 6 258 bp / 85 AAs yes no 0%    
Chro.80427 hypothetical protein cgd8_2490 6 276 bp / 91 AAs yes no 0%    
Chro.80041 hypothetical protein cgd1_2670 6 279 bp / 92 AAs yes no 0%    
Chro.60044 hypothetical protein cgd5_3460 6 252 bp / 83 AAs yes no 0%    
Chro.80550 hypothetical protein cgd2_3580 6 267 bp / 88 AAs yes no 0%    
Chro.80379 hypothetical protein cgd4_1340 6 243 bp / 80 AAs yes no 0%    
Chro.40398 hypothetical protein cgd8_2630 6 246 bp / 81 AAs yes no 0%    
Chro.80356 hypothetical protein cgd3_3230 6 252 bp / 83 AAs yes no 0%    
Chro.50283 hypothetical protein cgd5_1030 6 243 bp / 80 AAs yes no 13% 2e-07 C hominis Chro.50284 
Chro.80606 hypothetical protein cgd5_2790 6 237 bp / 78 AAs yes no 0%    
Chro.40237 hypothetical protein cgd5_4000 6 282 bp / 93 AAs yes no 0%    
Chro.80064 hypothetical protein cgd6_4460 6 246 bp / 81 AAs yes no 0%    
Chro.50315 hypothetical protein cgd8_1610 6 273 bp / 90 AAs yes no 0%    
Chro.10077 hypothetical protein cgd5_540 6 252 bp / 83 AAs yes no 0%    
Chro.80417 hypothetical protein cgd7_3670 6 270 bp / 89 AAs yes no 0%    
Chro.70543 hypothetical protein cgd8_490 6 249 bp / 82 AAs yes no 0%    
Chro.70268 hypothetical protein cgd8_3470 6 300 bp / 99 AAs yes no 0%    
Chro.70073 hypothetical protein cgd2_2400 6 246 bp / 81 AAs yes no 0%    
Chro.80322 hypothetical protein cgd1_2740 6 246 bp / 81 AAs yes no 0%    
Chro.30365 hypothetical protein cgd6_1940 7 213 bp / 70 AAs yes no 0%    
Chro.70195 hypothetical protein cgd8_3700 7 273 bp / 90 AAs yes no 0%    
Chro.50199 hypothetical protein cgd8_3260 7 297 bp / 98 AAs yes no 0%    
  
 
Chro.40229 hypothetical protein cgd2_1440 7 237 bp / 78 AAs yes no 0%    
Chro.10090 hypothetical protein cgd1_3220 7 234 bp / 77 AAs yes no 0%    
Chro.40228 hypothetical protein cgd2_1430 7 282 bp / 93 AAs yes no 0%    
Chro.30104 hypothetical protein cgd8_4030 7 291 bp / 96 AAs yes no 0%    
Chro.70398 hypothetical protein cgd5_2440 7 228 bp / 75 AAs yes no 0%    
Chro.40211 hypothetical protein cgd6_610 7 207 bp / 68 AAs yes no 0%    
Chro.70179 hypothetical protein cgd8_550 7 234 bp / 77 AAs yes no 0%    
Chro.10127 hypothetical protein cgd4_1390 7 270 bp / 89 AAs yes no 0%    
Chro.30364 hypothetical protein cgd3_50 7 240 bp / 79 AAs yes no 0%    
Chro.80169 hypothetical protein cgd4_650 8 204 bp / 67 AAs yes no 0%    
Chro.20113 hypothetical protein cgd5_210 8 207 bp / 68 AAs yes no 0%    
Chro.80037 hypothetical protein cgd5_3420 8 222 bp / 73 AAs yes no 0%    
Chro.40286 hypothetical protein cgd7_5480 8 222 bp / 73 AAs yes no 0%    
Chro.40012 hypothetical protein cgd2_1380 8 225 bp / 74 AAs yes no 0%    
Chro.80531 hypothetical protein cgd3_400 8 231 bp / 76 AAs yes no 0%    
Chro.40447 hypothetical protein cgd5_500 8 213 bp / 70 AAs yes no 0%    
Chro.70522 hypothetical protein cgd2_470 8 225 bp / 74 AAs yes no 0%    
Chro.70158 hypothetical protein cgd4_770 8 378 bp / 125 AAs yes no 0%    
Chro.10340 hypothetical protein cgd4_1360 8 222 bp / 73 AAs yes no 0%    
Chro.80349 hypothetical protein cgd8_4410 8 210 bp / 69 AAs yes no 0%    
Chro.50216 hypothetical protein cgd8_3220 8 273 bp / 90 AAs yes no 0%    
Chro.40091 hypothetical protein cgd6_2260 8 183 bp / 60 AAs yes no 0%    
Chro.10351 hypothetical protein cgd5_4130 8 207 bp / 68 AAs yes no 0%    
Chro.30130 hypothetical protein cgd3_260 8 228 bp / 75 AAs yes no 0%    
Chro.80489 hypothetical protein cgd2_1980 8 240 bp / 79 AAs yes no 0%    
Chro.80248 hypothetical protein cgd8_2060 8 222 bp / 73 AAs yes no 0%    
Chro.30028 hypothetical protein cgd6_3160 8 207 bp / 68 AAs yes no 0%    
Chro.40251 hypothetical protein cgd6_5110 8 318 bp / 105 AAs yes no 0%    
Chro.70478 hypothetical protein cgd8_620 8 213 bp / 70 AAs yes no 0%    
Chro.70515 hypothetical protein cgd3_600 9 222 bp / 73 AAs yes no 0%    
Chro.70026 hypothetical protein cgd4_820 9 216 bp / 71 AAs yes no 0%    
Chro.70011 hypothetical protein cgd1_3430 9 243 bp / 80 AAs yes no 0%    
Chro.20319 hypothetical protein cgd7_3810 9 207 bp / 68 AAs yes no 0%    
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chro.50247 hypothetical protein cgd5_4190 10 312 bp / 103 AAs yes no 0%    
Chro.80118 hypothetical protein cgd2_1590 10 228 bp / 75 AAs yes no 0%    
Chro.80410 hypothetical protein cgd1_2850 10 300 bp / 99 AAs yes no 0%    
  
 
Reciprocal  BLAST 
 
Data from CryptoDB and NCBI Blast 
 
BLAST 
  
C. parvum 
gene 
Function 
 
C. hominis 
target % identity 
Sequence 
length C hominis C parvum % identity Probability  Homologous gene(s)  
cgd6_5320 
 
hypothetical protein with similarity to many 
plasmodium proteins 
Chro.60073 
 
0 
 
2811 bp / 
936 AAs no yes 0%    
cgd2_80 
 
 ABC transporter family protein, 2x AAA domain 
 
Chro.80487 
 
0 
 
4431 bp / 
1476 AAs no yes 0%    
cgd5_330 
 
hypothetical protein 
 
Chro.70096 
 
0 
 
3504 bp / 
1167 AAs no yes 0% 
0.91 
 
C hominis TU502 hypothetical protein 
Chro.70096 
cgd5_1000 
 
hypothetical protein 
 
Chro.60190 
 
0 
 
2112 bp / 
703 AAs no yes 0%    
cgd4_1740 
 
possible HSMGG motif (esterase?) 
 
Chro.80330 
 
1 
 
3078 bp / 
1025 AAs no yes 0%    
cgd4_1330 
 
NADPH-dependent FMN FAD containing 
oxidoreductase , transcripts identified by EST 
Chro.60070 
 
1 
 
2460 bp / 
819 AAs no yes 0%    
cgd4_290 
 
 
putative protein phosphatase 2A regulatory B 
subunit, highly conserved but no plasmodium 
hits 
Chro.80116 
 
 
1 
 
 
2076 bp / 
691 AAs no yes 0%    
cgd3_500 
 
 
putative fucose translocator with 8 
transmembrane domains, within locus of 3 
paralogous genes 
Chro.40126 
 
 
1 
 
 
1185 bp / 
394 AAs no yes 0%    
cgd3_2870 
 
 
similarity of possible bacterial origin within 
discrete region similar to long-chain fatty acid 
acyl-CoA synthetases 
Chro.00004 
 
 
1 
 
 
2334 bp / 
777 AAs no yes 0%    
cgd6_440 
 
PP2Cc like protein phosphatise 
 
Chro.80459 
 
1 
 
1602 bp / 
533 AAs no yes 0%    
cgd1_110 
 
predicted secreted protein, signal peptide, 
paralogs 
Chro.10158 
 
1 
 
1221 bp / 
406 AAs no yes 0%    
cgd6_540 
 
Ser/Thr protein kinase 
 
Chro.10402 
 
1 
 
2841 bp / 
946 AAs no yes 0%    
cgd4_1570 
 
hypothetical protein, possible conserved 
 
Chro.50401 
 
1 
 
1224 bp / 
407 AAs no yes 0%    
cgd3_4240 
 
insulinase like peptidase 
 
Chro.50235 
 
1 
 
3342 bp / 
1113 AAs no yes 0% 0.87 C parvum Chr 6 
cgd3_2640 
 
hypothetical protein with conserved domain 
 
Chro.40078 
 
1 
 
1311 bp / 
436 AAs no yes 0%    
cgd5_4190 
 
hypothetical protein 
 
Chro.20329 
 
1 
 
2247 bp / 
748 AAs no yes 0%    
B: C. parvum specific genes 
 
  
 
cgd4_1130 
 
PhnP like hydrolase of the 
metallobetalactamase fold 
Chro.10012 
 
1 
 
1065 bp / 
354 AAs no yes 0%    
cgd2_4380 
 
signal peptide, repeats, gene anchored to 
telomere 
Chro.10099 
 
1 
 
1434 bp / 
477 AAs no yes 0%    
cgd5_4000 
 
hypothetical protein 
 
Chro.40042 
 
1 
 
2034 bp / 
677 AAs no yes 0%    
cgd3_510 
 
 
putative fucose translocatorw ith 8 
transmembrane domains, within locus of 3 
paralogous genes 
Chro.30381 
 
 
1 
 
 
1170 bp / 
389 AAs no yes 0%    
cgd6_320 
 
 
 
hypothetical protein with signal peptide and 8 
transmembrane domains, amino terminl region 
conserved in plasmodium, transcripts identified by 
EST 
Chro.80433 
 
 
 
1 
 
 
 
2427 bp / 
808 AAs no yes 0%    
cgd2_10 
 
 hypothetical protein 
 
Chro.50504 
 
1 
 
1338 bp / 
445 AAs no yes 0%    
cgd8_2370 
 
 
adenosine kinase like ribokinase 
 
 
Chro.40163 
 
 
1 
 
 
1188 bp / 
395 AAs no yes 
97%                  
1% 
 
0.0                 
0.31 
 
C parvum adenosine kinase (AK) gene                                       
C parvum Iowa II hypothetical protein 
cgd8_4780 
cgd6_670 
 
 
extacellular protein with a signal peptide, 
clostripain like caspase/hemoglobinase 
domain, notch domain and 2 EGF domains 
Chro.70432 
 
 
1 
 
 
4824 bp / 
1607 AAs no yes 0%    
cgd1_360 
 
similar to Noc2p N-terminus 
 
Chro.60406 
 
1 
 
2511 bp / 
836 AAs no yes 0%    
cgd4_1780 
 
ring domain protein 
 
Chro.50317 
 
1 
 
1434 bp / 
477 AAs no yes 0%    
cgd6_5120 
 
protein with two PHD Zn fingers that is probably 
involved in chromatin function 
Chro.40494 
 
2 
 
687 bp / 
228 AAs no yes 0%    
cgd4_3990 
 
hypothetical protein with possible 
transmembrane domain near N-terminus 
Chro.70342 
 
2 
 
1743 bp / 
580 AAs no yes 0%    
cgd6_1130 
 
hypothetical protein with signal peptide 
 
Chro.40330 
 
2 
 
1827 bp / 
608 AAs no yes 0%    
cgd6_5510 
 
 
 
 
 
telomeric insulinase-like protease with signal 
peptide 
 
 
 
 
Chro.40328 
 
 
 
 
 
2 
 
 
 
 
 
1473 bp / 
490 AAs no yes 41% 0.0 
C parvum isolate Ontario zinc protease 
telomerase  
C parvum isolate Michigan zinc protease 
telomerase                              
C parvum isolate Georgia zinc protease 
telomerase  
cgd2_3800 
 
hypothetical protein 
 
Chro.60478 
 
2 
 
1110 bp / 
369 AAs no yes 2% 
4.5 
 
C parvum Iowa II DHHC family palmitoyl 
transferase cgd8_4730 
cgd5_4510 
 
hypothetical protein 
 
Chro.40216 
 
2 
 
789 bp / 
262 AAs no yes 0%    
cgd5_320 
 
carboxylesterase , lysophospholipase, signal 
peptide 
Chro.10070 
 
2 
 
1422 bp / 
473 AAs no yes 0%    
  
 
cgd2_2430 
 
ximpact ortholog conserved protein seen in 
bacteria and eukaryotes 
Chro.10042 
 
2 
 
873 bp / 
290 AAs no yes 0%    
cgd2_100 
 
hypothetical protein 
 
Chro.30403 
 
2 
 
723 bp / 
240 AAs no yes 0%    
cgd3_1090 
 
Rrp9p/U3-55K-family snoRNP-associated 
protein with several WD40 repeats 
Chro.50400 
 
2 
 
1374 bp / 
457 AAs no yes 0%    
cgd8_3150 
 
hypothetical conserved protein, transcripts 
identified by EST 
 
Chro.30367 
 
2 
 
582 bp / 
193 AAs no yes 0%    
cgd4_4160 
 
possible carboxypeptidase 
 
Chro.20426 
 
2 
 
1371 bp / 
456 AAs no yes 0%    
cgd1_960 
 
RING finger containing protein 
 
Chro.20379 
 
2 
 
1458 bp / 
485 AAs no yes 0%    
cgd5_3290 
 
transcription elongation factor TFIIS 
 
Chro.60122 
 
2 
 
702 bp / 
233 AAs no yes 0%    
cgd2_3970 
 
RRM domain containing protein 
 
Chro.40100 
 
2 
 
670 bp / 
222 AAs no yes 0%    
cgd8_620 
 
hypothetical protein 
 
Chro.20223 
 
2 
 
783 bp / 
260 AAs no yes 0%    
cgd6_1810 hypothetical protein Chro.10285 2 
675 bp / 
224 AAs no yes 0%    
cgd6_5520 peptidase'insulinase like peptidase' Chro.40162 2 
1713 bp / 
570 AAs no yes 0%    
cgd6_5020 protein with WD40 repeats Chro.50196 3 
651 bp / 
216 AAs no yes 0%    
cgd5_3250 
secreted lipopolysaccharide sugar transferase 
like family 8 glycosyltransferase Chro.10377 3 
477 bp / 
158 AAs no yes 0%    
cgd5_190 plasmodium conserved protein Chro.20379 3 
1041 bp / 
346 AAs no yes 0%    
cgd4_3920 DinB/family X-type DNA polymerase Chro.30486 3 
1077 bp / 
358 AAs no yes 4% 
3e-04 
 
C parvum Iowa II archeo-eukaryotic 
exosomal RNAse cgd4_3930 
cgd4_90  hypothetical protein, similarity to Rrp7p Chro.70603 3 
531 bp / 
176 AAs no yes 0%    
cgd1_3280 hypothetical protein Chro.40376 3 
939 bp / 
312 AAs no yes 0%    
cgd6_220 hypothetical protein, possible G-patch domain Chro.30092 3 
534 bp / 
177 AAs no yes 3% 
2.1 
 
C parvum Iowa II hypothetical protein 
cgd5_260 
cgd7_730 hypothetical protein Chro.40021 3 
441 bp / 
146 AAs no yes 0%    
  
 
cgd6_3440 hypothetical protein Chro.30421 3 
570 bp / 
189 AAs no yes 0%    
cgd5_4460 hypothetical protein Chro.20065 3 
1023 bp / 
340 AAs no yes 0%    
cgd3_990 CG6144-like AlkB Chro.30338 3 
543 bp / 
180 AAs no yes 0%    
cgd8_210 transcription factor TFIID, TBP Chro.60267 3 
588 bp / 
195 AAs no yes 0%    
cgd4_20 
 hypothetical protein having a signal peptide, 
telomeric gene Chro.30460 3 
1008 bp / 
335 AAs no yes 0%    
cgd5_210 hypothetical protein Chro.50157 3 
3258 bp / 
1085 AAs no yes 0%    
cgd4_4000 
 
possible ribosomal-protein-alanine 
acetyltransferase 
Chro.30486 
 3 
459 bp / 
152 AAs no yes 0%    
cgd5_290 hypothetical protein, 6 transmembrane domains Chro.10356 3 
762 bp / 
253 AAs no yes 0%    
cgd8_3690 mitosis protein DIM1 Chro.70416 3 
429 bp / 
142 AAs no yes 0%    
cgd3_2660 hypothetical protein Chro.30288 3 
612 bp / 
203 AAs no yes 0%    
cgd6_1650 conserved hypothetical protein Chro.30100 3 
618 bp / 
205 AAs no yes 0%    
cgd8_5070 hypothetical protein Chro.10357 3 
487 bp / 
161 AAs no yes 0%    
cgd6_3000 ferredoxin-like protein Fd1, putative Chro.30168 3 
937 bp / 
311 AAs no yes 0%    
cgd6_970 hypothetical protein Chro.40119 3 
607 bp / 
201 AAs no yes 
4%                   
6% 
 
0.13             
2.1 
 
C parvum Iowa II protein kinase cgd1_400                                   
C parvum Iowa II putative peptidase family 
C54 cgd3_2920 
cgd3_4320 possible similarity to RNA polymerase Rpb4 Chro.50268 4 
427 bp / 
141 AAs no yes 0%    
cgd3_1410 
 
small hypothetical protein with transcripts 
identified by EST 
Chro.60411 
 
4 
 
333 bp / 
110 AAs no yes 0%    
cgd2_4000 hypothetical protein Chro.40338 4 
405 bp / 
134 AAs no yes 0%    
cgd6_200 
 
cryptosporidium oocyst wall protein 8, 
CpCOWP8, signal peptide 
Chro.60138 
 
4 
 
1374 bp / 
457 AAs no yes 0%    
cgd6_4980 hypothetical protein Chro.80548 4 
384 bp / 
127 AAs no yes 0%    
  
 
cgd3_3760 
small protein with possible EF hand domains, 
calmodulin like Chro.60242 4 
432 bp / 
143 AAs no yes 0%    
cgd8_5100 hypothetical protein Chro.30413 4 
525 bp / 
174 AAs no yes 0%    
cgd6_380 
 
 
hypothetical protein with signal peptide and 4 
transmembrane domains, possible 
apicomplexan conserved 
Chro.10229 
 
 
4 
 
 
444 bp / 
147 AAs no yes 0%    
cgd4_2400 
 
60S ribosomal protein L31, transcript identified 
by EST 
Chro.50110 
 
4 
 
426 bp / 
141 AAs no yes 0%    
cgd6_930 Dim1p-like ERMB/KSGA methylase Chro.70119 4 
1158 bp / 
385 AAs no yes 0%    
cgd5_4530 
 
hypothetical protein with signal peptide and 2 
cryptosporidium-specific paralogs 
Chro.20423 
 
4 
 
819 bp / 
272 AAs no yes 0%    
cgd4_2290 hypothetical protein Chro.70304 4 
417 bp / 
138 AAs no yes 0%    
cgd5_260 hypothetical protein Chro.60196 4 
2478 bp / 
825 AAs no yes 0%    
cgd1_3770 hypothetical protein Chro.10098 4 
303 bp / 
100 AAs no yes 0%    
cgd7_2120 hypothetical protein Chro.70293 4 
411 bp / 
136 AAs no yes 0%    
cgd5_2650 hypothetical protein Chro.50182 4 
423 bp / 
140 AAs no yes 0%    
cgd6_1240 hypothetical protein Chro.50381 4 
468 bp / 
155 AAs no yes 0%    
cgd7_5070 small conserved protein Chro.70226 4 
387 bp / 
128 AAs no yes 0%    
cgd6_910 
 
 
 
protein with possible 2 transmembrane 
domains, possible ER retention signal, similar 
to Sec20 is a membrane glycoprotein 
associated with secretory pathway 
Chro.30424 
 
 
 
4 
 
 
 
405 bp / 
134 AAs no yes 0%    
cgd3_2290 possible domain AAA, ATpase family Chro.20457 4 
393 bp / 
130 AAs no yes 0%    
cgd1_430 
 
 
possible emp24/gp25L/p24 family protein, 
transmembrane domain, trancript detected by 
EST 
Chro.70470 
 
 
4 
393 bp / 
130 AAs no yes 0%    
cgd5_4550 hypothetical protein Chro.80514 4 
426 bp / 
141 AAs no yes 0%    
cgd5_570 
 
hypothetical protein, 5 transmembrane domains 
near N-terminus 
Chro.80285 
 4 
408 bp / 
135 AAs no yes 0%    
cgd8_4590 hypothetical protein Chro.10011 4 
675 bp / 
224 AAs no yes 0%    
  
 
cgd1_2270 40S ribosomal protein S26 Chro.10099 4 
324 bp / 
107 AAs no yes 0%    
cgd6_1850 
 
anaphase promoting complex subunit 10, 
putative 
Chro.70143 
 4 
441 bp / 
146 AAs no yes 0%    
cgd6_2400 hypothetical protein Chro.30048 4 
355 bp / 
117 AAs no yes 0%    
cgd8_2140 hypothetical protein Chro.60133 5 
312 bp / 
103 AAs no yes 0%    
cgd1_900 hypothetical protein Chro.50153 5 
318 bp / 
105 AAs no yes 0%    
cgd5_3440 hypothetical protein Chro.10387 5 
312 bp / 
103 AAs no yes 0%    
cgd6_4100 hypothetical protein Chro.80087 5 
306 bp / 
101 AAs no yes 0%    
cgd5_4200 transcription initiation factor IIA Chro.80451 5 
336 bp / 
111 AAs no yes 0%    
cgd7_1880 60S ribosomal protein L44 Chro.10216 5 
315 bp / 
104 AAs no yes 0%    
cgd8_1130 hypothetical protein Chro.80542 5 
384 bp / 
127 AAs no yes 0%    
cgd6_5220 cysteine-rich protein with zinc finger Chro.30098 5 
1929 bp / 
642 AAs no yes 0%    
cgd3_3400 
 
 
similar to hypothetical protein, domain with 
limited similarity to a domain RPA14, replication 
protein A (RPA), subunit RPA14 
Chro.60246 
 
 
5 
 
 
333 bp / 
110 AAs no yes 0%    
cgd3_1040 hypothetical protein Chro.70399 5 
345 bp / 
114 AAs no yes 0%    
cgd1_3140 P-loop nucleotide (UMP) kinase Chro.80460 5 
618 bp / 
205 AAs no yes 0%    
cgd1_3560 hypothetical protein Chro.80398 5 
381 bp / 
126 AAs no yes 0%    
cgd4_1260 possible tRNA-INTRON ENDONUCLEASE Chro.40032 5 
477 bp / 
158 AAs no yes 0%    
cgd3_2550 
 
 
hypothetical protein with carboxy terminus motif 
shared with DNA-directed RNA polymerase 
subunit and TFIIS 
Chro.80053 
 
 
5 
 
 
612 bp / 
203 AAs no yes 0%    
cgd3_3890 
 
60S ribosomal protein L30, pelota RNA binding 
domain containing protein 
Chro.40217 
 
5 
 
336 bp / 
111 AAs no yes 0%    
cgd7_1070 
 
snRNP core protein homolog Sm-X5.  SM 
domain containing protein. 
Chro.70451 
 
5 
 
324 bp / 
107 AAs no yes 0%    
cgd8_1710 hypothetical protein Chro.70483 5 
375 bp / 
124 AAs no yes 0%    
  
 
cgd7_1870 hypothetical protein Chro.70265 5 
312 bp / 
103 AAs no yes 0%    
cgd7_690 small nuclear ribonucleoprotein Chro.30192 5 
288 bp /   
95 AAs no yes 0%    
cgd4_1250 hypothetical protein Chro.80610 5 
306 bp / 
101 AAs no yes 0%    
cgd4_1500 hypothetical protein Chro.10355 5 
378 bp / 
125 AAs no yes 0%    
cgd4_2030 centromeric histone h3-like protein, cse4 like Chro.80310 5 
297 bp /   
98 AAs no yes 0%    
cgd3_2380 hypothetical protein Chro.30018 5 
366 bp / 
121 AAs no yes 0%    
cgd1_1190 hypothetical protein Chro.70205 5 
324 bp / 
107 AAs no yes 0%    
cgd4_2830 
 
Mra1/NEP1 like protein, involved in pre-rRNA 
processing, adjacent genes putative paralogs 
Chro.80070 
 
5 
 
651 bp / 
216 AAs no yes 0%    
cgd6_4900 acylphosphatase, putative Chro.20235 5 
417 bp / 
138 AAs no yes 0%    
cgd3_2340 hypothetical protein Chro.50232 6 
309 bp / 
102 AAs no yes 0%    
cgd1_300 40S ribosomal protein S21 Chro.80601 6 
243 bp /   
80 AAs no yes 0%    
cgd1_2880 
 
 
13 kda membrane protein subunit 
[cryptosporidium parvum, sporozoites, peptide, 
119 aa], transcript identified by EST 
Chro.40430 
 
 
6 
 
 
234 bp /   
77 AAs no yes 0%    
cgd6_340 hypothetical protein Chro.50342 6 
333 bp / 
110 AAs no yes 0%    
cgd3_1070 synaptobrevin like SNARE Chro.70137 6 
312 bp / 
103 AAs no yes 0%    
cgd8_4560 hypothetical protein Chro.70144 6 
486 bp / 
161 AAs no yes 0%    
cgd3_1420 
 
conserved small protein, transcript identified by 
EST 
Chro.80150 
 6 
231 bp /   
76 AAs no yes 0%    
cgd7_170 hypothetical protein Chro.20017 6 
285 bp /   
94 AAs no yes 0%    
cgd5_470 
 
hypothetical protein, transcripts identified by 
EST 
Chro.30098 
 
6 
 
534 bp / 
177 AAs no yes 0%    
cgd3_2250 
 
60S ribosomal protein L37A, transcripts 
identified by EST 
Chro.80242 
 
6 
 
264 bp /   
87 AAs no yes 0%    
cgd7_3520 hypothetical protein Chro.80114 7 
222 bp /   
73 AAs no yes 0%    
cgd8_3550 hypothetical protein Chro.40249 7 
309 bp / 
102 AAs no yes 0%    
  
 
cgd8_4050 ribosomal protein S29 Chro.40360 7 
195 bp /   
64 AAs no yes 0%    
cgd1_3410 
 
 
possible domain similar to DUF392, domain of 
unknown function (DUF392), probable DNA 
replication complex GINS protein PSF2 
Chro.30126 
 
 7 
273 bp /   
90 AAs no yes 0%    
cgd2_620 
 
similar to protein translocation complex beta; 
protein transport protein SEC61 beta subunit 
Chro.50406 
 
7 
 
201 bp /   
66 AAs no yes 0%    
cgd5_1430 hypothetical protein Chro.60269 7 
387 bp / 
128 AAs no yes 0%    
cgd1_3430 hypothetical protein Chro.70011 7 
312 bp / 
103 AAs no yes 0%    
cgd1_3370 
 
similarity to domain KOG2265, KIAA1068 
protein and nuclear distribution protein NUDC 
Chro.20426 
 
7 
 
636 bp / 
211 AAs no yes 0%    
cgd2_2150 hypothetical protein Chro.10022 7 
408 bp / 
135 AAs no yes 0%    
cgd2_320 similar to uncharacterized expressed protein Chro.80073 7 
481 bp / 
159 AAs no yes 0%    
cgd5_280 
 
signal peptide containing protein with 6 
transmembrane domains 
Chro.50351 
 
8 
 
963 bp / 
320 AAs no yes 2% 
0.25 
 
C parvum Iowa II mannose-1-phosphate 
guanylyltransferase cgd2_1770 
cgd4_1810 hypothetical protein Chro.40032 8 
354 bp / 
117 AAs no yes 0%    
cgd7_510 RNA polymerase III subunit C11 Chro.50080 8 
189 bp /   
62 AAs no yes 0%    
cgd3_370 hypothetical protein Chro.40348 8 
315 bp / 
104 AAs no yes 0%    
cgd6_3710 
 
40S ribosomal protein S30, transcripts 
identified be EST 
Chro.40296 
 
8 
 
180 bp /   
59 AAs no yes 0%    
cgd5_4060 
 
protein with N-terminal region ZnF U1 domain, 
similar to U1 snRNP-specific protein 
Chro.80265 
 
8 
 
597 bp / 
198 AAs no yes 0%    
cgd2_140 
 
similar to IMP4 family, transcript identified by 
EST 
Chro.60522 
 
8 
 
321 bp / 
106 AAs no yes 0%    
cgd3_3730 hypothetical protein Chro.30098 8 
369 bp / 
122 AAs no yes 5% 
5.6 
 
C parvum Iowa II RAD1, NH2 terminal 
ERCC4-like helicase domain cgd4_2970 
cgd4_4070 hypothetical protein Chro.20236 9 
315 bp / 
104 AAs no yes 0%    
cgd4_4170 hypothetical protein Chro.40476 9 
462 bp / 
153 AAs no yes 10% 
9e-18 
 
C parvum Iowa II hypothetical protein 
cgd4_4180 
cgd2_3280 
 
 
hypothetical protein Chro.40348 9 
375 bp / 
124 AAs no yes 0%    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cgd4_1750 hypothetical protein Chro.70464 9 
333 bp / 
110 AAs no yes 0%    
cgd2_2870 
 
similar to 40S ribosomal protein S28, no good 
start Met 
Chro.10245 
 
9 
 
207 bp /   
68 AAs no yes 0%    
cgd6_3320 
 
ypothetical protein (user's comment: partially 
encodes an MHC binding peptide) 
Chro.10343 
 
9 
 
321 bp / 
106 AAs no yes 0%    
cgd2_350 
 
60S ribosomal protein L39, transcripts identified 
be EST 
Chro.80185 
 
10 
 
168 bp /   
55 AAs no yes 0%    
cgd3_3810 
 
similar to clathrin adaptor complex, small 
subunit 
Chro.40020 
 
10 
 
420 bp / 
139 AAs no yes 0%    
cgd1_1770 
 
domain similar to KOG3415, putative Rab5-
interacting protein 
Chro.70125 
 
10 
 
288 bp /   
95 AAs no yes 0%    
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Appendix IV: Alignment of PCR product sequences of Cryptosporidium DNA from 
clinical isolates and reference strains amplified using newly designed primers. Ch2, 
Ch3, Ch4, TU502 are C. hominis isolates. Cp2, Cp3, Cp4, Iowa, Moredun are 
C. parvum isolates. W65, W66, W67, W70 are anthroponotic C. parvum isolates. 
Rabbit genotype isolates are labelled rabbit 1,2,3 and 4. 
 
 
 
 
 
 
                             1                                                         60 
          ch2_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTGTTTCCAGTTTAGCACCAGT 
          ch3_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTGTTTCCAGTTTAGCACCAGT 
          ch4_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTGTTTCCAGTTTAGCACCAGT 
        TU502_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTGTTTCCAGTTTAGCACCAGT 
      rabbit1_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAATCAATTGTTTCCAGTTTAGCACCAGT 
      rabbit2_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAATCAATTGTTTCCAGTTTAGCACCAGT 
      rabbit3_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAATCAATTGTTTCCAGTTTAGCACCAGT 
      rabbit4_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAATCAATTGTTTCCAGTTTAGCACCAGT 
          cp2_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          cp3_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          cp4_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
         Iowa_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
      Moredun_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          w65_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          w66_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          w67_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
          w70_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
c.meleagridis_cgd2_80    (1) TGATATGTTGATTATAGATACATGTATTGTGAAGTCAATTATTTCCAGTTTAGCACCAGT 
                             61                                                       120 
          ch2_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
          ch3_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
          ch4_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
        TU502_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
      rabbit1_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
      rabbit2_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
      rabbit3_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
      rabbit4_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACGCCATT 
          cp2_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          cp3_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          cp4_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
         Iowa_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
      Moredun_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          w65_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          w66_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          w67_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
          w70_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
c.meleagridis_cgd2_80   (61) ATTGACAATCATAGGTCAGACAATATTTATTGTATATACATTTCCTTATTTTACACCATT 
                             121                                                      180 
          ch2_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
          ch3_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
          ch4_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
        TU502_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
      rabbit1_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
      rabbit2_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
      rabbit3_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
      rabbit4_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAACCAATATGTCTCAAATTTATTTCATCTTA 
          cp2_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          cp3_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          cp4_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
         Iowa_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
      Moredun_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          w65_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          w66_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          w67_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
          w70_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
c.meleagridis_cgd2_80  (121) TTTTCTTATATGGATAATGCTTATTATAAAGCCGATATGCCTTAAATTTATTTCATCTTA 
                             181                                                      240 
          ch2_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          ch3_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          ch4_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
        TU502_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
      rabbit1_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
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      rabbit2_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
      rabbit3_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
      rabbit4_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          cp2_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          cp3_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          cp4_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
         Iowa_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
      Moredun_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          w65_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          w66_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          w67_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
          w70_cgd2_80  (181) TAGGGAATATCAGAGGTTTTCAATATCTCTTTTTTCCTCAATATGTGGAATATTTTCTGG 
c.meleagridis_cgd2_80  (181) TAGGGAATATCAGAGGTTTGCAATATCTCCTTTTTCCTCAATATGTGGAATATTTTCTGG 
                             241 
          ch2_cgd2_80  (241) AACACAGC 
          ch3_cgd2_80  (241) AACACAGC 
          ch4_cgd2_80  (241) AACACAGC 
        TU502_cgd2_80  (241) AACACAGC 
      rabbit1_cgd2_80  (241) AACACAGC 
      rabbit2_cgd2_80  (241) AACACAGC 
      rabbit3_cgd2_80  (241) AACACAGC 
      rabbit4_cgd2_80  (241) AACACAGC 
          cp2_cgd2_80  (241) AACACAGC 
          cp3_cgd2_80  (241) AACACAGC 
          cp4_cgd2_80  (241) AACACAGC 
         Iowa_cgd2_80  (241) AACACAGC 
      Moredun_cgd2_80  (241) AACACAGC 
          w65_cgd2_80  (241) AACACAGC 
          w66_cgd2_80  (241) AACACAGC 
          w67_cgd2_80  (241) AACACAGC 
          w70_cgd2_80  (241) AACACAGC 
c.meleagridis_cgd2_80  (241) AACACAGC 
 
 
 
 
 
 
 
 
 
 
                               1                                                         60 
           ch2_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           ch3_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           ch4_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
         TU502_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
       rabbit1_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
       rabbit2_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
       rabbit3_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
       rabbit4_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           cp2_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           cp3_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           cp4_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
          Iowa_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
       Moredun_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           w65_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           w66_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           w67_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
           w70_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGACAATGCGTTGCTAGAGAGGAGAT 
C. meleagridis_cgd6_200    (1) GGTGTGTCCAACAGGATATACTTTGGATTCAAATAGGCAATGCGTTGCTAGAGAAGAGAT 
                               61                                                       120 
           ch2_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
           ch3_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
           ch4_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
         TU502_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
       rabbit1_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
       rabbit2_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
       rabbit3_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
       rabbit4_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTGAACTGTATGAA 
           cp2_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGCGATTTTAATTGTATGAA 
           cp3_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGCGATTTTAATTGTATGAA 
           cp4_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGCGATTTTAATTGTATGAA 
          Iowa_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGCGATTTTAATTGTATGAA 
       Moredun_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGCGATTTTAATTGTATGAA 
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           w65_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTTAATTGTATGAA 
           w66_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTTAATTGTATGAA 
           w67_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTTAATTGTATGAA 
           w70_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAGTGATTTTAATTGTATGAA 
C. meleagridis_cgd6_200   (61) AATGCCAGAAAGAGTCTGCTTGAATGGAGGAGAATTAATGAATGATTTTAATTGTTTGAA 
                               121                                                      180 
           ch2_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           ch3_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           ch4_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
         TU502_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
       rabbit1_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
       rabbit2_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
       rabbit3_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
       rabbit4_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           cp2_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           cp3_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           cp4_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
          Iowa_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
       Moredun_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           w65_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           w66_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           w67_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
           w70_cgd6_200  (121) GACAACAAACCCAATCATGAAATGTCCAGTGGAATATACATTGGTAGGTGAAAATATGTG 
C. meleagridis_cgd6_200  (121) GACAACAAACCCAATAATGAAATGCCCAGTAGAATATACATTGGTAGGTGAAAATATGTG 
                               181                                                      240 
           ch2_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           ch3_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           ch4_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
         TU502_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
       rabbit1_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
       rabbit2_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
       rabbit3_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
       rabbit4_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           cp2_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           cp3_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           cp4_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
          Iowa_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
       Moredun_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           w65_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           w66_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           w67_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
           w70_cgd6_200  (181) TCAAAAGAATGTTGAGATCGACCCAGTTGCTGTATGCCCATCAGGATTTACTTTAACTGA 
C. meleagridis_cgd6_200  (181) TCAAAAGAATGTTGAGATCGATCCAGTTGCTGTTTGCCCATCAGGATTCACTTTAACTGA 
                               241                                                      300 
           ch2_cgd6_200  (241) CGGTCAAATGTGCAGCGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
           ch3_cgd6_200  (241) CGGTCAAATGTGCAGCGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
           ch4_cgd6_200  (241) CGGTCAAATGTGCAGCGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
         TU502_cgd6_200  (241) CGGTCAAATGTGCAGCGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
       rabbit1_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
       rabbit2_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
       rabbit3_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
       rabbit4_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAAACTGTTGCACCCATCAAGAAATGTATGCAAGGAGT 
           cp2_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           cp3_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           cp4_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
          Iowa_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
       Moredun_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           w65_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           w66_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           w67_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
           w70_cgd6_200  (241) CGGTCAAATGTGCAGTGGCTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
C. meleagridis_cgd6_200  (241) CGGTCAAATGTGCAGTGGTTCAAAGACTGTTGCACCAATCAAGAAATGTATGCAAGGAGT 
                               301                                                      360 
           ch2_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           ch3_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           ch4_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
         TU502_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
       rabbit1_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
       rabbit2_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
       rabbit3_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
       rabbit4_cgd6_200  (301) TTTAAATGAAATGCAAACTGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           cp2_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           cp3_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           cp4_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
          Iowa_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
       Moredun_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           w65_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           w66_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           w67_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
           w70_cgd6_200  (301) TTTAAATGAAATGCAAAATGAATGTATCTTACAAAAGAGTGTATCCCCAATTAGTACCTG 
C. meleagridis_cgd6_200  (301) CTTAAATGAAATGCAAACAGAATGCATCTTGCAAAAGAGTGTATCCCCAATTAGTACCTG 
                               361                                                      420 
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           ch2_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           ch3_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           ch4_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
         TU502_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
       rabbit1_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
       rabbit2_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
       rabbit3_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
       rabbit4_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           cp2_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           cp3_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           cp4_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
          Iowa_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
       Moredun_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           w65_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           w66_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           w67_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
           w70_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
C. meleagridis_cgd6_200  (361) TCCATCACCTGATTTCACTTTAGTTAGTAATGAAAGATGTGTAAGAGAAGTTTTATATGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               1                                                         60 
          ch2_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          ch3_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          ch4_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
        TU502_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
      rabbit1_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
      rabbit2_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
      rabbit3_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
      rabbit4_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          cp2_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          cp3_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          cp4_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
         Iowa_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
      Moredun_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          w65_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          w66_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          w67_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
          w70_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAATTCCATATTACTAACAAGGCGAATCTGGAAACAGCA 
c.meleagridis_cgd8_2370    (1) ACGGAAATTGGAATTGAATTTGAGTTCCATATTGCTAAAAAGGCGAATCTGGAAACAGCA 
                               61                                                       120 
          ch2_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTAGCAGGATTAGGAGCTGCT 
          ch3_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTAGCAGGATTAGGAGCTGCT 
          ch4_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTAGCAGGATTAGGAGCTGCT 
        TU502_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTAGCAGGATTAGGAGCTGCT 
      rabbit1_cgd8_2370   (61) AAATGCGTAGTATTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
      rabbit2_cgd8_2370   (61) AAATGCGTAGTATTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
      rabbit3_cgd8_2370   (61) AAATGCGTAGTATTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
      rabbit4_cgd8_2370   (61) AAATGCGTAGTATTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          cp2_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          cp3_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          cp4_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
         Iowa_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
      Moredun_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          w65_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          w66_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          w67_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
          w70_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACGCTTCTCGCAGGATTAGGAGCTGCT 
c.meleagridis_cgd8_2370   (61) AAATGCGTAGTTTTTGTAACTGAAGAAGAGAGAACACTTCTCGCGGGATTAGGAGCTGCT 
                               121                                                      180 
          ch2_cgd8_2370  (121) AAGGAATATTCAATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          ch3_cgd8_2370  (121) AAGGAATATTCAATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
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          ch4_cgd8_2370  (121) AAGGAATATTCAATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
        TU502_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
      rabbit1_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
      rabbit2_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
      rabbit3_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
      rabbit4_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          cp2_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          cp3_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          cp4_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
         Iowa_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
      Moredun_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          w65_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          w66_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          w67_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
          w70_cgd8_2370  (121) AAGGAATATTCGATTACCACTTTTGAGTCAGAAAATATTCAACATGCTTTAAAGACCGCA 
c.meleagridis_cgd8_2370  (121) AAGGAATATTCTATTTCCACTTTTGAGTCAGAAAAGATTCAAAATGCTTTAAAGACCGCA 
                               181                                                      240 
          ch2_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          ch3_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          ch4_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
        TU502_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
      rabbit1_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
      rabbit2_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
      rabbit3_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
      rabbit4_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          cp2_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          cp3_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          cp4_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
         Iowa_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
      Moredun_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          w65_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          w66_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          w67_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
          w70_cgd8_2370  (181) AATATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
c.meleagridis_cgd8_2370  (181) AGTATATTCGCAACAAGTGGATTCTTTGTTGAAGTTTGTTTCCAGGCAATTCTTAAATCT 
                               241                                                      300 
          ch2_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
          ch3_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
          ch4_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
        TU502_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
      rabbit1_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
      rabbit2_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
      rabbit3_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
      rabbit4_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCTTTTGTATTTGGACTTTCAGCT 
          cp2_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGACTTTCAGCT 
          cp3_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGACTTTCAGCT 
          cp4_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGACTTTCAGCT 
         Iowa_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGACTTTCAGCT 
      Moredun_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGACTTTCAGCT 
          w65_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGGCTTTCAGCT 
          w66_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGGCTTTCAGCT 
          w67_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGGCTTTCAGCT 
          w70_cgd8_2370  (241) GCTCAATATATTCATCAATTTAGATCTAACGAATGTTCATTTGTATTTGGGCTTTCAGCT 
c.meleagridis_cgd8_2370  (241) GCTCAATATATTCATCAATTCAGGTCTGACGAATGTTCCTTTGTGTTCGGACTTTCAGCT 
                               301                                                      360 
          ch2_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          ch3_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          ch4_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
        TU502_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
      rabbit1_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
      rabbit2_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
      rabbit3_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
      rabbit4_cgd8_2370  (301) ACTTATATTCCGGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          cp2_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          cp3_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          cp4_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
         Iowa_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
      Moredun_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          w65_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          w66_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          w67_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
          w70_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATGAATGAGTTATTCCAACTTCTACCAATGATTGATTAT 
c.meleagridis_cgd8_2370  (301) ACTTATATTCCAGAAAAGTATATAAATGAGTTAATTCAACTTTTTCCAATGATTGACTAT 
                               361                                                      420 
          ch2_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
          ch3_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
          ch4_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
        TU502_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
      rabbit1_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
      rabbit2_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
      rabbit3_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
      rabbit4_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATTCTTCAA 
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          cp2_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          cp3_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          cp4_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
         Iowa_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
      Moredun_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          w65_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          w66_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          w67_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
          w70_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTCTCTTTATATAAAAGTATCAACAATATCCTTCAA 
c.meleagridis_cgd8_2370  (361) ATCATTGGAAACCAAGAAGAATTTGTATCTCTATTTAAAAGTATCAACAGTATTTTTCAA 
                               421                                                      480 
          ch2_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
          ch3_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
          ch4_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
        TU502_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
      rabbit1_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
      rabbit2_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
      rabbit3_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
      rabbit4_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCACAGGATAATATAAATCAACCAGAAAACGAT 
          cp2_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          cp3_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          cp4_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
         Iowa_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
      Moredun_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          w65_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          w66_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          w67_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
          w70_cgd8_2370  (421) ATTGAAGACGATGACCAACTATTACTTTCGCAGGATAATATAAATCAACCAGAAAACGAT 
c.meleagridis_cgd8_2370  (421) ATTAAAGACGATGATCAACTATTACTTTCACAAGATAACATTGGTCAGCCAGAAAATGAT 
                               481                                                      540 
          ch2_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
          ch3_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
          ch4_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
        TU502_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
      rabbit1_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
      rabbit2_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
      rabbit3_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
      rabbit4_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAACATCTTAAACCCACATGTATTATACTA 
          cp2_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          cp3_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          cp4_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
         Iowa_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
      Moredun_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          w65_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          w66_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          w67_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
          w70_cgd8_2370  (481) GCTTTAGAAAGAATTCTCACAGAAATTCATAAGCATCTTAAACCCACATGTATTATACTA 
c.meleagridis_cgd8_2370  (481) GTTTTAGAAATCATTCTCACAGAAATTCATAAACATCTTAAGCCCACATGTATTATGCTA 
                               541                                                      600 
          ch2_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
          ch3_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
          ch4_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
        TU502_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
      rabbit1_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
      rabbit2_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
      rabbit3_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
      rabbit4_cgd8_2370  (541) TGTACAAGAGCCCATTTACCCGTTATTTCATTCAACCCCAAAGATCCTAATAGTTATATA 
          cp2_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          cp3_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          cp4_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
         Iowa_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
      Moredun_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          w65_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          w66_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          w67_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
          w70_cgd8_2370  (541) TGCACAAGAGCCCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATAGTTGTATA 
c.meleagridis_cgd8_2370  (541) TGTACAAGAGCTCATTTACCCGTTATTTCATTCAACCCTAAAGATCCTAATGGCTATATA 
                               601                                                      660 
          ch2_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          ch3_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          ch4_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
        TU502_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
      rabbit1_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
      rabbit2_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
      rabbit3_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
      rabbit4_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          cp2_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          cp3_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          cp4_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
         Iowa_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
      Moredun_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          w65_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
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          w66_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          w67_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
          w70_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAGGCTCATTGATGTTAATGGCTGTGGG 
c.meleagridis_cgd8_2370  (601) AAATATCATGAATGTATTCACGTCCCTAAAGAAAAGCTCGTTGATGTTAATGGCTGTGGG 
                               661 
          ch2_cgd8_2370  (661) G 
          ch3_cgd8_2370  (661) G 
          ch4_cgd8_2370  (661) G 
        TU502_cgd8_2370  (661) G 
      rabbit1_cgd8_2370  (661) G 
      rabbit2_cgd8_2370  (661) G 
      rabbit3_cgd8_2370  (661) G 
      rabbit4_cgd8_2370  (661) G 
          cp2_cgd8_2370  (661) G 
          cp3_cgd8_2370  (661) G 
          cp4_cgd8_2370  (661) G 
         Iowa_cgd8_2370  (661) G 
      Moredun_cgd8_2370  (661) G 
          w65_cgd8_2370  (661) G 
          w66_cgd8_2370  (661) G 
          w67_cgd8_2370  (661) G 
          w70_cgd8_2370  (661) G 
c.meleagridis_cgd8_2370  (661) G 
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    ch2_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCATGTAAGGTAGAAACAGTTGA 
    ch3_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCATGTAAGGTAGAAACAGTTGA 
    ch4_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCATGTAAGGTAGAAACAGTTGA 
  TU502_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCATGTAAGGTAGAAACAGTTGA 
rabbit1_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
rabbit2_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
rabbit3_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
rabbit4_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    cp2_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    cp3_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    cp4_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
   Iowa_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
Moredun_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    w65_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    w66_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    w67_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
    w70_cgd2_2430    (1) ACCTATAATTGATCGAAAAAGTGTTTTCCAAGCTCATGCGTGTAAGGTAGAAACAGTTGA 
                         61                                                       120 
    ch2_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
    ch3_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
    ch4_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
  TU502_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
rabbit1_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
rabbit2_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
rabbit3_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
rabbit4_cgd2_2430   (61) ACAAGTTAAAAAGATTATTAAATGGTTGCTTTCAAACCCAAAGATTGCTAAAGCAACGCA 
    cp2_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    cp3_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    cp4_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
   Iowa_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
Moredun_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    w65_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    w66_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    w67_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
    w70_cgd2_2430   (61) ACAAGTTAAAAAAGTTATCAAATGGTTGCTTTCGAACCCAAAGATTGCTAAAGCAACGCA 
                         121                                                      180 
    ch2_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAAGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
    ch3_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAAGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
    ch4_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAAGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
  TU502_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAAGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
Cgd2_2430 gene PCR products 
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rabbit1_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
rabbit2_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
rabbit3_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
rabbit4_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTATCTGAAGGATC 
    cp2_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    cp3_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    cp4_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
   Iowa_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
Moredun_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    w65_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    w66_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    w67_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
    w70_cgd2_2430  (121) CAATATTTGGTCATATAGAATATTCAAGGAGAAAAATTTCGCAGAAGTAACTGAAGGATC 
                         181                                                      240 
    ch2_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
    ch3_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
    ch4_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
  TU502_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
rabbit1_cgd2_2430  (181) TTTCCCCATCGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
rabbit2_cgd2_2430  (181) TTTCCCCATCGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
rabbit3_cgd2_2430  (181) TTTCCCCATCGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
rabbit4_cgd2_2430  (181) TTTCCCCATCGGGTACGATATCATATCACAAGATCATGACTCGGATGGCGAGAATGCAGC 
    cp2_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    cp3_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    cp4_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
   Iowa_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
Moredun_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    w65_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    w66_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    w67_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
    w70_cgd2_2430  (181) TTTCCCCATTGGGTACGATATCATATCACAAGATCACGACTCGGATGGCGAGAATGCAGC 
                         241                                                      300 
    ch2_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
    ch3_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
    ch4_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
  TU502_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
rabbit1_cgd2_2430  (241) AGGAGGTAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
rabbit2_cgd2_2430  (241) AGGAGGTAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
rabbit3_cgd2_2430  (241) AGGAGGTAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
rabbit4_cgd2_2430  (241) AGGAGGTAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTCATGGT 
    cp2_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    cp3_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    cp4_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
   Iowa_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
Moredun_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    w65_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    w66_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    w67_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
    w70_cgd2_2430  (241) AGGAGGCAGACTTCAACATCTTCTTGAAATTACTAATGCAAAGAATGTATTCGTTATGGT 
                         301                                                      360 
    ch2_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
    ch3_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
    ch4_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
  TU502_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
rabbit1_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
rabbit2_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
rabbit3_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
rabbit4_cgd2_2430  (301) GTCTAGATGGTACGGGGGTGTTCAACTAGGGCCAGACAGGTTTAAGCATATTAATAATGC 
    cp2_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    cp3_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    cp4_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
   Iowa_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
Moredun_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    w65_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    w66_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    w67_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
    w70_cgd2_2430  (301) GTCTAGATGGTACGGGGGTATTCAACTAGGGCCAGACAGGTTTAAACATATTAATAATGC 
                         361 
    ch2_cgd2_2430  (361) T 
    ch3_cgd2_2430  (361) T 
    ch4_cgd2_2430  (361) T 
  TU502_cgd2_2430  (361) T 
rabbit1_cgd2_2430  (361) T 
rabbit2_cgd2_2430  (361) T 
rabbit3_cgd2_2430  (361) T 
rabbit4_cgd2_2430  (361) T 
    cp2_cgd2_2430  (361) T 
    cp3_cgd2_2430  (361) T 
    cp4_cgd2_2430  (361) T 
   Iowa_cgd2_2430  (361) T 
Moredun_cgd2_2430  (361) T 
    w65_cgd2_2430  (361) T 
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    w66_cgd2_2430  (361) T 
    w67_cgd2_2430  (361) T 
    w70_cgd2_2430  (361) T 
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          ch2_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
          ch3_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
          ch4_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
        TU502_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
      rabbit1_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
      rabbit2_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
      rabbit3_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
      rabbit4_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
         Iowa_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
      moredun_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
          cp2_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
          cp3_chro.30149    (1) CAGGTGGTGTAACTAGAGAATGGTATAATATTCTAGCTAGAGAAATGTTCAATCCTGATT 
c.meleagridis_chro.30149    (1) CAGGTGGTGTAACAAGGGAATGGTATAATATTCTAGCTAGGGAGATGTTTAATCCCGACT 
                                61                                                       120 
          ch2_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
          ch3_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
          ch4_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
        TU502_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
      rabbit1_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
      rabbit2_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
      rabbit3_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
      rabbit4_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
         Iowa_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
      moredun_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
          cp2_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
          cp3_chro.30149   (61) ATGCTTTATTTAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAATCCATTAAGTT 
c.meleagridis_chro.30149   (61) ACGCTTTGTTCAGAAGAGAAGGATCAAAGAGTGAATTTAACCATCCAAACCCATTAAGTT 
                                121                                                      180 
          ch2_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
          ch3_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
          ch4_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
        TU502_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
      rabbit1_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
      rabbit2_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
      rabbit3_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
      rabbit4_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
         Iowa_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
      moredun_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
          cp2_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
          cp3_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAATTTATTGGACGTATAATAGGGAAATGTA 
c.meleagridis_chro.30149  (121) ATATAAATGCTGATCATCTTCATTTCTTTAAGTTTATCGGACGTATCATAGGTAAATGCA 
                                181                                                      240 
          ch2_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
          ch3_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
          ch4_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
        TU502_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
      rabbit1_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
      rabbit2_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
      rabbit3_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
      rabbit4_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
         Iowa_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
      moredun_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
          cp2_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
          cp3_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAATATGTTAG 
c.meleagridis_chro.30149  (181) TTTATGATGGTCAACATTTGGATGCATGGTTTACTCGATCATTTTATAAGAACATGTTAG 
                                241                                                      300 
          ch2_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
          ch3_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
          ch4_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
        TU502_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
      rabbit1_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
      rabbit2_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
      rabbit3_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
      rabbit4_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
         Iowa_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
      moredun_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
          cp2_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
          cp3_chro.30149  (241) GACAACCAATAACACCATCAGATGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
c.meleagridis_chro.30149  (241) GACAGCCAATAACACCGTCAGACGCAGAATCAATAGATCCTGAACTTTATAAGAATTTGA 
                                301 
          ch2_chro.30149  (301) ATGTAATG 
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          ch3_chro.30149  (301) ATGTAATG 
          ch4_chro.30149  (301) ATGTAATG 
        TU502_chro.30149  (301) ATGTAATG 
      rabbit1_chro.30149  (301) ATGTAATG 
      rabbit2_chro.30149  (301) ATGTAATG 
      rabbit3_chro.30149  (301) ATGTAATG 
      rabbit4_chro.30149  (301) ATGTAATG 
         Iowa_chro.30149  (301) ATGTAATG 
      moredun_chro.30149  (301) ATGTAATG 
          cp2_chro.30149  (301) ATGTAATG 
          cp3_chro.30149  (301) ATGTAATG 
c.meleagridis_chro.30149  (301) ATGTAATG 
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        ch2_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        ch3_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        ch4_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
      TU502_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
    rabbit1_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
    rabbit2_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
    rabbit3_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
    rabbit4_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        cp2_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        cp3_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        cp4_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
       Iowa_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
    Moredun_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        w65_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        w66_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        w67_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
        w70_chro.20156    (1) TTTCGCTTGAAGCCGTAAACTTTAGGATGTTACCAAGGGCAGAGTCTCAAAAAGAATGTA 
                              61                                                       120 
        ch2_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
        ch3_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
        ch4_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
      TU502_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
    rabbit1_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
    rabbit2_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
    rabbit3_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
    rabbit4_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGGAAGACGGC 
        cp2_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        cp3_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        cp4_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
       Iowa_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
    Moredun_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        w65_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        w66_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        w67_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
        w70_chro.20156   (61) AACTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGGAAGACGGC 
                              121                                                      180 
        ch2_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        ch3_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        ch4_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
      TU502_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
    rabbit1_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
    rabbit2_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
    rabbit3_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
    rabbit4_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        cp2_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        cp3_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        cp4_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
       Iowa_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
    Moredun_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        w65_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        w66_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        w67_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
        w70_chro.20156  (121) ATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATATCAAATCCTGAAGATATAG 
                              181                                                      240 
        ch2_chro.20156  (181) AAGAAAGTCCAGCTCAAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
        ch3_chro.20156  (181) AAGAAAGTCCAGCTCAAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
        ch4_chro.20156  (181) AAGAAAGTCCAGCTCAAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
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      TU502_chro.20156  (181) AAGAAAGTCCAGCTCAAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
    rabbit1_chro.20156  (181) AAGAAAGTCCAGCTCTAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
    rabbit2_chro.20156  (181) AAGAAAGTCCAGCTCTAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
    rabbit3_chro.20156  (181) AAGAAAGTCCAGCTCTAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
    rabbit4_chro.20156  (181) AAGAAAGTCCAGCTCTAGTAAATGAAGTCGAAAACATGGTCCCAGAAAACTTGCCTGGTA 
        cp2_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        cp3_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        cp4_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
       Iowa_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
    Moredun_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        w65_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        w66_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        w67_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
        w70_chro.20156  (181) AAGAAGGTCCAGCTCAAGTAAATGAAGCCGAAAACATGGTCCCAGACCACTTGCCTGGTA 
                              241 
        ch2_chro.20156  (241) TCAATGCC 
        ch3_chro.20156  (241) TCAATGCC 
        ch4_chro.20156  (241) TCAATGCC 
      TU502_chro.20156  (241) TCAATGCC 
    rabbit1_chro.20156  (241) TCAATGCC 
    rabbit2_chro.20156  (241) TCAATGCC 
    rabbit3_chro.20156  (241) TCAATGCC 
    rabbit4_chro.20156  (241) TCAATGCC 
        cp2_chro.20156  (241) TCAATGCC 
        cp3_chro.20156  (241) TCAATGCC 
        cp4_chro.20156  (241) TCAATGCC 
       Iowa_chro.20156  (241) TCAATGCC 
    Moredun_chro.20156  (241) TCAATGCC 
        w65_chro.20156  (241) TCAATGCC 
        w66_chro.20156  (241) TCAATGCC 
        w67_chro.20156  (241) TCAATGCC 
        w70_chro.20156  (241) TCAATGCC 
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          ch2_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          ch3_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          ch4_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
        TU502_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
      rabbit1_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
      rabbit2_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
      rabbit3_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
      rabbit4_chro.50317    (1) GGTCTCGGTCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          cp2_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          cp3_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          cp4_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
         Iowa_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
      Moredun_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          w65_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          w66_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          w67_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
          w70_chro.50317    (1) GGTCTCGGCCTGATCGCAAAAAAGAACCAAAGAGTGAGGATGACAGTGGAAATAATACTA 
C.meleagridis_chro.50317    (1) -----------------------GAACCAAAGAGCGAGGATGACAATGGAAATAATACTA 
                                61                                                       120 
          ch2_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          ch3_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          ch4_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
        TU502_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
      rabbit1_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
      rabbit2_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
      rabbit3_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
      rabbit4_chro.50317   (61) AAAAGGAAGAAATTGATGATGCAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          cp2_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          cp3_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          cp4_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
         Iowa_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
      Moredun_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
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          w65_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          w66_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          w67_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
          w70_chro.50317   (61) AAAAGGAAGAAATTGATGATGTAGATAATGATATGAATAATGAAATGGATGGAGATGATA 
C.meleagridis_chro.50317   (38) AAAAAGAAGAGATGGATGATGGAGATAATGATATGAATAATGAAATGGACGGAGATGATA 
                                121                                                      180 
          ch2_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          ch3_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          ch4_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
        TU502_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
      rabbit1_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
      rabbit2_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
      rabbit3_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
      rabbit4_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          cp2_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          cp3_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          cp4_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
         Iowa_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
      Moredun_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          w65_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          w66_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          w67_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
          w70_chro.50317  (121) AAGATAAAAACGATGATGATGATAATTCATCGGTAGAATCTTCATCATCAACTTCCGAGG 
C.meleagridis_chro.50317   (98) AAGATGAAAACGAAGATGATGATAATTCATCTTTAGAATCTTCATCATCAACTTCCGAGG 
                                181                                                      240 
          ch2_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          ch3_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          ch4_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
        TU502_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
      rabbit1_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
      rabbit2_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
      rabbit3_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
      rabbit4_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          cp2_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          cp3_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          cp4_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
         Iowa_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
      Moredun_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATGGAAAATTTACTG 
          w65_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATAGAAAATTTACTG 
          w66_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATAGAAAATTTACTG 
          w67_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATAGAAAATTTACTG 
          w70_chro.50317  (181) AGGAAAATGGTAAAGATGATAGTGATGAAGAAACTGAAATGAATAATAGAAAATTTACTG 
C.meleagridis_chro.50317  (155) AGGAAAATGGTAAAGATGATAGCGATGAAGAAAGTGAAGTTAATAATGGGAAATTTACAG 
                                241                                                   297 
          ch2_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          ch3_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          ch4_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
        TU502_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
      rabbit1_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
      rabbit2_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
      rabbit3_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
      rabbit4_chro.50317  (241) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          cp2_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          cp3_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          cp4_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
         Iowa_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
      Moredun_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          w65_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          w66_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          w67_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
          w70_chro.50317  (241) AAGAAGCTAATGAGAATGATGAATCTGGAAGTGAAGAAGATGGAGATTTAGTTAGGA 
C.meleagridis_chro.50317  (215) AAGAGGCTAATGAGAATGATGAGTCTGGAAGTGAAGAAGATGGAGATTTAGTCAGGA 
                                298                                                      360 
          ch2_chro.50317  (298) GGAGTTTAAATGGAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
          ch3_chro.50317  (298) GGAGTTTAAATGGAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
          ch4_chro.50317  (298) GGAGTTTAAATGGAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
        TU502_chro.50317  (298) GGAGTTTAAATGGAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
      rabbit1_chro.50317  (298) GGAGTTTAAATGCAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
      rabbit2_chro.50317  (298) GGAGTTTAAATGCAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
      rabbit3_chro.50317  (298) GGAGTTTAAATGCAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
      rabbit4_chro.50317  (298) GGAGTTTAAATGCAAGGAATAATTTTACTGGTGAAAATCTAACGGAGAATGATTCAAAAA 
          cp2_chro.50317  (298) GGAGTTTAAGTGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          cp3_chro.50317  (298) GGAGTTTAAGTGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          cp4_chro.50317  (298) GGAGTTTAAGTGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
         Iowa_chro.50317  (298) GGAGTTTAAGTGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
      Moredun_chro.50317  (298) GGAGTTTAAGTGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          w65_chro.50317  (298) GGAGTTTAAATGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          w66_chro.50317  (298) GGAGTTTAAATGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          w67_chro.50317  (298) GGAGTTTAAATGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
          w70_chro.50317  (298) GGAGTTTAAATGCAAGGAATAGTTTTACTGGTGAAAATCTAATGGAGAATGATTCAAAAA 
C.meleagridis_chro.50317  (275) AAAGTTTAAATGCAAGGAATAGTTTTGCTGGTGGAAATCTAATGGAGAATGATTCAAAAA 
                                361                                                      420 
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          ch2_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          ch3_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          ch4_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
        TU502_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
      rabbit1_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
      rabbit2_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
      rabbit3_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
      rabbit4_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          cp2_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          cp3_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          cp4_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
         Iowa_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
      Moredun_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          w65_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          w66_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          w67_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
          w70_chro.50317  (358) TACCATGCATAAACTTAAAAATCTTGACTAAAGATGTATTAAAACATGTCATTGATTTTA 
C.meleagridis_chro.50317  (335) TACCATCCATAAACTTAAAAATCTTGACTAAAGATGTACTAAAACATGTCATTGACTTTA 
                                421                                                      480 
          ch2_chro.50317  (418) ACATTGGTAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
          ch3_chro.50317  (418) ACATTGGTAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
          ch4_chro.50317  (418) ACATTGGTAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
        TU502_chro.50317  (418) ACATTGGTAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
      rabbit1_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
      rabbit2_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
      rabbit3_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
      rabbit4_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCAGTTATAAGATGCC 
          cp2_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          cp3_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          cp4_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
         Iowa_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
      Moredun_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          w65_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          w66_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          w67_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
          w70_chro.50317  (418) ACATTGATAGAAAAACCAATATTTTGAGTATTAAATTGGGGTGGCCGGTTATAAGATGCC 
C.meleagridis_chro.50317  (395) ACATTGATAGAAAGACCAATATTTTGAGTATTAAATTGGGATGGCCGGTTATAAGATGTC 
                                481                                                      540 
          ch2_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
          ch3_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
          ch4_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
        TU502_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
      rabbit1_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
      rabbit2_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
      rabbit3_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
      rabbit4_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAGGACAAATATCCAGT 
          cp2_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATCCAGT 
          cp3_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATCCAGT 
          cp4_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATCCAGT 
         Iowa_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATCCAGT 
      Moredun_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATCCAGT 
          w65_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATTCAGT 
          w66_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATTCAGT 
          w67_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATTCAGT 
          w70_chro.50317  (478) CACATTATATTGATTTCTTACCTGTCTTAAAAAATTGTATTTTAAAGACAAATATTCAGT 
C.meleagridis_chro.50317  (455) CACATTATATTGATTTTTTACCTGTCTTAAAAAATTGTATTTTAAAAACAAATATCCATT 
                                541                                                      600 
          ch2_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          ch3_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          ch4_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
        TU502_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
      rabbit1_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
      rabbit2_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
      rabbit3_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
      rabbit4_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          cp2_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          cp3_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          cp4_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
         Iowa_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
      Moredun_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          w65_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          w66_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          w67_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
          w70_chro.50317  (538) CAATTTCATGTTTGAAAAATGCAAGAATTACTAGGAACCAGAAAGAAACTTCAGACAAAA 
C.meleagridis_chro.50317  (515) CAATTTCATGTTTGAAAAATGCAAGAATTACCAGGAACCAGAAGGAGACTTCAGACAAGA 
                                601                                                      660 
          ch2_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
          ch3_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
          ch4_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
        TU502_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
      rabbit1_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
      rabbit2_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
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      rabbit3_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
      rabbit4_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACCAATGTAGGGCATGTTTTTAAGATTT 
          cp2_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          cp3_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          cp4_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
         Iowa_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
      Moredun_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          w65_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          w66_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          w67_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
          w70_chro.50317  (598) GTTTGTCTCAGTTTGAAGTTACCGTGGAGGGAACCAATGTAGGGCATATTTTTAAGATTT 
C.meleagridis_chro.50317  (575) GTTTGTCTCAGTTTGAAGTTACTGTGGAGGGAACTAATGTGGGGCATATTTTTAAGATTT 
                                661                                                      720 
          ch2_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          ch3_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          ch4_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
        TU502_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
      rabbit1_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
      rabbit2_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
      rabbit3_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
      rabbit4_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          cp2_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          cp3_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          cp4_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
         Iowa_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
      Moredun_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          w65_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          w66_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          w67_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
          w70_chro.50317  (658) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGATATTCAAACAGTATATAAAT 
C.meleagridis_chro.50317  (635) CGCCACGTTACATTAATCACGATAAAATTAGATTCAATGTT---------------- 
                                721 
          ch2_chro.50317  (718) ATTATGGTGT 
          ch3_chro.50317  (718) ATTATGGTGT 
          ch4_chro.50317  (718) ATTATGGTGT 
        TU502_chro.50317  (718) ATTATGGTGT 
      rabbit1_chro.50317  (718) ATTATGGTGT 
      rabbit2_chro.50317  (718) ATTATGGTGT 
      rabbit3_chro.50317  (718) ATTATGGTGT 
      rabbit4_chro.50317  (718) ATTATGGTGT 
          cp2_chro.50317  (718) ATTATGGTGT 
          cp3_chro.50317  (718) ATTATGGTGT 
          cp4_chro.50317  (718) ATTATGGTGT 
         Iowa_chro.50317  (718) ATTATGGTGT 
      Moredun_chro.50317  (718) ATTATGGTGT 
          w65_chro.50317  (718) ATTATGGTGT 
          w66_chro.50317  (718) ATTATGGTGT 
          w67_chro.50317  (718) ATTATGGTGT 
          w70_chro.50317  (718) ATTATGGTGT 
C.meleagridis_chro.50317  (678) ---------- 
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    ch2_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    ch3_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    ch4_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
  TU502_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    cp2_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    cp3_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    cp4_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
   Iowa_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
Moredun_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    w65_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    w66_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    w67_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
    w70_chro.50330    (1) CAGGTTCAAAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
rabbit1_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
rabbit2_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
rabbit3_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
rabbit4_chro.50330    (1) CAGGTTCAGAAACTCTGGGAAGAGAGTCAAATATATGAGGCAGATGTAGATCCATCTCGT 
                          61                                                       120 
    ch2_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    ch3_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    ch4_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
  TU502_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    cp2_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
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    cp3_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    cp4_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
   Iowa_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
Moredun_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    w65_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    w66_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    w67_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
    w70_chro.50330   (61) GAAAAATACATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
rabbit1_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
rabbit2_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
rabbit3_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
rabbit4_chro.50330   (61) GAAAAATATATGATTACATTTCCATATCCATATATGAATGGAAGGTTACATTTGGGGCAT 
                          121                                                      180 
    ch2_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    ch3_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    ch4_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
  TU502_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    cp2_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    cp3_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    cp4_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
   Iowa_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
Moredun_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    w65_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    w66_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    w67_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
    w70_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
rabbit1_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
rabbit2_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
rabbit3_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
rabbit4_chro.50330  (121) GCCTTTACGTTGACAAAAGCAGATTTTCAAGCAAGATTCCAAAGAATGAATAATAAAAAT 
                          181                                                      240 
    ch2_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    ch3_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    ch4_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
  TU502_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    cp2_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    cp3_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    cp4_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
   Iowa_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
Moredun_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    w65_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    w66_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    w67_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
    w70_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACGGGAATGCCAATTTGTGCAAGCGCAGATAAG 
rabbit1_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
rabbit2_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
rabbit3_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
rabbit4_chro.50330  (181) GTATTATTTCCATTTGGTTTTCATTGTACAGGAATGCCAATTTGTGCAAGCGCAGATAAG 
                          241                                                      300 
    ch2_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    ch3_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    ch4_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
  TU502_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    cp2_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    cp3_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    cp4_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
   Iowa_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
Moredun_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    w65_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    w66_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    w67_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
    w70_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
rabbit1_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
rabbit2_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
rabbit3_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
rabbit4_chro.50330  (241) TTAAAGATGGAGTTGAATTCACCAAAGTTAGCTGAAACTGATGATGATAAAGAACAAGAG 
                          301                                        346 
    ch2_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    ch3_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    ch4_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
  TU502_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    cp2_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    cp3_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    cp4_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
   Iowa_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
Moredun_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    w65_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    w66_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    w67_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
    w70_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
rabbit1_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
rabbit2_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
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rabbit3_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
rabbit4_chro.50330  (301) ACAAGCCAAGTACAACTTAAAAGTAAGGTTGCAGCTAAAACTGGGG 
 
 
 
 
                                1                                                         60 
          ch2_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
          ch3_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
          ch4_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
        TU502_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
          cp2_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          cp3_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          cp4_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
         Iowa_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
      Moredun_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          w65_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          w66_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          w67_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
          w70_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATCAAAGGAAAATTATTC 
      rabbit1_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
      rabbit2_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
      rabbit3_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
      rabbit4_chro.50457    (1) TCCCGAATATAGTATTAATAATGATAAACTCGAGCTTGATAAATTAAAAGAAAATTATTC 
C.meleagridis_chro.50457    (1) TCCCGAATATAACATTAATAATGATAAGCTTGAGCTTAATAAGACAAAAATAAATTATTC 
                                61                                                       120 
          ch2_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
          ch3_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
          ch4_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
        TU502_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
          cp2_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          cp3_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          cp4_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
         Iowa_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
      Moredun_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          w65_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          w66_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          w67_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
          w70_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCATTGTTAAAAAGAAGCCTCTCCC 
      rabbit1_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
      rabbit2_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
      rabbit3_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
      rabbit4_chro.50457   (61) ACAAAATAATGAATTACTTCCATATTCATCTTTATGCGTTGTTAAAAAGAAGCCTCTCCC 
C.meleagridis_chro.50457   (61) ACAAAATAATGAGTTACTTCCATACTCATCCTTGTGTGTTGTTAAAAGGAAGCCTCTCCC 
                                121                                                      180 
          ch2_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
          ch3_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
          ch4_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
        TU502_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
          cp2_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          cp3_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          cp4_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
         Iowa_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
      Moredun_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          w65_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          w66_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          w67_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
          w70_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCAAATGATGGTAAAGTTGAGCCTATAAA 
      rabbit1_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
      rabbit2_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
      rabbit3_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
      rabbit4_chro.50457  (121) TGTTATATCTTTTTGGTTAAGTCAAACTGATTCGAATGATAATAAAGTCGAGCCTATAAA 
C.meleagridis_chro.50457  (121) TGTTATATCTTTTTGGTTAAGCCAAGCTGATTCAAATAATGATAAAGTGGAGCCTATGAA 
                                181                                                      240 
          ch2_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
          ch3_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
          ch4_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
        TU502_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
          cp2_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          cp3_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          cp4_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
         Iowa_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
      Moredun_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          w65_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          w66_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          w67_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
          w70_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATTAA 
      rabbit1_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
      rabbit2_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
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      rabbit3_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
      rabbit4_chro.50457  (181) GATCTTTTTGGATGATTATATTATTCATTTTAATAATATTGACTATCTATGTGTAATCAA 
C.meleagridis_chro.50457  (181) GATCTTTTTGGATGACTATATTATTCATTTTAATAATATTGACTATTTGTGTGTAATTAA 
                                241                                                      300 
          ch2_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          ch3_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          ch4_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
        TU502_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          cp2_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          cp3_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          cp4_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
         Iowa_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
      Moredun_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          w65_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          w66_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          w67_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
          w70_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAATTAATTACATACCTTACAGTGAAGGTAATAGTTA 
      rabbit1_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
      rabbit2_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
      rabbit3_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
      rabbit4_chro.50457  (241) TTCAACACTAGGTACTTTTGGAAAAGTTAATTACATACCTTACAGTGAAGGTAATAGTTA 
C.meleagridis_chro.50457  (241) CTCAACTCTAGGTACTTTTGGAAAGGTCAACTACATACCTTATAGTGAAGGTAATAGTTA 
                                301                                                      360 
          ch2_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
          ch3_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
          ch4_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
        TU502_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
          cp2_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          cp3_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          cp4_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
         Iowa_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
      Moredun_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          w65_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          w66_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          w67_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
          w70_chro.50457  (301) TAACTACTTTACTCCTTATTATTCATCCTCTAATACTCCTTTGATACTCCTTGGTTCTCT 
      rabbit1_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
      rabbit2_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
      rabbit3_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
      rabbit4_chro.50457  (301) TAACTACTTCACTCCTTATTATTCATCCTCTAATACTCCCTTGATACTCTTTGGTTCTCT 
C.meleagridis_chro.50457  (301) TAACTATTTTACCCCGTATTATTCATCCTCCAATGCTCCTTTGATACTCTTTGGTTCTCT 
                                361       373 
          ch2_chro.50457  (361) TTTTCTCAAATCA 
          ch3_chro.50457  (361) TTTTCTCAAATCA 
          ch4_chro.50457  (361) TTTTCTCAAATCA 
        TU502_chro.50457  (361) TTTTCTCAAATCA 
          cp2_chro.50457  (361) TTTTCTCAAATCA 
          cp3_chro.50457  (361) TTTTCTCAAATCA 
          cp4_chro.50457  (361) TTTTCTCAAATCA 
         Iowa_chro.50457  (361) TTTTCTCAAATCA 
      Moredun_chro.50457  (361) TTTTCTCAAATCA 
          w65_chro.50457  (361) TTTTCTCAAATCA 
          w66_chro.50457  (361) TTTTCTCAAATCA 
          w67_chro.50457  (361) TTTTCTCAAATCA 
          w70_chro.50457  (361) TTTTCTCAAATCA 
      rabbit1_chro.50457  (361) TTTTCTCAAATCA 
      rabbit2_chro.50457  (361) TTTTCTCAAATCA 
      rabbit3_chro.50457  (361) TTTTCTCAAATCA 
      rabbit4_chro.50457  (361) TTTTCTCAAATCA 
C.meleagridis_chro.50457  (361) TTTTCTCAAATCA 
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                               1                                                         60 
          ch2_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
          ch3_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
          ch4_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
        TU502_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
      rabbit1_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
      rabbit2_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
      rabbit3_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
      rabbit4_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTACTGATGAGCCAATAATGA 
          cp2_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          cp3_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          cp4_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
         Iowa_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
      Moredun_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          w65_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          w66_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          w67_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
          w70_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGATCTCAGAACAAGTTGTATTGATGAGCCAATAATGA 
C.meleagridis_cgd6_5020    (1) ACGATTGCTCTTTATCTTTATGGGACCTCAGAACAAGTTTTACTGATGAGCCGATAATGA 
                               61                                                       120 
          ch2_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          ch3_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          ch4_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
        TU502_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
      rabbit1_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
      rabbit2_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
      rabbit3_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
      rabbit4_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          cp2_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          cp3_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          cp4_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
         Iowa_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
      Moredun_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          w65_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          w66_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          w67_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
          w70_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
C.meleagridis_cgd6_5020   (61) AGAACAAGAAATCCCATTCTATGGGTGTAACTTGTATCCAAAAGTCGAATAGAAATCATC 
                               121                                                      180 
          ch2_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          ch3_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          ch4_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
        TU502_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
      rabbit1_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
      rabbit2_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
      rabbit3_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
      rabbit4_cgd6_5020  (121) AATTTTGGTCAGGTAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          cp2_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          cp3_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          cp4_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
         Iowa_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
      Moredun_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          w65_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          w66_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          w67_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
          w70_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTTTAGGATGATAAACT 
C.meleagridis_cgd6_5020  (121) AATTTTGGTCAGGAAGTTACGACGAAACCCTTAGATTCTGGGATTCTAGGATGATAAACT 
                               181                                                      240 
          ch2_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          ch3_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          ch4_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
        TU502_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
      rabbit1_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
      rabbit2_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
      rabbit3_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
      rabbit4_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          cp2_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          cp3_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          cp4_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
         Iowa_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
      Moredun_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          w65_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          w66_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          w67_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
          w70_cgd6_5020  (181) CTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
C.meleagridis_cgd6_5020  (181) TTCCTATTTATGAGCACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATT 
                               241 
Cgd6_5020 gene PCR products 
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          ch2_cgd6_5020  (241) ACCTTGGA 
          ch3_cgd6_5020  (241) ACCTTGGA 
          ch4_cgd6_5020  (241) ACCTTGGA 
        TU502_cgd6_5020  (241) ACCTTGGA 
      rabbit1_cgd6_5020  (241) ACCTTGGA 
      rabbit2_cgd6_5020  (241) ACCTTGGA 
      rabbit3_cgd6_5020  (241) ACCTTGGA 
      rabbit4_cgd6_5020  (241) ACCTTGGA 
          cp2_cgd6_5020  (241) ACCTTGGA 
          cp3_cgd6_5020  (241) ACCTTGGA 
          cp4_cgd6_5020  (241) ACCTTGGA 
         Iowa_cgd6_5020  (241) ACCTTGGA 
      Moredun_cgd6_5020  (241) ACCTTGGA 
          w65_cgd6_5020  (241) ACCTTGGA 
          w66_cgd6_5020  (241) ACCTTGGA 
          w67_cgd6_5020  (241) ACCTTGGA 
          w70_cgd6_5020  (241) ACCTTGGA 
C.meleagridis_cgd6_5020  (241) ACCTTGGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          1                                                         60 
          ch2_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          ch3_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          ch4_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
        TU502_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
      rabbit1_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
      rabbit2_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
      rabbit3_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
      rabbit4_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          cp2_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          cp3_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          cp4_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
         Iowa_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
      Moredun_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          w65_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          w66_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          w67_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
          w70_COWP    (1) CAGGCATTATCTTGTAATACTGTACCTGGAGGGCAGACAGGTTGAGTTGGAGCAGAACTA 
C.meleagridis_COWP    (1) CAGGCATTATCTTGTAGCACTGTACCTGTAGGGCATACAGGTTGTGTTGGAGCGGAACTA 
                          61                                                       120 
          ch2_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          ch3_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          ch4_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
        TU502_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
      rabbit1_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
      rabbit2_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
      rabbit3_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
      rabbit4_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          cp2_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          cp3_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          cp4_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
         Iowa_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
      Moredun_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          w65_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          w66_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          w67_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
          w70_COWP   (61) GTTTGTATACATTGGAGGCCTTGTAAAATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
C.meleagridis_COWP   (61) GTTTGAATACACTGGAGGCCTTGTAATATGAAATTTGGTGGGCATTCCTTTGCAGGAGCT 
                          121                                                      180 
          ch2_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
          ch3_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
          ch4_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
        TU502_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
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      rabbit1_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
      rabbit2_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
      rabbit3_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
      rabbit4_COWP  (121) ACATATAGTACACAATCATCTCCTGAATCTGTATATCCTGGTGGGCAGACCATATCAATA 
          cp2_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          cp3_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          cp4_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
         Iowa_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
      Moredun_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          w65_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          w66_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          w67_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
          w70_COWP  (121) ACATATAGTACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
C.meleagridis_COWP  (121) ACATATAGAACACAATCATCTCCTGAGTCTGTATATCCTGGTGGGCAGACCATATCAATA 
                          181                                                      240 
          ch2_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          ch3_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          ch4_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
        TU502_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
      rabbit1_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
      rabbit2_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
      rabbit3_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
      rabbit4_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          cp2_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          cp3_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          cp4_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
         Iowa_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
      Moredun_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          w65_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          w66_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          w67_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
          w70_COWP  (181) TTTTTAATCACTTTACATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTCGATTCT 
C.meleagridis_COWP  (181) TTTTTAATCACTTTGCATTTTCCATTTTCAAATATTGAATTAGGTGGGCATGTAGATTCT 
                          241                                                      300 
          ch2_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          ch3_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          ch4_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
        TU502_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
      rabbit1_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
      rabbit2_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
      rabbit3_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
      rabbit4_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          cp2_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          cp3_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          cp4_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
         Iowa_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
      Moredun_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          w65_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          w66_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          w67_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
          w70_COWP  (241) AATTCAGCTGATTCTGGTGCCATACATTGTTGTCCTGACAAATTGAATCCAGGAGGACAG 
C.meleagridis_COWP  (241) AATTCAGCAGATTCTGGTGCCATACATTGTTGTCCTGACAAATTAAATCCAGGAGGACAG 
                          301                                                      360 
          ch2_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          ch3_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          ch4_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
        TU502_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
      rabbit1_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
      rabbit2_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
      rabbit3_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
      rabbit4_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          cp2_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          cp3_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          cp4_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
         Iowa_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
      Moredun_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          w65_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          w66_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          w67_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
          w70_COWP  (301) ATTTTATTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
C.meleagridis_COWP  (301) ATTTTGTTTGCAGGGAGATATTGAACACATCTATTTCCTTCTTCAACAAAACCAGAAGGA 
                          361                                                      420 
          ch2_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
          ch3_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
          ch4_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
        TU502_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
      rabbit1_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
      rabbit2_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
      rabbit3_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
      rabbit4_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTTTCCAGTATAGTACCTGGA 
          cp2_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
          cp3_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
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          cp4_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
         Iowa_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
      Moredun_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
          w65_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
          w66_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
          w67_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
          w70_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTGCCATTCTCCAGTATAGTGCCTGGA 
C.meleagridis_COWP  (361) CAAACGGTATCAATTTGTTGAATTAATTTACATGTACCATTCTCTAGTATAGTGCCTGGA 
                          421                                                      480 
          ch2_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
          ch3_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
          ch4_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
        TU502_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
      rabbit1_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
      rabbit2_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
      rabbit3_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
      rabbit4_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAGACG 
          cp2_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          cp3_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          cp4_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
         Iowa_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
      Moredun_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          w65_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          w66_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          w67_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
          w70_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGTTTTCCAGAAAAAACG 
C.meleagridis_COWP  (421) GGACATTCTGGATTAGGAGGAGCTGTGTCTGATTGAACACATTGCTTTCCAGAAAAAACG 
                          481                                           529 
          ch2_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          ch3_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          ch4_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
        TU502_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
      rabbit1_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
      rabbit2_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
      rabbit3_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
      rabbit4_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          cp2_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          cp3_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          cp4_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
         Iowa_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
      Moredun_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          w65_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          w66_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          w67_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
          w70_COWP  (481) AATCCTGGGGGACATGATTTTTCAGGCATAGTGAATGCAACACAATCTC 
C.meleagridis_COWP  (481) AATCCTGGAGGACATGATTTTTCAGGCATAGTAAATGCAACACAATCTC 
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Appendix V: Summary of SNP type and position for each gene tested. Information 
for each gene was presented on each table, including gene size, chromosome 
number and location, expected PCR product size and number of high quality base 
pair sequence retrieved.  
The SNPS were then used to identify species and subtypes pattern using colour 
legend. Each SNP was labelled based on its gene location and a colour was used to 
attribute the SNP to a species/subtype, the same colour legend was used to 
determine the species/subtype profile: 
 
 
 
                    Species-specific SNP 
                    Rabbit genotype SNP 
         C. meleagridis SNP 
                    C. hominis SNP 
                      C. parvum SNP 
           Anthroponotic C. parvum SNP 
                        TU502 SNP 
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Cgd2_80 (4431 bp) 
  
    Chr2 (23.97k- 28.85k)    
    PCR product 266 bp    
    total number of bp 248    
            
Isolates 34 41 115 151 154 160 163 200 210 
Ch2 G G G A A T C T T 
Ch3 G G G A A T C T T 
Ch4 G G G A A T C T T 
TU502 G G G A A T C T   
Cp2 G A A G G C T T T 
Cp3 G A A G G C T T T 
Cp4 G A A G G C T T T 
Iowa G A A G G C T T T 
Moredun G A A G G C T T T 
w65 G A A G G C T T T 
w66 G A A G G C T T T 
w67 G A A G G C T T T 
w70 G A A G G C T T T 
Rabbit1 A G G A A T C T T 
Rabbit2 A G G A A T C T T 
Rabbit3 A G G A A T C T T 
Rabbit4 A G G A A T C T T 
C.meleagridis G A A G G C T G C 
     
Cgd2_2430 (873 bp) 
     
     Chr2 (492.39k- 493.35k)       
     PCR product 389 bp        
     total number of bp 361       
                
Isolates 40 73 74 79 94 148 170 190 217 247 295 320 346 
Ch2 A G A T A A T T T C C G G 
Ch3 A G A T A A T T T C C G G 
Ch4 A G A T A A T T T C C G G 
TU502 A G A T A A T T T C C G G 
Cp2 G A G C G G A T C C T A A 
Cp3 G A G C G G A T C C T A A 
Cp4 G A G C G G A T C C T A A 
Iowa G A G C G G A T C C T A A 
Moredun G A G C G G A T C C T A A 
w65 G A G C G G A T C C T A A 
w66 G A G C G G A T C C T A A 
w67 G A G C G G A T C C T A A 
w70 G A G C G G A T C C T A A 
Rabbit1 G G A T A G T C T T C G G 
Rabbit2 G G A T A G T C T T C G G 
Rabbit3 G G A T A G T C T T C G G 
Rabbit4 G G A T A G T C T T C G G 
  
 
       
cgd6_200 (1374 pb)  
           
      chr.6 (50.41k- 51.92k)             
      PCR product 447 bp              
      total number of bp 420              
                      
Isolates 37 55 102 103 109 112 116 136 145 151 202 256 259 265 277 301 318 319 325 331 
Ch2 A G G T G C A C T G T C C A C T C T T A 
Ch3 A G G T G C A C T G T C C A C T C T T A 
Ch4 A G G T G C A C T G T C C A C T C T T A 
TU502 A G G T G C A C T G T C C A C T C T T A 
Cp2 A G G C T T A C T G C T C G A T A T T A 
Cp3 A G G C T T A C T G C T C G A T A T T A 
Cp4 A G G C T T A C T G C T C G A T A T T A 
Iowa A G G C T T A C T G C T C G A T A T T A 
Moredun A G G C T T A C T G C T C G A T A T T A 
w65 A G G T T T A C T G C T C G A T A T T A 
w66 A G G T T T A C T G C T C G A T A T T A 
w67 A G G T T T A C T G C T C G A T A T T A 
w70 A G G T T T A C T G C T C G A T A T T A 
Rabbit1 A G G T G C A C T G T T C A C T C T T A 
Rabbit2 A G G T G C A C T G T T C A C T C T T A 
Rabbit3 A G G T G C A C T G T T C A C T C T T A 
Rabbit4 A G G T G C A C T G T T C A C T C T T A 
C.meleagridis G A A T T T T A C A T T T G A C C A C G 
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cgd6_5020 (651 bp) 
  
 
  Chr.6 (1189.88k- 1190.60k)   
  PCR product 271 bp    
  total number of bp 248     
        
Isolates 26 40 43 53 134 166 181 
Ch2 T G C A T T C 
Ch3 T G C A T T C 
Ch4 T G C A T T C 
TU502 T G C A T T C 
Cp2 T G T A A T C 
Cp3 T G T A A T C 
Cp4 T G T A A T C 
Iowa T G T A A T C 
Moredun T G T A A T C 
w65 T G T A A T C 
w66 T G T A A T C 
w67 T G T A A T C 
w70 T G T A A T C 
Rabbit1 T G C A T T C 
Rabbit2 T G C A T T C 
Rabbit3 T G C A T T C 
Rabbit4 T G C A T T C 
C.meleagridis C T C G A C T 
 
 
 
 
 
 
 
 
  
   
cgd8_2370 (1188 bp) 
    
 
  
   chr.8 (631.04K- 632.35K)     
 
  
   PCR product 685 bp      
 
  
   total number of bp 661     
              
Isolates 72 102 132 279 291 312 414 450 513 543 579 596 
Ch2 T A A T A G T A A T C A 
Ch3 T A A T A G T A A T C A 
Ch4 T A A T A G T A A T C A 
TU502 T A G T A G T A A T C A 
Cp2 T C G A A A C G G C T G 
Cp3 T C G A A A C G G C T G 
Cp4 T C G A A A C G G C T G 
Iowa T C G A A A C G G C T G 
Moredun T C G A A A C G G C T G 
w65 T C G A G A C G G C T G 
w66 T C G A G A C G G C T G 
w67 T C G A G A C G G C T G 
w70 T C G A G A C G G C T G 
Rabbit1 A C G T A G T A A T C A 
Rabbit2 A C G T A G T A A T C A 
Rabbit3 A C G T A G T A A T C A 
Rabbit4 A C G T A G T A A T C A 
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Chro.20156 (795 bp) 
 
   Chr.2 (310.76- 311.551K)  
   PCR product 247 bp   
   total number of bp 248  
        
Isolates 107 186 196 208 227 228 
Ch2 G A A T A A 
Ch3 G A A T A A 
Ch4 G A A T A A 
TU502 G A A T A A 
Cp2 A G A C C C 
Cp3 A G A C C C 
Cp4 A G A C C C 
Iowa A G A C C C 
Moredun A G A C C C 
w65 A G A C C C 
w66 A G A C C C 
w67 A G A C C C 
w70 A G A C C C 
Rabbit1 G A T T A A 
Rabbit2 G A T T A A 
Rabbit3 G A T T A A 
Rabbit4 G A T T A A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
chro.50330 (681 bp) 
 chr.5 (148.97K- 151.05K ) 
 PCR product 368 bp 
 total number of bp 346 
      
Isolates 9 69 210 
Ch2 G T A 
Ch3 G T A 
Ch4 G T A 
TU502 G T A 
Cp2 A C G 
Cp3 A C G 
Cp4 A C G 
Iowa A C G 
Moredun A C G 
w65 A C G 
w66 A C G 
w67 A C G 
w70 A C G 
Rabbit1 G T A 
Rabbit2 G T A 
Rabbit3 G T A 
Rabbit4 G T A 
  
 
           
chro.50317 (1419 bp) 
      
 
           chr.5 (173.60K- 179.56K )       
           PCR product 752 bp         
           total number of bp 727         
                         
Isolates 9 35 46 65 71 74 82 110 126 134 152 153 203 214 219 221 228 230 239 245 263 293 298 
Ch2 T T G G A T C T A T G G T C A G G A T G G T G 
Ch3 T T G G A T C T A T G G T C A G G A T G G T G 
Ch4 T T G G A T C T A T G G T C A G G A T G G T G 
TU502 T T G G A T C T A T G G T C A G G A T G G T G 
Cp2 C T G G A T T T A T G G T C A G G A T A A T G 
Cp3 C T G G A T T T A T G G T C A G G A T A A T G 
Cp4 C T G G A T T T A T G G T C A G G A T A A T G 
Iowa C T G G A T T T A T G G T C A G G A T A A T G 
Moredun C T G G A T T T A T G G T C A G G A T A A T G 
w65 C T G G A T T T A T G G T C A G A A T A A T G 
w66 C T G G A T T T A T G G T C A G A A T A A T G 
w67 C T G G A T T T A T G G T C A G A A T A A T G 
w70 C T G G A T T T A T G G T C A G A A T A A T G 
Rabbit1 T T G G A T C T A T G G T C A G G A T G G T G 
Rabbit2 T T G G A T C T A T G G T C A G G A T G G T G 
Rabbit3 T T G G A T C T A T G G T C A G G A T G G T G 
Rabbit4 T T G G A T C T A T G G T C A G G A T G G T G 
C.meleagridis 
  C A A G G G C G A T T C G G T G G A G G C A 
 
 
 
 
 
 
 
 
 
 
  
        
chro.50317 (1419 bp) 
 
    
   
    
     
        
chr.5 (173.60K- 
179.56K )                  
        PCR product 752 bp                  
        total number of bp 727                  
                              
Isolate 299 307 310 319 324 331 340 364 396 413 424 431 458 464 476 494 523 524 533 536 569 581 584 596 620 632 638 645 
Ch2 G A G A A A C G T T G A G A G G G G C G T A A A T C A G 
Ch3 G A G A A A C G T T G A G A G G G G C G T A A A T C A G 
Ch4 G A G A A A C G T T G A G A G G G G C G T A A A T C A G 
TU502 G A G A A A C G T T G A G A G G G G C G T A A A T C A G 
Cp2 G G C G A A T G T T A A G G G G A G C G T A A A C C A A 
Cp3 G G C G A A T G T T A A G G G G A G C G T A A A C C A A 
Cp4 G G C G A A T G T T A A G G G G A G C G T A A A C C A A 
Iowa G G C G A A T G T T A A G G G G A G C G T A A A C C A A 
Moredun G G C G A A T G T T A A G G G G A G C G T A A A C C A A 
w65 G A C G A A T G T T A A G G G G A G T G T A A A C C A A 
w66 G A C G A A T G T T A A G G G G A G T G T A A A C C A A 
w67 G A C G A A T G T T A A G G G G A G T G T A A A C C A A 
w70 G A C G A A T G T T A A G G G G A G T G T A A A C C A A 
Rabbit1 G A C A A A C G T T A A G A G G G G C G T A A A T C A G 
Rabbit2 G A C A A A C G T T A A G A G G G G C G T A A A T C A G 
Rabbit3 G A C A A A C G T T A A G A G G G G C G T A A A T C A G 
Rabbit4 G A C A A A C G T T A A G A G G G G C G T A A A T C A G 
C.melea- 
gridis A A C G G G T C C C A G A G T T A A C T C G G G T T G A 
 
 
 
 
 
 
 
 
 
 
  
            
chro.50457 (1080 bp) 
     
            Chr.5 (903.26K- 905.12K )      
            PCR product 394 bp      
            total number of bp 373       
                            
Isolates 12 13 28 31 38 43 44 45 49 50 51 73 85 91 94 97 98 108 142 146 154 158 161 162 169 178 
Ch2 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Ch3 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Ch4 G T A C G A T T A G A A T T A C G A T A G G A A C A 
TU502 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Cp2 G T A C G A T C G G A A T T A C A A T A A G G G T A 
Cp3 G T A C G A T C G G A A T T A C A A T A A G G G T A 
Cp4 G T A C G A T C G G A A T T A C A A T A A G G G T A 
Iowa G T A C G A T C G G A A T T A C A A T A A G G G T A 
Moredun G T A C G A T C G G A A T T A C A A T A A G G G T A 
w65 G T A C G A T C G G A A T T A C A A T A A G G G T A 
w66 G T A C G A T C G G A A T T A C A A T A A G G G T A 
w67 G T A C G A T C G G A A T T A C A A T A A G G G T A 
w70 G T A C G A T C G G A A T T A C A A T A A G G G T A 
Rabbit1 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Rabbit2 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Rabbit3 G T A C G A T T A G A A T T A C G A T A G G A A C A 
Rabbit4 G T A C G A T T A G A A T T A C G A T A G G A A C A 
C.meleagridis A C G T A G A C A A T G C C G T G G C G A A G A G G 
 
 
 
 
 
 
 
 
 
 
     
chro.50457 (1080 bp) 
           
  
     Chr.5 (903.26K- 905.12K )           
     PCR product 394 bp            
     total number of bp 373             
                    
Isolates 196 227 229 238 241 247 265 266 268 271 283 307 310 313 316 331 335 340 350 
Ch2 T C A C T A A G T T C C C T T T A C T 
Ch3 T C A C T A A G T T C C C T T T A C T 
Ch4 T C A C T A A G T T C C C T T T A C T 
TU502 T C A C T A A G T T C C C T T T A C T 
Cp2 T C A T T A A A T T C C T T T T A T C 
Cp3 T C A T T A A A T T C C T T T T A T C 
Cp4 T C A T T A A A T T C C T T T T A T C 
Iowa T C A T T A A A T T C C T T T T A T C 
Moredun T C A T T A A A T T C C T T T T A T C 
w65 T C A T T A A A T T C C T T T T A T C 
w66 T C A T T A A A T T C C T T T T A T C 
w67 T C A T T A A A T T C C T T T T A T C 
w70 T C A T T A A A T T C C T T T T A T C 
Rabbit1 T C A C T A A G T T C C C T T T A C T 
Rabbit2 T C A C T A A G T T C C C T T T A C T 
Rabbit3 T C A C T A A G T T C C C T T T A C T 
Rabbit4 T C A C T A A G T T C C C T T T A C T 
C.meleagridis C T G T C T G G C C T T T C G C G T T 
 
 
 
 
 
 
 
 
 
     Chro.30149 (1500 bp)              
     chr.3 (9.7K- 11.5 K)              
     PCR product 331 bp              
  
     total number of bp 308              
                       
Isolates 14 17 41 44 50 56 59 62 68 71 110 152 158 167 173 179 233 245 257 263 
Ch2 T A A A C T T T A T T A T A G T T A A T 
Ch3 T A A A C T T T A T T A T A G T T A A T 
Ch4 T A A A C T T T A T T A T A G T T A A T 
TU502 T A A A C T T T A T T A T A G T T A A T 
Cp2 T A A A C T T T A T T A T A G T T A A T 
Cp3 T A A A C T T T A T T A T A G T T A A T 
Cp4 
                      
Iowa T A A A C T T T A T T A T A G T T A A T 
Moredun T A A A C T T T A T T A T A G T T A A T 
w65 T A A A C T T T A T T A T A G T T A A T 
w66 T A A A C T T T A T T A T A G T T A A T 
w67 T A A A C T T T A T T A T A G T T A A T 
w70 T A A A C T T T A T T A T A G T T A A T 
Rabbit1 T A A A C T T T A T T A T A G T T A A T 
Rabbit2 T A A A C T T T A T T A T A G T T A A T 
Rabbit3 T A A A C T T T A T T A T A G T T A A T 
Rabbit4 T A A A C T T T A T T A T A G T T A A T 
C.meleagridis A G G G T C C C G C C G C C T C C G G C 
 
 
 
 
 
 
 
 
 
 
 
  
   COWP (Cryptosporidium oocyst wall protein) 4890 bp 
          
        Chr.6 (493.95K- 499.32K)             
      PCR product 555 bp             
  
      total number of bp 529             
                           
Isolates 17 18 29 36 45 54 66 72 87 129 147 195 234 249 285 306 396 402 405 414 465 477 489 513 
Ch2 A T G G A A A C A T A A C T G G G T C A T G G G 
Ch3 A T G G A A A C A T A A C T G G G T C A T G G G 
Ch4 A T G G A A A C A T A A C T G G G T C A T G G G 
TU502 A T G G A A A C A T A A C T G G G T C A T G G G 
Cp2 A T G G A A T T A T G A C T G A G C C G T A G G 
Cp3 A T G G A A T T A T G A C T G A G C C G T A G G 
Cp4 A T G G A A T T A T G A C T G A G C C G T A G G 
Iowa A T G G A A T T A T G A C T G A G C C G T A G G 
Moredun A T G G A A T T A T G A C T G A G C C G T A G G 
w65 A T G G A A T T A T G A C T G A G C C G T A G G 
w66 A T G G A A T T A T G A C T G A G C C G T A G G 
w67 A T G G A A T T A T G A C T G A G C C G T A G G 
w70 A T G G A A T T A T G A C T G A G C C G T A G G 
Rabbit1 A T G G A A A C A T A A C T G G G T C A T G G G 
Rabbit2 A T G G A A A C A T A A C T G G G T C A T G G G 
Rabbit3 A T G G A A A C A T A A C T G G G T C A T G G G 
Rabbit4 A T G G A A A C A T A A C T G G G T C A T G G G 
C.meleagridis G C T T T G A C T A G G A A A G A C T G C A A A 
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COWP gene PCR product 
Appendix VI: Alignment of PCR products sequences for W15507, W15519, W15511, 
W15516 and C. parvum IOWA isolates before and after WGA using illustra GenomiPhi, 
REPLI-g and GenomePlex kits.  
 
 
 
 
 
 
 
 
 
                                         1                                               50 
                         IOWA_cry    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
  IOWA_cry_WGA_illustra_GenomiPhi    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
             IOWA_cry_WGA_REPLI-g    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
          IOWA_cry_WGA_GenomePlex    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
                       W15511_cry    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
W15511_cry_WGA_illustra_GenomiPhi    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
           W15511_cry_WGA_REPLI-g    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
        W15511_cry_WGA_GenomePlex    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
                       W15516_cry    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
W15516_cry_WGA_illustra_GenomiPhi    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
           W15516_cry_WGA_REPLI-g    (1) GTTTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
        W15516_cry_WGA_GenomePlex    (1) GTTTTTTCTGGAAAACAATGTGATCAATCAGACACAGCTCCTCCTAATCC 
                       W15507_cry    (1) GTCTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
W15507_cry_WGA_illustra_GenomiPhi    (1) GTCTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
           W15507_cry_WGA_REPLI-g    (1) GTCTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
        W15507_cry_WGA_GenomePlex    (1) GTCTTTTCTGGAAAACAATGTGTTCAATCAGACACAGCTCCTCCTAATCC 
                                         51                                             100 
                         IOWA_cry   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
  IOWA_cry_WGA_illustra_GenomiPhi   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
             IOWA_cry_WGA_REPLI-g   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
          IOWA_cry_WGA_GenomePlex   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
                       W15511_cry   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
W15511_cry_WGA_illustra_GenomiPhi   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
           W15511_cry_WGA_REPLI-g   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
        W15511_cry_WGA_GenomePlex   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
                       W15516_cry   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
W15516_cry_WGA_illustra_GenomiPhi   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
           W15516_cry_WGA_REPLI-g   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
        W15516_cry_WGA_GenomePlex   (51) AGAATGTCCTCCAGGCACTATACTGGAGAATGGCACATGTAAATTAATTC 
                       W15507_cry   (51) AGAATGTCCTCCAGGTACTATACTGGAAAATGGCACATGTAAATTAATTC 
W15507_cry_WGA_illustra_GenomiPhi   (51) AGAATGTCCTCCAGGTACTATACTGGAAAATGGCACATGTAAATTAATTC 
           W15507_cry_WGA_REPLI-g   (51) AGAATGTCCTCCAGGTACTATACTGGAAAATGGCACATGTAAATTAATTC 
        W15507_cry_WGA_GenomePlex   (51) AGAATGTCCTCCAGGTACTATACTGGAAAATGGCACATGTAAATTAATTC 
                                         101                                            150 
                         IOWA_cry  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
  IOWA_cry_WGA_illustra_GenomiPhi  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
             IOWA_cry_WGA_REPLI-g  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
          IOWA_cry_WGA_GenomePlex  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
                       W15511_cry  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
W15511_cry_WGA_illustra_GenomiPhi  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
           W15511_cry_WGA_REPLI-g  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
        W15511_cry_WGA_GenomePlex  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
                       W15516_cry  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
W15516_cry_WGA_illustra_GenomiPhi  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
           W15516_cry_WGA_REPLI-g  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAAAAGGAAATAGA 
        W15516_cry_WGA_GenomePlex  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
                       W15507_cry  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
W15507_cry_WGA_illustra_GenomiPhi  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
           W15507_cry_WGA_REPLI-g  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
        W15507_cry_WGA_GenomePlex  (101) AACAAATTGATACCGTTTGTCCTTCTGGTTTTGTTGAAGAAGGAAATAGA 
                                         151                                            200 
                         IOWA_cry  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
  IOWA_cry_WGA_illustra_GenomiPhi  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
             IOWA_cry_WGA_REPLI-g  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
          IOWA_cry_WGA_GenomePlex  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
                       W15511_cry  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
W15511_cry_WGA_illustra_GenomiPhi  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
           W15511_cry_WGA_REPLI-g  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
        W15511_cry_WGA_GenomePlex  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
                       W15516_cry  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
W15516_cry_WGA_illustra_GenomiPhi  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
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           W15516_cry_WGA_REPLI-g  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
        W15516_cry_WGA_GenomePlex  (151) TGTGTTCAATATCTCCCTGCAAATAAAATCTGTCCTCCTGGATTCAATTT 
                       W15507_cry  (151) TGTGTTCAATATCTCCCTGCAAACAAAATCTGTCCTCCTGGATTCAATTT 
W15507_cry_WGA_illustra_GenomiPhi  (151) TGTGTTCAATATCTCCCTGCAAACAAAATCTGTCCTCCTGGATTCAATTT 
           W15507_cry_WGA_REPLI-g  (151) TGTGTTCAATATCTCCCTGCAAACAAAATCTGTCCTCCTGGATTCAATTT 
        W15507_cry_WGA_GenomePlex  (151) TGTGTTCAATATCTCCCTGCAAACAAAATCTGTCCTCCTGGATTCAATTT 
                                         201                                            250 
                         IOWA_cry  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
  IOWA_cry_WGA_illustra_GenomiPhi  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
             IOWA_cry_WGA_REPLI-g  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
          IOWA_cry_WGA_GenomePlex  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
                       W15511_cry  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
W15511_cry_WGA_illustra_GenomiPhi  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
           W15511_cry_WGA_REPLI-g  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
        W15511_cry_WGA_GenomePlex  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
                       W15516_cry  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
W15516_cry_WGA_illustra_GenomiPhi  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
           W15516_cry_WGA_REPLI-g  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAAAATCGACAT 
        W15516_cry_WGA_GenomePlex  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
                       W15507_cry  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
W15507_cry_WGA_illustra_GenomiPhi  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
           W15507_cry_WGA_REPLI-g  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
        W15507_cry_WGA_GenomePlex  (201) GTCAGGACAACAATGTATGGCACCAGAATCAGCTGAATTAGAATCGACAT 
                                         251                                            300 
                         IOWA_cry  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
  IOWA_cry_WGA_illustra_GenomiPhi  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
             IOWA_cry_WGA_REPLI-g  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
          IOWA_cry_WGA_GenomePlex  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
                       W15511_cry  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
W15511_cry_WGA_illustra_GenomiPhi  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
           W15511_cry_WGA_REPLI-g  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
        W15511_cry_WGA_GenomePlex  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
                       W15516_cry  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
W15516_cry_WGA_illustra_GenomiPhi  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
           W15516_cry_WGA_REPLI-g  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
        W15516_cry_WGA_GenomePlex  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
                       W15507_cry  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
W15507_cry_WGA_illustra_GenomiPhi  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
           W15507_cry_WGA_REPLI-g  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
        W15507_cry_WGA_GenomePlex  (251) GCCCACCTAATTCAATATTTGAAAATGGAAAATGTAAAGTGATTAAAAAT 
                                         301                                            350 
                         IOWA_cry  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
  IOWA_cry_WGA_illustra_GenomiPhi  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
             IOWA_cry_WGA_REPLI-g  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
          IOWA_cry_WGA_GenomePlex  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
                       W15511_cry  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
W15511_cry_WGA_illustra_GenomiPhi  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
           W15511_cry_WGA_REPLI-g  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
        W15511_cry_WGA_GenomePlex  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
                       W15516_cry  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
W15516_cry_WGA_illustra_GenomiPhi  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
           W15516_cry_WGA_REPLI-g  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAAATGATTGTGT 
        W15516_cry_WGA_GenomePlex  (301) ATTGATATGGTCTGCCCACCAGGATATACAGACTCAGGAGATGATTGTGT 
                       W15507_cry  (301) ATTGATATGGTCTGCCCACCAGGATATACAGATTCAGGAGATGATTGTGT 
W15507_cry_WGA_illustra_GenomiPhi  (301) ATTGATATGGTCTGCCCACCAGGATATACAGATTCAGGAGATGATTGTGT 
           W15507_cry_WGA_REPLI-g  (301) ATTGATATGGTCTGCCCACCAGGATATACAGATTCAGGAGATGATTGTGT 
        W15507_cry_WGA_GenomePlex  (301) ATTGATATGGTCTGCCCACCAGGATATACAGATTCAGGAGATGATTGTGT 
                                         351                                            400 
                         IOWA_cry  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
  IOWA_cry_WGA_illustra_GenomiPhi  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
             IOWA_cry_WGA_REPLI-g  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
          IOWA_cry_WGA_GenomePlex  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
                       W15511_cry  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
W15511_cry_WGA_illustra_GenomiPhi  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
           W15511_cry_WGA_REPLI-g  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
        W15511_cry_WGA_GenomePlex  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
                       W15516_cry  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
W15516_cry_WGA_illustra_GenomiPhi  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
           W15516_cry_WGA_REPLI-g  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
        W15516_cry_WGA_GenomePlex  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
                       W15507_cry  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
W15507_cry_WGA_illustra_GenomiPhi  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
           W15507_cry_WGA_REPLI-g  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
        W15507_cry_WGA_GenomePlex  (351) ACTATATGTAGCTCCTGCAAAGGAATGCCCACCAAATTTCATTTTACAAG 
                                         401                                            450 
                         IOWA_cry  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
  IOWA_cry_WGA_illustra_GenomiPhi  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
             IOWA_cry_WGA_REPLI-g  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
          IOWA_cry_WGA_GenomePlex  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
                       W15511_cry  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
W15511_cry_WGA_illustra_GenomiPhi  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
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           W15511_cry_WGA_REPLI-g  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
        W15511_cry_WGA_GenomePlex  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
                       W15516_cry  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
W15516_cry_WGA_illustra_GenomiPhi  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
           W15516_cry_WGA_REPLI-g  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
        W15516_cry_WGA_GenomePlex  (401) GCCTCCAATGTATACAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
                       W15507_cry  (401) GCCTCCAGTGTATTCAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
W15507_cry_WGA_illustra_GenomiPhi  (401) GCCTCCAGTGTATTCAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
           W15507_cry_WGA_REPLI-g  (401) GCCTCCAGTGTATTCAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
        W15507_cry_WGA_GenomePlex  (401) GCCTCCAGTGTATTCAAACTAGTTCTGCTCCAACTCAACCTGTCTGCCCT 
                                         451              470 
                         IOWA_cry  (451) CCAGGTACAGTATTACAAGA 
  IOWA_cry_WGA_illustra_GenomiPhi  (451) CCAGGTACAGTATTACAAGA 
             IOWA_cry_WGA_REPLI-g  (451) CCAGGTACAGTATTACAAGA 
          IOWA_cry_WGA_GenomePlex  (451) CCAGGTACAGTATTACAAGA 
                       W15511_cry  (451) CCAGGTACAGTATTACAAGA 
W15511_cry_WGA_illustra_GenomiPhi  (451) CCAGGTACAGTATTACAAGA 
           W15511_cry_WGA_REPLI-g  (451) CCAGGTACAGTATTACAAGA 
        W15511_cry_WGA_GenomePlex  (451) CCAGGTACAGTATTACAAGA 
                       W15516_cry  (451) CCAGGTACAGTATTACAAGA 
W15516_cry_WGA_illustra_GenomiPhi  (451) CCAGGTACAGTATTACAAGA 
           W15516_cry_WGA_REPLI-g  (451) CCAGGTACAGTATTACAAGA 
        W15516_cry_WGA_GenomePlex  (451) CCAGGTACAGTATTACAAGA 
                       W15507_cry  (451) CCAGGTACAGTATTACAAGA 
W15507_cry_WGA_illustra_GenomiPhi  (451) CCAGGTACAGTATTACAAGA 
           W15507_cry_WGA_REPLI-g  (451) CCAGGTACAGTATTACAAGA 
        W15507_cry_WGA_GenomePlex  (451) CCAGGTACAGTATTACAAGA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                             1                                               50 
                         IOWA_cgd5020    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
  IOWA_cgd5020_WGA_illustra_GenomiPhi    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
             IOWA_cgd5020_WGA_REPLI-g    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
          IOWA_cgd5020_WGA_GenomePlex    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
                       W15511_cgd5020    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
W15511_cgd5020_WGA_illustra_GenomiPhi    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
           W15511_cgd5020_WGA_REPLI-g    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
        W15511_cgd5020_WGA_GenomePlex    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
                       W15516_cgd5020    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
W15516_cgd5020_WGA_illustra_GenomiPhi    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
           W15516_cgd5020_WGA_REPLI-g    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
        W15516_cgd5020_WGA_GenomePlex    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
                       W15507_cgd5020    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
W15507_cgd5020_WGA_illustra_GenomiPhi    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
           W15507_cgd5020_WGA_REPLI-g    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
        W15507_cgd5020_WGA_GenomePlex    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
                       W15519_cgd5020    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
WW15519_cgd5020_WGA_illustraGenomiPhi    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
       WW15519_cgd5020_WGA_GenomePlex    (1) ATGAGCCAATAATGAAGAACAAGAAATCCCATTCTATGGGTGTAACTTGT 
                                             51                                             100 
                         IOWA_cgd5020   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
  IOWA_cgd5020_WGA_illustra_GenomiPhi   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
             IOWA_cgd5020_WGA_REPLI-g   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
          IOWA_cgd5020_WGA_GenomePlex   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
                       W15511_cgd5020   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
W15511_cgd5020_WGA_illustra_GenomiPhi   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
           W15511_cgd5020_WGA_REPLI-g   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
        W15511_cgd5020_WGA_GenomePlex   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
                       W15516_cgd5020   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
W15516_cgd5020_WGA_illustra_GenomiPhi   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
           W15516_cgd5020_WGA_REPLI-g   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
        W15516_cgd5020_WGA_GenomePlex   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGAAGTTACGACGA 
                       W15507_cgd5020   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
W15507_cgd5020_WGA_illustra_GenomiPhi   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
           W15507_cgd5020_WGA_REPLI-g   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
        W15507_cgd5020_WGA_GenomePlex   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
                       W15519_cgd5020   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
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WW15519_cgd5020_WGA_illustraGenomiPhi   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
       WW15519_cgd5020_WGA_GenomePlex   (51) ATCCAAAAGTCGAATAGAAATCATCAATTTTGGTCAGGTAGTTACGACGA 
                                             101                                            150 
                         IOWA_cgd5020  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
  IOWA_cgd5020_WGA_illustra_GenomiPhi  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
             IOWA_cgd5020_WGA_REPLI-g  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
          IOWA_cgd5020_WGA_GenomePlex  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
                       W15511_cgd5020  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
W15511_cgd5020_WGA_illustra_GenomiPhi  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
           W15511_cgd5020_WGA_REPLI-g  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
        W15511_cgd5020_WGA_GenomePlex  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
                       W15516_cgd5020  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
W15516_cgd5020_WGA_illustra_GenomiPhi  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
           W15516_cgd5020_WGA_REPLI-g  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
        W15516_cgd5020_WGA_GenomePlex  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
                       W15507_cgd5020  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
W15507_cgd5020_WGA_illustra_GenomiPhi  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
           W15507_cgd5020_WGA_REPLI-g  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
        W15507_cgd5020_WGA_GenomePlex  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
                       W15519_cgd5020  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
WW15519_cgd5020_WGA_illustraGenomiPhi  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
       WW15519_cgd5020_WGA_GenomePlex  (101) AACCCTTAGATTCTGGGATTTTAGGATGATAAACTCTCCTATTTATGAGC 
                                             151                                            200 
                         IOWA_cgd5020  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
  IOWA_cgd5020_WGA_illustra_GenomiPhi  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
             IOWA_cgd5020_WGA_REPLI-g  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
          IOWA_cgd5020_WGA_GenomePlex  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
                       W15511_cgd5020  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
W15511_cgd5020_WGA_illustra_GenomiPhi  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
           W15511_cgd5020_WGA_REPLI-g  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
        W15511_cgd5020_WGA_GenomePlex  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
                       W15516_cgd5020  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
W15516_cgd5020_WGA_illustra_GenomiPhi  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
           W15516_cgd5020_WGA_REPLI-g  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
        W15516_cgd5020_WGA_GenomePlex  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
                       W15507_cgd5020  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
W15507_cgd5020_WGA_illustra_GenomiPhi  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
           W15507_cgd5020_WGA_REPLI-g  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
        W15507_cgd5020_WGA_GenomePlex  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
                       W15519_cgd5020  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
WW15519_cgd5020_WGA_illustraGenomiPhi  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
       WW15519_cgd5020_WGA_GenomePlex  (151) ACAAAACTAATGGAGGAATTTGGAGAATTAACCAATTTGAAGATTACCTT 
                                             201 
                         IOWA_cgd5020  (201) GGA 
  IOWA_cgd5020_WGA_illustra_GenomiPhi  (201) GGA 
             IOWA_cgd5020_WGA_REPLI-g  (201) GGA 
          IOWA_cgd5020_WGA_GenomePlex  (201) GGA 
                       W15511_cgd5020  (201) GGA 
W15511_cgd5020_WGA_illustra_GenomiPhi  (201) GGA 
           W15511_cgd5020_WGA_REPLI-g  (201) GGA 
        W15511_cgd5020_WGA_GenomePlex  (201) GGA 
                       W15516_cgd5020  (201) GGA 
W15516_cgd5020_WGA_illustra_GenomiPhi  (201) GGA 
           W15516_cgd5020_WGA_REPLI-g  (201) GGA 
        W15516_cgd5020_WGA_GenomePlex  (201) GGA 
                       W15507_cgd5020  (201) GGA 
W15507_cgd5020_WGA_illustra_GenomiPhi  (201) GGA 
           W15507_cgd5020_WGA_REPLI-g  (201) GGA 
        W15507_cgd5020_WGA_GenomePlex  (201) GGA 
                       W15519_cgd5020  (201) GGA 
WW15519_cgd5020_WGA_illustraGenomiPhi  (201) GGA 
       WW15519_cgd5020_WGA_GenomePlex  (201) GGA 
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                                             1                                               50 
                         IOWA_chro156    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
  IOWA_chro156_WGA_illustra_GenomiPhi    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
             IOWA_chro156_WGA_REPLI-g    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
          IOWA_chro156_WGA_GenomePlex    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
                       W15511_chro156    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
 W15511_chro156_WGA_illutra_GenomiPhi    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
           W15511_chro156_WGA_REPLI-g    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
        W15511_chro156_WGA_GenomePlex    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
                       W15516_chro156    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
W15516_chro156_WGA_illustra_GenomiPhi    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
           W15516_chro156_WGA_REPLI-g    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
        W15516_chro156_WGA_GenomePlex    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACAGCAGG 
                       W15507_chro156    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGG 
W15507_chro156_WGA_illustra_GenomiPhi    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGG 
           W15507_chro156_WGA_REPLI-g    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGG 
        W15507_chro156_WGA_GenomePlex    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGG 
        W15519_chro156_WGA_GenomePlex    (1) CTGCCAAGCGGAAAAAAGAGTAGTAGAATTTTATGTTTTACAACGGCAGG 
                                             51                                             100 
                         IOWA_chro156   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
  IOWA_chro156_WGA_illustra_GenomiPhi   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
             IOWA_chro156_WGA_REPLI-g   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
          IOWA_chro156_WGA_GenomePlex   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
                       W15511_chro156   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
 W15511_chro156_WGA_illutra_GenomiPhi   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
           W15511_chro156_WGA_REPLI-g   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
        W15511_chro156_WGA_GenomePlex   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
                       W15516_chro156   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
W15516_chro156_WGA_illustra_GenomiPhi   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
           W15516_chro156_WGA_REPLI-g   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
        W15516_chro156_WGA_GenomePlex   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
                       W15507_chro156   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
W15507_chro156_WGA_illustra_GenomiPhi   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
           W15507_chro156_WGA_REPLI-g   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
        W15507_chro156_WGA_GenomePlex   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
        W15519_chro156_WGA_GenomePlex   (51) AAGACGGCATATTGATCCAACCGAACAAATGATTGAGACAATGTCAATAT 
                                             101                                            150 
                         IOWA_chro156  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
  IOWA_chro156_WGA_illustra_GenomiPhi  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
             IOWA_chro156_WGA_REPLI-g  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
          IOWA_chro156_WGA_GenomePlex  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
                       W15511_chro156  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
 W15511_chro156_WGA_illutra_GenomiPhi  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
           W15511_chro156_WGA_REPLI-g  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
        W15511_chro156_WGA_GenomePlex  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
                       W15516_chro156  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
W15516_chro156_WGA_illustra_GenomiPhi  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
           W15516_chro156_WGA_REPLI-g  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
        W15516_chro156_WGA_GenomePlex  (101) CAAATCCTGAAGATATAGAAGAAGGTCCAGCTCAAGTAAATGAAGCCGAA 
                       W15507_chro156  (101) CAAATCCTGAAGATATAGAAGAAAGTCCAGCTCAAGTAAATGAAGTCGAA 
W15507_chro156_WGA_illustra_GenomiPhi  (101) CAAATCCTGAAGATATAGAAGAAAGTCCAGCTCAAGTAAATGAAGTCGAA 
           W15507_chro156_WGA_REPLI-g  (101) CAAATCCTGAAGATATAGAAGAAAGTCCAGCTCAAGTAAATGAAGTCGAA 
        W15507_chro156_WGA_GenomePlex  (101) CAAATCCTGAAGATATAGAAGAAAGTCCAGCTCAAGTAAATGAAGTCGAA 
        W15519_chro156_WGA_GenomePlex  (101) CAAATCCTGAAGATATAGAAGAAAGTCCAGCTCAAGTAAATGAAGTCGAA 
                                             151                              186 
                         IOWA_chro156  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
  IOWA_chro156_WGA_illustra_GenomiPhi  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
             IOWA_chro156_WGA_REPLI-g  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
          IOWA_chro156_WGA_GenomePlex  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
                       W15511_chro156  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
 W15511_chro156_WGA_illutra_GenomiPhi  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
           W15511_chro156_WGA_REPLI-g  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
        W15511_chro156_WGA_GenomePlex  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
                       W15516_chro156  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
W15516_chro156_WGA_illustra_GenomiPhi  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
           W15516_chro156_WGA_REPLI-g  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
        W15516_chro156_WGA_GenomePlex  (151) AACATGGTCCCAGACCACTTGCCTGGTATCAATGCC 
                       W15507_chro156  (151) AACATGGTCCCAGAAAACTTGCCTGGTATCAATGCC 
W15507_chro156_WGA_illustra_GenomiPhi  (151) AACATGGTCCCAGAAAACTTGCCTGGTATCAATGCC 
           W15507_chro156_WGA_REPLI-g  (151) AACATGGTCCCAGAAAACTTGCCTGGTATCAATGCC 
        W15507_chro156_WGA_GenomePlex  (151) AACATGGTCCCAGAAAACTTGCCTGGTATCAATGCC 
        W15519_chro156_WGA_GenomePlex  (151) AACATGGTCCCAGAAAACTTGCCTGGTATCAATGCC 
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Appendix VII: Alignment of Cops-1 PCR product sequences from clinical isolates and 
reference strains amplified using Cgd2_4380 F and R primers. 
 
 
 
                               1                                                         60 
          Cp2_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          Cp3_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          Cp4_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
         Iowa_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
      Moredun_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          W65_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          W66_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          W67_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          W70_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
C.meleagridis_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          Ch2_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          Ch3_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
          Ch4_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
        TU502_cgd2_4380    (1) AGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAGTGT 
                               61                                                       120 
          Cp2_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          Cp3_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          Cp4_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
         Iowa_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
      Moredun_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          W65_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          W66_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          W67_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          W70_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
C.meleagridis_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          Ch2_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          Ch3_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
          Ch4_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
        TU502_cgd2_4380   (61) TCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGATTT 
                               121                                                      180 
          Cp2_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          Cp3_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          Cp4_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
         Iowa_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
      Moredun_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          W65_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACATGGTCCAACTTTAGGGCTATTT 
          W66_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACATGGTCCAACTTTAGGGCTATTT 
          W67_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACATGGTCCAACTTTAGGGCTATTT 
          W70_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACATGGTCCAACTTTAGGGCTATTT 
C.meleagridis_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          Ch2_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          Ch3_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
          Ch4_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
        TU502_cgd2_4380  (121) TTAAATCCAGGATATGGTTCACGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTT 
                               181                                                      240 
          Cp2_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          Cp3_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          Cp4_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
         Iowa_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
      Moredun_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          W65_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          W66_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          W67_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          W70_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
C.meleagridis_cgd2_4380  (181) ACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATTTTGCTTACCTCT 
          Ch2_cgd2_4380  (181) ACTAGATCACGCCCACCTCTTCCA------------------------------------ 
          Ch3_cgd2_4380  (181) ACTAGATCACGCCCACCTCTTCCA------------------------------------ 
          Ch4_cgd2_4380  (181) ACTAGATCACGCCCACCTCTTCCA------------------------------------ 
        TU502_cgd2_4380  (181) ACTAGATCACGCCCACCTCTTCCA------------------------------------ 
                               241                                                      300 
          Cp2_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          Cp3_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          Cp4_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
         Iowa_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
      Moredun_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          W65_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          W66_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          W67_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          W70_cgd2_4380  (241) AGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
C.meleagridis_cgd2_4380  (241) AGTGGTTCGAACTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCATCAAGTTCTCAT 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
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          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               301                                                      360 
          Cp2_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          Cp3_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          Cp4_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
         Iowa_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
      Moredun_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          W65_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCCACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          W66_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCCACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          W67_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCCACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          W70_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCCACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
C.meleagridis_cgd2_4380  (301) TCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGATTTTTGAGTCCA 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               361                                                      420 
          Cp2_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          Cp3_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          Cp4_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
         Iowa_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
      Moredun_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          W65_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          W66_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          W67_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          W70_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
C.meleagridis_cgd2_4380  (361) GGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTATTTACTAGATCA 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               421                                                      480 
          Cp2_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
          Cp3_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
          Cp4_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
         Iowa_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
      Moredun_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
          W65_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGCTTACTTCTAGCAGTTTT 
          W66_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGCTTACTTCTAGCAGTTTT 
          W67_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGCTTACTTCTAGCAGTTTT 
          W70_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGCTTACTTCTAGCAGTTTT 
C.meleagridis_cgd2_4380  (421) CGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACTTCTAGCAGTTTT 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               481                                                      540 
          Cp2_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          Cp3_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          Cp4_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
         Iowa_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
      Moredun_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          W65_cgd2_4380  (481) AGATCTTCTAATGCTTCAGGCGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          W66_cgd2_4380  (481) AGATCTTCTAATGCTTCAGGCGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          W67_cgd2_4380  (481) AGATCTTCTAATGCTTCAGGCGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          W70_cgd2_4380  (481) AGATCTTCTAATGCTTCAGGCGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
C.meleagridis_cgd2_4380  (481) AGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCTCGTTTTACAGGT 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               541                                                      600 
          Cp2_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          Cp3_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          Cp4_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
         Iowa_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
      Moredun_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          W65_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          W66_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          W67_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          W70_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
C.meleagridis_cgd2_4380  (541) ACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGTCCAGGATACGGT 
          Ch2_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch3_cgd2_4380  (205) ------------------------------------------------------------ 
          Ch4_cgd2_4380  (205) ------------------------------------------------------------ 
        TU502_cgd2_4380  (205) ------------------------------------------------------------ 
                               601                                              652 
          Cp2_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          Cp3_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          Cp4_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
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         Iowa_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
      Moredun_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          W65_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          W66_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          W67_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
          W70_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGATCAC 
C.meleagridis_cgd2_4380  (601) TTACAACCAGGTTCAGCACGCGGTCCA------------------------- 
          Ch2_cgd2_4380  (205) ---------------------------------------------------- 
          Ch3_cgd2_4380  (205) ---------------------------------------------------- 
          Ch4_cgd2_4380  (205) ---------------------------------------------------- 
        TU502_cgd2_4380  (205) ---------------------------------------------------- 
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Appendix VIII: Alignment of Cops-1 gene and downstream sequences from C. parvum 
and C. hominis. The gene sequence was retrieved using a primer walking approach. 
The 3’ end of the gene in C. hominis was determined by the identification of a stop 
codon in the right open reading frame (ORF). The stop codon is highlighted in blue. 
 
 
                  
                   1                                                         60 
 C. parvum     (1) ATGGGTAATAGTTTAAATGTTTTTTTTGCTATTTTTCTAGTTGTTTTTCTTAATTTTTTG 
C. hominis     (1) ATGGGTAATAGTTTAAATGTTTTTTTTGTTATTTTTCTAGTTGTTTTTCTTAATTTTTTG 
                   61                                                       120 
 C. parvum    (61) GGGTTACAAACTTTTTTTAATACCAGAAATGTTGAAAGCAATTTATTTTTAATTTTAAAT 
C. hominis    (61) GGGTTCCAAACTTTTTTTAATACCGGAAATGTTGAAAGCAATTTATTTTTTATTTTAAAT 
                   121                                                      180 
 C. parvum   (121) TCTTATCCATCATTCATTAAGCTTGGAGGAATAAATGGTAGAGAAGGGAGTTCTAGTGGA 
C. hominis   (121) TCTTATCCATCATTCATTAAGCTTGGAGGAATAAAAGGTAGAGAAGGGAGTTCTAACGGA 
                   181                                                      240 
 C. parvum   (181) TTTTCGTCTGGAGGTAGACATGGTTCATTGCAAGGAGGATCATTAAGAGATAGTGCGCGT 
C. hominis   (181) TTTTCGTCTGGAGGTGGACATAGTTCATTTCAAGGAAGATCATTAAGAGATAGTGGGCGT 
                   241                                                      300 
 C. parvum   (241) TCAAGGGGTGGACCTAGATGCTCAAGAGCCCCGCATCCTAGACTCCAAACCATTATTGAG 
C. hominis   (241) TCAAGGGGTAGATCTAGATGCTCAAGAGCTCCGGATCCTAAACTCCAAACCATTATTGAG 
                   301                                                      360 
 C. parvum   (301) TGTTCAGAAACAGATTCAACTGATGGAGGTAGCAATACTGCAAGTCAACCAAATGGCAGA 
C. hominis   (301) TGTTCAGAAACAGATTCACCTGATGGAGTTAGCAATACTGGAAATCAACCAACTGGCAGA 
                   361                                                      420 
 C. parvum   (361) TTTTTAAATCCAGGATATGGTTCACGACCAGG---------TTCAACACGTGGTCCAACT 
C. hominis   (361) TTTTCAAATCCAGGAGGTGGCTTGCAACCAGGCCCACGTGTTGGATCACGTGGGCCAACT 
                   421                                                      480 
 C. parvum   (412) TTAGGGCTATTTACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAATT 
C. hominis   (421) TTAGGGCTATTTACTAGATCACGTCCAACTATTCCAACTCGTAGACCATATTCAGGAATT 
                   481                                                      540 
 C. parvum   (472) TTGCTTACCTCTAGTGGTTCGAAGTCCTCTGCTCTTTCAAGCAGATTTGGACAAAAGCCA 
C. hominis   (481) TTGCTTACCTCTGGTGGGTTGAACTCTTCTGGTCTTTCAAGCAGATTAGGAAAAGCATCA 
                   541                                                      600 
 C. parvum   (532) TCAAGTTCTCATTCTACAAGTACAGGAACTCGTGCTCTACAAAGCGGTGTAGGAAGCAGA 
C. hominis   (541) TCGAGTTCTCATTCTACAAGTGTAGGAACTCGTGGTCCACAAAGCGGTGTAGGAAGCAAA 
                   601                                                      660 
 C. parvum   (592) TTTTTGAGTCCAGGATATGGTTCAAGACCAGGTTCAACACGTGGTCCAACTTTAGGGCTA 
C. hominis   (601) TTTTTGAGTCCAGGATATGGTTCACGACCAGGTTCAGCACGCGGTCCAACTTTAGGGCTA 
                   661                                                      720 
 C. parvum   (652) TTTACTAGATCACGTCCAGTTTTTCCAACTCGTAGACCATATTCAGGAAGTTTGTTTACT 
C. hominis   (661) TTTACTAGATCAAGTCCAACTCTTCCAACTCGTAGACCATATTCAGGAAGTTTGCTTACT 
                   721                                                      780 
 C. parvum   (712) TCTAGCAGTTTTAGATCTTCTAATGCTTCAGACGGATCAGGAGATTCGTCATATAGTTCT 
C. hominis   (721) TCTAGCAGTTTAAGTTCTTCTAATGCTTCAGGTGGATTAGGACAATCGTCATATAGTTCT 
                   781                                                      840 
 C. parvum   (772) CGTTTTACAGGTACAGGAACTCGTGGTTCACAAGGCGGTGTAGGAAGCAGATTTTTGAGT 
C. hominis   (781) CGTTTTACAAGTACAGGAACTC---------AAGG------------------------- 
                   841                                                      900 
 C. parvum   (832) CCAGGATACGGTTTACAACCAGGTTCAGCACGCGGTCCAACTTTGGGGCTATTTACTAGA 
C. hominis   (807) ------------------------------------------------------------ 
                   901                                                      960 
 C. parvum   (892) TCACGCCCACCTCTTCCAACTCGTAAACCATATTCAGGAAGTTTGCTTACTTCTAGCAGA 
C. hominis   (807) --------------------------ACCATAT---GGAA-------------------- 
                   961                                                     1020 
 C. parvum   (952) TTGAGTTCTTCTAATGCTTCAGGTGGATTAGGACAATCGTCATCTAGTTCTCGTTTTACA 
C. hominis   (818) ----------------CTTCAGGT--AATAGA----------------------TTTTCT 
                   1021                                                    1080 
 C. parvum  (1012) AGTACAGGACCTCAAGGACCA--TATGGAACTTCAGGAGTTGGTACACCGTTGGGCCACT 
C. hominis   (838) AGTATTGGA-----AGGACCAGTTCTGTAACTTCAGGAGCTGGTACAGCATCGGGCCAGT 
                   1081                                                    1140 
 C. parvum  (1070) CTGTTTCACCTGAAGGAAAACCACAAGGTTTACTAGCTAGAGGATATATAACATCAAATT 
C. hominis   (893) CTGTTTCATCTGAAAGAATACCACAAGGTTTACAAGCTAGAGGATATATGACATCAAATT 
                   1141                                                    1200 
 C. parvum  (1130) GTCCACGTGGTATTCCAGGTGAGCATCGAGTAGATGTTACTAGTAACGGTTCTTTGATAT 
C. hominis   (953) GTCCACGTGGCATTCCAGGTGAGCATCGAGTAGATATTACTAGTAACGGTTCTTTGATGT 
                   1201                                                    1260 
 C. parvum  (1190) GCTGTTATTGTTATAATAGATGTGATCATGAAGGTTTTAAGCCACCAAGACGAACAACAA 
C. hominis  (1013) GGTGTTATTGTTATAATAGATGTGATCATGAAGGTTTTAAGCCACCAAGACGAACAACGA 
                   1261                                                    1320 
 C. parvum  (1250) CAACAACAACACAATCACCACCATATTCTTCTAGGGGGTACCTGACATTAGATTGTCCAC 
C. hominis  (1073) CAACAACTACACAATCACCACCATATTCTTCTAGGGGGTACTTGACATTAGATTGTCCAC 
                   1321                                                    1380 
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 C. parvum  (1310) TTGGTACCCCAGGTGAACATCGCTTAGATGTTGATAATTCTGGCGTCTTATTTTGCGCTA 
C. hominis  (1133) TTGGTACCCCAGGCGAACATCGCTTAGATGTTACTAGTGATGGCGTGTTATTTTGTGCTA 
                   1381                                                    1440 
 C. parvum  (1370) CTTGTGGTAACAGGTTTAGTCATCAAGGGTGCCCACCACCGAAAATACCGTTATGCCGAA 
C. hominis  (1193) CTTGTGGTAACAAGTTTAGTCATCAAGGGTGCCCACCACCGAAAATACCGAAATGCCGAA 
                   1441                                                    1500 
 C. parvum  (1430) AATAAAACATGAAACAGCACCCATTTCATTATTATTTTCAAACATTTTACACCAAAAACA 
C. hominis  (1253) AA-AAAACATGAAACAGCACCTATTTCATTATTATTTTCGATCATCTTACACTATAAACA 
                   1501                                                    1560 
 C. parvum  (1490) GTTTGCGGTCTAAATACGGCTGCTATATTTTATTTTATATAGATTCCGTTTTTACTTTTG 
C. hominis  (1312) GTTTGCGGTCTAAATACGGCTGCTATATTTTATTTTATATAGATTCCGTTTTTACTTTTG 
                   1561                                                    1620 
 C. parvum  (1550) TAGCACAAAAATGATTGGATTGAAGTCACCGAGTTTTGTAATAGTTTATTTCTAAAAAGG 
C. hominis  (1372) TAGCGCAAAAATAATTGGATTGAAGTTACCGAGTTTTTTAATGATTTGTTTCTAAAAATG 
                   1621                                                    1680 
 C. parvum  (1610) CTAGTAAAGTTGCTTATTTTAATATCTATCCTTTACAATGTTATGTTATAAGTTTGTGCT 
C. hominis  (1432) CTAGTAAAGTTGCTTATTTTAATATCTTTCCTTTACAATGTTAT-----AAGTTTATATT 
                   1681                                                    1740 
 C. parvum  (1670) ATAATTTCGAG---ATCTTAATGCAAAGATTCTTGGATTATAACTTTCGAAACTTTAGGG 
C. hominis  (1487) ATCATTTCAAGAAGATTTTAATGCAAAGATTCTTGGATTATAGCTTTCAGCCAATTAGTG 
                   1741     1753 
 C. parvum  (1727) TT--TTAGGGTTT 
C. hominis  (1547) ATCGTAATGGTTT 
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Appendix IX: Diagram of the recombinant pET100/D-TOPO
® 
plasmid (Invitrogen) 
containing Cops-1 gene. The cloning site corresponds to the Topoisomerase recognition 
site (position: 396-400) and the overhang sequence (401-404). The position of Cops-1 is 
shown in red. The plasmid map was drawn using PlasMapper software 
(http://wishart.biology.ualberta.ca/PlasMapper/). 
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